Bio SB Antibodies Reagents 2014 Femg

Bio SB, Inc.
Mission Statement
At Bio SB, Inc., we are proud to develop, manufacture and distribute unique products for
Immunohistochemistry, FISH, CISH, Liquid Cytology and PCR technologies that meet the highest
international standards for applications in Molecular Pathology. We have a talented, dedicated, and
vibrant team of professionals that excel in the R&D, Production and Marketing of Immunochemicals
for Cancer Research, Microbiology, Immunology and Genetics. BIO SB manufactures and develops
products in accordance with FDA QSR 21 CFR Part 820 cGMP. These guidelines enable us to produce
an IVD product that meets the highest in vitro diagnostic standards.
Our mission is to develop high-quality immunochemicals while providing outstanding technical

service to our customers. We develop rabbit and mouse monoclonal antibodies and detection
systems for Immunohistochemistry and Immunocytochemistry using proprietary technologies.
Our ImmunoDetector, PolyDetector and CytoDetector systems are unique, high-sensitivity detection systems already in use in
laboratories worldwide. Our Liquid Cytology offers an affordable, easy-to-use alternative to the traditional Pap smear.
Our strategic alliance with ZytoVision of Germany has added a complete range of products for chromogenic (CISH) and florescent
in situ hybridization (FISH). These technologies are designed for the evaluation and detection of genetic aberrations such as
translocations, deletions, amplifications, chromosomal aneuploidy and gene amplifications. We also offer outstanding fast detection
and discrimination of human pathogenic viruses in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone
marrow smears, and metaphase chromosome spreads.
We are very proud to share with our partners and customers our association with Celerus Diagnostics of Carpinteria, CA that will enable
us to offer our customers with the most sophisticated automated system for Immunohistochemistry (IHC): The Wave RPD System.
The Wave RPD System performs totally automated, rapid IHC in one hour. The sophisticated features and innovative components of the
Wave RPD System combine for standardized results, ease-of-use and high-quality staining to accelerate patient care.
Our partnership with Maxim Biotech of Rockville, MD has expanded our capacity to provide our customers with single, dual and
multiplex PCR technologies for Nucleic Acid Amplification. Maxim’s core competency, the development of multiplex amplification-assay
systems, affords researchers the opportunity to significantly increase assay through-put while reducing the typical time required for
many of today’s amplification-assay systems. Maxim’s diverse line of kits and services is designed to make molecular biology research
techniques faster, more cost- effective, and more accessible to researchers working in a broad range of disciplines.
Our alliance with Shanghai ZJ Bio-Tech Co. Ltd., of Shanghai, China, has expanded our range of products for Real Time PCR. Shanghai
ZJ Bio-Tech Co. Ltd., is a leading Diagnostics company, focused on developing and manufacturing Real Time PCR Diagnostic reagents
with applications in Microbiology, Molecular Biology, Cell Biology, and Immunology. Complete PCR kits for Hepatitis Virus, HIV,
Sexually- transmitted Diseases, Respiratory Diseases (Including complete kits for Influenza A H1N1), Infectious Diarrhea, Organ
Transplantation, Insect Vector Diseases and Zoonosis Diseases are effectively used in clinical diagnosis, public health, entry-exit
inspection and quarantine, food safety inspection, and animal husbandry.
At Bio SB our passion is providing biomedical laboratories with the tools to improve the diagnosis, prognosis and therapies that benefit
patients worldwide.
Dr. Alfonso Heras

President & CEO
info@biosb.com • www.biosb.com
BIO SCIENCE FOR THE WORLD
Bio SB
Immunopathology
• Rabbit and Mouse Antibodies for Immunohistochemistry (IHC)
• HRP & AP Detection Systems for IHC
• Heat Epitope Retrieval Solutions
• Substrate-chromogens for HRP & AP
• Equipment and Ancillaries
• CytoLayer Liquid Based Cytology
Shanghai ZJ Bio-Tech
Kits for Real Time PCR
• Bacterial and Viral Load Quantification • SNP Genotyping
• Pathogen Detection & Typing • Validation of RNAi
• Differential Gene Expression • Forensic Studies
• Therapeutic Drug Monitoring
• Genetic Disease Analysis
• Food & Environmental Pathogen Detection
Celerus Diagnostics
Totally Automated IHC in One Hour!
• Rapid IHC in one hour
• Standard Results, ease-of-use and high-quality IHC
• Limitless Flexibility
• Lean Process Maximized
• Smarter, Faster-Rapid IHC
ZytoVision
CISH and FISH
ZytoLight – Products for FISH HER2 | EGFR | MDM2 | ESR1 | MEC | RMS | FHIT | p16 | CCND1 | FGFR1 | nMYC | cMYC
PTEN | MDM4 | FGFR3 | MET | TERT | EWSR1 | SYT | CHOP | CDK4 | ALK/EML4
ZytoLight® products for Fluorescence in situ Hybridization (FISH) are designed for the identification
of genetic aberrations such as translocations, deletions, amplifications, and chromosomal aneuploi-
dies associated with tumors and genetic diseases.
ZytoDot – Products for CISH HER2 | FGR1 | TOPO2A | EGFR | cMYC | XY | MDM2 | cMYC | TOPOZA | FGR1
ESR1 | nMYC | CCND1
ZytoDot® products for Chromogenic in situ Hybridization (CISH) are designed for the detection of
aneuploidies and gene amplifications associated with tumors and genetic disease using an IHC-like
procedure and light microscopy.
ZytoFast – Products for CISH HPV | EBV | CMV | Ig-Kappa | Ig-Lambda
ZytoFast® products for Chromogenic in situ Hybridization (CISH) are designed for the detection and
discrimination of human pathogen viruses such as HPV, EBV, CMV, and the determination of lymphocyte
clonality by detecting Ig-κ and Ig-λ light chains RNA.
Ancillaries for FISH & CISH

Equipment, High quality detection substrates, chromogens, essential washing solutions and control
slides for CISH and FISH.
Maxim Biotech
Single, Dual and Multiplex PCR
Complete kits for single, dual and multiplex PCR
Nucleic Acid Extraction Kits Detection and
quantification kits for
• Interleukins
• Apoptosis
• Receptors
• Growth Factors
• Oncogenes
• Genetic Diseases
• Microorganisms
New Rabbit Monoclonal Antibodies

from Bio SB, Inc.
Higher Affinity | Higher Sensitivity | Higher Specificity
• ALK-1, RBT-ALK1 • CD5, RBT-CD5 • CK17, EP98 • ER, RBT11 • PAX-5, RBT-PAX-5
• AMACRacemase, RBT-AMACR • CD21, EP64 • CK19, EP72 • HER-2 neu, RBT-HER2 • PLAP, EPR6141
• Calretinin, EP1798 • CD117, YR145 • Cyclin D1, RBT14 • Ki67, EP5 • PR, RBT22
• CD1a, EP80 • CDX-2, EP25 • DOG-1, RBT-DOG1 • Mammaglobin, 31A5 • PSMA, EPR6253
• CD3, RBT-CD3 • COX-2, RBT-COX2 • E-Cadherin, EP700Y • MCM2, RBT-MCM2 • Topoisomerase IIa, RBT-Topo2a
• CD4, RBT-CD4 • VEGF, RBT-VEGF
Bio SB, Inc., 69 Santa Felicia Dr., Santa Barbara, CA 93117, USA
Tel: (805) 692-2768 | Tel: (800) 561-1145 | Fax: (805) 692-2769
E-mail: info@biosb.com | Website: www.biosb.com
Table of Contents
Antibodies for Immunohistochemistry . . . . . . . . . . . . . . . . . . 7
Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Antibodies for Immunofluorescence. . . . . . . . . . . . . . . . . . . . 71
Detection Systems for IHC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .73

ImmunoDetector HRP Detection Systems . . . . . . . . . . . . . . . . . . . . . .74
ImmunoDetector AP Detection Systems . . . . . . . . . . . . . . . . . . . . . . .75
PolyDetector HRP Detection Systems . . . . . . . . . . . . . . . . . . . . . . . . . .76
Mouse/Rabbit PolyDetector HRP w/DAB . . . . . . . . . . . . . . . . . . . . . . .76
Mouse/Rabbit PolyDetector HRP w/AEC . . . . . . . . . . . . . . . . . . . . . . .76
Mouse PolyDetector HRP w/DAB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76
Mouse PolyDetector HRP w/AEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76
Rabbit PolyDetector HRP w/DAB. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76
Rabbit PolyDetector HRP w/AEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76
Complete Detection Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .77
HPV CytoDetector HRP/DAB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .77
HER2 neu PolyDetector HRP/DAB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .78 7
ER/PR PolyDetector HRP/DAB. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79
CD117 c-Kit PolyDetector HRP/DAB . . . . . . . . . . . . . . . . . . . . . . . . . . . .80
71
Substrate Chromogen Systems . . . . . . . . . . . . . . . . . . . . . . . . 81
HRP Substrate Chromogen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .82
ImmunoDetector Liquid AEC Ready-To-Use . . . . . . . . . . . . . . . . . . . .82
ImmunoDetector Liquid DAB kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .82
ImmunoDetector DAB Buffer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .82
ImmunoDetector DAB Chromogen . . . . . . . . . . . . . . . . . . . . . . . . . . . .82
PolyDetector HRP Black kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .82
AP Substrate Chromogen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .83
PolyDetector Alk Blue Ready-To-Use . . . . . . . . . . . . . . . . . . . . . . . . . . .83
PolyDetector Alk Red Ready-To-Use . . . . . . . . . . . . . . . . . . . . . . . . . . . .83
PolyDetector Alk Brown Ready-To-Use . . . . . . . . . . . . . . . . . . . . . . . . .83
PolyDetector Alk Magenta. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .83
Ancilliaries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
ImmunoDNA Retrievers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
ImmunoDNA Retriever 20X with Citrate. . . . . . . . . . . . . . . . . . . . . . . .86
ImmunoDNA Retriever 20X with EDTA . . . . . . . . . . . . . . . . . . . . . . . . .86
Protein Block / Antibody Diluent. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
Negative Controls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
Immuno/DNA Washer 10X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
PolyDetector HRP and AP Buffers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
Tween 20 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
Mounting Media . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
Aqua Mounter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
Perma Mounter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
PolyDetector Peroxidase Block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
PolyDetector AP Block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
ImmunoDetector Biotin Blocker . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86 81
ImmunoDNA Background Blocker . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
HybriWash 20X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
Hematoxylin Counterstainer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86 85
Nuclear Fast Red Counterstainer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
Methyl Green Counterstainer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86
Analyte Specific Reagent

For in Vitro Diagnostic Use Analytical and performance characteristics are not established. For Research Use Only
FISH & CISH Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

FISH-ZytoLight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .88
ZytoLight FISH probes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .89
ZytoLight FISH Kits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .89
CISH-ZytoDot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .90
ZytoDot CISH probes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .91
ZytoDot CISH Kits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .91
CISH-ZytoFast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .92
ZytoFast Probes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93
ZytoFast Detection Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93
Ancillaries for FISH & CISH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .94
Equipment and Slides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95

Wave RPD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .96
Pressure Cooker and Staining Dishes . . . . . . . . . . . . . . . . . . . . . . . . 103
Digital Pressure Cooker. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Plastic Staining Dish. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Slide Holder, 24 places . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Slides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 87
Probe On Plus Slides, Box of 72 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Probe On Slides, Box of 72 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Superfrost Plus Slides, Box of 72 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 95
Colorfrost Slides, Box of 72 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Capillary-gap Slides width: 130um; Color, Gold . . . . . . . . . . . . . . . 103
Microscope Slides for Liquid Cytology, Box of 72 . . . . . . . . . . . . . 103
Hydrophilic Plus Slides for Molecular Pathology . . . . . . . . . . . . . . 104
Liquid-Based Cytology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109

Equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Gynecological Liquid Cytology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Non-Gynecological Liquid Cytology . . . . . . . . . . . . . . . . . . . . . . . . . 111
Accessories for Liquid Cytology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
CytoLayer Fixitive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Gyn Accessories Cytology Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Non-Gyn Accessories Cytology Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Cervex Brush. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
CytoLayer Sedimentation Chambers . . . . . . . . . . . . . . . . . . . . . . . . . 111
15 ml Conical Centrifuge Tubes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
1 ml Transfer Pipettes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Microscope Slides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Slide Treatment Solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Density Gradient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Lysis Solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
DNA/RNA Isolation Kits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
RT PCR Kits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Ancillary Products. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Single & Multiplex PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Real Time PCR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139 109
Automated Nucleic Acid Extraction System . . . . . . . . . . . . . . . . . . 154
Molecular Pathology Technical Index . . . . . . . . . . . . . . . . . . 157 113

Product Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
Ordering Information/Distributors . . . . . . . . . . . . . . . . . . . . 175
Analyte Specific Reagent

For in Vitro Diagnostic Use Analytical and performance characteristics are not established. For Research Use Only
Antibodies for Immunohistochemistry
Gretchen King –
Histology
“Our Objective is to develop, manufacture and market easy-to-use, safe,

reliable and economical products for Cancer Prognostics and Diagnostics
that meet the most stringent International standards.”
Alpha-1-Antichymotrypsin A-1-Antitrypsin ACTH
IHC of Alpha-1-Antichymotrypsin on an IHC of Alpha-1- Antitrypsin on an FFPE Tonsil IHC of ACTH on an FFPE Pituitary Tissue
FFPE Tonsil Tissue
Alpha-1-Antichymotrypsin is a glycoprotein found Alpha-1-Antitrypsin (A1AT) is a glycoprotein Adrenocorticotropic Hormone (ACTH or

in the alpha (1)-globulin region in human serum. generally known as serum trypsin inhibitor. corticotropin) is a polypeptide hormone
It inhibits chymotrypsin-like proteinases in vivo Alpha-1-Antitrypsin is also referred to as alpha-1 synthesized from POMC, (Pro-opiomelanocortin)
and has cytotoxic killer-cell activity in vitro. proteinase inhibitor (A1PI) because it is a serine and secreted from corticotropes in the
The protein also has a role as an acute-phase protease inhibitor (serpin), inhibiting a wide anterior lobe of the pituitary gland in response
protein and is active in the control of immuno- variety of proteases. It protects tissues from to Corticotropin-releasing Hormone (CRH)
logic and inflammatory processes, and as a tumor enzymes of inflammatory cells, especially released by the hypothalamus. It consists of 39
marker. It is a member of the serpin superfamily. elastase, and has a reference range in blood amino acids.
of 1.5 - 3.5 gram/liter (in the U.S. the reference
Alpha-1-Antichymotrypsin antibody reacts range is generally expressed as mg/dL or ACTH is a useful marker in the classification of
with histiocytes and histiocytic neoplasms. Its micromoles), but the concentration can rise pituitary tumors and the study of pituitary
major application is defining the presence of many fold upon acute inflammation. In its disease. It reacts with ACTH-producing cells
Alpha-1-Antichymotrypsin in histiocytes and absence, elastase is free to break down elastin, (corticotrophs), as well as other tumors (e.g.,
tumors derived from them. In eosinophilic which contributes to the elasticity of the lungs, some Small-Cell Carcinomas present in lung
granuloma and malignant histiocytosis, the resulting in respiratory complications such as tissue) causing Paraneoplastic Syndromes by
reaction for this marker is heterogeneous in emphysema, or COPD (Chronic Obstructive secreting ACTH.
intensity and distribution. In fibrous histiocy- Pulmonary Disease) in adults and cirrhosis in
tomas, under certain circumstances, a diffuse adults or children.
homogeneous reaction may be observed.
Alpha-1-Antitrypsin is considered to be very
useful in the study of inherited AAT deficiency,
benign and Malignant Hepatic Tumors and
Yolk-Sac Carcinomas. Positive staining for A-1-
Antitrypsin may also be used in detection of
benign and malignant lesions of a histiocytic
nature. Sensitivity and specificity of the results
have made this antibody a useful tool in the
screening of patients with Cryptogenic Cirrhosis
or other forms of liver disease with portal fibrosis
of unknown etiology.
ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Rabbit Polyclonal
CLONE N/A CLONE N/A CLONE N/A
ISOTYPE N/A ISOTYPE N/A ISOTYPE N/A
CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node CONTROL Normal Pituitary
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic
CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

BSB 5001 prediluted 3.0 ml BSB 5008 prediluted 3.0 ml BSB 5015 prediluted 3.0ml
BSB 5002 prediluted 7.0 ml BSB 5009 prediluted 7.0 ml BSB 5016 prediluted 7.0 ml
BSB 5004 concentrated 0.1 ml BSB 5011 concentrated 0.1 ml BSB 5018 concentrated 0.1 ml
BSB 5007 control slides 5 BSB 5014 control slides 5 BSB 5021 control slides 5
9
Actin, Muscle-Specific Actin, Smooth-Muscle Adenovirus
IHC of Actin, Muscle-Specific on an IHC of Actin, Smooth-Muscle on an IHC of Adenovirus on a FFPE Infected Liver Tissue
FFPE Skeletal Muscle Tissue FFPE Appendix Tissue
Actin is a globular-structural, 345 kDa protein Actin is a major component of the cytoskel- Adenoviruses belong to the family Adenoviridae.
that polymerizes in a helical fashion to form eton and is present in every cell type. Actins are They infect both humans and animals. Adenovirus
an actin filament (or microfilament). Actin highly conserved proteins that are involved in was first isolated in human adenoids (tonsils),
filaments provide mechanical support for the various types of cell motility and are ubiquitously from which the name is derived. Adenoviruses are
cell, determine the cell shape, enable cell expressed in all eukaryotic cells. In vertebrates classified as group I under the Baltimore
movements (through lamellipodia, filopodia, 3 main groups of actin isoforms (alpha, beta classification scheme. They are medium-sized
or pseudopodia); and participate in certain and gamma) have been identified. The alpha (60-90 nm), non-enveloped icosahedral viruses
cell junctions, in cytoplasmic streaming and actins are found in muscle tissues and are a major containing double-stranded DNA.
in contraction of the cell during cytokinesis. In constituent of the contractile apparatus. The beta
muscle cells they play an essential role, along and gamma actins coexist in most cell types as
with myosin, in muscle contraction. In the components of the cytoskeleton and as mediators
cytosol, actin is predominantly bound to ATP, of internal cell motility.
but can also bind to ADP.
Smooth-Muscle Actin antibody does not stain
This antibody recognizes actin of skeletal, cardiac or skeletal muscle; however, it will stain
cardiac, and smooth-muscle cells. It is not myofibroblasts and myoepithelial cells. This
reactive with other mesenchymal cells except for antibody could be used together with Muscle-
myoepithelium. Muscle-Specific Actin recognizes Specific Actin to distinguish Leiomyosarcoma
alpha and gamma isotypes of all muscle groups. from Rhabdomyosarcoma. In most cases of
Non-muscle cells such as vascular endothelial cells Rhabdomyosarcoma, this antibody gives
and connective tissues are non-reactive. negative results whereas M. S. Actin is positive
Neoplastic cells of non-muscle-derived tissue in the rhabdomyoblasts. Leiomyosarcomas are
such as Carcinomas, Melanomas and Lymphomas positive with both M. S. Actin and S. M. Actin
are negative. This antibody is useful in the antibodies.
identification of rhabdoid cellular elements.
ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Mouse Monoclonal
CLONE HHF-35 CLONE ASM/H12 CLONE 20/11 and 2/6
ISOTYPE IgG1/K ISOTYPE IgG2a/K ISOTYPE IgG1
CONTROL Skeletal Muscle CONTROL Appendix, Uterus CONTROL Infected Tissue
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic, Nuclear

ALK-1/CD246 Alpha-Fetoprotein Alpha-Methylacyl-CoA

Racemase/P504S
IHC of ALK-1/CD246 on an IHC of AFP on an FFPE Fetal Liver Tissue IHC of AMACR on an
FFPE Anaplastic Large Cell Lymphoma Tissue FFPE Prostatic Adenocarcinoma Tissue
Anaplastic Lymphoma Kinase (ALK) was originally Alpha-fetoprotein (AFP) is a protein which in AMACR (P504S) is an acronym for the protein
discovered as a NPM (Nucleophosmin)-ALK humans is encoded by the AFP gene. This gene alpha-methylacyl CoA racemase that helps to
fusion protein. The ALK gene is on chromosome encodes alpha-fetoprotein, a major plasma metabolize certain fatty acids within the body.
2. Upon translocation between chromosome 2 protein produced by the yolk sac and the liver AMACR has been recently described as a prostate
and chromosome 5 t(2;5), the ALK gene fuses with during fetal life. This protein is thought to be the cancer-specific gene that encodes a protein
the NPM gene. The chimeric product (NPM ALK) fetal counterpart of serum albumin, and the involved in the beta-oxidation of branched chain
resulting from t(2;5) translocation is a protein of alpha-fetoprotein and albumin genes are present fatty acids. Expression of AMACR protein is found
80 kDa with the N terminal portion of NPM linked in tandem on chromosome 4. in Prostatic Adenocarcinoma but not in benign
to the complete intracellular portion of ALK. prostatic tissue. It stains premalignant lesions of
Positive staining with this antibody is seen in the prostate: High-Grade Prostatic Intraepithelial
This antibody recognizes a human p80 protein, hepatocytes of fetal liver and hepatoma. Neoplasia (PIN) and Atypical Adenomatous
identified as a hybrid of the Anaplastic Lymphoma Since only traces of AFP are found in adult Hyperplasia. Several studies have suggested
Kinase (ALK) gene and the Nucleophosmin serum, elevated levels suggest either a benign or that AMACR can be used as a prostate cancer
(NPM) gene resulting from the t(2;5)(p23;q35) malignant lesion of the liver, a Yolk-Sac biomarker.
translocation found in a third of Large-Cell Carcinoma, or one of a few other tumors. In
Lymphomas. ALK-1/CD246 is detected in 60% of conjunction with elevated serum levels, AFP High expression of AMACR (P504S) protein is
Anaplastic Large-Cell Lymphomas and has has been immunohistochemically demonstrated usually found in Prostatic Adenocarcinoma but not
proven to indicate a better prognosis in the ALK-1 in Yolk-Sac Carcinomas in gonadal and in benign prostatic tissue by immunohistochemical
(+) group. extragonadal sites of hepatic malignancies and staining in paraffin-embedded tissues. Using
a few other neoplasms. AMACR as a positive marker along with basal-cell
staining (34βE12 or p63) as a negative marker
could help to confirm the diagnosis of small foci of
Prostate Carcinoma on needle biopsies.
ANTIBODY TYPE Rabbit Monoclonal ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Rabbit Monoclonal
CLONE RBT-ALK1 CLONE N/A CLONE RBT-AMACR
ISOTYPE IgG ISOTYPE N/A ISOTYPE IgG
CONTROL Anaplastic Large Cell Lymphoma CONTROL Fetal Liver CONTROL Prostatic Adenocarcinoma
LOCALIZATION Cytoplasmic, Nuclear LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic

11
Androgen Receptor Bax BCA-225
IHC of Androgen Receptor on an IHC of Bax on an FFPE Hodgkin’s Lymphoma Tissue IHC of BCA-225 on an FFPE Breast Carcinoma Tissue
FFPE Prostate Tissue
The androgen receptor (AR) is a type of nuclear Bax is a protein of the bcl-2 gene family. It This antibody recognizes a human Breast
receptor which is activated by binding of either promotes apoptosis by competing with bcl-2 Carcinoma-associated glycoprotein, BCA-225
of the androgenic hormones testosterone or proper. The Bax gene contains a small promoter (220-225 kDa). This protein differs in size and
dihydrotestosterone. The main function of the element that complements a binding domain on distribution from other Breast Carcinoma
androgen receptor is as a DNA-binding the multi-faceted p53 tumor suppressor. Wild- antigens. Unlike other carcinoma antibodies
transcription factor which regulates gene type p53 has been demonstrated to upregulate against Breast Carcinoma antigens, this
expression. However, the androgen receptor the transcription of a chimeric reporter plasmid, antibody does not react with benign or malignant
has additional functions independent of DNA utilizing the consensus promoter sequence of Bax colonic tissues. Since this antigen is localized
binding. The AR signaling pathway plays a key role approx. 50-fold over mutant p53. Mutations in in malignancies of Breast Carcinomas and
in development and function of male reproductive this consensus sequence eliminate transcription Carcinoma of the Uterine Cervix, it can be
organs, including the prostate and epididymis. of the reporter gene. Thus, it is likely that p53 effectively used to identify metastatic Breast
AR also plays a role in nonreproductive organs, promotes Bax’s apoptotic faculties in vivo as a Carcinoma lesions.
such as muscle, hair follicles, and the brain. primary transcription factor.
Strong intracytoplasmic staining is seen in
This antibody reacts with the androgen receptor Bax exerts a pro-apoptotic rather than an anti- primary and metastatic Breast Carcinoma tissue,
and also with the newly-described A form of apoptotic effect on cells. Bax targets mitochondrial as well as in Cervical Carcinomas. Apical staining
the receptor. This antibody does not cross-react membranes, inducing mitochondrial damage and is seen in normal kidney, lung, Fallopian tube,
with estrogen, progesterone or glucocorticoid cell death in a caspase-independent manner. Bad liver, skin (eccrine sweat glands) and uterus.
receptors. Abnormalities in the AR-signaling plays a critical role in the Bax-mediated apoptosis Similar staining patterns are observed in lung,
pathway have been linked to a number of pathway by dimerizing with BclxL, causing the ovarian, and endometrial cancers. Carcinomas
diseases, including Prostate Cancer, Kennedy’s displacement of Bax. The displacement of Bax of the colon, stomach, prostate, urinary bladder,
Disease and male infertility. allows apoptosis to proceed. liver, pancreas, thyroid, and parotid are negative,
as are Sarcomas and Lymphoid Cancers.
CLONE AR-D12 CLONE SPM336 CLONE Cu-18
ISOTYPE IgG1 ISOTYPE IgG1/K ISOTYPE IgG1/K
CONTROL Prostatic Adenocarcinoma CONTROL Hodgkin’s Lymphoma, CONTROL Breast Carcinoma
LOCALIZATION Nuclear Normal Breast, Tonsil LOCALIZATION Cytoplasmic
LOCALIZATION Cytoplasmic & Cell Membrane

bcl-2 bcl-6 bcl-X
IHC of bcl-2 on an FFPE Tonsil Tissue IHC of bcl-6 on an FFPE Tonsil Tissue IHC of Bcl-X on an FFPE Hodgkin’s Lymphoma Tissue
bcl-2 is an integral outer mitochondrial membrane bcl-6 is a transcriptional regulator gene which bcl-X, or bcl-2-like 1 protein, a member of the
protein that blocks the apoptotic death of some codes for a 706-amino-acid nuclear zinc finger bcl-2 protein family, inhibits cell death, or apop-
cells such as lymphocytes. Constitutive expression protein. Antibodies to this protein stain the tosis and functions as a regulator of apoptosis.
of bcl-2, such as in the case of translocation of germinal center cells in lymphoid follicles, bcl-X has two isoforms: bcl-XL (Long), a 241-amino
bcl-2 to Ig heavy-chain loci, is thought to be the follicular cells and interfollicular cells in Follicular acid protein; and bcl-XS (Short), a 178-amino acid
cause of Follicular Lymphoma. Lymphoma, Diffuse Large B-Cell Lymphomas, protein lacking a 63-amino acid domain that is
Burkitt’s Lymphoma, and the majority of the well conserved among members of the bcl-2
Anti-bcl-2 has shown consistent negative reaction Reed-Sternberg cells in Nodular Lymphocyte- family.
on reactive germinal centers and positive staining Predominant Hodgkin’s Disease.
of neoplastic follicles in Follicular Lymphoma. bcl-X is typically present in the cytosol in
Consequently, this antibody is valuable when bcl-6 is also useful in identifying neoplastic cells association with the mitochondrial membrane.
distinguishing between reactive and neoplastic in cases of nodular Lymphocyte-Predominant bcl-XL forms heterodimers with various proteins,
follicular proliferation in lymph node biopsies. Hodgkin’s Disease. In contrast, anti-bcl-6 rarely including Bax, Bak and bcl-2. It has been found
This antibody may also be used in distinguishing stains Mantle-Cell Lymphoma and MALT that heterodimerization with Bax does not seem
between those Follicular Lymphomas that express Lymphoma. bcl-6 expression is seen in to be required for anti-apoptotic activity.
bcl-2 protein and the small number in which the approximately 45% of CD30+ Anaplastic Large-
neoplastic cells are bcl-2-negative. Anti-bcl-2 Cell Lymphomas but is consistently absent in
has been used as a predictive biomarker for other peripheral T-cell Lymphomas.
recurrence of Cancer of the Breast and Non-Small-
Cell Carcinoma of the Lung.
ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Polyclonal
CLONE BCL2/A4 CLONE BCL6/12 CLONE N/A
ISOTYPE IgG1/K ISOTYPE IgG2b ISOTYPE N/A
CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node CONTROL Hodgkin’s Lymphoma
LOCALIZATION Cytoplasmic LOCALIZATION Nuclear LOCALIZATION Cytoplasmic and Cell/
Nuclear Membrane

13
Beta-Catenin CA-125 CA15-3
IHC of Beta-Catenin on an FFPE Breast Tissue IHC of CA-125 on an IHC of CA15-3 on an FFPE Breast Tissue
FFPE Ovarian Carcinoma Tissue
Beta-Catenin is a subunit of the Cadherin CA-125 reacts with malignant ovarian epithelial This antibody has been used for evaluating the
protein complex. Cadherins are a type of protein cells. CA-125 also reacts with antigens in Seminal primary site of a metastatic carcinoma of unknown
normally expressed on the surface of certain Vesicle Carcinoma and Anaplastic Lymphoma. origin and distinguishing between benign and
cells. Specifically, Beta Cateinin is a 92 kDa protein malignant lesions. It is believed that CA15-3
normally found in the cytoplasm of the cell in In adult tissues, CA-125 is found in epithelial cells reacts primarily with the DF3-antigen, a 300 kDa
the sub-membranous location. This protein is of Fallopian tube, endometrium and endocervix, mucin-like glycoprotein present on the apical
associated with E-Cadherin and may be essential pancreas, colon, gall bladder, stomach, kidney, border of secretory mammary epithelial cells.
for the function of E-Cadherin. apocrine sweat gland, and mammary gland.
It is also found in mesothelial cell lining of pleura, CA15-3 has been detected with immunohisto-
Mutations in the Beta-Catenin gene result in the pericardium and peritoneum. It is found in ovarian chemistry in a wide spectrum of carcinomas,
nuclear accumulation of this protein. Nuclear tumors of serous, endometrioid or clear-cell types including Breast Carcinomas (ductal and lobular),
accumulation of this protein has been demon- and Adenocarcinomas of Mullerian type. Sarcomas (Synovial Sarcoma and Malignant Fibrous
strated in Fibromatosis lesions of the breast and Histiocytomas), and Lung Carcinomas. CA15-3
abdomen, and therefore is useful in differentiating can be used as a supplementary marker for
this lesion from other spindle-cell lesions that may epithelial differentiation. CA15-3 does not stain
occur in these locations. Melanomas or Ewing’s Sarcomas. Approximately
30% of Hepatocellular Carcinomas are positive for
CA15-3.
CLONE 14 CLONE OC125 CLONE DF3
ISOTYPE IgG1 ISOTYPE IgG1/K ISOTYPE IgG1/K
CONTROL Breast, Abdomen CONTROL Ovarian Carcinoma, CONTROL Breast, Pancreas, Salivary Gland
LOCALIZATION Nuclear Epithelioid Mesothelioma LOCALIZATION Cytoplasmic and Membranous
LOCALIZATION Cytoplasmic and Membranous

CA19-9 Calcitonin Caldesmon
IHC of CA19-9 on an FFPE Salivary Gland Tissue IHC of Calcitonin on an FFPE Thyroid Tissue IHC of Caldesmon on an FFPE Appendix Tissue
CA19-9 (carbohydrate antigen 19-9 or sialylated Calcitonin is a 32-amino acid polypeptide Caldesmon 1, also known as CALD1, is a hu-
Lewis (a) antigen) is a blood test from the tumor hormone that is produced in humans primarily by man gene. Caldesmon is a calmodulin-binding
marker category. It was discovered in patients C-cells located in the thyroid, and in many other protein. Like Calponin, Caldesmon tonically
with Colon Cancer and Pancreatic Cancer in animals in the ultimobranchial gland. It acts to inhibits the ATPase activity of myosin in smooth
1981. Increased levels of CA19-9 are also found in reduce blood calcium (Ca2+), opposing the muscle. This gene encodes a Calmodulin and
non-malignant conditions, such as Mirizzi’s effects of parathyroid hormone (PTH). It has actin-binding protein that play an essential role in
Syndrome and diseases of the bile duct and liver. been found in fish, reptiles, birds, and mammals. the regulation of smooth muscle and nonmuscle
The main use of CA19-9 is to determine whether Its importance in humans has not been as well contraction.
a pancreatic tumor is secreting it; if that is the established as in other animals.
case, then the levels should fall when the tumor Two closely-related variants of human Caldesmon
is treated, and they may rise again if the disease Immunohistochemical staining with Calcitonin have been identified. The h-Caldesmon variant
recurs. antibody has proven to be an effective way (120–150 kD) is predominantly expressed in
of demonstrating the existence of Calcitonin- smooth muscle, whereas I-Caldesmon (70–80 kD)
CA19-9 antigen is highly expressed in Gas- producing cells in the thyroid. C-cell Hyperplasia is found in non-muscle tissue and cells. Neither
trointestinal (gastric, pancreatic, and colonic) and Medullary Thyroid Carcinomas stain positive of the two variants has been detected in skel-
Adenocarcinomas and salivary gland Mucoepi- for Calcitonin. Studies of Calcitonin have resulted etal muscle. Anti-Caldesmon recognizes only the
dermoid Carcinomas. CA19-9 is usually not reac- in the identification of a wide spectrum of C-cell h-Caldesmon variant. Anti-Caldesmon antibody
tive with breast, kidney, and prostate Carcinomas, proliferative abnormalities. labels smooth muscle and tumors of smooth
but is reactive with sialylated Lea-active muscle, myofibroblastic, and myoepithelial
pentasaccharide (sialylated lacto-N-fucopentaose differentiation. Anti-Caldesmon has also been
II), which is enzymatically synthesized by used to differentiate Epithelioid Mesothelioma
sialylation of Type 1 carbohydrate chains. from Serous Papillary Carcinoma of the ovary.
ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Mouse Monoclonal
CLONE 121SLE CLONE N/A CLONE CALD-31
ISOTYPE IgM ISOTYPE N/A ISOTYPE IgG1/K
CONTROL Colon, Salivary Gland CONTROL Thyroid, Medullary CONTROL Appendix, Uterus, Leiomyoma
LOCALIZATION Cytoplasmic Carcinoma of Thyroid LOCALIZATION Cytoplasmic
LOCALIZATION Cytoplasmic

15
Calponin Calretinin CD1a
IHC of Calponin on an FFPE Leiomyoma Tissue IHC of Calretinin on an FFPE Mesothelioma Tissue IHC of CD1a on an FFPE Thymus Tissue
Calponin is a 34 kDa polypeptide that interacts with Calretinin is a vitamin D-dependent calcium- CD1 proteins have been demonstrated to restrict
actin, tropomyosin, and calmodulin. It is involved binding protein involved in calcium signaling. It T-cell response to non-peptide lipid and glycolipid
in smooth-muscle contraction mechanisms and is expressed in the central and peripheral nervous antigens. At least five CD1 genes (CD1a, b, c, d,
is restricted exclusively to smooth-muscle tissue. system and in many normal and pathological and e) have been identified. CD1a belongs to a
Calponin is a calcium-binding protein. Calponin tissues. It stains Mesothelioma and can be used to family of glycoproteins expressed on the surface
tonically inhibits the ATPase activity of myosin in help differentiate lung tumors. Calretinin is also of various human antigen-presenting cells. In
smooth muscle. Phosphorylation of calponin by a considered an important diagnostic tool in the particular, CD1a is a protein of 43 to 49 kDa, and
protein kinase (which is dependent upon calcium differential diagnosis of cystic and solid has been shown to be expressed on dendritic cells
binding to calmodulin) releases the calponin’s Ameloblastic Tumors. and cortical thymocytes. Langerhans cells in the
inhibition of the smooth-muscle ATPase. skin and some epithelia also express this protein.
Anti-calretinin has been shown to be useful in This antigen is expressed in cells comprising
Calponin has been found to be useful in differentiating Mesothelioma from Adenocarcino- Langerhans Cell Histiocytosis and Langerhans
differentiating benign sclerosing lesions of the mas of the lung and other sources. It is also useful Cell Sarcoma.
breast from Carcinoma. Calponin positivity has in differentiating adrenal-cortical neoplasms from
also been noted in Malignant Myoepithelioma Pheochromocytomas. Anti-CD1a has been used to differentiate
and Pleomorphic Adenoma of Salivary Gland various cutaneous Lymphomas (T-cell) from B-cell
origin, as well as in Angiomatoid Malignant Lymphomas and Pseudolymphomas. CD1a is also
Fibrous Histiocytoma. expressed by some malignancies of T-cell lineage
and in Histiocytosis X.
ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Monoclonal ANTIBODY TYPE Rabbit Monoclonal
CLONE CALP-A6 CLONE EP1798 CLONE EP80
ISOTYPE IgG1/K ISOTYPE IgG ISOTYPE IgG
CONTROL Appendix, Uterus, Leiomyoma CONTROL Malignant Mesothelioma, CONTROL Skin, Thymus
LOCALIZATION Cytoplasmic Benign Mesothelial Cells LOCALIZATION Cytoplasmic, Membranous
LOCALIZATION Cytoplasmic, Nuclear

CD2 CD3 CD4
IHC of CD2 on an FFPE Tonsil Tissue IHC of CD3 on an FFPE Tonsil Tissue IHC of CD4 on an FFPE Tonsil Tissue
CD2 is a cell-adhesion molecule found on the The CD3 antigen is a protein complex composed CD4 is a glycoprotein expressed on the surface
surface of T-cells and natural killer (NK) cells. It has of three distinct chains (CD3γ, CD3δ and CD3ε) of T-helper cells, regulatory T-cells, monocytes,
also been called T-cell surface antigen T11/Leu-5, that associate with T-cell receptors and the ζ-chain macrophages, and dendritic cells. On T-cells, CD4
LFA-2, LFA-3 receptor, erythrocyte receptor and to generate an activation signal in T-lymphocytes. is the co-receptor for the T-cell receptor (TCR).
rosette receptor. Due to its structural character- The TCR, ζ-chain and CD3 molecules together It amplifies the signal generated by the TCR by
istics, CD2 is a member of the immunoglobulin comprise the TCR complex. The CD3γ, CD3δ, recruiting the tyrosine kinase that is essential
superfamily; it possesses two immunoglobulin- and CD3ε chains are highly-related cell surface for activating many molecules involved in the
like domains in its extracellular portion. It proteins of the immunoglobulin superfam- signaling cascade of an activated T-cell.
interacts with other adhesion molecules, such ily containing a single extracellular immuno-
as lymphocyte function-associated antigen-3 globulin domain. The intracellular tails of the CD3 CD4 antigen is involved in the recognition of Type
(LFA-3/CD58) in humans, or CD48 in rodents, molecules contain a single conserved motif II Major Histocompatability Complex antigens
which are expressed on the surfaces of other cells. known as an immunoreceptor tyrosine-based (MHC-II). CD4 is also the receptor for Human
In addition to its adhesive properties, CD2 also acts activation motif (or ITAM for short), which is Immunodeficiency Virus (HIV). It is present on
as a co-stimulatory molecule on T and NK cells. essential for the signaling capacity of the TCR. most T-helper cells and normal thymocytes.
Phosphorylation of the ITAM on CD3 renders the
CD2 is a surface antigen of the human T-lympho- CD3 chain capable of binding the enzyme ZAP70
cyte lineage that is expressed on all peripheral (zeta-associated protein), a kinase important in
blood T-cells. It is one of the earliest T-cell markers, the signaling cascade of the T-cell.
being present on more than 95% of thymocytes;
it is also found on some natural killer cells but CD3 has been considered the best all-around
not on B-lymphocytes. CD2 is implicated in the T-cell marker. This antibody reacts with an antigen
triggering of T-cells; the cytoplasmic domain is present in early thymocytes. The positive staining
implicated in the signaling function. It is useful for of this marker may represent a sign of early
the identification of Lymphomas and Leukemias commitment to the T-cell lineage.
of T-cell origin. As with other pan-T cell antigens,
CD2 may be aberrantly deleted in some neoplas-
tic T-cell populations, especially Peripheral T-cell
Lymphomas.
CLONE AB75 CLONE RBT-CD3 CLONE RBT-CD4
ISOTYPE IgG1/K ISOTYPE IgG ISOTYPE IgG
CONTROL Tonsil CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node
LOCALIZATION Membranous LOCALIZATION Membranous LOCALIZATION Membranous

17
CD5 CD7 CD8
IHC of CD5 on an IHC of CD7 on an FFPE Tonsil Tissue IHC of CD8 on an FFPE Tonsil Tissue
FFPE Non-Hodgkin’s Lymphoma Tissue
CD5 is a glycoprotein monomer with an MW of CD7 is a 40 kDa transmembrane, single-chain CD8 is a transmembrane glycoprotein that serves
67 kDa belonging to the scavenger receptor glycoprotein, which is a member of the immuno- as a co-receptor for the T-cell receptor (TCR). Like
cysteine-rich (SRCR) family of extracellular globulin gene superfamily. It is expressed in the the TCR, CD8 binds to a major histocompatibility
domain-like structures, and it possesses a large majority of immature and mature T-lymphocytes, complex (MHC) molecule that is specific for the
cytoplasmic domain suitable for signal and T-cell Leukemia. It is also found in natural Class I MHC protein. To function, CD8 forms a
transduction. killer cells, a small subpopulation of normal dimer, consisting of a pair of CD8 chains. The most
B-cells and in malignant B-cells. It plays an common form of CD8 is composed of a CD8-α and
CD5 is a T-cell marker that also reacts with a essential role in T-cell interactions and also in CD8-β chain, both members of the immunoglob-
range of neoplastic B-cells, e.g., B-cell Chronic T-cell/B-cell interaction during early lymphoid ulin superfamily with an immunoglobulin variable
Lymphocytic Leukemia (B-CLL), B-cell Small development. (IgV)-like extracellular domain connected to the
Lymphocytic Lymphoma (B-SLL), and Mantle Cell membrane by a thin stalk, and an intracellular tail.
Lymphoma. CD5 is expressed in T-lymphocyte CD7 is a consistently-expressed T-cell antigen
subsets and is modulated during cellular in Lymphoblastic Lymphomas and Leukemias; CD8 is a T-cell marker for the detection of
activation; however, it does not react with therefore, it is a useful marker in the identification cytotoxic/suppressor cells of blood lymphocytes.
granulocytes or monocytes. of such neoplastic proliferations. CD7 is expressed CD8 is also detected on NK cells, most thymocytes,
in the majority of mature peripheral T-cells, the a subpopulation of null cells and bone marrow
majority of post-thymic T-cells, NK cells, some cells. This antibody is used to distinguish between
myeloid cells, T-cell Acute Lymphoblastic reactive and neoplastic T-cells.
Leukemia/Lymphoma, Acute Myelogenous
Leukemia and Chronic Myelogenous Leukemia.
Interestingly, CD7 is conspicuously absent in adult
T-cell Leukemia/Lymphoma and is not expressed
in Sezary cells.
ANTIBODY TYPE Rabbit Monoclonal ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Mouse Monoclonal
CLONE RBT-CD5 CLONE LP15 CLONE C8/144B
ISOTYPE IgG ISOTYPE IgG2b ISOTYPE IgG/K
CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node

CD10 CD15 CD19
IHC of CD10 on an FFPE Tonsil Tissue IHC of CD15 on an IHC of CD19 on an FFPE Tonsil Tissue
FFPE Hodgkin’s Lymphoma Tissue
CD10, also known as neutral endopeptidase (NEP), CD15 is a phosphatidylinositol-anchored CD19 is a human protein encoded by the CD19
Neprilysin, and common Acute Lymphoblastic transmembrane protein found on neutrophils gene. CD19 is expressed on follicular dendritic
Leukemia antigen (CALLA), is a zinc-dependent and which may be involved in phagocytosis. It is cells and B-cells; it is present on B-cells from
metalloprotease enzyme that degrades a number expressed in patients with Hodgkin’s Disease, earliest recognizable B-lineage cells during
of small secreted peptides, most notably the some B-cell Chronic Lymphocytic Leukemias, development to B-cell blasts, but is lost on
amyloid beta peptide whose abnormal misfolding Acute Lymphoblastic Leukemias, and most Acute maturation to plasma cells. In normal lymphoid
and aggregation in neural tissue has been Non-Lymphocytic Leukemias. It is also called tissue, CD19 is observed in germinal centers
implicated as a cause of Alzheimer’s Disease. Lewis x. (on both B-cells and follicular dendritic cells),
in mantle-zone cells, and in scattered cells in
CD10 is a useful marker for the characterization A positive reaction for CD15 combined with a the interfollicular areas, with an overall
of childhood Leukemia and B-cell Lymphomas. negative reaction for CD45 and other B and immunoreactivity pattern similar to that of
This antibody reacts with the antigens of T-lineage markers provides support for Reed- CD20 and CD22. However, in contrast to CD20,
Lymphoblastic, Burkitt’s, and Follicular Sternberg cells found in Hodgkin’s disease. Also, CD19 is also expressed in pre-B-cells.
Lymphomas, and Chronic Myelocytic Leukemia. this antibody does not detect Mesotheliomas,
Also, CD10 detects the antigen of glomerular making it a more frequently used antibody CD19 positivity is seen in the vast majority of
epithelial cells and the brush border of the to distinguish Epithelial Mesothelioma from B-cell neoplasms (B-Lymphoblastic Lymphoma,
proximal tubules. This characteristic may be Adenocarcinoma. Small Lymphocytic Lymphoma/CLL, Mantle
helpful in interpreting renal ontogenesis, Cell Lymphoma, Follicular Lymphoma, Burkitt’s
in conjunction with other markers. Other Lymphoma, Marginal Zone Lymphoma,
non-lymphoid cells that are reactive with Diffuse Large B-cell Lymphoma, T-cell-rich B-cell
CD10 are breast myoepithelial cells, bile Lymphoma, Lymphoblastic Lymphoma, Hairy Cell
canaliculi, neutrophils, a small population Leukemia), and commonly at a lower
of bone marrow cells, fetal small intestine intensity than normal B-cell elements. Plasma
epithelium, and normal fibroblasts. cell neoplasms are consistently negative, as are
T-cell neoplasms. CD19 expression is not seen in
Reed-Sternberg cells of classic Hodgkin’s Disease.
CLONE 56C6 CLONE SPM119 CLONE MRQ-36
ISOTYPE IgG1 ISOTYPE IgM/K ISOTYPE IgG1/K
CONTROL Kidney, Tonsil, Lymph Node CONTROL Hodgkin’s Lymphoma CONTROL Tonsil, Lymph Node
LOCALIZATION Cytoplasmic, Membranous LOCALIZATION Cytoplasmic, Membranous LOCALIZATION Membranous

19
CD20 CD21 CD23
CD20 is a transmembrane, non-glycosylated CD21, also known as CR2, complement component CD23, also known as Fc epsilon RII, is the “low
protein expressed on B-cell precursors and (3d/Epstein Barr virus) receptor 2, is an integral affinity” receptor for IgE, an antibody isotype
mature B-cells, but lost following differen- membrane glycoprotein of molecular weight involved in allergy and (arguably) resistance to
tiation into plasma cells. This antibody does not 140 kDa, involved in the complement system. parasites, and is important in regulation of IgE
cross-react with non-hematopoietic neoplasms. CD21 binds to C3d. B-cells have CR2 receptors levels. Unlike many of the antibody receptors,
CD20 (B-cell Pan) reacts with a membrane antigen on their surfaces, allowing the complement CD23 is a C-type lectin. It is found on mature
present in B-cells. system to play a role in B-cell activation and B-cells, activated macrophages, eosinophils,
maturation. Complement component receptor-2 follicular dendritic cells and platelets.
This antibody strongly recognizes Reed-Sternberg (CR2) is the membrane protein on B-lymphocytes
cells predominant in Hodgkin’s disease. Since no to which the Epstein-Barr virus (EBV) binds This is a B-cell antibody that is useful for
staining of histiocytes or plasma cells has been during infection of these cells. differentiating between B-CLL and B-SLL’s that
observed and CD20 has not been detected in are CD23-positive from Mantle-cell Lymphomas
T-cell malignancies, it is a very strong marker of Anti-CD21 is useful in the identification of and Small-Cleaved Lymphomas that are CD23-
B-cell Lymphomas. B-cell Panmarker recognizes a follicular dendritic cell matrixes found in normal negative. This antibody reacts with the
formalin-resistant intracytoplasmic antigen. lymph nodes and tonsillar tissue. This antibody antigen that is found on a subpopulation of
also labels Follicular Dendritic Cell Tumor/ peripheral blood cells, B-lymphocytes and on
Sarcomas. The antigen is absent on T-lymphocytes, EBV-transformed B-lymphoblastoid cell lines.
monocytes, and granulocytes.
ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Monoclonal ANTIBODY TYPE Mouse Monoclonal
CLONE L26 CLONE EP64 CLONE 1B12
ISOTYPE IgG2a/K ISOTYPE IgG ISOTYPE IgG

BSB 5192 prediluted 15 ml BSB 5199 prediluted 15.0 ml BSB 5206 prediluted 15.0 ml
CD25 CD30 CD31
IHC of CD25 on an FFPE Tonsil Tissue IHC of CD30 on an IHC of CD31 on an FFPE Tonsil Tissue
CD25 is the alpha chain of the IL-2 receptor. It CD30 is a transmembrane cytokine receptor CD31 is also called PECAM-1 for platelet
is a Type I transmembrane protein present on belonging to the tumor necrosis factor (TNF) endothelial cell-adhesion molecule. It plays a
activated T-cells, activated B-cells, some receptor superfamily. Mature CD30 has a key role in removing aged neutrophils from the
thymocytes, myeloid precursors, and oligoden- molecular mass of 120 kDa and is derived from a body. CD-31 is normally found on stem cells,
drocytes that associates with CD122 to form 90 kDa precursor protein. endothelial cells, platelets, macrophages and
a heterodimer that can act as a high-affinity Kupffer cells, granulocytes, T/NK cells, lympho-
receptor for IL-2. It is expressed in most B-cell CD30 antibody detects an epitope which is cytes, megakaryocytes, fibroblasts, osteoclasts
neoplasms, some Acute Non-lymphocytic expressed by Reed-Sternberg cells in Hodgkin’s and neutrophils. CD-31 is also expressed in
Leukemias, and Neuroblastomas. Disease, the majority of Anaplastic Large-cell certain tumors, including Epithelioid Heman-
Lymphomas, and in Embryonal Carcinomas and gioendothelioma, Epithelioid Sarcoma-like
Expression of CD25 is a reliable diagnostic tool for Seminomas. This antibody also stains plasma cells Hemangioendothelioma, other vascular tumors,
distinguishing neoplastic mast-cell aggregates intensely in paraffin-embedded tissue. Histiocytic malignancies, and Plasmacytomas.
from reactive proliferations, and has, therefore, It is rarely found in some sarcomas and carcino-
recently become a minor criterion for the diag- mas. CD-31 and macrophages play a key role in
nosis of Systemic Mastocytosis (SM). Anti-CD25 tissue regeneration.
antibodies have also been useful in identify-
ing mast cells in skin biopsies in the setting of CD31 is widely used to identify the vascular origin
Urticaria Pigmentosa, which is predictive of of neoplasms, as it is a highly specific and sensitive
Systemic Mastocytosis. Quantitation of regula- marker for vascular endothelial cells.
tory T-cells (Treg) in the setting of hepatocellular
carcinoma has been used as an independent
predictive factor for tumor recurrence after
hepatic resection for HCC. Also, the percentage
of tumor-infiltrating CD25+FOXP3+ regulatory
T-cells among tumor cells, inside tumor
parenchyma and at its periphery are significantly
higher in recurrent Cutaneous Melanoma than in
Non-recurrent Melanoma.
CLONE 4C9 CLONE Ber-H2 CLONE 1A10
ISOTYPE IgG2b ISOTYPE IgG1/K ISOTYPE IgG1/K
CONTROL Mastocytosis, Tonsil, Small Bowel CONTROL Hodgkin’s Lymphoma CONTROL Tonsil, Placenta, Appendix
LOCALIZATION Cytoplasmic, Membranous LOCALIZATION Membranous LOCALIZATION Membranous

21
CD34 CD35 CD38
CD34 functions as a cell-cell adhesion factor and CD35 (erythrocyte complement receptor 1 or CR1, CD38 is a glycoprotein found on the surface
cell-surface glycoprotein. It may also mediate the also known as C3b/C4b receptor and immune of many immune cells (white blood cells),
attachment of stem cells to bone marrow extra- adherence receptor) serves as the main system including CD4+, CD8+, B and natural killer cells.
cellular matrixes or directly to stromal cells. Cells for processing and clearance of complement- It is a marker of cell activation. The CD38 protein
expressing CD34 are normally found in the um- opsonized immune complexes. The number has been connected to HIV infection, Leukemias,
bilical cord and bone marrow as hematopoletic of CR1 molecules decreases with aging of Myelomas, solid tumors, Type II Diabetes Mellitus
cells, and in vascular endothelium. In addition erythrocytes in normal individuals and is also and bone metabolism, as well as some genetical-
to stem cell recognition, CD34 is expressed by decreased in pathological conditions such as ly-determined conditions. It has also been used as
vascular endothelium; it appears that Systemic Lupus Erythematosus (SLE), HIV infection, a prognostic marker in Leukemia. CD38 is highly
proliferating endothelial cells express this some Hemolytic Anemias and other conditions expressed on thymocytes. It is also expressed by
molecule in greater amounts than resting cells. featuring immune complexes. early cells of B and T lineages, NK cells, plasma
In comparison to factor VIII R Antigen, CD34 stains cells, monocytes and macrophages, and may be
are stronger and appear to be more sensitive Anti-CD35 is considered a mature B-cell marker, detected on cells from Multiple Myeloma, ALL
in nature. which labels follicular dendritic reticulum cells (B and T) and some AML.
and tumors derived from such cells such as
In tumors, CD34 is found in Alveolar Soft Part Follicular Dendritic Cell Tumor/Sarcoma. CD35 Monoclonal antibodies to CD38 have been
Sarcoma, pre B-ALL (positive in 75%), AML antigen is found in erythrocytes, B-cells, and shown to be useful in subtyping of Lymphomas
(40%), AMLM7 (most), Dermatofibrosarcoma a subset of T-cells, monocytes, as well as in and Leukemias, inhibition of B-lymphopoiesis,
Protuberans, Gastrointestinal Stromal Tumors, eosinophils and neutrophils. detection of plasma cells, protection of B-cells
Giant Cell Fibroblastoma, Granulocytic Sarcoma, from apoptosis, and as a marker for activated
Kaposi’s Sarcoma, Liposarcoma, Malignant Fibrous B and T-cell proliferation.
Histiocytoma, Malignant Peripheral Nerve Sheath
tumors, Mengingeal Hemangiopericytomas,
Meningiomas, Neurofibromas, Schwannomas,
and Papillary Thyroid Carcinoma. A negative
CD34 may exclude Ewing’s Sarcoma/PNET,
Myofibrosarcoma of the breast, and Inflammatory
Myofibroblastic tumors of the stomach.
CLONE QBEnd/10 CLONE RLB25 CLONE SPC32
ISOTYPE IgG1 ISOTYPE IgG2b ISOTYPE IgG1
CONTROL Tonsil, Placenta, Appendix CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node

CD43 CD44 CD45
IHC of CD43 on an FFPE Tonsil Tissue IHC of CD44 on an FFPE Kidney Tissue IHC of CD45 on an FFPE Tonsil Tissue
CD43 (leukosialin, sialophorin, or leukocyte The CD44 protein is a cell-surface glycoprotein The CD45 antigen is a protein which was originally
sialoglycoprotein) is one of the major glycoproteins involved in cell-cell interactions, cell adhesion called Leukocyte Common Antigen. It is a Type I
expressed in all thymocytes and T-cells. It plays and migration. CD44 is also known as Homing-cell transmembrane protein which is in various forms
a role in the physiochemical properties of the adhesion molecule (H-CAM) and Phago- present on all differentiated hematopoietic cells
T-cell surface and in lectin binding. During cytic glycoprotein-1 (PgP-1). A specialized except erythrocytes and assists in the activation
T-cell activation, CD43 is actively removed from sialofucosylated glycoform of CD44 called HCELL of those cells (a form of co-stimulation). It is
the T-cell antigen-presenting cell contact site, is found natively on human hematopoietic stem expressed in Lymphomas, B-cell Chronic Lympho-
suggesting a negative regulatory role in adaptive cells and functions as a “bone-homing receptor”, cytic Leukemia, Hairy Cell Leukemia, and Acute
immune response. directing migration of human hematopoietic stem Non-lymphocytic Leukemia.
cells and mesenchymal stem cells to bone marrow.
This antibody has been found useful in CD45 is a monoclonal antibody that is
identification and classification of T-cell This protein participates in a wide variety of routinely used to aid in the differential diagnosis
malignancies and low grade B-cell Lymphomas. cellular functions including lymphocyte of undifferentiated neoplasms, whenever
CD43 expression is seen in some cases of activation, recirculation and homing, hemato- malignant Lymphoma is suspected by
B-cell Lymphocytic Lymphoma and Centrocytic poiesis, and tumor metastasis. Transcripts for this the morphological or clinical data. It is a
Lymphoma. When used in combination with gene undergo complex alternative splicing that highly specific antibody; thus, a positive result is
CD45 and CD20, effective immunophenotyping results in many functionally distinct isoforms; highly indicative of lymphoid or myeloid
of the majority of Lymphomas can be obtained. however, the full-length nature of some of these origin. Certain types of lymphoid neoplasms
Co-staining of a lymphoid infiltrate with CD20 variants has not been determined. Splice variants may lack CD45 (Hodgkin’s Disease, some
and CD3 argues against a reactive process and of CD44 on Colon Cancer cells display the HCELL T-cell Lymphomas and some Leukemias) so its
favors Lymphoma. glycoform, which mediates binding to vascular absence does not rule out a hematolymphoid
E-selectin under hemodynamic flow conditions, tumor. This antibody is exclusively expressed
a critical step in Colon Cancer metastasis. by cells of hematopoietic lineage and is present
In addition, variations in CD44 are reported as in most benign and malignant lymphocytes,
cell surface markers for some breast and prostate erythrocytes and plasma cell precursors.
cancer stem cells and have been seen as an
indicator of increased survival time in Epithelial
Ovarian Cancer patients.
CLONE MT1 CLONE MRQ-13 CLONE 2B11 & PD7/26
ISOTYPE IgG1 ISOTYPE IgG2a ISOTYPE IgG1/K
CONTROL Tonsil, Lymph Node CONTROL Tonsil, Kidney, Esophageal CA CONTROL Tonsil, Lymph Node

23
CD45R CD45RA CD45RO
IHC of CD45R on an FFPE Tonsil Tissue IHC of CD45RA on an FFPE Tonsil Tissue IHC of CD45 RO on an FFPE Tonsil Tissue
CD45R contains an extracellular domain, a CD45 is a complex molecule and is comprised of The CD45 family consists of multiple members
single transmembrane segment and two tandem different glycoproteins ranging from 180-240 kDa. that are all products of a single complex gene.
intracytoplasmic catalytic domains. It is specifically Expression of CD45 is found on all hemopoietic Three isoforms of CD45 exist: on B-lymphocytes,
expressed in hematopoietic cells and has been cells. Detection of the different isoforms can where the protein is called B220 (its molecular
shown to be an essential regulator of T and B-cell distinguish between different cell forms (e.g., mass is 220 kDA); on naive T-lymphocytes, where
antigen-receptor signaling. It functions through naive T-cells and memory T-cells). CD45RA it is called CD45 RA, and on activated and
either direct interaction with components of the is an isoform of the CD45 complex and has memory T-lymphocytes, where it is called CD45
antigen receptor complexes, or by activating restricted expression between different subtypes RO. CD45RO is a single-chain, transmembraneous
various Src family kinases required for the of lymphoid cells. glycoprotein which represents the low molecular
antigen-receptor signaling. CD45R also suppresses weight isoform of the Leukocyte Common
JAK kinases, and thus functions as a regulator of CD45RA antibody reacts with mature, non- Antigen (LCA). It is expressed on most thymocytes,
cytokine-receptor signaling. activated T and B-cells. CD45RA is also reactive about 45% of peripheral blood T-cells, virtually all
with medullary thymocytes, mantle-zone T-cells in skin reactive infiltrates, and the majority
CD45R represents a restricted form of the CD45 lymphocytes in follicles of lymph nodes, spleen of T-cell malignancies. It is also found on a subset
family, which primarily recognizes only cells and lymphocytes of the paracortex. CD45RA of B-cells and on exceptional B-cell Lymphomas.
of B lineage from proB-cell through mature shows no reactivity with cortical thymocytes,
B lymphocytes and, prior to the availability of immature T-cells or activated B-cells in germinal CD45RO (T-Cell, Pan) antibody reacts with
anti-CD19 MAbs, was commonly used as a pan centers. thymocytes and activated T-cells, but only on a
B-cell marker. It also reacts with certain activated subpopulation of resting T-cells. This antibody
T-cells, as well as non-MHC restricted lytically shows no reactivity with B-cells, making it a good
active lymphokine-activated killer (LAK) cells. MB1 marker for T-cell tumors to be phenotyped. In
antibody stains preferentially B-cells and their addition, granulocytes and monocytes are also
neoplasms but is less specific, as it will also react labeled with this antibody. T-Cell, Pan has been
with some T-cell Lymphomas and Non-lymphoid designated as CD45RO at The International
Tumors. The antigen for this antibody is in the Leukocyte Typing Workshop.
membrane of all B-cells with the exception of
plasma cells and some mature T-cells.
CLONE MB1 CLONE 111-1C5 CLONE UCHL-1
ISOTYPE IgG1 ISOTYPE IgG1/K ISOTYPE IgG2a/K

BSB 6260 control slides BSB 5259 control slides 5 BSB 5266 control slides 5
CD56 CD57 CD61
IHC of CD56 on an FFPE Neuroblastoma Tissue IHC of CD57 on an FFPE Tonsil Tissue IHC of CD61 on an FFPE Bone Marrow Tissue
CD56 or Neural-Cell Adhesion Molecule (NCAM) is CD57 (NK-1) recognizes an oligosaccharide CD61 is a glycoprotein found on megakaryocytes
a homophilic binding glycoprotein expressed on (MW 100-110 kDa) antigenic determinant on (bone marrow cells), platelets and their precursors.
the surface of neurons, glia and skeletal muscle. myeloid cells and on a variety of polypeptides, CD61 antigen plays a role in platelet aggregation
CD56 has been implicated in cell-cell adhesion, lipids and chondroitan sulfate proteoglycans. and also as a receptor for fibrinogen, fibronectin,
neurite outgrowth, synaptic plasticity, and learn- This surface antigen is associated with myelin- von Willebrand factor and vitronectrin.
ing and memory. associated glycoprotein (MAG). The CD57 antigen
is present on 15-20% of normal peripheral blood CD61 labels the IIIa subunit of the noncovalently-
Normal cells that stain positively for CD56 include mononuclear cells. It is expressed on a subset linked glycoprotein heterodimer IIb/IIIa complex
NK cells, activated T-cells, brain and cerebellum, of natural killer cells (60%) and on a subset of present on human platelets and their precursors.
and neuroendocrine tissues. Tumors that are T-lymphocytes. This carbohydrate is also present This antibody is useful in identifying megakaryo-
CD56-positive are Myeloma, Myeloid Leukemia, on N-CAM in the nervous system. blastic differentiation as seen in Megakaryoblastic
Neuroendocrine tumors, Wilm’s Tumor, Adult Leukemia.
Neuroblastoma, NK/T cell Lymphomas, Pancreatic Follicular Center-cell Lymphomas often contain
Acinar-cell Carcinoma, Pheochromocytoma, many NK cells within the neoplastic follicles.
and Small-cell Lung Carcinoma. It is also NK-1 reportedly also reacts with a variety of cell
expressed on some mesodermally-derived types in non-lymphoid tissues. NK-1 stains neu-
tumors (Rhabdomyosarcoma). Ewing’s Sarcoma/ roendocrine cells and their tumors, including
PNET is CD56-negative. Carcinoid Tumor and Medulloblastomas. NK-1 also
reacts with a variety of cell types in non-lymphoid
tissues, including Neurofibroma, Ganglioneuroma,
and Prostate Carcinoma.
CLONE 123C3.D5 CLONE CD57/B8 CLONE 2f2
ISOTYPE IgG1/K ISOTYPE IgM/K ISOTYPE IgG1/K
CONTROL Neuroblastoma CONTROL Tonsil, Lymph Node CONTROL Bone Marrow
LOCALIZATION Membranous LOCALIZATION Membranous LOCALIZATION Cytoplasmic

25
CD63 CD68 CD74
IHC of CD63 on an FFPE Melanoma Tissue IHC of CD68 on an FFPE Tonsil Tissue IHC of CD74 on an FFPE Tonsil Tissue
The protein encoded by CD63 gene is a member The CD68 antigen is a heavily glycosylated CD74, also known as the MHC Class II-associated
of the transmembrane-4 superfamily, also transmembrane protein of 87-115 kDa which is invariant chain (II), is a Type II transmembrane
known as the tetraspanin family, and mediates specifically expressed by tissue macrophages, protein which binds to the peptide-binding
signal-transduction events that play a role in Langerhans cells and, at low levels, by dendritic groove of newly-synthesized MHC class II alpha/
the regulation of cell development, activation, cells. CD68 could play a role in phagocytic beta heterodimers and prevents their premature
growth and motility. This encoded protein is activities of tissue macrophages, both in intracel- association with endogenous polypeptides.
a cell-surface glycoprotein that is known to lular lysosomal metabolism and extracellular CD74 is expressed primarily by antigen-present-
complex with integrins. It may function as a cell-cell and cell-pathogen interactions. ing cells such as B-lymphocytes (from before the
blood-platelet activation marker. Deficiency of pre-B-cell stage to before the plasma-cell stage),
this protein is associated with Hermansky-Pudlak CD68 marks cells of monocyte/macrophage macrophages and monocytes, together with
Syndrome. This gene has been associated with lineage. This antibody is capable of staining mono- many epithelial cells.
tumor progression. CD63 is a good marker for cytes, Kupffer cells, osteoclasts, granulocytes and
flow-cytometric quantification of in vitro-activated their precursors; Lymphomas are negative or show CD74 stains predominantly germinal-center
basophils for diagnosis of IgE-mediated allergy. a few granules. This antibody may be useful for the lymphocytes and B-cell lymphomas but rarely
The test is commonly designated as a basophil identification of Myelomonocytic and Histiocytic T-cell lymphomas. It stains the cell membrane
activation test. Tumors. CD68 may help to distinguish Malignant but a paranuclear globular labeling is also
Fibrous Histiocytoma from other Pleomorphic noted. CD74 is useful in differentiating Atypical
Anti-CD63 reacts with a 53 kDa protein. The Sarcomas. However, since CD68 detects a forma- Fibroxanthoma from Malignant Fibrous
antigen was originally designated as a lysosomal lin-resistant epitope that may be associated with Histiocytoma, as well as Small-cell Lung
membrane protein characterized as an activation- lysosomal granules, other lysosome-rich cells may Carcinoma from Non-small cell Lung Carcinomas.
dependent platelet surface antigen. In fact, the also produce positive results.
CD63 antigen has a diverse distribution on the
surface and in the cytoplasm of many cell types
including lymphoid, myeloid and endothe-
lial cells and Melanoma. It is weakly expressed in
granulocytes, B and T-cells. It has been quite use-
ful in identifying Malignant Melanoma. CD63 is
thought to be associated with the early stages of
Melanoma tumor progression (in regulation of
motility and adhesion of Melanoma cells).
CLONE NKl/C3 CLONE CD68/G2 CLONE LN2
ISOTYPE IgG1/K ISOTYPE IgG1 ISOTYPE IgG1
CONTROL Malignant Melanoma CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node
LOCALIZATION Cytoplasmic, Membranous LOCALIZATION Cytoplasmic, Membranous LOCALIZATION Cytoplasmic, Membranous

CD79a CD99 CD105/Endoglin
IHC of CD79a on an FFPE Tonsil Tissue IHC of CD99 on an FFPE Ewing’s Sarcoma Tissue IHC of CD105 on an FFPE Tonsil Tissue
CD79a is non-covalently associated with CD99, also known as MIC-2 or single-chain Type-1 CD105/Endoglin is a Type I membrane glyco-
membrane-bound immunoglobulins on B-cells glycoprotein, is a human protein encoded by protein located on cell surfaces and is part of
to constitute the B-cell Ag receptor. CD79a first the CD99 gene. The protein has a MW of 32 kD. the TGF beta receptor complex. This protein
appears at pre B-cell stage and persists until the It is expressed on all leukocytes but highest on has been found on endothelial cells, activated
plasma-cell stage, where it is found as an intracel- thymocytes, and is believed to augment T-cell macrophages, fibroblasts, and smooth-muscle
lular component. CD79a is found in the majority of adhesion and apoptosis of double-positive T-cells. cells. Endoglin has a role in the development
Acute Leukemias of precursor B-cell type, in B-cell It also participates in migration and activation. of the cardiovascular system and in vascular
lines, B-cell Lymphomas, and in some Myelomas. remodeling. Its expression is regulated during
The CD99 antigen is found on the cell membrane heart development. In humans, Endoglin may
CD79a is a B-cell marker that is generally used to of Ewing’s Sarcoma and Primitive Peripheral be involved in the autosomal dominant disorder
complement CD20. This antibody will stain many Neuroectodermal Tumors (PNET). It is also present known as Hereditary Hemorrhagic Telangiectasia
of the same Lymphomas as CD20, but also stains on a variety of other cell types including bone Type 1.
more B-precursor Lymphoid Leukemias than marrow, lymph nodes, spleen, cortical thymo-
CD20. CD79a also stains more cases of Plasma-cell cytes, granulosa cells of the ovary, beta cells, CD105 is highly expressed in endothelial cells
Myeloma and occasionally some types of CNS ependymal cells, Sertoli’s cells of the testis during tumor angiogenesis and inflammation,
endothelial cells as well. CD79a will stain many and a few endothelial cells. Mature granulocytes, with weak or negative expression in vascular
cases of Acute Promyelocytic Leukemia (FAB-M3), however, tend to express very little or no CD99. endothelium of normal tissues. Angiogenesis
but only rarely stains other types of Myeloid MIC-2 has also been identified in Lymphoblastic is controlled by angiogenic factors, mostly
Leukemia. Lymphoma, Rhabdomyosarcoma, Mesenchymal secreted by tumor cells. Vascular Endothelial
Chondrosarcoma, and Thymoma. Growth Factor (VEGF) is a potent angiogenic
growth factor that stimulates endothelial cell
proliferation and induces microvessel
permeability. Studies have demonstrated
a correlation between VEGF expression
and vascular density. Angiogenesis has
been proposed as a promising prognostic
marker in a variety of tumors. Most studies
of angiogenesis have been done with pan-
endothelial markers such as CD31 or CD34.
Endoglin is a more specific and sensitive
marker for tumor angiogenesis than CD31, as
it labels only newly-formed blood vessels and
may serve as a prognostic marker for Prostate
Adenocarcinoma, and cancers of the lung,
stomach, breast, and brain. CD105 may serve as a
target for anti-angiogenesis therapy.
CLONE JCB117 CLONE CD99/B5 CLONE MRQ-14
ISOTYPE IgG1/K ISOTYPE IgG1/K ISOTYPE IgG1/K
CONTROL Tonsil, Lymph Node CONTROL Ependyma, Pancreas, CONTROL Tonsil, Renal Cell Carcinoma
LOCALIZATION Membranous LOCALIZATION Ewing’s Sarcoma, Thymus LOCALIZATION Cytoplasmic
LOCALIZATION Cytoplasmic, Membranous

27
CD117 CD123 CD138
IHC of CD117 on an FFPE GIST Tissue IHC of CD123 on an IHC of CD138 on an FFPE Tonsil Tissue
FFPE Kikuchi-Fujimoto Disease Tissue
CD117 is a tyrosine-kinase receptor for stem cell CD123 is α chain of the IL-3 receptor. This 60-70 CD138/Syndecan-1 is a transmembrane heparin-
factor (SCF), also known as “steel factor” or “c-kit kDa transmembrane protein, by itself, binds to IL-3 sulphate proteoglycan which is made up of one
ligand”. C-kit is a polypeptide that activates bone with rather low affinity. However, when associated core protein and five glycosaminoglycans. CD138
marrow precursors of a number of blood cells, with CD131 (common β chain), the protein binds is expected to play a role in cell adhesion. It is
but its receptor is also present in other cells. C-kit to IL-3 with high affinity. The gene coding for the expressed on the surface of pre B-cells and plasma
mutations in the interstitial cells of Cajal in the receptor is located in the pseudoautosomal region cells but is absent from mature B-cells.
digestive tract are probably the key to Gastroin- of the X and Y chromosomes. The receptor belongs
testinal Stromal Tumors (GISTs), and explain the to the Type I cytokine-receptor family and is a Anti-CD138/syndecan-1 is a useful marker for
efficacy of imatinib in the management of these heterodimer with a unique alpha chain paired with labeling normal and neoplastic plasma cells
rare malignancies. the common beta (beta c or CDw131) subunit. and Plasmacytoid Lymphomas. It is a selective
marker for B-cell Lymphoblastic Leukemia and
CD117 is found on interstitial cells of Cajal, germ The CD123 receptor, found on pluripotent Lymphoplasmocytoid Leukemia. It is lost from the
cells, bone marrow stem cells, melanocytes, breast progenitor cells, induces tyrosine phosphorylation apoptotic myeloma cells, and thus, is a useful
epithelium and mast cells. This receptor is found within the cell and promotes proliferation and marker for viable Myeloma cells. Various forms of
on a wide variety of tumor cells (Follicular and differentiation within the hematopoietic cell Hodgkin’s Disease have also shown positive
Papillary Carcinoma of the Thyroid, Adenocarci- lines. CD123 is expressed by myeloid precursors, staining with this antibody.
nomas from endometrium, lung, ovary, pancreas, macrophages, dendritic cells, mast cells, basophils,
breast; Malignant Melanoma, Endodermal Sinus and megakaryocytes.
Tumor, Small-cell Carcinoma) but has been par-
ticularly useful in differentiating Gastrointestinal
Stromal Tumors (GIST) from Kaposi’s Sarcoma and
tumors of smooth-muscle origin.
CLONE YR145 CLONE CD123-D3 CLONE B-A38
ISOTYPE IgG ISOTYPE IgG1/K ISOTYPE IgG1
CONTROL GIST, Skin, Testes, Breast CONTROL Tonsil, Lymph Node, CONTROL Tonsil, Plasmacytoma
LOCALIZATION Cytoplasmic, Membranous LOCALIZATION Kikuchi-Fujimoto Disease LOCALIZATION Membranous
LOCALIZATION Membranous

CD163 CDX2 CEA
IHC of CD163 on an FFPE Tonsil Tissue IHC of CDX2 on an IHC of CEA on an

FFPE Colon Adenocarcinoma Tissue FFPE Colon Adenocarcinoma Tissue
CD163 is a 130 kDa membrane glycoprotein. CDX2 is a caudal-type homeobox gene that Carcinoembryonic antigen (CEA) is a glycoprotein
CD163 was recently identified as an acute encodes an intestine-specific transcription factor involved in cell adhesion. It is normally produced
phase-regulated transmembrane protein whose expressed early in intestinal development and that during fetal development, but the production
function is to mediate the endocytosis of may be involved in the regulation of proliferation of CEA stops before birth. Therefore, it is not
haptoglobin-hemoglobin complexes. Solubilized and differentiation of intestinal epithelial cells. usually present in the blood of healthy adults,
in plasma, CD163 functions as an anti-inflammatory It is expressed in the nuclei of epithelial cells although levels are raised in heavy smokers. CEA is
signal and has many roles in disease processes throughout the intestine, from duodenum to synthesized during development in the fetal
that range from autoimmune conditions such as rectum. gut, and is re-expressed in increased amounts in
Rheumatoid Arthritis to Atherosclerosis. CD163 Intestinal Carcinomas and several other tumors.
is expressed exclusively on the cell surface of The CDX2 protein is expressed in Primary and
human monocytes and macrophages that evolve Metastatic Colorectal Carcinomas and has also CEA is employed essentially as a tool to assist in
predominantly in the late phase of inflammation, been demonstrated in the intestinal metaplasia of the distinction between Adenocarcinoma and
and is, therefore, very useful for macrophage- the stomach and intestinal-type gastric cancer. It is Malignant Mesotheliomas of the epithelial type,
phenotyping. This receptor is expressed on not expressed in the normal gastric mucosa. Loss along with other markers for mucosubstances
the surface of monocytes (low expression) and of CDX2 protein expression has been correlated such as Leu M1 and Ber-EP4. Another suggested
histiocytes (high expression). with loss of differentiation in colorectal cancers. use of CEA is the immunophenotyping of
Anti-CDX2 antibody has been useful in distin- various Metastatic Adenocarcinomas as a means
Staining for CD163 has been helpful in guishing the gastrointestinal origin of Metastatic of identifying their origin.
distinguishing synovial macrophages from Adenocarcinomas and carcinoids. Studies have
synovial intimal fibroblasts in the setting of shown that CDX2 is a superior marker compared
Rheumatoid Arthritis, where its specificity for to CK20. A high percentage of Mucinous
macrophages was found to be superior to that Carcinomas of the Ovary also stain positively with
of CD68, which does not discriminate between this antibody, as well as Carcinomas from the
these cell types. Flow-cytometry studies upper gastrointestinal tract.
have confirmed that CD163 expression
is limited to Leukemias with monocytic
differentiation. Positive staining can be seen in
the skin (histiocytes), gut, Kupffer cells, a few
aveolar macrophages, the main population of
macrophages in the placenta, and in varying
degrees in macrophages in inflammed tissue
including tumor tissue, depending on the
inflammatory stage. Red-pulp, not white-
pulp, macrophages in the spleen and cortical
macrophages of the thymus are stained by
CD163.
CLONE MRQ-26 CLONE EP25 CLONE CEA31
ISOTYPE IgG1 ISOTYPE IgG ISOTYPE IgG1/K
CONTROL Placenta, Tonsil, Lymph Node CONTROL Adenocarcinoma of Colon, CONTROL Colon
LOCALIZATION Cytoplasmic, Membranous Normal Colon LOCALIZATION Cytoplasmic
LOCALIZATION Nuclear

BSB 6307 concentrated 0.5 ml BSB 6061 concentrated 0.5 ml BSB 5341 concentrated 3 ml
BSB 6309 control slides 5 BSB 6063* control slides 5 BSB 5343 control slides 5
29
Chromogranin A Collagen Type IV COX-2
IHC of Chromogranin A on an FFPE Pancreas Tissue IHC of Collagen IV on an FFPE Skin Tissue IHC of COX-2 on an
FFPE Colon Adenocarcinoma Tissue
Chromogranin A is a member of the chromo- Collagen is the main protein of connective Cyclooxygenase (COX) is an enzyme that
granin/secretogranin family of neuroendocrine tissue in animals and the most abundant is responsible for formation of important
secretory proteins. Examples of cells producing protein in mammals, making up about 25% of biological mediators called prostanoids (including
chromogranin A are the adrenal medulla, entero- the total protein content. Collagen IV is a major prostaglandins, prostacyclin and thromboxane).
chromaffin-like cells and beta cells of the pancreas. constituent of the basement membranes, along Pharmacological inhibition of COX can provide
The function of chromogranin A is unknown but it with laminins and enactins. It is composed of relief from the symptoms of inflammation and
is a precursor to 3 functional peptides: vasostatin, the alpha 1 IV chain and alpha 2 IV chain in a pain; this is the method of action of well-known
pancreastatin and parastatin. These peptides 2:1 ratio. It can form insoluble fibers with high drugs such as aspirin and ibuprofen. COX-2
negatively modulate the neuroendocrine function tensile strength. inhibition by nonsteroidal anti-inflammatory
of the releasing cell (autocrine) or nearby cells agents has been shown to decrease angiogenesis
(paracrine). Normal tissue stains with this antibody in a and tumor growth, and promote apoptosis.
manner consistent with the sites of mesenchymal
Chromogranin A is an excellent marker for Carcinoid elements and epithelial basal laminae. Antibody to COX-2 overexpression has been associated with
Tumors, Pheochromocytomas, Paragangliomas, collagen IV is useful in detecting the loss of parts increased microvascular density, and VEGF protein
and other Neuroendocrine Tumors. Coexpression of basement membrane in carcinomas. Collagen expression in head and neck Squamous-cell
of chromogranin A and neuron-specific enolase IV can also be useful in the classification of soft Carcinomas and is a poor prognostic indicator in
(NSE) is common in neuroendocrine neoplasms. tissue tumors; Schwanomas, Leiomyomas, and their this entity as well. COX-2 overexpression has also
It has been identified in a wide variety of endocrine well-differentiated malignant counterparts usually been suggested as a poor prognostic indicator
tissues including the pituitary, pancreas, immunoreact to this antibody. The vascular in Carcinomas of the colon, breast, pancreas, and
hypothalamus, thymus, thyroid, intestine and nature of neoplasms, Hemangiopericytoma, Adenocarcinomas of the lung.
parathyroid. It is generally accepted that the Angiosarcoma and Epithelioid Hemangioendo-
coexpression of certain keratins and chromogranin thelioma can be observed with this antibody.
means neuroendocrine lineage. The presence
of strong chromogranin staining and absence
of keratin staining should raise the possibility of
paraganglioma. Most pituitary adenomas and
prolactinomas readily express chromogranin.
ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Monoclonal
CLONE LK2H10 CLONE CIV22 CLONE RBT-COX2
ISOTYPE IgG1/K ISOTYPE IgG1/K ISOTYPE IgG
CONTROL Pancreas CONTROL Muscle, Lung CONTROL Adenocarcinoma of Colon

Cyclin D1 Cyclin D3 Cytokeratin 5 & 6
IHC of Cyclin D1 on an IHC of Cyclin D3 on an IHC of CK 5 and 6 on an FFPE Prostate Tissue

FFPE Mantle Cell Lymphoma Tissue FFPE Breast Carcinoma Tissue
Cyclins are a family of proteins involved in the Cyclin D3, also known as CCND3, is a human Cytokeratin 5 (58 kDa) is a high-molecular weight,
progression of cells through the cell cycle. gene. The protein encoded by this gene belongs basic type of cytokeratin expressed in basal,
Cyclins form a complex with their partner, cyclin- to the highly-conserved cyclin family, whose intermediate and superficial-cell layers of stratified
dependent kinase (Cdk), which activates the members are characterized by a dramatic epithelia as well as transitional epithelia, complex
latter’s protein kinase function. Cyclins are periodicity in protein abundance through the epithelia, mesothelial cells and Mesothelioma.
so named because they are produced or cell cycle. Cyclins function as regulators of Cdk Cytokeratin 6 (56 kD) is also a high-molecular
degraded as needed in order to drive the kinases. This cyclin forms a complex with and weight, basic type cytokeratin expressed by pro-
cell through the different stages of the cell functions as a regulatory subunit of Cdk4 or liferating squamous epithelium often paired with
cycle. When its concentrations in the cell are low, Cdk6, whose activity is required for cell-cycle Cytokeratin 16.
the cyclin detaches from the Cdk, inhibiting G1/S transition. This protein has been shown to
the enzyme’s activity, probably by causing a interact with and be involved in the CK 5 and 6 are positively seen in nearly 100% of
protein chain to block the enzymatic site. phosphorylation of tumor suppressor protein Malignant Mesotheliomas and is rarely seen in
Rb. The Cdk4 activity associated with this cyclin Lung Adenocarcinomas. CK 5 and 6 can positively
Cyclin D1 or PRAD-1 or bcl-1 is one of the key was reported to be necessary for cell-cycle be seen in undifferentiated Large-cell Carcinoma
cell-cycle regulators, and functions in association progression through G2 phase into mitosis after as well as Squamous Carcinoma. Fewer than 10%
with Cdk4 and/or Cdk6 by phosphorylating the UV radiation. of Carcinomas of the breast, colon, and prostate
Rb protein. It is a putative proto-oncogene stain positively for this marker. CK 5 and 6 have
overexpressed in a wide variety of human In normal adult tissues, Cyclin D3 shows two also been used successfully as a myoepithelial cell
neoplasms including Mantle Cell Lymphomas patterns of distribution: in lymphoid tissues it is marker in the prostate to determine malignancy.
(MCL). expressed in proliferative compartments, while
in most other tissues it is expressed by terminally
differentiated/quiescent cells. In non-Hodgkin’s
Lymphomas, Cyclin D3 immunolabelling
correlates with proliferative activity and
progression. Benign endocrine tumors are
frequently strongly Cyclin D3-positive, while high-
grade (Small-cell) Neuroendocrine Carcinomas
are always negative. In Breast Carcinomas, no
relationship has been seen between ER status and
Ki67 labelling. In soft tissue neoplasms, Cyclin D3
is consistently expressed in some tumors, such as
Stromal Tumors of the Gastrointestinal Tract and
Embryonal Rhabdomyosarcomas.
CLONE RBT14 CLONE SPM241 CLONE D5/16B4
ISOTYPE IgG ISOTYPE IgG1/K ISOTYPE IgG1
CONTROL Breast Carcinoma, CONTROL Tonsil, Breast Carcinoma CONTROL Mesothelioma, Prostate
Mantle Cell Lymphoma LOCALIZATION Nuclear LOCALIZATION Cytoplasmic

31
Cytokeratin 7 Cytokeratin 8/35βH11 Cytokeratin 8 & 18
IHC of CK 7 on an IHC of CK 8/35βH11 on an IHC of CK 8 and 18 on an

FFPE Lung Adenocarcinoma Tissue FFPE Prostatic Adenocarcinoma Tissue FFPE Colon Carcinoma Tissue
Cytokeratin 7 (CK7) reacts with proteins that Cytokeratin 8 belongs to the Type II (basic) Cytokeratin 8 belongs to the Type II (basic)
are found in most ductal, glandular and transi- subfamily of high molecular-weight keratins subfamily of high molecular-weight keratins
tional epithelium of the urinary tract and bile duct and exists in combination with cytokeratin 18. and exists in combination with Cytokeratin 18
epithelial cells. CK 7 distinguishes between lung Cytokeratin 8 is primarily found in the non- (Type I [acidic] subfamily of low molecular weight
and breast epithelium that stain positive, and colon squamous epithelia and is present in the keratins). They are perhaps the most commonly
and prostate epithelial cells that are negative. majority of Adenocarcinomas and Ductal found products of the intermediate filament gene
Carcinomas. It is absent in Squamous Cell family, and are expressed in single-layer epithelial
This antibody also reacts with many benign and Carcinomas. Hepatocellular Carcinomas are tissues of the body.
malignant epithelial lesions (e.g., Adenocarcinomas defined by the use of antibodies that recognize
of the ovary, breast and lung). Further, in frozen only cytokeratin polypeptides 8 and 18. Cytokeratins 8 and 18 can be found in most
sections, the antibody has been shown to label the simple epithelium (e.g., thyroid, female breast,
rete epithelium in the testis, epididymis Anti-Cytokeratin 8/35βH11 stains most Non- gastrointestinal tract, and respiratory tract).
epithelium, and the surface epithelium of Squamous Epithelial tumors; Squamous tumors Adenocarcinomas and most Non-keratinizing
the stomach and duodenum. Transitional-cell are negative for this antibody as a rule. This anti- Squamous Carcinomas will stain, but Keratinizing
Carcinomas are positive and Prostate Cancers body stains Adenocarcinomas of the breast, ovary, Squamous Carcinomas will not. This antibody
are negative. This antibody does not recognize gastrointestinal tract, thyroid, pancreas, bile duct, is used when attempting to demonstrate the
intermediate filament proteins, nor does it and salivary glands. This antibody does not react presence of Paget cells; there is very
recognize non-epithelial tissues such as blood with skeletal muscle or nerve cells. little keratin 18 in the normal epidermis so only
vessels, connective tissue, etc. Paget cells will stain. This approach facilitates
the interpretation using immunostains and is
more sensitive than mucin histochemistry.
CLONE K72 CLONE 35βH11 CLONE B22.1 & B23.1
ISOTYPE IgG1/K ISOTYPE IgM ISOTYPE IgG1
CONTROL Salivary Gland, CONTROL Prostate, Colon CONTROL Prostate, Pancreas,
Lung Adenocarcinoma LOCALIZATION Cytoplasmic Salivary Gland
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic

Cytokeratin 14 Cytokeratin 17 Cytokeratin 19
IHC of CK 14 on an FFPE Cervical Tissue IHC of CK 17 on an FFPE Cervical Cancer Tissue IHC of CK 19 on an
Cytokeratin 14 is a Type I polypeptide found in Cytokeratin 17 is a Type I cytokeratin with a Cytokeratin 19 is a Type I cytokeratin. Unlike its
basal cells of squamous epithelia, some glandular MW of 46 kD found sometimes in association related family members, this smallest-known
epithelia, myoepithelium, and mesothelial cells. with Cytokeratin 7. It is found in nail beds, hair acidic cytokeratin is not paired with a basic
It is usually found as a heterotetramer with two follicles, sebaceous glands, and other epidermal cytokeratin in epithelial cells. It is specifically
cytokeratin 5 molecules, and a Type II keratin. appendages. Mutations in the gene encoding this found in the periderm, the transiently-superficial
Together, they form the cytoskeleton of epithelial protein lead to Jackson-Lawler type Pachyonychia layer that envelopes the developing epidermis.
cells. Mutations in the genes for these cytokeratins Congenita and Steatocystoma Multiplex.
are associated with Epidermolysis Bullosa Simplex. Anti-Cytokeratin 19 reacts with a wide variety of
Cytokeratin 17 antibody has been used to distin- epithelium and epithelial malignancies including
Cytokeratin 14 has been studied as a prognostic guish immature Cervical Squamous Metaplasia Adenocarcinomas of the colon, stomach, pancreas,
marker in Breast Cancer. This antibody labels from high grade Cervical Intraepithelial Neoplasia biliary tract, liver and breast. Perhaps the most
the basal layer of stratifying squamous and non- (CIN III). Anti-CK 17 also labels myoepithelial cells useful application is the identification of Thyroid
squamous epithelia. The staining pattern is in the benign breast tissue. CK 17 labeling of Breast Carcinoma of the papillary type, although
cytoplasmic. It recognizes Basal Cell Carcinomas Carcinoma cells (so-called basal phenotype) has Follicular Carcinoma is also labeled by this
and Squamous Cell Carcinomas. Anti-CK 14 has been associated with a poor prognosis. antibody approximately 50-60% of the time.
been demonstrated to be useful in differentiat- Cytokeratin 19 is not expressed in hepato-
ing Squamous Cell Carcinomas from other cytes; therefore, this antibody is useful in the
epithelial tumors. This antibody has also been identification of liver metastasis. The degree
useful in separating oncocytic tumors of the of Cytokeratin 19 positivity in Breast Cancer
kidney from renal mimics, as well as in distinguishes malignant from benign tumors.
determining metaplastic Carcinomas of the Breast. Cytokeratin 19 is often coexpressed with
Cytokeratin 7.
CLONE LL002 CLONE EP98 CLONE EP72
ISOTYPE IgG3 ISOTYPE IgG ISOTYPE IgG
CONTROL Squamous Mucosa, CONTROL Small Intestine, Colon Mucosa, CONTROL Colon Carcinoma, Colon Mucosa,
Squamous Carcinoma Bladder, Thyroid Carcinoma Bladder, Thyroid Carcinoma

33
Cytokeratin 20 Cytokeratin HMW/34βE12 Cytokeratin HMW/AE3
IHC of CK 20 on an IHC of CK HMW/34βE12 on an IHC of CK HMW/AE3 on an

FFPE Colon Adenocarcinoma Tissue FFPE Prostatic Adenocarcinoma Tissue FFPE Salivary Gland Tissue
Cytokeratin 20 (CK 20) is a 46 kDa intermediate Cytokeratin 34βE12 is a High Molecular Weight Cytokeratins are intermediate-filament keratins
filament protein whose expression is restricted cytokeratin that reacts with all squamous and found in the intracytoplasmic cytoskeleton of
primarily to gastric and intestinal epithelium, ductal epithelium and stains carcinomas. This epithelial tissue. There are two types of cytokeratins:
urothelium, and Merkel cells. Cytokeratin 20 is a antibody recognizes cytokeratins 1, 5, 10, and 14 the low-weight, acidic Type I cytokeratins and the
Type I cytokeratin. It is a major cellular protein of that are found in complex epithelia. Cytokeratin high-weight, basic or neutral Type II cytokeratins.
mature enterocytes and goblet cells found in the 34βE12 shows no reactivity with hepatocytes, Cytokeratins are usually found in pairs comprising
gastric and intestinal mucosa. pancreatic acinar cells, proximal renal tubules or a Type I cytokeratin and a Type II cytokeratin.
endometrial glands; there has been no reactivity Expression of these cytokeratins is frequently organ
CK 20 is expressed in Adenocarcinomas of the with cells derived from simple epithelia. Nerve or tissue-specific.
colon, stomach, pancreas and biliary system. It cells, glial cells and mesenchymal tissue such
is also expressed in Mucinous Ovarian Tumors, as blood vessels containing only non-keratin Cytokeratin, High Molecular Weight AE3 (HMW, CK
Transitional-cell Carcinomas of the urinary tract, types of intermediate filaments are not labelled; 8) is capable of recognizing all basic cytokeratins;
and Merkel-cell Carcinomas. Cytokeratin 20 is however, reactivity with smooth-muscle cells has therefore, it is a broadly reactive antibody staining
useful in the differentiation of specific types of been occasionally observed. most epithelia and their neoplasms. Cytokeratin
simple epithelial cells of the urinary tract and HMW/AE3 stains normal and neoplastic cells
normal and malignantly-transformed epithelia. Mesenchymal Tumors, Lymphomas, Melanomas, of epithelial origin. CK HMW is primarily found
This antibody is essentially non-reactive in Neural Tumors and Neuroendocrine Tumors are in the non-squamous epithelia and is present in
Squamous Cell Carcinomas and Adenocarci- unreactive with this antibody. Cytokeratin 34βE12 the majority of Adenocarcinomas and Ductal
nomas of the Breast, Lung, and Endometrium, has been shown to be useful in distinguishing Carcinomas. It is absent in Squamous Cell
Non-mucinous Tumors of the Ovary, and Small- Prostatic Adenocarcinoma from Hyperplasia of Carcinomas. Hepatocellular Carcinomas are
cell Carcinomas. This antibody is often used in the Prostate. defined by the use of antibodies that recognize
conjunction with CK 7 and other antibodies to only cytokeratin 8 and 18.
distinguish Colon Carcinomas (CK20+) from
Ovarian, Pulmonary, and Breast Carcinomas.
CLONE Ks20.8 CLONE 34βE12 CLONE AE3
ISOTYPE IgG2a/K ISOTYPE IgG1/K ISOTYPE IgG1
CONTROL Colon Carcinoma, Colon CONTROL Prostate CONTROL Prostate, Bladder, Salivary Gland
Mucosa, Bladder LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic

Cytokeratin LMW/AE1 Cytokeratin Pan Cocktail Cytokeratin Pan-OSCAR

AE1 & AE3
IHC of Cytokeratin LMW/AE1 on an IHC of CK AE1 & AE3 on an IHC of CK OSCAR on an

FFPE Prostate Tissue FFPE Breast Carcinoma Tissue FFPE Colon Carcinoma Tissue
Cytokeratins are intermediate-filament keratins Cytokeratins are intermediate-filament keratins Anti-Cytokeratin OSCAR is well-suited to
found in the intracytoplasmic cytoskeleton of found in the intracytoplasmic cytoskeleton of distinguish Epithelial Carcinoma from Non-
epithelial tissue. There are two types of epithelial tissue. There are two types of epithelial malignancies and is used to aid
cytokeratins: the low-weight, acidic Type I cytokeratins: the low-weight, acidic Type I Epithelial Tumor classification. Anti-Cyto-
cytokeratins and the high-weight, basic or neutral cytokeratins and the high-weight, basic or neutral keratin OSCAR identifies a number of bands
Type II cytokeratins. Cytokeratins are usually found Type II cytokeratins. Cytokeratins are usually found corresponding to cytokeratins 7, 8, 18 and 19
in pairs comprising a Type I cytokeratin and a Type in pairs comprising a Type I cytokeratin and a Type (additional bands – cytokeratins – may also
II cytokeratin. Expression of these cytokeratins is II cytokeratin. Expression of these cytokeratins is be detected). This antibody has been used to
frequently organ or tissue-specific. frequently organ or tissue-specific. characterize the source of various neoplasms and
to study the distribution of keratin-containing
Cytokeratin Low Molecular Weight AE1 can Cytokeratin cocktail AE1/AE3 is well suited to cells in epithelia during normal development
recognize most acidic keratins, making it a distinguish Epithelial Carcinoma from Non- and during the development of epithelial
broadly reactive antibody that stains most epithelial malignancies and is used to aid Epithelial neoplasms.
epithelia and their neoplasms. Members of the Tumor classification. This antibody has been used
acidic and basic subfamilies are found in pairs. to characterize the source of various neoplasms In normal tissues, OSCAR is reactive with most
Each epithelium contains at least one acidic and to study the distribution of keratin-containing epithelial types tested including bile ducts and
and one basic keratin so this antibody can show cells in epithelia during normal development and hepatocytes in liver, bladder epithelium, breast
the distribution of keratin-containing cells in during the development of epithelial neoplasms. ducts, bronchial epithelium, endometrium,
epithelia. Cytokeratin AE1 is particularly suited This antibody stains cytokeratins present in follicular dendritic cells of lymph node and
to distinguish poorly-differentiated Carcinomas normal and abnormal human tissues. This tonsil, intestinal epithelium of the stomach,
from non-epithelial Neoplasms. This marker stains antibody has shown high sensitivity and specificity duodenum, ileum, colon, rectum, pancreas,
both normal and neoplastic cells of epithelial in recognizing epithelial cells of neoplastic origin. ovarian epithelium, pancreatic acini, pituitary
origin. acini, pneumocytes, prostate, thyroid and skin. In
tumors, OSCAR is reactive with most Carcinomas
including Breast, TCC, RCC, Lung, Endometrial
CA, Prostate CA, Ovarian CA, HCC, Colorectal CA,
Stomach CA and Thyroid CA. It is negative
in certain normal tissues including brain,
lymphocytes and all cells of hematolymphoid
origin, muscle, brain, nerves, endothelium
and in certain tumors including Melanoma,
Sarcoma, Lymphoma, PNET/Ewing’s and GIST.
This antibody has shown high sensitivity in
recognizing epithelial cells and carcinomas.
CLONE AE1 CLONE AE1 & AE3 CLONE OSCAR
ISOTYPE IgG1 ISOTYPE IgG1 ISOTYPE IgG2a
CONTROL Prostate, Salivary Gland CONTROL Prostate, Skin, Colon, CONTROL Prostate, Skin, Colon,
LOCALIZATION Cytoplasmic Stomach, Salivary Gland Stomach

35
Cytomegalovirus Desmin DOG1
IHC of CMV on an FFPE Infected Lung Tissue IHC of Desmin on an FFPE Skeletal Muscle Tissue IHC of DOG1 on an FFPE GIST Tissue
Cytomegalovirus (CMV) is a virus of the Herpes- Desmin is a type of intermediate filament found DOG1 (discovered on GIST 1), a cell-surface
virus group; in humans it is commonly known near the Z line in sarcomeres. Both vimentin protein of unknown function, is expressed
as HCMV or Human Herpesvirus 5 (HHV-5). CMV and desmin are characteristics of mesenchymal strongly on the cell surface of GISTs and is rarely
belongs to the Betaherpesvirinae subfamily of cells. expressed in other soft tissue tumors. Among GIST
Herpesviridae, which also includes Roseolovirus. cases with c-Kit mutations, the DOG1 antibody
CMV especially attacks salivary glands. CMV Desmin antibody detects a protein that is expressed identified 11% more cases than a c-Kit antibody.
infection can also be life-threatening for patients by cells of normal smooth, skeletal and cardiac
who are immunocompromised (e.g., patients with muscles. Light microscopy studies of Desmin DOG1 identifies the vast majority of both c-Kit
HIV or organ-transplant recipients). CMV viruses have suggested that it is primarily located at or negative and PDGFRA mutated GIST cases that may
are found in many mammal species, but CMV near the periphery of Z lines in striated muscle still benefit from imatinib mesylate (Gleevac), an
species isolated from animals differ from human fibrils. In smooth muscle, Desmin interconnects inhibitor of the kit tyrosine kinase. In addition,
CMV in terms of genomic structure, and have not cytoplasmic dense bodies with membrane-bound DOG1 immunoreactivity is seen in fewer cases
been reported to cause human disease. dense plaques. Desmin antibody reacts with of mesenchymal and epithelial tumors, and
Leiomyomas, Rhabdomyomas, and Perivascular melanomas when compared with c-Kit. The use
This Anti-cytomegalovirus antibody cocktail cells of Glomus Tumors of the skin (if they are of this highly-sensitive and specific novel marker
reacts with two different epitopes. The DDG9 an- of myogenic nature). This antibody is used to should increase the accuracy of GIST diagnosis.
tibody reacts with a 76 kDa protein produced by demonstrate the myogenic components/
CMV. CCH2 antibody reacts with the early DNA- derivation of tumors.
binding protein p52. There is no cross-reactivity
with other Herpesviruses or Adenoviruses. CMV
infection is usually seen in immunocompromised
patients and involves the GI tract, lung, heart and
liver, as well as other organs.
CLONE DDG9 & CCH2 CLONE D33 CLONE RBT-DOG1
ISOTYPE IgG2/K & IgG1/K ISOTYPE IgG1/K ISOTYPE IgG
CONTROL Infected Tissue CONTROL Skeletal Muscle CONTROL GIST
LOCALIZATION Nuclear LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic, Membranous

E-Cadherin EGFR EMA
IHC of E-Cadherin on an IHC of EGFR on an FFPE Colon Carcionma Tissue IHC of EMA on an FFPE Breast Tissue
FFPE Prostatic Adenocarcinoma Tissue
Cadherins are a class of transmembrane Epidermal Growth Factor Receptor (EGFR) is the Epithelial Membrane Antigen (EMA) antibody is a
proteins. They play an important role in cell receptor for epidermal growth factor (EGF). It is a mucin-like glycoprotein, shown to be useful as
adhesion by ensuring cells within tissues are member of the ErbB family receptors, a subfamily a pan-epithelial marker for detecting early
bound together. E-Cadherin is an adhesion of four closely related receptor tyrosine kinases: metastatic loci of carcinoma in the bone marrow
protein that is expressed in cells of epithelial EGFR (ErbB-1), HER-2 neu (ErbB-2), HER-3 (ErbB-3) or liver. It stains normal and neoplastic cells from
lineage. It stains positively in glandular and HER-4 (ErbB-4). various tissues, including mammary epithelium,
epithelium as well as Adenocarcinomas sweat glands and squamous epithelium.
of the lung and G.I. tract, and ovary.
E-Cadherin has been useful in distinguishing Hepatocellular Carcinoma, Adrenal Carcinoma
Adenocarcinoma from Mesothelioma. It has and Embryonal Carcinomas are consistently EMA
also been shown to be positive in some Thyroid negative, so keratin positivity with negative EMA
Carcinomas. It can be used to differentiate Ductal favors one of these tumors. EMA is frequently
Carcinomas (positive for E-Cadherin) from Lobular positive in meningioma, which can be useful
Breast Carcinomas. when distinguishing it from other intracranial
neoplasms. The absence of EMA can also be of
Loss of E-Cadherin function or expression has value since negative EMA is characteristic of some
been implicated in cancer progression and tumors including Adrenal Carcinoma, Seminomas,
metastasis. E-Cadherin downregulation decreases Paraganglioma and Hepatoma.
the strength of cellular adhesion within a tissue,
resulting in an increase in cellular motility. This
may then allow cancer cells to cross the basement
membrane and invade surrounding tissues. Loss
of E-Cadherin expression has been suggested as
a poor prognostic sign in Breast Carcinoma and
Non-Small Cell Lung Carcinomas.
CLONE EP700Y CLONE 31G7 CLONE E29
ISOTYPE IgG ISOTYPE IgG1 ISOTYPE IgG2a/K
CONTROL Pancreas, Lung Carcinoma CONTROL Skin, Placenta or Squamous CONTROL Breast, Skin
LOCALIZATION Membranous Cell Carcinoma LOCALIZATION Membranous
LOCALIZATION Cell Membrane

37
EpCAM/Epithelial Epstein Barr Virus, LMP Estrogen Receptor

Specific Antigen/BER-EP4
IHC of EpCAM on an FFPE Breast Cancer Tissue IHC of Epstein Barr Virus on an IHC of Estrogen Receptor on an FFPE Breast Tissue
Epithelial Cell Adhesion Molecule (EpCAM) or The Epstein-Barr virus (EBV), also called Human Estrogen receptor (ER) is a nuclear receptor for
Epithelial Specific Antigen is a 40kD cell surface Herpesvirus 4 (HHV-4), is a virus of the Herpes estrogens such as estradiol (the main endogenous
antigen that is broadly distributed in epithelial family, and is one of the most common viruses human estrogen). The two different estrogen
cells and displays a highly conserved expression in humans. The virus can execute many distinct receptor proteins produced from the ESR1 and
in carcinomas. These glycoproteins are located on programs of gene expression, which can ESR2 genes are usually called the alpha and beta
the cell membrane surface and in the cytoplasm be broadly categorized as being lytic receptors. This ER antibody recognizes a protein
of virtually all epithelial cells, with the exception cycle or latent cycle. The lytic cycle, or productive of 67 kDa, which is identified as estrogen receptor
of most squamous epithelia, hepatocytes, renal infection, results in staged expression of (ER) alpha.
proximal tubular cells, gastric parietal cells and several viral proteins with the ultimate objective of
myoepithelial cells. However, focal positivity producing infectious virions. The latent cycle
may be seen in the basal layer of squamous cell (lysogenic) programs are those that do not result
epithelium of endoderm (e.g., palatine tonsils) in production of virions. A very limited, distinct
and mesoderm (e.g., uterine cervix). set of viral proteins are produced during latent
cycle infection. These include Epstein-Barr nuclear
EpCAM expression has been reported to be antigens EBNA-1, EBNA-2, EBNA-3A, EBNA-3B,
a possible marker of early malignancy, with EBNA-3C, EBNA-leader protein (EBNA-LP), latent
expression being increased in tumor cells, and membrane proteins LMP-1, LMP-2A and LMP-2B
de novo expression being seen in dysplastic and the Epstein-Barr encoded RNAs (EBERs).
squamous epithelium. Epithelial specific antigen In addition, EBV codes for at least twenty
has been known to play an important role as a microRNAs which are expressed in latently
tumor-cell marker in lymph nodes from patients infected cells.
with esophageal carcinoma. EpCAM can be used
to distinguish among Basal Cell, Basosquamous
Carcinomas and Squamous Cell Carcinomas of
the skin.
CLONE Ber-EP4 CLONE CS1-4 CLONE RBT11
ISOTYPE IgG1/K ISOTYPE IgG1 ISOTYPE IgG
CONTROL Adenocarcinoma CONTROL Infected Tissue, CONTROL Breast Carcinoma
LOCALIZATION Cytoplasmic Hodgkin’s Lymphoma LOCALIZATION Nuclear

Factor VIII Factor XIIIa Fascin
IHC of Factor VIII on an FFPE Placenta Tissue IHC of Factor XIIIa on an FFPE Placenta Tissue IHC of Fascin on an
Factor VIII (F VIII) is an essential clotting factor. Factor XIII or fibrin stabilizing factor is an enzyme Fascin, encoded by the human homolog for sn
The lack of normal F VIII causes Hemophilia A, an of the blood coagulation system that crosslinks (hsn) gene, has been localized to microspikes and
inherited bleeding disorder. FVIII is a glycoprotein fibrin. When thrombin has converted fibrinogen stress fibers of cultured cells where it is thought
procofactor synthesized and released into the to fibrin, the latter forms a proteinaceous network to be involved in the formation of microfilament
bloodstream by the liver. In the circulating blood, in which every E-unit is crosslinked to only one bundles. It is expressed predominantly in dendritic
it is mainly bound to von Willebrand factor (vWF, D-unit. Factor XIII is activated by thrombin into cells. Lymphoid cells, myeloid cells and plasma
also known as Factor VIII-related antigen) to form Factor XIIIa; its activation into Factor XIIIa requires cells are negative. However, Reed Sternberg cells
a stable complex. Upon activation by thrombin calcium as a cofactor. Factor XIIIa has been in Hodgkin’s Lymphoma are positive for Fascin
or Factor Xa, it dissociates from the complex to identified in platelets, megakaryocytes, and staining. Epstein-Barr virus may induce expression
interact with Factor IXa, the coagulation cascade. fibroblast-like mesenchymal or histiocytic cells of Fascin in B-cells.
It is a cofactor to Factor IXa in the activation of present in the placenta, uterus, and prostate; it
Factor X, which, in turn, with its cofactor Factor is also present in monocytes, macrophages and Fascin is a very sensitive marker for Reed-
Va, activates more thrombin. Thrombin cleaves dermal dendritic cells. Sternberg cells and variants in nodular sclerosis,
fibrinogen into fibrin which polymerizes and mixed cellularity, and lymphocyte depletion
crosslinks (using Factor XIII) into a blood clot. Anti-Factor XIIIa has been found to be useful in Hodgkin’s Disease. This marker might be helpful
differentiating between Dermatofibroma (90% in distinguishing between Hodgkin’s Disease and
This antibody reacts with endothelial cells in (+)), Dermatofibrosarcoma Protuberans (25%(+)) Non-Hodgkin Lymphoma in difficult cases. Also,
normal, reactive, and neoplastic blood cells. F VIII and Desmoplastic Malignant Melanoma (0%(+)). the lack of expression of Fascin in the neoplastic
antibody has helped to establish the endothelial Factor XIIIa positivity is also seen in Capillary follicles in Follicular Lymphoma can be helpful in
nature of some lesions of disputed histogenesis, Hemagioblastoma (100%(+)), Hemangioendothe- distinguishing these lymphomas from reactive
e.g., Kaposi`s Sarcoma and Cardiac Myxoma. Not lioma (100%(+)), Hemangiopericytoma (100%(+)), Follicular Hyperplasia in which the number of
all endothelial cells synthesize (or store) this Xanthogranuloma (100%(+)), Xanthoma (100(+)), follicular dendritic cells is normal or increased.
molecule; therefore, it should not be surprising Hepatocellular Carcinoma (93%(+)), Glomus
that not all tumors of endothelial differentiation Tumor (80%(+)), and Meningioma 80%(+)).
(benign or malignant) react with this antigen.
ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Mouse Monoclonal
CLONE N/A CLONE AC-1A1 CLONE 55-k2
ISOTYPE N/A ISOTYPE IgG1 ISOTYPE IgG1
CONTROL Skin, Placenta CONTROL Dermatofibroma, Placenta CONTROL Hodgkin’s Lymphoma,
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic Lymph Node, Tonsil

39
Fli-1 Follicular Dendritic Cell FSH
IHC of Fli-1 on an FFPE Renal Cell Carcinoma Tissue IHC of FDC on an FFPE Tonsil Tissue IHC of FSH on an FFPE Pituitary Tissue
Fli-1 protein, a member of the ETS family of Follicular Dendritic Cells (FDC) are immune cells Follicle stimulating hormone (FSH) is a hormone
DNA binding transcription factors, is involved whose main function is to process antigen mate- synthesized and secreted by gonadotropes in
in cellular proliferation and tumorigenesis. rial and present it superficially to other cells of the the anterior pituitary gland. In the ovary, FSH
Approximately 90% of Ewing’s Sarcoma/Primitive immune system. Dendritic cells are present in small stimulates the growth of immature Graafian
Neuroectodermal Tumors (ES/PNET) have a quantities in tissues that are in contact with the follicles to maturation. As the follicle grows,
specific translocation, t(11;22)(q24;q12), which external environment, mainly the skin (where they it releases inhibin, which deactivates the FSH
results in fusion of EWS to Fli-1, and production are often called Langerhans cells) and the inner production. In men, FSH enhances the production
of an EWS-Fli-1 fusion protein, which can be lining of the nose, lungs, stomach and intestines. of androgen-binding protein by the Sertoli cells of
detected by this antibody. Among normal tissues They can also be found in an immature state in the testis and is critical for spermatogenesis. FSH
only endothelial cells and small lymphocytes the blood. Once activated, they migrate to the and LH act synergistically in reproduction.
express Fli-1. Fli-1 has been found to be expressed lymphoid tissues where they interact with T-cells
in the great majority of vascular tumors including and B-cells to initiate and shape the immune FSH is a useful marker in the classification of
Angiosarcomas, Hemangioendotheliomas, Hem- response. pituitary tumors and the study of pituitary
angiomas, and Kaposi’s Sarcomas. disease. It reacts with FSH-producing cells.
Anti-FDC is useful in the identification of follicular
It has been reported that the high sensitivity and dendritic cell matrix found in normal lymph nodes
specificity of Fli-1 is equal to or exceeds that of and tonsillar tissue. This antibody has been found
the established vascular markers, CD31, CD34, and to label cells in approximately 60% of Anaplastic
Factor VIII. As the first nuclear marker of endothe- Large-Cell Lymphomas, and approximately 45%
lium (rather than cytoplasmic or membranous), of T-cell Lymphomas. This antibody also labels
Fli-1 immunostaining also generally lacks Follicular Dendritic Cell Tumors. Several
cytoplasmic staining artifacts that are the result normal non-lymphoid tissues are labeled with
of endogenous peroxidases or biotin. anti-FDC: pancreatic islet cells, gastric chief cells,
myelin sheaths, salivary glands, Leydig cells of
the testis, and endothelial cells.
CLONE MRQ-1 CLONE CAN.42 CLONE N/A
ISOTYPE IgG2b ISOTYPE IgM/K ISOTYPE N/A
CONTROL Angiosarcoma, Hemangiomas CONTROL Tonsil, Lymph Node CONTROL Normal Pituitary
LOCALIZATION Nuclear LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic

Galectin-3 Gastrin GCDFP-15
IHC of Galectin-3 on an IHC of Gastrin on an FFPE Stomach Tissue IHC of GCDFP-15 on an

FFPE Follicular Carcinoma of Thyroid Tissue FFPE Breast Carcinoma Tissue
Galectin-3 is a 31 kDa beta-galactosidase binding Gastrin is a linear peptide hormone produced by Gross Cystic Disease is a common premenopausal
lectin. It has been associated with binding to G-cells of the duodenum and in the pyloric antrum disorder in which gross cysts are the predominant
the basement membrane glycoprotein laminin. of the stomach. It is secreted into the bloodstream. pathologic lesion. It is characterized by production
Galectin-3 is normally distributed in epithelia of a fluid secretion which accumulates in the breast
of many organs and various inflammatory cells, Gastrin antibody gives positive staining of cysts. Gross Cystic Disease fluid is a pathologic
including macrophages, as well as dendritic G-cells of human antral/pyloric mucosa and cells secretion from breast composed of several
cells and Kupffer cells. The expression of this producing gastrin or a structural gastrin analogue glycoproteins, including a unique 15 kDa monomer
lectin is up-regulated during inflammation, cell as is seen in the stomach. No staining of other cells protein, GCDFP-15. The cells within the body that
proliferation, cell differentiation and through or tissue types has been observed. This antibody produce GCDFP-15 appear to be restricted primarily
trans-activation by viral proteins. may react with sulfated and non-sulfated forms of to those with apocrine function such as breast
gastrin. The antibody cross-reacts with more than cysts and in apocrine glands in the axilla, vulva,
Anti-Galectin-3 has been demonstrated to be 50% of the present choleocystokinin octapeptide. eyelid, and ear canal.
valuable in differentiating between benign and
malignant thyroid neoplasms in both histologic Studies have found GCDFP-15 to be a highly
sections and Fine Needle Aspiration Biopsy specific and sensitive marker for breast cancer.
material. Anti-Galectin-3 antibody has also Approximately 70% of breast carcinomas stain
been useful in identifying Anaplastic Large Cell positive with antibody to GCDFP-15. In contrast,
Lymphoma. Colorectal Carcinomas, as well as Mesothe-
liomas, do not stain with this antibody. Lung
Adenocarcinomas rarely stain with this antibody.
CLONE 9C4 CLONE N/A CLONE 23A3
ISOTYPE IgG1 ISOTYPE N/A ISOTYPE IgG2a
CONTROL Papillary, Follicular CONTROL Stomach CONTROL Breast, Breast Carcinoma,
Carcinoma of Thyroid LOCALIZATION Cytoplasmic Sweat Glands in Skin

41
GFAP GH Glucagon
IHC of GFAP on an FFPE on a Brain Tissue IHC of GH on an FFPE on a Pituitary Tissue IHC of Glucagon on an FFPE Pancreas Tissue
Glial fibrillary acidic protein or GFAP is a Type III Growth hormone (GH or somatotropin) is a 191 Glucagon is a 29-amino acid polypeptide acting
protein of the intermediate filaments principally amino acid, single-chain polypeptide hormone as an important hormone in carbohydrate
found in astrocytes in the central nervous system, which is synthesized, stored and secreted by the metabolism. The hormone is synthesized and
but can also be found in neurons, hepatic stellate somatotroph cells within the lateral wings of the secreted from alpha cells of the islets of Langerhans,
cells, kidney mesangial cells, pancreatic stellate anterior pituitary gland, which stimulates growth which are located in the endocrine portion of the
cells, and Leydig cells. It has a role in the and cell reproduction in humans and other pancreas. Abnormally-elevated levels of glucagon
cytoskeleton of the astrocyte and possibly many animals. may be caused by pancreatic tumors such as
other stellate-shaped cells. glucagonoma, symptoms of which include
GH is a useful marker in classification of pituitary necrolytic migratory erythema (NME), elevated
Antibodies to GFAP are very useful as markers of tumors and the study of pituitary disease amino acids and hyperglycemia. It may occur alone
astrocytic cells. In addition, many types of brain (acromegaly). It reacts with GH-producing cells. or in the context of Multiple Endocrine Neoplasia
tumors, presumably derived from astrocytic cells, Type 1.
heavily express GFAP. This marker is mainly used
to distinguish neoplasms of astrocytic origin from Glucagon antibody detects glucagon-secreting
other neoplasms in the central nervous system. cells and tumors such as glucagonomas. Studies
show that approximately 80% of glucagonomas
are malignant and these patients have a syndrome
most often initially recognized by dermatologists.
Symptoms include necrolytic migratory erythema
as well as diabetes, anemia, stomatitis, weight
loss, frequent venous thromboses, and in some
instances, diarrhea and psychiatric disturbances.
The diagnosis may be readily confirmed by the
demonstration of elevated plasma glucagon
concentration.
ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Rabbit Polyclonal
CLONE G-A-5 CLONE N/A CLONE N/A
ISOTYPE IgG1 ISOTYPE N/A ISOTYPE N/A
CONTROL Brain CONTROL Normal Pituitary CONTROL Pancreas

Glycophorin A Glypican-3 Granzyme B
IHC of Glycophorin A on an IHC of Glypican-3 on an IHC of Granzyme B on an FFPE Tonsil Tissue

FFPE Bone Marrow Tissue FFPE Hepatocellular Carcinoma Tissue
Glycophorins A (GPA) and B (GPB) are single pass Glypican 3, also known as GPC3, is a human gene. Granzymes are exogenous serine proteases that
membrane sialoglycoproteins. GPA is the carrier The protein encoded by this gene is a member of are released by cytoplasmic granules within
of blood group M and N specificities, while GPB the glypican family. Cell surface heparan sulfate cytotoxic T-cells and natural killer cells. Their
accounts for S and U specificities. GPA and GPB proteoglycans are composed of a membrane- purpose is to induce apoptosis within
provide the cells with a large mucin-like surface associated protein core substituted with a virus-infected cells, thus destroying them.
and it has been suggested this provides a bar- variable number of heparan sulfate chains.
rier to cell fusion, thus minimizing aggregation Members of the glypican-related integral Anti-Granzyme B antibodies have been useful
between red blood cells in the circulation. membrane proteoglycan family (GRIPS) contain in diagnosing Natural Killer/T-cell Lymphoma, as
a core protein anchored to the cytoplasmic well as Anaplastic Large Cell Lymphoma. High
Anti-Glycophorin A has been used to characterize membrane via a glycosyl-phosphatidylinositol percentages of cytotoxic T-cells have been shown
erythroid cell development and in the diagnosis linkage. These proteins may play a role in the to be an unfavorable prognostic indicator in
of Erythroid Leukemias. control of cell division and growth regulation. Hodgkin’s Disease.
GPC3 has been identified to be a useful tumor

marker for the diagnosis of Hepatocellular
Carcinoma (HCC), Hepatoblastoma, Melanoma,
Testicular Germ Cell Tumors, and Wilms Tumor.
In patients with HCC, GPC3 was overexpressed in
neoplastic liver tissue and elevated in serum but
was undetectable in normal liver, benign liver, and
the serum of healthy donors. GPC3 expression
was also found to be higher in HCC liver tissue
than in cirrhotic liver or liver with focal lesions
such as dysplastic nodules and areas of hepatic
adenoma (HA) with malignant transformation.
In the context of Testicular Germ Cell Tumors,
GPC3 expression is up-regulated in certain
histologic subtypes, specifically Yolk Sac Tumors
and Choriocarcinoma. A high level of GPC3
expression has also been found in some types
of embryonal tumors, such as Wilms Tumor and
Hepatoblastoma.
CLONE GA-R2 CLONE 1G12 CLONE N/A
ISOTYPE IgG2b/K ISOTYPE IgG1 ISOTYPE N/A
CONTROL Bone Marrow CONTROL Hepatocellular Carcinoma CONTROL Tonsil, Lymph Node
LOCALIZATION Membranous LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic (Granular)

43
hCG Helicobacter Pylori Hepatitis B Virus Core Antigen
IHC of hCG on an FFPE Placenta Tissue IHC of Helicobacter pylori on an IHC of HBcAg on an FFPE Infected Liver Tissue
FFPE Infected Stomach Tissue
Human chorionic gonadotropin (hCG) is a peptide This antibody reacts with H. pylori on the surface Hepatitis B virus is spherical in shape with a
hormone produced in pregnancy, made by the of epithelial cells of pyloric and stomach mucosa. diameter of 42 nm. It contains a 27 nm partially
embryo soon after conception and later by the double-stranded DNA core enclosed within a
syncytiotrophoblast. Its role is to prevent the lipoprotein coat. The antigenic activity of the
disintegration of the corpus luteum of the ovary nucleocapsid core is designated as Hepatitis B
and thereby maintain progesterone production core antigen.
that is critical for a pregnancy in humans. hCG
may have additional functions; for instance, it is
thought to affect the immune tolerance of the
pregnancy. Early pregnancy testing generally is
based on the detection or measurement of hCG.
hCG antibody detects cells and tumors of

trophoblastic origin such as Choriocarcinomas.
Large Cell Carcinoma and Adenocarcinoma
of the Lung demonstrate hCG positivity in 90%
and 60% of cases respectively. 20% of Squamous
Cell Lung Carcinomas are positive for hCG. hCG
expression by non-trophoblastic tumors may
indicate aggressive behavior since it has been
observed that hCG may play a role in the host
response to a given tumor.
ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Rabbit Polyclonal
CLONE N/A CLONE N/A CLONE N/A
ISOTYPE N/A ISOTYPE N/A ISOTYPE N/A
CONTROL Placenta CONTROL Infected Stomach Mucosa CONTROL Infected Liver
LOCALIZATION Cytoplasmic LOCALIZATION Cell Wall LOCALIZATION Nuclear

Hepatitis B Virus Hepatocyte Specific Antigen/ HER-2 neu, MMab

Surface Antigen Hep Par 1
IHC of HBsAg on an FFPE Infected Liver Tissue IHC of Hepatocyte Specific Antigen on an IHC of HER-2 neu on an
FFPE Liver Tissue FFPE Breast Carcinoma Tissue
Hepatitis B virus is spherical in shape with a Hepatocyte Specific Antigen (HSA or Hep Par 1) HER-2 neu (also known as c-erbB-2) is a member
diameter of 42 nm. It contains a 27 nm partially has been demonstrated consistently in the vast of the epidermal growth factor receptor (EGFR)
double-stranded DNA core enclosed within a majority of Hepatocellular Carcinomas. Studies family. It is a cell membrane surface-bound
lipoprotein coat. have shown the utility of HSA in the differential tyrosine kinase and is normally involved in the
diagnosis of Hepatocellular Carcinoma, Cholan- signal transduction pathways leading to cell
giocarcinoma and Hepatoblastomas. growth and differentiation.
HSA recognizes both benign and malignant liver

derived tissues including such tumors as Hepato-
blastoma, Hepatocellular Carcinoma, and Hepatic
Adenoma. It recognizes both normal adult and
fetal liver tissue. The typical pattern is a granular
cytoplasmic staining. This antibody is useful in
differentiating Hepatocellular Carcinomas with
adenoid features from Adenocarcinomas, either
primary in the liver or metastatic lesions to the
liver. In recognizing Hepatoblastoma, it is useful in
differentiating this entity from other small round
cell tumors.
CLONE T9 CLONE OCH1E5 CLONE HER-24
ISOTYPE IgG1 ISOTYPE IgG1/K ISOTYPE IgG1
CONTROL Infected Liver CONTROL Liver CONTROL Breast Carcinoma
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic LOCALIZATION Membranous

45
HER-2 neu, RMab Herpes Simplex Virus I and II HHV-8
IHC of HER-2 neu on an IHC of HSV on an FFPE Infected Tissue IHC of HHV-8 on an FFPE Pleura Tissue
FFPE Breast Carcinoma Tissue
HER-2 neu (also known as c-erbB-2) is a member Herpes simplex virus I and II (HSV-I and HSV-II) Kaposi’s Sarcoma-associated herpes virus is the
of the epidermal growth factor receptor (EGFR) are two strains of the Herpes virus family, eighth human herpes virus; its formal name
family. It is a cell membrane surface-bound Herpesviridae. This antibody reacts with HSV-I according to the International Committee on
tyrosine kinase and is normally involved in the and HSV-II Herpes viruses. There may be cross- Taxonomy of Viruses is HHV-8. Anti-HHV-8
signal transduction pathways leading to cell reactivity with varicella zoster virus at higher labels the latent nuclear antigen protein via
growth and differentiation. concentrations. Cross-reactivity with CMV or immunohistochemistry.
Epstein-Barr virus is not seen with this antibody.
ANTIBODY TYPE Rabbit Monoclonal ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Mouse Monoclonal
CLONE RBT-HER2 CLONE N/A CLONE 13B10
ISOTYPE IgG ISOTYPE N/A ISOTYPE IgG1
CONTROL Breast Carcinoma CONTROL Infected Tissue CONTROL Kaposi’s Sarcoma
LOCALIZATION Membranous LOCALIZATION Nuclear, Cytoplasmic LOCALIZATION Nuclear

BSB 2038-2 prediluted 3.0 ml BSB 5638 prediluted 3.0 ml BSB 5645 prediluted 3.0 ml
BSB 2040-2 concentrated 0.1 ml BSB 5641 concentrated 0.1 ml BSB 5648 concentrated 0.1 ml
HPV IgA IgD
IHC of HPV on an FFPE LSIL of the Cervix IHC of IgA on an FFPE Tonsil Tissue IHC of IgD on an FFPE Tonsil Tissue
Papillomaviruses are a diverse group of DNA- Immunoglobulin A (IgA) is the main immunoglob- IgD makes up about 1% of proteins in the
based viruses. More than 100 different ulin in mucous secretions, including tears, saliva, plasma membranes of immature B-lymphocytes
human papillomavirus (HPV) types have been and colostrum, as well as respiratory, intestinal, (coexpressed with IgM) and is also found in
characterized. Some HPV types cause benign skin prostatic, and vaginal secretions. It is also found in serum in very small amounts. It is monomeric and
warts, or papillomas, for which the virus family is small amounts in blood. Because it is resistant to incorporates the alpha-heavy chain in its struc-
named. HPVs associ. Anti-human papillomavirus, degradation by enzymes, secretory IgA provides ture. IgD’s function is currently unknown, as mice
clone SB24 reacts with an epitope of a major protection against microbes proliferating in body lacking IgD seem to retain normal immune
capsid protein of HPV, which is broadly expressed secretions, especially those of the digestive and responses (implying redundancy if not lack of
among the different HPV subtypes. respiratory tracts. function), and IgD ceases to be expressed in
activated B-lymphocytes. It may function as a
IgA antibody reacts with surface immunoglobulin regulatory antigen receptor.
IgA alpha chains. It is extremely useful when
identifying Acute Leukemias, IgA Myelomas, IgD antibody reacts with surface immunoglobulin
Plasmacytomas, and B-cell lineage derived IgD delta chains. This antibody is useful when
Hodgkin’s Lymphomas. However, due to the identifying Leukemias, Plasmacytomas, and B-cell
restricted expression of heavy and light chains in lineage derived from Lymphomas, specifically
these diseases, demonstration of B-cell Lymphomas Marginal Zone Lymphoma.
is possible with clonal gene-rearrangement studies.
ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Rabbit Polyclonal
CLONE SB24 CLONE N/A CLONE N/A
ISOTYPE IgG1/K ISOTYPE N/A ISOTYPE N/A
CONTROL HPV Infected Tissue CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node

47
IgG IgM Inhibin Alpha
IHC of IgG on an FFPE Tonsil Tissue IHC of IgM on an FFPE Axilar Lymph Node IHC of Inhibin Alpha on an FFPE Placenta Tissue
with Metastatic Breast Carcinoma
IgG is a monomeric immunoglobulin, built of two IgM forms polymers where multiple immunoglob- Inhibins are peptide hormones produced by the
heavy chains and two light chains. This is the most ulins are covalently linked together with disulfide granulosa cells in female follicles and by Sertoli
abundant immunoglobulin and is approximately bonds, normally as a pentamer or occasionally cells in the male seminiferous tubules. They are
equally distributed in blood and tissue liquids, as a hexamer. It has a large molecular mass of selectively expressed by cells of sex-cord stromal
constituting 75% of serum immunoglobulins in approximately 900 kDa (in its pentamer form). In derivation, and inhibit the secretion of follitropin
humans. This is the only isotype that can pass germline cells, the gene segment encoding the by the pituitary gland. Inhibin contains an alpha
through the placenta and bind to many kinds of constant region of the heavy chain is positioned and beta subunit linked by disulfide bonds. Two
pathogens. IgG protects the body against them first among other constant region gene segments. forms of inhibin differ in their beta subunits (A or
by complement activation (classic pathway), For this reason, IgM is the first immunoglobulin B), while their alpha subunits are identical. Inhibin
opsonization for phagocytosis and neutralization expressed by mature B-cells. belongs to the transforming growth factor-beta
of their toxins. There are 4 subclasses: IgG1 (66%), (TGF-beta) family.
IgG2 (23%), IgG3 (7%) and IgG4 (4%). IgM antibody reacts with surface immunoglobulin
IgM mu chains. IgM is one of the predominant Anti-Inhibin Alpha has demonstrated utility in
IgG antibody reacts with surface immunoglobulin surface immunoglobulins on B-lymphocytes, and is differentiation between Adrenal Cortical Tumors
IgG gamma chains. This antibody is useful when useful when identifying Leukemias, Plasmacytomas, and Renal Cell Carcinoma. Sex-Cord Stromal
identifying Leukemias, Plasmacytomas, and B-cell and B-cell lineage derived Hodgkin’s Lymphomas. Tumors of the Ovary as well as Trophoblastic
lineage derived Hodgkin’s Lymphomas. Due to the Due to the restricted expression of heavy and Tumors also demonstrate cytoplasmic positivity
restricted expression of heavy and light chains in light chains in these diseases, demonstration of with this antibody.
these diseases, demonstration of B-cell Lymphomas B-cell Lymphomas is possible with clonal gene-
is possible with clonal gene-rearrangement studies. rearrangement studies.
ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Mouse Monoclonal
CLONE N/A CLONE N/A CLONE R1
ISOTYPE N/A ISOTYPE N/A ISOTYPE IgG2a
CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node CONTROL Adrenal Cortex, Placenta,
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic LOCALIZATION Testis, Corpus Luteum

BSB 5673 prediluted 3.0 ml BSB 5680 prediluted 3 .0ml BSB 5687 prediluted 3.0 ml
BSB 5679 control slides 5 BSB 5686 control slides 5 BSB 5693 control Slides 5
Insulin Kappa Light Chains Ki-67
IHC of Insulin on an FFPE Pancreas Tissue IHC of Kappa on an FFPE Tonsil Tissue IHC of Ki-67 on an FFPE HSIL of the Cervix
Insulin is produced in the beta cells of the Islets Kappa detects surface immunoglobulin on normal The Ki-67 protein is a cellular marker for prolifera-
of Langerhans in the pancreas. It is a polypeptide and neoplastic B-cells. In paraffin-embedded tion. It is strictly associated with cell proliferation.
hormone that regulates carbohydrate metabolism. tissue, Kappa exhibits strong staining of kappa- During the interphase, the Ki-67 antigen can
Apart from being the primary agent in carbohydrate positive plasma cells and cells that have absorbed be exclusively detected within the cell nucleus,
homeostasis, insulin has effects on fat metabolism exogenous immunoglobulin. whereas in mitosis most of the protein is relocated
and changes the liver’s ability in storing or releas- to the surface of the chromosomes. Ki-67 protein
ing glucose and processing blood lipids, and in When studying B-cell neoplasms, the determina- is present during all active phases of the cell cycle
other tissues such as fat and muscle. The amount of tion of light-chain ratios remains the centerpiece. (G1, S, G2, and mitosis), but is absent from resting
insulin in circulation has extremely widespread This is sound reasoning because most B-cell cells (G0).
effects throughout the body. Lymphomas express either kappa or lambda light
chains, whereas reactive proliferations display a Ki-67 is an excellent marker to determine the
The presence of insulin in the cytoplasm of mixture of kappa and lambda-positive cells. If only growth fraction of a given cell population. The
Islet Tumors is the most reliable indication of a single light-chain type is detected, a lympho- fraction of Ki-67-positive tumor cells (the Ki-67
functional Insulinomas. Defective insulin storage proliferative disorder is very likely. Monoclonality labeling index) is often correlated with the clinical
occurs in Insulinomas; therefore, many sections of is determined by a kappa-lambda ratio greater course of cancer. The best-studied examples in
the tumor should be stained with both insulin and than or equal to 3:1, a lambda-kappa ratio greater this context are Carcinomas of the Prostate and
C-peptide. than or equal to 2:1, or a monoclonal population the Breast.
of 75% or more of the total population.
ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Monoclonal
CLONE N/A CLONE Kap-56 CLONE EP5
ISOTYPE N/A ISOTYPE IgG1/K ISOTYPE IgG
CONTROL Pancreas CONTROL Tonsil, Lymph Node CONTROL Breast Carcinoma,
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic Astrocytoma, Colon Carcinoma

49
Ksp-Cadherin Lambda LH
IHC of Ksp-Cadherin on an FFPE Kidney Tissue IHC of Lambda on an FFPE Tonsil Tissue IHC of LH on an FFPE Pituitary Tissue
Ksp-Cadherin (Kidney-specific Cadherin) is a novel, Lambda detects surface immunoglobulin on Luteinizing hormone (LH) is a hormone
kidney-specific member of the Cadherin family normal and neoplastic B-cells. Lambda staining is synthesized and secreted by gonadotropes in the
of cell-adhesion molecules. Within the kidney, seen in B-cell follicles of human lymphoid tissue. anterior lobe of the pituitary gland. In concert
Ksp-Cadherin is found exclusively in the basolat- with the other pituitary gonadotropin follicle-
eral membrane of renal tubular epithelial cells When studying B-cell neoplasms, the stimulating hormone (FSH), it is necessary for proper
and collecting duct cells, and not in glomeruli, determination of light chain ratios remains the reproductive function. In the female, an acute rise
renal interstitial cells, or blood vessels. Different centerpiece. This is sound reasoning because most of LH levels triggers ovulation. In the male, where
Cadherins, including E-Cadherin, Cadherin-6, and B-cell Lymphomas express either kappa or lambda LH has also been called Interstitial Cell-Stimulating
N-Cadherin, have been investigated in Renal Cell light chains, whereas reactive proliferations Hormone (ICSH), it stimulates Leydig cell
Cancers, demonstrating possible correlations of display a mixture of kappa and lambda-positive production of testosterone.
tumor differentiation and the presence of lymph cells. If only a single light-chain type is detected,
node metastasis with loss of Cadherins. a lymphoproliferative disorder is very likely. LH is a useful marker in classification of Pituitary
Monoclonality is determined by a kappa- Tumors and the study of pituitary disease.
Ksp-Cadherin has been used to distinguish lambda ratio greater than or equal to 3:1, LH antibody reacts with LH-producing cells
Chromophobe Renal-Cell Carcinoma from a lambda-kappa ratio greater than or equal to (gonadotrophs).
Oncocytoma. Studies have found a membranous 2:1, or a monoclonal population of 75% or more
pattern of staining in 96% of 30 Chromophobe of the total population.
Carcinomas, and in only 6% of 31 Oncocytomas,
leading to conclude that this is a useful
antibody in differentiating these two lesions.
On the other hand, another study found
Ksp-Cadherin positivity in 100% of 13
chromophobe RCCs, and 95% of 20
Oncocytomas.
CLONE MRQ-33 CLONE Lamb14 CLONE N/A
ISOTYPE IgG1 ISOTYPE IgG2a ISOTYPE N/A
CONTROL Kidney, Chromophobe CONTROL Tonsil, Lymph Node CONTROL Normal Pituitary
Renal Cell Carcinoma LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic
LOCALIZATION Membranous, Cytoplasmic

BSB 6287 concentrated 1.0 ml BSB 5720 prediluted 1.0ml BSB 5727 concentrated 1.0 ml
Lysozyme Macrophage/HAM-56 Mammaglobin
IHC of Lysozyme on an FFPE Tonsil Tissue IHC of Macrophage on an FFPE Tonsil Tissue IHC of Mammaglobin on an FFPE Breast Tissue
Lysozyme is a 14.4 kDa enzyme, commonly Macrophages comprise many forms of Mammaglobin is a gene that encodes a 10 kDa
referred to as the “body’s own antibiotic” since mononuclear phagocytes found in tissues that glycoprotein. In humans, expression of the gene is
it kills bacteria. Lysozyme is an enzyme that derive from hematopoietic stem cells in the limited to the adult mammary gland. A correlation
destroys bacterial cell walls by hydrolyzing the bone marrow. Among the functions of between increased expression of the gene and
polysaccharide component of the cell wall. It is macrophages are nonspecific phagocytosis and Breast Cancer has been reported. Mammaglobin
abundantly present in a number of secretions, pinocytosis, killing of ingested microorganisms, mRNA is present in high levels in human Breast
including tears. This protein is present in and digestion and presentation of antigens to Cancer cell lines and primary Breast Cancers. High
cytoplasmic granules of the polymorphonuclear T and B-lymphocytes. Macrophages work to levels of mRNA have been detected in normal
neutrophils (PMN) and released through secrete a large number of diverse products human sweat glands as well, but are absent in
mucosal secretions such as tears and saliva. such as lysozyme and collagenases, several Sweat Gland Tumors.
They can also be found in high concentration in complement components and coagulation
egg white. factors, some prostaglandins and leukotrienes, Anti-Mammaglobin (31A5) has been shown to
and many regulatory molecules (Interferon, be effective in detecting up to 85% of Breast
Lysozyme stains myeloid cells, histiocytes, Interleukin 1). Carcinomas using immunohistochemical
granulocytes, macrophages, and monocytes in techniques. Studies investigating the detection
human tonsil, colon and skin. It is an important Macrophage HAM-56 reacts with tingible of mRNA by RT PCR from circulating carcinoma
marker that may demonstrate the myeloid macrophages (found in the germinal centers cells in the peripheral blood of Breast Cancer
or monocytic nature of Acute Leukemia. The of lymph nodes), interdigitating macrophages patients have shown that mammaglobin is
restrictive nature of Lysozyme antibody staining of lymph nodes and tissue macrophages, (e.g., a highly-specific marker and correlates with
suggests that Lysozyme may be synthesized Kupffer cells of the liver and alveolar macro- several prognostic factors, such as lymph node
predominantly in reactive histiocytes rather than phages of the lung). This antibody also stains a involvement.
in resting, unstimulated phagocytes. It has not subpopulation of endothelial cells, most
been determined whether Lysozyme stains any prominently those of the capillaries and smaller
other cell or tissue type. Lysozyme may aid in the blood vessels. HAM-56 reacts with monocytes,
identification of histiocytic neoplasias and large but is unreactive with B and T-lymphocytes.
lymphocytes, as well as classifying lymphoprolif-
erative disorders.
ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Monoclonal
CLONE N/A CLONE HAM-56 CLONE 31A5
ISOTYPE N/A ISOTYPE IgM/K ISOTYPE IgG
CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node CONTROL Breast Carcinoma

51
MART-1/Melan-A MCM-2 Melanoma/HMB-45
IHC of MART-1/Melan-A on an IHC of MCM-2 on an FFPE HSIL of the Cervix IHC of Melanoma/HMB-45 on an
FFPE Melanoma Tissue FFPE Malignant Melanoma Tissue
MART-1/Melan-A is a putative 18 kDa transmem- MCM-2 (mini-chromosome maintenance 2) is a HMB-45 is a mouse monoclonal antibody that
brane protein consisting of 118 amino acids. It human gene. The protein encoded by this gene reacts against an antigen present in melanocytic
has a single transmembrane domain. MART-1/ is one of the highly conserved mini-chromosome tumors such as Melanomas. The antibody was
Melan-A is a protein antigen found on melano- maintenance proteins (MCM) that is involved in generated to an extract of Melanoma. It reacted
cytes. Antibodies against this antigen are used the initiation of eukaryotic genome replication. positively against Melanocytic Tumors but not
to recognize cells of melanocytic differentiation, The hexameric protein complex formed by MCM other tumors, thus demonstrating specificity and
useful for the diagnosis of Melanoma. The same proteins is a key component of the pre-replication sensitivity. Moreover, this antibody reacts positively
name is used to refer to the gene which codes for complex, and may be involved in the formation of against junctional nevus cells but not intradermal
this antigen. replication forks and in the recruitment of other nevi, and against fetal melanocytes but not normal
DNA replication-related proteins. This protein adult melanocytes.
The MART-1/Melan-A antigen is specific for forms a complex with MCM-4, 6, and 7, and has
the melanocyte lineage found in normal skin, been shown to regulate the helicase activity of the This antibody is very useful to identify Malignant
retina, and melanocytes, but not in other complex. This protein is phosphorylated, and thus Melanoma. Metastatic Amelanotic Melanoma can
normal tissues. It is thus useful as a marker for regulated by protein kinases CDC2 and CDC7. often be confused with a variety of poorly dif-
Melanocytic Tumors, with the caveat that it is ferentiated Carcinomas, Large Cell Lymphomas,
normally found in benign nevi as well. This MCM-2 is essential for eukaryotic DNA replication Sarcomas, Spindle Cell Carcinomas and various
antibody is very useful in establishing the and drives the formation of pre-replicative com- types of mesenchymal neoplasms. A keratin-
diagnosis of Metastatic Melanomas. plexes, which is the key first step during the G1 negative, vimentin-rich neoplasm that immuno-
phase. Therefore, altered MCM-2 expression may reacts with antibody to S-100 protein and with
be a hallmark of cell-cycle deregulation, which this melanoma antibody, is, with rare exception,
could be the most essential mechanism in the a Melanoma.
development and progression of human cancers.
MCM2 has been identified by DNA microarray and
transcriptional profiling as a gene that is over-
expressed in Cervical Carcinomas. This protein is
over-expressed in Cervical Dysplasia as a result
of HPV infection. The over-expression of MCM-2
provides the link between oncogenic HPV
infection and the molecular event of Cervical
Dysplasia.
CLONE M2-7C10 CLONE RBT-MCM2 CLONE HMB-45
ISOTYPE IgG2b/K ISOTYPE IgG ISOTYPE IgG1/K
CONTROL Normal Skin, Melanoma CONTROL HSIL, Cervical, Breast Cancer CONTROL Melanoma
LOCALIZATION Cytoplasmic LOCALIZATION Nuclear LOCALIZATION Cytoplasmic

BSB 5752 prediluted 15.0 ml BSB 6333 prediluted 15.0 ml BSB 5759 concentrated 15.0 ml
MiTF MLH1 MSH2
IHC of MiTF on an FFPE Melanoma Tissue IHC of MLH1 on an FFPE Colon Carcinoma Tissue IHC of MSH2 on an FFPE Colon Carcinoma Tissue
Microphthalmia-associated Transcription Factor MLH1 is a mismatch repair gene of around 87 MSH2 is a mismatch repair gene commonly
(MiTF) is a basic helix-loop-helix leucine zipper kDa, commonly associated with Hereditary Non- associated with Hereditary Non-Polyposis
transcription factor involved in melanocyte and Polyposis Colorectal Cancer (HNPCC). This gene Colorectal Cancer (HNPCC). This gene was
osteoclast development. Mutations in MiTF was identified as a locus frequently mutated identified as a locus frequently mutated in HNPCC.
cause auditory pigmentary syndromes, such as in HNPCC. It is a human homolog of the E. coli When cloned, it is a human homolog of the E. coli
Waardenburg Syndrome Type II, Type IIa and DNA mismatch repair gene mutL, consistent with DNA mismatch repair gene mutS, consistent with
Tietz Syndrome in humans. There are two known the characteristic alterations in microsatellite the characteristic alterations in microsatellite
isoforms of MiTF differing by 66 amino acids at sequences (RER+ phenotype) found in HNPCC. sequences (RER+ phenotype) found in HNPCC.
the NH2 terminus. Shorter forms are expressed Alternatively spliced transcript variants encoding
in melanocytes and run as two bands at 52 kDa different isoforms have been described, but their MSH2 is abnormally deficient in a high proportion
and 56 kDa, while the longer Mi form runs as a full-length natures have not been determined. of patients with microsatellite instability (MSI-H).
cluster of bands at 60-70 kDa in osteoclasts and This finding is associated with the autosomal
in B16 Melonoma cells (but not other Melanoma In a high proportion of patients with microsatellite dominant condition found in Hereditary
cell lines), as well as mast cells and heart cells. instability (MSI-H), the MLH1 protein is typically Non-Polyposis Colon Cancer. This anti-MSH2
MiTF plays a critical role in the differentiation of deficient. This protein deficiency is linked to the antibody (along with MLH1 antibody) is useful
various cell types such as neural crest-derived autosomal dominant condition of Hereditary in screening patients and families for this rare
melanocytes, mast cells, osteoclasts and optic Non-Polyposis Colon Cancer. The anti-MLH1 condition. Colon cancers that are microsatellite
cup-derived retinal pigment epithelium. antibody is useful in screening patients and unstable have a better prognosis than their
families for this condition. Colon cancers that are microsatellite stable counterparts.
This antibody recognizes serine phosphorylated microsatellite-unstable have a better prognosis
and non-phosphorylated melanocytic isoforms than their microsatellite stable counterparts.
of microphthalmia. It is useful in identifying
Malignant Melanoma, and distinguishing mast
cell lesions from lesions of myeloid derivation. A
relatively rare class of tumors known as PEComas
(tumors showing perivascular epithelioid cell
differentiation) express MiTF in a high percentage
of cases (~90%).
CLONE C5/D5 CLONE G168-728 CLONE G219-1129
ISOTYPE IgG1/K ISOTYPE IgG2a ISOTYPE IgG1
CONTROL Melanoma CONTROL Colon Mucosa, CONTROL Colon Mucosa,
LOCALIZATION Nuclear LOCALIZATION Colon Carcinoma LOCALIZATION Colon Carcinoma
LOCALIZATION Nuclear LOCALIZATION Nuclear

BSB 6249 concentrated 15.0 ml BSB 5766 prediluted 15.0 ml BSB 5773 prediluted 15.0 ml
53
MSH6 MUC1 MUC2
IHC of MSH6 on an FFPE Colon Carcinoma Tissue IHC of MUC1 on an FFPE Colon Carcinoma Tissue IHC of MUC2 on an FFPE Small Intestine Tissue
MSH6 is a gene commonly associated with Mucin 1, also known as MUC1, is a human Mucin 2, also known as MUC2, is a human gene.
Hereditary Non-Polyposis Colorectal Cancer gene. This gene is a member of the mucin This gene encodes a member of the mucin protein
(HNPCC). HNPCC is an autosomal, dominantly family and encodes a membrane-bound, family. The protein encoded by this gene forms
inherited disease associated with marked increase glycosylated phosphoprotein. The protein is an insoluble mucous barrier that protects the gut
in cancer susceptibility. It is characterized by a anchored to the apical surface of many epithelia lumen. The protein polymerizes into a gel of which
familial predisposition to early onset Colorectal by a transmembrane domain, the degree of 80% is composed of oligosaccharide side chains.
Carcinoma and extra-colonic cancers of the glycosylation varying with cell type. Mucins are
gastrointestinal, urological and female reproduc- high molecular-weight glycoproteins which MUC2 expression is detected in such human
tive tracts. HNPCC is reported to be the most constitute the major component of the mucus tissues as normal colon, breast, prostate, salivary
common form of inherited Colorectal Cancer in layer that protects the gastric epithelium from gland, and in gastrointestinal, colonic, breast and
the western world. MSH6 is a mismatch repair chemical and mechanical aggressions. The prostate neoplasia. This antibody labels MUC2 in
gene which is deficient in a high proportion of MUC1 protein serves a protective function by normal Colon and Colonic Carcinomas where it
patients with microsatellite instability (MSI-H). binding to pathogens and also functions in a produces intense perinuclear staining in goblet
cell-signaling capacity. Overexpression, aberrant cells. It also reacts with normal and neoplastic breast
The anti-MSH6 antibody is useful in screening intracellular localization, and changes in tissues and with Prostate Adenocarcinoma.
patients and families for HNPCC. Colon cancers glycosylation of this protein have been associated
that are microsatellite-unstable have a better with carcinomas. Multiple alternatively-spliced
prognosis than their microsatellite-stable transcript variants that encode different iso-
counterparts. forms of this gene have been reported, but the
full-length nature of only some has been
determined.
MUC1 is a large cell, surface-mucin glycoprotein

expressed by most glandular and ductal epithelial
cells and some hematopoietic cell lineages. It is
expressed on most secretory epithelium, including
mammary gland and some hematopoietic cells.
It is expressed in lactating mammary glands
and overexpressed in more than 90% Breast
Carcinomas and metastases. Transgenic MUC1
has been shown to associate with all four cebB
receptors and localize with erbB1 (EGFR) in
lactating glands.
CLONE 44 CLONE MRQ-17 CLONE MRQ-18
ISOTYPE IgG1 ISOTYPE IgG1 ISOTYPE IgG1/K
CONTROL Colon Mucosa CONTROL Breast, Colon CONTROL Small Intestine, Colon,
LOCALIZATION Colon Carcinoma LOCALIZATION Adenocarcinoma LOCALIZATION Colon Adenocarcinoma
LOCALIZATION Nuclear LOCALIZATION Cytoplasmic, Cell Surface LOCALIZATION Cytoplasmic, Cell Surface

MUC5AC MUC6 Myelin Basic Protein
IHC of MUC5AC on an FFPE Stomach Tissue IHC of MUC6 on an FFPE Stomach Tissue IHC of Myelin Basic Protein on an FFPE Brain Tissue
Mucin 5AC, also known as MUC5AC, is a human Mucin 6, also known as MUC6, is a human gene. Myelin Basic Protein (MBP) is a protein believed
gene. The Mucin 5AC antigen is found in columnar Mucin is a high M.W. (>1,000 kDa) glycoprotein, to be important in the process of myelination
mucous cells of surface gastric epithelium and in expressed by mucous cells of the gastric epithe- of nerves in the central nervous system (CNS).
goblet cells of the fetal and precancerous colon lium and by goblet cells of the fetal, precancerous The pool of MBP in the central nervous system
but not in normal colon cells. Mucin genes are and cancerous colon, but not by those of the is very diverse, with several splice variants being
expressed in a regulated cell- and tissue-specific normal colon. It also appears in other epithelial expressed and a large number of post-transla-
manner. MUC1 is detected in mucous cells of the tissues, which are embryologically derived from tional modifications on the protein, which include
surface epithelium and neck region of the gastric the foregut (epigastric and bronchial epithelium) phosphorylation, methylation, deamidation and
antrum, as well as in pyloric glands and oxynthic and in Müller ducts (mucous cells of the citrullination.
glands of the body region. MUC5AC is highly endocervix and urethral epithelium near the
expressed in foveolar epithelium of both body prostatic utriculus). MBP has been demonstrated in Neuromas,
and antrum, whereas MUC6 protein expression Neurofibromas, and Neurogenic Sarcomas.
is limited to mucous neck cells of the body and MUC6 antibody works well with ethanol-fixed, However, other spindle-cell neoplasms do not
pyloric glands of the antrum. cultured epithelial cells and ethanol- or formalin- stain with this antibody. Immunoreactivity for MBP
fixed, paraffin-embedded tissue sections. It in Granular-cell Tumors strengthens the concept
The mucin expression pattern of Gastric Carcinoma stains the surface gastric epithelium of normal of a Schwann-cell derivation of these lesions.
is heterogeneous. It includes mucins normally human gastrointestinal tract and reacts with fetal, Unlike other nervous system proteins such as
expressed in gastric mucosa (MUC1, MUC5AC and precancerous and cancerous colonic mucosa, but GFAP and S-100, MBP has not been demonstrated
MUC6) and de novo expression of the intestinal not with normal colon. in melanocytes or tumors derived from them.
mucin MUC2. The heterogeneous pattern of
mucin expression, including the expression of the
intestinal mucin MUC2, may provide new insights
into the differentiation pathways of Gastric
Carcinoma. It has been shown that in Gastric
Carcinomas evaluated for expression of several
mucins (MUC1, MUC2, MUC5AC and MUC6),
mucin expression is associated with tumor type
(MUC5AC with Diffuse and Infiltrative Carcinomas
and MUC2 with Mucinous Carcinomas) but not
with the clinico-biological behavior of the tumors.
Mucin expression is associated with tumor
location (MUC5AC with Antrum Carcinomas
and MUC2 with Cardia Carcinomas), indirectly
reflecting differences in tumor differentiation
according to tumor location.
CLONE CLH2 CLONE CLH5 CLONE N/A
ISOTYPE IgG1 ISOTYPE IgG1 ISOTYPE N/A
CONTROL Stomach CONTROL Stomach CONTROL Brain

55
Myeloperoxidase Myogenin Myoglobin
IHC of Myeloperoxidase on an IHC of Myogenin on an IHC of Myoglobin on an FFPE Skeletal Muscle Tissue
FFPE Bone Marrow Tissue FFPE Rhabdomyosarcoma Tissue
Myeloperoxidase (MPO) is a peroxidase en- Myogenin is a transcription factor active in Myoglobin is a single-chain globular protein
zyme most abundantly present in neutrophil muscles. In particular, it is a myogenic regulatory of 153 amino acids, containing a heme (iron-
granulocytes. It is a lysosomal protein stored in factor. Myogenin is a member of a family of containing porphyrin) prosthetic group in the
azurophilic granules of the neutrophil. MPO has myogenic regulatory genes, which includes center around which the remaining apoprotein
a heme pigment, which causes its green color in MyoD, myf5 and MRF4. These genes encode a folds. With a molecular weight of 16.7 kDa, it is
secretions rich in neutrophils, such as pus and set of transcription factors which are essential for the primary oxygen-carrying pigment of muscle
some forms of mucus. Historically, immunohisto- muscle development. Expression of myogenin tissues.
chemical staining for myeloperoxidase was used is restricted to cells of skeletal-muscle origin. It
in the diagnosis of Acute Myeloid Leukemia to is, therefore, a useful marker for tumors of the Immunostaining with Myoglobin provides
demonstrate that the leukemic cells were derived muscle lineage, being strongly expressed in a specific, sensitive and practical procedure
from the myeloid lineage. Myeloperoxidase Alveolar Rhabdomyosarcomas. for the identification of Rhabdomyosarcoma.
staining is still important in the diagnosis of Since myoglobin is found exclusively in skeletal
Extramedullary Leukemia or Chloroma. Anti-myogenin labels the nuclei of myoblasts and cardiac muscle and is not present in any
in developing muscle tissue, and is expressed in other cells of the human body, it may be used to
Myeloperoxidase detects granulocytes and tumor cell nuclei of Rhabdomyosarcoma and distinguish Rhabdomyosarcoma from other
monocytes in blood and precursors of some Leiomyosarcomas. Positive nuclear staining soft-tissue tumors. Myoglobin staining is also
granulocytes in the bone marrow. This antibody may occur in Wilm’s Tumor. useful when demonstrating rhabdomyoblastic
can detect myeloid cell populations of the bone differentiation in other tumors, e.g., Neurogenic
marrow as well as in other sites. Sarcomas and Malignant Mixed Mesodermal
Tumors of the uterus and ovary.
ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Rabbit Polyclonal
CLONE N/A CLONE F5D CLONE N/A
ISOTYPE N/A ISOTYPE IgG1/K ISOTYPE N/A
CONTROL Bone Marrow CONTROL Rhabdomyosarcoma CONTROL Skeletal Muscle
LOCALIZATION Cytoplasmic LOCALIZATION Nuclear LOCALIZATION Cytoplasmic

Myosin, Smooth Muscle Neuroblastoma Neurofilament

Heavy Chain
IHC of Myosin Smooth Muscle Heavy Chain on an IHC of Neuroblastoma on an IHC of Neurofilament on an FFPE Brain Tissue
FFPE Appendix Tissue FFPE Neuroblastoma Tissue
Myosins are a large family of motor proteins Neuroblastoma is the most common extracranial Neurofilaments are the Type IV family of
found in eukaryotic tissues. They are responsible solid cancer in infancy and childhood. It is a intermediate filaments that are found in high
for actin-based motility. Smooth Muscle Myosin, neuroendocrine tumor, arising from any neural concentrations along the axons of vertebrate
Heavy Chain is a cytoplasmic structural protein crest element of the sympathetic nervous system. neurons.
that is a major component of the contractile The incidence of Neuroblastoma is about 1 per
apparatus of the smooth muscle cells, as well as a 100,000 infants. Neurofilament antibody stains an antigen local-
myoepithelium-associated protein. ized in a number of neural, neuroendocrine and
Anti-Neuroblastoma is a monoclonal antibody endocrine tumors. Neuromas, Ganglioneuromas,
SMM-H24 is a mouse monoclonal antibody produced using human Neuroblastoma tissue as a Gangliogliomas, Ganglioneuroblastomas and
to Smooth Muscle Myosin, Heavy Chain that source of antigen. It recognizes an uncharacterized Neuroblastomas stain positively for neuro-
reacts with human visceral and vascular smooth 57 kDa molecule. It is useful in identifying filament. Neurofilaments are also present in
muscle cells. The antibody also reacts with human Neuroblastoma (99% (+)) and Desmoplastic Small Paragangliomas and Adrenal and Extra-Adrenal
myoepithelial cells. It is very helpful in Round-Cell Tumors (50% (+)). A small percentage of Pheochromocytomas. Carcinoids, Neuroendocrine
distinguishing between benign sclerosing breast Ewing’s Sarcoma (20%) and Rhabdomyosarcomas Carcinomas of the Skin, and Oat Cell Carcinomas
lesions and infiltrating Carcinomas in difficult (20%) stain positive with this antibody. of the Lung also express neurofilament.
cases, since it strongly stains the myoepithelial
layer in the benign lesions while it is negative in
the infiltrating Carcinomas.
CLONE SMM-H24 CLONE NB84a CLONE 2F11
ISOTYPE IgG1/K ISOTYPE IgG1 ISOTYPE IgG1/K
CONTROL Intestine, Breast CONTROL Neuroblastoma CONTROL Brain

57
NGFR NSE p27
IHC of NGFR on an FFPE Brain Tissue IHC of NSE on an FFPE Pancreas Tissue IHC of p27 on an
NGFR (Nerve Growth Factor Receptor), also Neuron-Specific Enolase (NSE, Enolase 2) is a p27KIP1 is a cell cycle regulatory mitotic inhibitor
termed p75 or CD271, is the low-affinity NGFR human gene. It makes a phosphopyruvate of Cdk activity. p27KIP1 is a candidate-tumor
(LNGFR) which binds NGF and other neurotrophins, hydratase. This gene encodes one of the three suppressor gene, and has been proposed to
including BDNF, NT3 and NT4/5 with similar enolase isoenzymes found in mammals. This function as a possible mediator of TGF beta
low-affinity. NGFR p75 is a 75 kD transmembrane isoenzyme, a homodimer, is found in mature induced G1 arrest. p27 is up-regulated in response
glycoprotein that is mainly expressed in Schwann neurons and cells of neuronal origin. A switch from to antimitogenic stimuli. The increased protein
cells and neurons and in a variety of non-neuronal alpha enolase to gamma enolase occurs in neural expression of p27 results in cellular arrest by
cells. NGFR p75 is necessary for regulating neuronal tissue during development in rats and primates. binding to cyclin/Cdk complexes such as cyclin
growth, migration, differentiation and cell death D1/Cdk4.
during development of the central and peripheral NSE is present in high concentration in neurons
nervous system. NGFR p75 plays a central role in the and in central and peripheral neuroendocrine Low p27 expression has been associated with
regulation of cell number by apoptosis in the devel- cells; therefore, NSE reacts with cells of neural unfavorable prognosis in Renal-cell Carcinoma,
oping CNS. During early development, activation of and neuroendocrine lineage. If neoplastic cells Colon Carcinoma, Small Breast Carcinomas,
NGFR p75 by NGF induces apoptotic cell death in coexpress keratins and NSE, neuroendocrine Non-small-cell Lung Carcinoma, Hepatocel-
some neuronal cells, probably through activation differentiation is probable. However, neural lular Carcinoma, Multiple Myeloma, lymph node
of the sphingomyelinase/ceramide pathway, the tumors that do not express keratin, and show no metastases in Papillary Carcinoma of the Thyroid,
ICE-like proteases and the JNK pathway. CD271 staining with NSE, would not exclude neural or and a more aggressive phenotype of Carcinoma
has recently been described as being expressed in neuroendocrine differentiation. Thus, detection in the Cervix.
mesenchymal stem cells (bone marrow stromal cells). of neural and neuroendocrine lineage requires
the use of panels which include NSE and
NGFR is expressed not only in sympathetic and sen- other markers such as keratin, chromogranin,
sory neurons, but also in various neural crest cell or synaptophysin and neurofilament.
tumor derivatives such as melanocytes, Melanomas,
Neuroblastomas, Pheochromocytomas, Neurofibro-
mas, and neurotized nevi (Type C melanocytes). It is
now apparent that expression of NGFR is ubiquitous
and not limited to the nervous system, being
expressed in mature non-neural cells such as peri-
vascular cells, dental pulp cells, lymphoid follicular
dendritic cells, basal epithelium of oral mucosa and
hair follicles, prostate basal cells and myoepithelial
cells. Studies in Prostate and Urothelial Cancer sug-
gest that NGFR may act as a tumor suppressor,
negatively regulating cell growth and proliferation.
NGFR labels the myoepithelial cells of breast ducts
and intralobular fibroblasts of breast ducts and, thus,
aids in the diagnosis of malignancy in the breast.
CLONE NGFR/c10 CLONE SPM347 CLONE SX53G8
ISOTYPE IgG1 ISOTYPE IgG2a ISOTYPE IgG1/K
CONTROL Breast, CNS Tumor CONTROL Pancreas CONTROL Colon Adenocarcinoma, Non-Small
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic LOCALIZATION Cell Lung Carcinoma, Prostate

p53 p57 p63
IHC of p53 on an FFPE Breast Carcinoma Tissue IHC of p57 on an FFPE Placenta Tissue IHC of p63 on an FFPE Prostate Tissue
p53 (also known as tumor protein 53 [TP53]) p57 or p57KIP2 is a tumor-suppressor human In addition to p53, mammalian cells contain two
is a transcription factor that regulates the cell gene that belongs to the cip/kip gene family. homologous genes, p63 and p73. These genes
cycle and, hence, functions as a tumor suppressor. It encodes a cell cycle inhibitor that binds to G1 give rise to the expression of proteins that are
p53 has been described as ”the guardian of cyclin-CDK complexes. Thus, p57 causes arrest of highly similar to p53 in structure and function.
the genome”, referring to its role in conserving the cell-cycle in G1 phase. A mutation of this gene In particular, p63 and p73 proteins can induce
stability by preventing genome mutation. p53 may lead to loss of control over the cell-cycle p53-responsive genes and elicit programmed cell
has many anti-cancer mechanisms. It can activate leading to uncontrolled cellular proliferation. death. p73 and p63 are more important during
DNA repair proteins when DNA has sustained The gene encoding human p57KIP2 is located development and differentiation. In particular,
damage; it can also hold the cell cycle at the G1/S on chromosome 11p15.5, a region implicated p63 appears to be primarily implicated in
regulation point on DNA damage recognition. in sporadic cancers, Wilm’s Tumor and Beckwith epithelial development.
It can initiate apoptosis, programmed cell Wiedemann Syndrome (BWS is characterized by
death, if DNA damage proves to be irreparable. increased risk of tumor formation in childhood), Anti-p63 to human p63 protein labels an epitope
p53 is central to many of the cell’s anti-cancer making it a tumor suppressor candidate. common to all six p63 isotypes (TAp63α, TAp63β,
mechanisms. It can induce growth arrest, TAp63γ, ΔNp63α, ΔNp63β, ΔNp63γ). p63 labels
apoptosis and cell senescence. Anti-p57 has been used to aide in discriminating the nuclei of myoepithelial cells in the prostate
Complete Hydatidiform Mole (CHM) (no gland as well as breast tissue, making it useful
Mutations involving p53 have been found in a nuclear labeling of cytotrophoblasts) from Partial in differentiating benign vs. malignant prostate
wide variety of malignant tumors, including Breast, Hydatidiform Mole (PHM) and hydropic abortion. lesions and breast lesions.
Ovarian, Bladder, Colon, Lung, and Melanoma. In normal placenta, many cytotrophoblast nuclei
and stromal cells are labelled with this antibody.
Similar findings apply to PHM and hydropic abortus
tissues. Intervillous Trophoblastic Islands (IVTIs)
demonstrate nuclear labeling in all three entities
and serve as an internal control.
CLONE DO7 CLONE Kp10 CLONE 4A4
ISOTYPE IgG2b/K ISOTYPE IgG2b/K ISOTYPE IgG2a/K
CONTROL Colon, Breast Carcinoma CONTROL Placenta, Colon Carcinoma CONTROL Normal Prostate, Breast
LOCALIZATION Nuclear LOCALIZATION Nuclear LOCALIZATION Nuclear

BSB 5847 control slides 5 BSB 6197 control slides 5 BSB 5854-1 control slides 5
59
Parvovirus B19 PAX-5 PD-1/CD279
IHC of Parvovirus B19 on a FFPE Placenta Tissue IHC of PAX-5 on an FFPE Tonsil Tissue IHC of PD-1 on an FFPE Tonsil Tissue
Parvovirus B19 belongs to the Parvoviridae family The PAX proteins are important regulators in early Programmed Death 1, (PD-1 or CD279), is a Type I
of small DNA viruses. It is classified as Erythrovirus development, and alterations in the expression membrane protein comprised of 268 amino acids.
because of its capability to invade red blood cell of their genes are thought to contribute to PD-1 is a member of the extended CD28/CTLA-4
precursors in the bone marrow. Anti-Parvovirus neoplastic transformation. The PAX-5 gene family of T-cell regulators. PD-1 is expressed
antibody targets the capsid proteins VP1 and VP2 encodes the B-cell lineage-specific activator on the surface of activated T-cells, B-cells, and
on Human Parvovirus. protein (BSAP) that is expressed at early, but not macrophages. In comparison to CTLA-4, PD-1
late, stages of B-cell differentiation. Its expression more broadly negatively regulates immune
has also been detected in developing CNS and responses.
testis; therefore, PAX-5 gene product may not only
play an important role in B-cell differentiation, but New data suggests that expression of PD-L1 on
also in neural development and spermatogenesis. tumor cells inhibits anti-tumor activity through
engagement of PD-1 on effector T-cells. Expres-
PAX-5 expression is not only continuously sion of PD-L1 on tumors is correlated with reduced
required for B-cell lineage commitment during survival in esophageal, pancreatic and other types
early B-cell development but also for B-cell lineage of cancers, highlighting the relevance of exploring
maintenance. PAX-5 is found in most cases of the PD-1 pathway as a target for immunotherapy.
mature and precursor B-cell Non-Hodgkin’s Studies have found that PD-1 is expressed on most
Lymphomas/Leukemias. PAX-5 is not detected T-cells and a small subset of B-cells in the light
in Multiple Myeloma and solitary Plasmacytoma, zone of germinal centers, but not elsewhere in the
making it useful for such differentiation. Diffuse tonsil. On that basis, it was postulated that PD-1
Large B-cell Lymphomas do express PAX-5, except may play a role in the process of clonal selection
for those with terminal B-cell differentiation. T-cell of centrocytes, which occurs in this subanatomic
neoplasms do not stain with anti-PAX-5; however, site in germinal centers. PD-1 is a new marker of
there is a strong association with CD20 expression. Angioimmunoblastic Lymphoma and suggests
a unique cell of origin for this neoplasm. Unlike
CD10 and bcl-6, PD-1 is expressed by few B-cells,
so it may be a more specific and useful diagnostic
marker in Angioimmunoblastic Lymphoma. It
also seems to stain a greater percentage of CD3-
positive neoplastic cells in Angioimmunoblastic
Lymphoma than either CD10 or bcl-6.
CLONE R92F6 CLONE RBT-PAX5 CLONE MRQ-22
ISOTYPE IgG1 ISOTYPE IgG ISOTYPE IgG1
CONTROL Infected Tissue CONTROL Tonsil, Lymph Node CONTROL Tonsil, Lymph Node
LOCALIZATION Nuclear, Cytoplasmic LOCALIZATION Nuclear LOCALIZATION Cytoplasmic

BSB 5859 concentrated 1.0 m BSB 5866 concentrated 1.0 ml BSB 6217 concentrated 1.0 ml
PLAP Pneumocystis Carinii Podoplanin/D2-40
IHC of PLAP on an FFPE Placenta Tissue IHC of Pneumocystis on an FFPE Lung Tissue IHC of Podoplanin/D2-40 on an FFPE Tonsil Tissue
Placental Alkaline Phosphatase (PLAP) is found Anti Pneumocystis carinii antibody reacts with an Podoplanin is a transmembrane mucoprotein
in trophoblast cells of normal mature human epitope on the yeast-like fungal microorganism, (38 kDa) recognized by the D2-40 monoclonal
placenta, Seminomas of testis and Ovarian Pneumocystis carinii. that is resistant to formalin, antibody. Podoplanin is specifically expressed
Carcinomas. Detection of alkaline phosphatase in picric acid, paraffin, as well as alcohol and xylene. in the endothelium of lymphatic capillaries but
serum is a marker for Ovarian and Testicular Cancer. No cross-reactivity has been demonstrated with not in the blood vasculature. In normal skin and
This antibody reacts with a membrane-bound other fungi or parasitic organisms. kidney, podoplanin is co-localized with VEGFR3/
isoenzyme of placental alkaline phosphatase FLT4, another marker for lymphatic endothelial cells.
occurring in the placenta during the 3rd trimester
of gestation. Podoplanin is selectively expressed in lymphatic
endothelium as well as Lymphangiomas, Kaposi’s
This antibody immunoreacts with Germ Cell Sarcomas and in subset Angiosarcomas with
Tumors and can discriminate between these and probable lymphatic differentiation. Podoplanin
other neoplasms. Somatic neoplasms (e.g., breast, has also been shown to be expressed in
gastrointestinal, prostatic and urinary cancers) Epithelioid Mesotheliomas, Hemangioblastomas
may also immunoreact with antibodies to PLAP. and Seminomas.
PLAP positivity, in conjunction with keratin
negativity, favors Seminoma over Carcinoma.
Germ Cell Tumors are usually keratin positive but
they regularly fail to stain with EMA, whereas most
Carcinomas stain with anti-EMA. This antibody
has shown cross-reaction with human intestinal
alkaline phosphatase.
CLONE EPR6141 CLONE 3F6 CLONE D2-40
ISOTYPE IgG ISOTYPE IgM ISOTYPE IgG1
CONTROL Placenta CONTROL Infected Tissue CONTROL Tonsil, Lymph Node,
LOCALIZATION Cytoplasmic LOCALIZATION Membranous LOCALIZATION Lymphangioma

61
Progesterone Receptor Prolactin PSA
IHC of Progesterone Receptor on an IHC of Prolactin on an FFPE Pituitary Tissue IHC of Prostate-Specific Antigen on an
FFPE Breast Carcinoma Tissue FFPE Prostatic Adenocarcinoma Tissue
The progesterone receptor (PR) also known as Prolactin is a peptide hormone primarily Prostate-specific antigen (PSA) is a protein
NR3C3 (nuclear receptor subfamily 3, group C, associated with lactation. It is synthesized and produced by the cells of the prostate gland. PSA is
member 3), is an intracellular steroid receptor that secreted by lactotrope cells in the adenohypophy- present in small quantities in the serum of normal
specifically binds progesterone. PR is encoded sis (anterior pituitary gland). It is also produced men, and is often elevated in the presence of
by a single gene PGR residing on chromosome in other tissues including the breast and the prostate cancer and in other prostate disorders.
11q22; it has two main forms, A and B, which decidua. Pituitary prolactin secretion is regulated Higher than normal levels of PSA are associated
differ in their molecular weight. Like all steroid by neuroendocrine neurons in the hypothalamus, with both localized and metastatic prostate cancer.
receptors, the progesterone receptor has an most importantly by neurosecretory dopamine
amino and a carboxyl terminal, and between neurons of the arcuate nucleus, which inhibit The PSA antibody recognizes primary and
them the regulatory domain, a DNA binding prolactin secretion. metastatic prostatic neoplasms but not tumors
domain, the hinge section, and the hormone of nonprostatic origin. The antigen is a 33-34 kDa
binding domain. Prolactin is a useful marker in classification of glycoprotein that is restricted to cells of prostatic
pituitary tumors and the study of pituitary disease. origin. An immunohistochemical study showed
It reacts with lactotrope cells. more than 95% of prostatic carcinomas stained
with PSA. PSA is demonstrable in the cytoplasm
of acinar and ductal cells of normal or malignant
prostate tissue.
CLONE RBT22 CLONE N/A CLONE A6-B/E3
ISOTYPE IgG ISOTYPE N/A ISOTYPE IgG1/K
CONTROL Breast Carcinoma CONTROL Normal Pituitary CONTROL Prostate

BSB 5882 prediluted 3.0 ml BSB 5889 prediluted 3 .0ml BSB 5896 prediluted 3 .0ml
BSB 5884 prediluted 15.0 ml BSB 5891 prediluted 15.0 ml BSB 5898 Prediluted 15.0 ml
PSAP PSMA Renal Cell Carcinoma
IHC of PSAP on an FFPE Prostate Tissue IHC of PSMA on an IHC of Renal Cell Carcinoma on an
FFPE Prostate Adenocarcinoma Tissue FFPE Kidney Tissue
Prostatic specific acid phosphatase (PSAP) is an PSMA, prostate specific membrane antigen, Renal Cell Carcinoma, also known as a Gurnistical
enzyme produced by the prostate. It may be found is a Type 2 integral membrane glycoprotein Tumor, is the most common form of kidney cancer
in increased amounts in men who have prostate found in prostate and a few other tissues. arising from the renal tubule. It is also the most
cancer or other diseases. The highest levels of acid Three functionally-distinct proteins are encoded, common type of kidney cancer in adults. Initial
phosphatase are found in metastasized prostate including folylpoly-gamma-glutamate car- treatment is surgery because it is notoriously
cancer. Diseases of the bone, such as Paget’s boxypeptidase in the intestine, N-acetylated resistant to radiation therapy and chemotherapy,
disease or hyperparathyroidism, diseases of alpha-linked acidic dipeptidase 1 in the brain although some cases respond to immunotherapy.
blood cells, (such as Sickle-Cell Disease), Multiple and prostate-specific membrane antigen in the
Myeloma or Lysosomal Storage Diseases, (such prostate. A mutation in the intestinal form may Renal Cell Carcinoma antibody recognizes a
as Gaucher’s disease), will show moderately be associated with impaired intestinal absorption 200 kDa glycoprotein localized in the brush
increased levels. Certain medications can of dietary folates, resulting in low blood folate border of the proximal renal tubule. This antibody
cause temporary increases or decreases in acid levels and consequent hyperhomocysteinemia. immunoreacts with approximately 90% of
phosphatase levels. Manipulation of the prostate The form expressed in the brain may be involved Primary Renal Cell Carcinomas and approxi-
gland through massage, biopsy or rectal exam in a number of pathological conditions associated mately 85% of Metastatic Renal Cell Carcinomas.
before a test may increase the levels of PSAP. with glutamate cytotoxicity. The prostate form Other tumors that may react with this antibody
is up-regulated in cancerous cells and is used as are Parathyroid Adenoma, an occasional Breast
This antibody reacts with prostatic specific acid an effective diagnostic and prognostic indicator Carcinoma. Nephroblastoma, Oncocytoma,
phosphatase in the glandular epithelium of the of prostate cancer. This gene likely arose from Mesoblastic Nephroma, Transitional Cell
normal and Hyperplastic Prostate, Carcinoma a duplication event of a nearby chromosomal Carcinoma, and Angiomyolipoma are not labeled
of the prostate and metastatic cells of Prostatic region. Alternative splicing gives rise to multiple with this antibody.
Carcinoma. This marker may be helpful in transcript variants.
pinpointing the site of origin in cases of
Metastatic Carcinoma of the prostate, and is Although PSMA expression is highest in the
considered a more sensitive marker than PSA. prostate, detectable levels of protein are also
However, it also offers less specificity. found in the small intestine and the brain.
PSMA is expressed in prostate cancer cells as a
noncovalently associated homodimer. Using
a secreted form of the protein, it has been
demonstrated that the extracellular domain is
sufficient for dimerization and that dimerization
is required for enzymatic activity. When used as
an immunogen, dimeric (but not monomeric)
PSMA is capable of efficiently eliciting antibodies
that recognize PSMA-expressing tumor cells. It is
a possible therapeutic target for prostate cancer
and it is being used (with radioactive antibodies)
to image prostate tissue.
CLONE PASE/4LJ CLONE EPR6253 CLONE PN-15
ISOTYPE IgG1 ISOTYPE IgG ISOTYPE IgG1/K
CONTROL Prostate CONTROL Prostate CONTROL Kidney, Renal Cell Carcinoma
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic, Membranous

63
Retinoblastoma/Rb S-100 Somatostatin
IHC of Retinoblastoma on an IHC of S-100 on an IHC of Somatostatin on an FFPE Pancreas Tissue

FFPE Colon Carcinoma Tissue FFPE Malignant Melanoma Tissue
The retinoblastoma protein (Rb) is a tumor- S-100 protein is a type of low-molecular weight Somatostatin is a peptide hormone that regulates
suppressor protein that is dysfunctional in many protein found in vertebrates, characterized by the endocrine system and affects neurotransmis-
types of cancer. One highly studied function of Rb two calcium-binding sites of the helix-loop-helix sion and cell proliferation via interaction with
is to prevent excessive cell growth by inhibiting conformation. S-100 is normally present in cells G-protein-coupled somatostatin receptors and by
cell-cycle progression until a cell is ready to divide. derived from the neural crest (Schwann cells, mela- inhibition of the release of numerous secondary
Rb prevents the cell from replicating damaged nocytes and glial cells), chondrocytes, adipocytes, hormones. Somatostatin has two active forms
DNA by preventing its progression along the cell myoepithelial cells, macrophages, Langerhans cells, produced by alternative cleavage of a single
cycle through G1 into S. dendritic cells, and keratinocytes. It may be present preproprotein: one of 14 amino acids; the other
in some breast epithelial cells. Several members of of 28 amino acids. Somatostatin is secreted not
Should an oncogenic protein (such as that the S-100 protein family are useful as markers for only by cells of the hypothalamus but also by the
produced by cells infected with high-risk types of certain tumors and epidermal differentiation. The stomach, intestine, and delta cells of the pancreas.
human papillomaviruses, SV40 or Adenoviruses) S-100 protein can be found in melanomas, 50% of It binds to somatostatin receptors.
bind and inactivate Rb, this can lead to cancer. Rb Malignant Peripheral Nerve Sheath Tumors, and
protein may act by regulating transcription; loss Clear Cell Sarcomas. Somatostatin is a useful marker of D-cells
of its function leads to uncontrolled cell growth. of pancreatic islet cells. D-cells are used to
Aberrations in the Rb gene have been implicated Almost all Malignant Melanomas and cases of identify hyperplasia of the pancreatic islets.
in cancers of breast, colon, prostate, kidney, Histiocytosis X are positive for S-100 protein. Most of these tumors are malignant, giving rise
nasopharynx, and Leukemia. Despite the fact that S-100 protein is a ubiquitous to Somatostatinomas. Somatostatin suppresses
substance, its demonstration is of great value gastric acid secretion, gallbladder contractions
in the identification of several neoplasms, and pancreatic enzyme secretion.
particularly Melanomas.
CLONE SPM353 CLONE 4C4.9 CLONE N/A
ISOTYPE IgG1/K ISOTYPE IgG2a ISOTYPE N/A
CONTROL Colon, Breast Carcinoma CONTROL Melanoma CONTROL Pancreas

Spectrin Synaptophysin TAG-72
IHC of Spectrin on an FFPE Bone Marrow Tissue IHC of Synaptophysin on an IHC of TAG-72 on an FFPE Breast Tissue
FFPE Neuroendocrine Tumor
Spectrin is a cytoskeletal protein that lines the Synaptophysin is a synaptic vesicle glycoprotein Tumor-associated glycoprotein (TAG-72) has
intracellular side of the plasma membrane of weighing 38 kDa. It is present in endocrine cells, been shown to be expressed in a wide variety of
many cell types in pentagonal or hexagonal the brain, spinal cord, and adrenal glands. It acts epithelial malignant tissues. TAG-72 antigen is a
arrangements, forming scaffolds and playing as a marker for neuroendocrine cells. high molecular glycoprotein found on the surface
an important role in maintenance of plasma- of many cancer cells, including breast, colon and
membrane integrity and cytoskeletal structure. Synaptophysin reacts with neuroendocrine cells pancreatic cells. It is present in human Adenocar-
The hexagonal arrangements are formed by of human adrenal medulla, carotid body, skin, cinomas and in lesser amounts, non-neoplastic
tetramers of spectrin associating with short actin pituitary, thyroid, lung, pancreas and gastrointesti- tissues. The majority of human Adenocarcinomas
filaments at either end of the tetramer. These nal mucosa. Positive staining is seen in neurons of including Colorectal, Pancreatic, Gastric, Ovarian,
short actin filaments act as junctional complexes, the brain, spinal cord, retina, and Paneth’s cells in Endometrial, Mammary, and Non-Small Cell Lung
allowing the formation of the hexagonal mesh. the gastrointestinal tract and gastric parietal cells. Cancer display some cell populations that are
This antibody identifies normal neuroendocrine positive for TAG-72.
Spectrin is found in the intracellular side of the cells and neuroendocrine neoplasms. Diffuse,
plasma membrane of many cell types found in finely-granular cytoplasmic staining is observed TAG-72 has also been found to be useful for the
muscles, red blood cells and red cell precursors. and probably correlates with the distribution of distinction between Mesothelioma and Adeno-
Anti-Spectrin antibody is useful in the diagnosis the antigen within neurosecretory vesicles. The carcinoma; however, false positive reactions can
of Erythroid Leukemias. expression of Synaptophysin is independent of occur so results must be interpreted with the
the presence of NSE or other neuroendocrine utmost caution.
markers. Synaptophysin is an independent broad-
range marker of neural and neuroendocrine
differentiation.
CLONE RBC2/3D5 CLONE N/A CLONE Tag72-22
ISOTYPE IgG2b/K ISOTYPE N/A ISOTYPE IgG1/K
CONTROL Bone Marrow CONTROL Pancreas CONTROL Breast Carcinoma
LOCALIZATION Membranous LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic

65
TdT Thyroglobulin TIA-1
IHC of TdT on an IHC of Thyroglobulin on an FFPE Thyroid Tissue IHC of TIA-1 on an FFPE Tonsil Tissue
FFPE Acute Lymphoblastic Lymphoma Tissue
Terminal Deoxynucleotidyl Transferase (also Thyroglobulin (Tg) is a 660 kDa, dimeric protein TIA-1 (T-cell intracytoplasmic antigen) is a 15 kDa
known as TdT and terminal transferase) is a produced by and used entirely within the thyroid cytoplasmic granule-associated protein,
specialized DNA polymerase expressed in gland. Tg is used by the thyroid gland to produce expressed in lymphocytes processing cytolytic
immature, pre-B, pre-T lymphoid cells and acute the thyroid hormones thyroxine (T4) and triio- potential. TIA-1 is a member of an RNA-binding
Lymphoblastic Leukemia/Lymphoma cells. TdT dothyronine (T3). The active form of thyroxine, protein family and possesses nucleolytic activity
catalyzes the addition of nucleotides to the 3’ triiodothyronine, is produced both within the thy- against cytotoxic lymphocyte (CTL) target cells.
terminus of a DNA molecule. Unlike most DNA roid gland and on the periphery by 5’-deiodinase, It has been suggested that this protein may
polymerases, it does not require a template. The which has been referred to as Tetraiodothyronine- be involved in the induction of apoptosis as it
preferred substrate of this enzyme is a protruding 5-deiodinase. preferentially recognizes poly(A) homopolymers
3’ overhang, but it can also add nucleotides to and induces DNA fragmentation in CTL targets.
blunt or recessed 3’ ends. This antibody reacts with human thyroglobulin as The major granule-associated species is a
demonstrated by a single band of immunoblot- 15 kDa protein thought to be derived from the
TdT is normally found in cortical thymocytes ting in a lysate of human thyroid tissue. The vast carboxyl terminus of the 40 kDa product by
and primitive lymphocytes. TdT antibody detects majority of follicular carcinomas of the thyroid will proteolytic processing.
its antigen found in the nucleus of normal give positive immunoreactivity for thyroglobulin,
hematopoietic cells, normal cortical thymocytes sometimes only focally. Poorly-differentiated The expression of TIA-1 has been studied in
and in the cytoplasm of megakaryocytes of the Carcinomas of the Thyroid are frequently Anaplastic Large Cell Lymphomas (ALCL), NK-cell
bone marrow. TdT expression is seen in over 90% thyroglobulin negative. Adenocarcinomas of Lymphomas, Peripheral T-cell Lymphomas, T-cell
of Acute Lymphocytic Leukemia cases with the non-thyroid origin do not react with this antibody. Lymphocytosis, B-cell Lymphomas and Lympho-
exception of pre-B-Cell ALL, and normal mature blastic Leukemia, Hodgkin’s, etc. Studies show that
T- or B-lymphocytes. TdT is positive for 60 to 70% of Anaplastic Large Cell Lymphomas
approximately one third of all cases of Chronic react with TIA-1. TIA-1 reacts with most Large
Myeloid Leukemia, making it a good indicator of Granular Lymphocytic Leukemias, Hepatosplenic
better response to chemotherapy. T-cell Lymphomas, intestinal T-cell Lymphomas,
NK-like T-cell Lymphomas, NK-cell Lymphomas,
nasal T/NK-cell Lymphomas, subcutaneous
T-cell Lymphomas and Pulmonary Angiocentric
Lymphomas of T- or NK-phenotype. All B-cell
Lymphomas, Hodgkin’s and Lymphoblastic
Leukemias are negative for TIA-1.
ANTIBODY TYPE Rabbit Polyclonal ANTIBODY TYPE Mouse Monoclonal ANTIBODY TYPE Mouse Monoclonal
CLONE N/A CLONE 2H11 + 6E1 CLONE TIA-1
ISOTYPE N/A ISOTYPE IgG1 ISOTYPE IgG1
CONTROL TdT Positive Lymphoma, CONTROL Thyroid CONTROL Tonsil, Spleen, Anaplastic
LOCALIZATION Thymus LOCALIZATION Cytoplasmic LOCALIZATION Large Cell Lymphoma
LOCALIZATION Nuclear LOCALIZATION Cytoplasmic (Granular)

Topoisomerase II alpha Toxoplasma gondii TRAcP
IHC of Topo IIa on an FFPE HSIL of the Cervix IHC of Toxoplasma gondii on an IHC of TRAcP on an FFPE Hairy Cell Leukemia Tissue
FFPE Brain Tissue
DNA Topoisomerase II alpha (Topo IIa) is a nucleic Toxoplasma gondii is a genus of parasitic protozoa Tartrate-resistant acid phosphatase (TRAcP)
enzyme that affects the topological structure of (cats being the definitive host). It can also be is a glycosylated monomeric metallo-enzyme
DNA by interacting with the double-helix DNA, carried by the vast majority of warm-blooded expressed in mammals. It has a molecular weight
thus playing an important role in DNA replication, animals, including humans. Toxoplasma gondii of approximately 35 kDa, a basic isoelectric
transcription, recombination, condensation, and belongs to the phylum Apicomplexa and is point (7.6 - 9.5), and optimal activity in acidic
segregation. Type II topoisomerases cut both the only known member species of the genus conditions. TRAcP is synthesized as a latent
strands of the DNA helix simultaneously in order to Toxoplasma. The life cycle of T. gondii has proenzyme and is activated by proteolytic cleavage
change the linking number of the molecule. Topo two phases. The sexual part of the life cycle and reduction. Normally, TRAcP is highly
IIa is essential in the separation of daughter strands (coccidia-like) occurs only in members of the expressed by osteoclasts, activated macrophages,
at the end of replication. Failure to separate these Felidae family (domestic and wild cats), which neurons and endometrium during pregnancy.
strands leads to cell death. In cancers, the Topo IIa makes these animals the parasite’s primary host. There are also certain pathological conditions
is highly expressed in highly-proliferating cells. The asexual part of the life cycle can occur in any whereby expression of TRAcP is increased. These
warm-blooded animal, such as other mammals include patients with Leukemic Reticuloendothe-
Topo IIa has been identified by DNA microarray (including felines) and birds. liosis (Hairy Cell Leukemia), Gaucher’s Disease,
and transcriptional profiling as a gene that is HIV-induced Encephalopathy, Osteoclastoma and
overexpressed in Cervical Carcinomas. The TOP2A in osteoporosis and metabolic bone diseases.
gene is approximately 30 kb in size and encodes
a 170 kDa protein. Topo IIa protein is expressed Anti-TRAcP antibody labels the cells of Hairy
in proliferating cells and in numerous human Cell Leukemia (HCL) with a high degree of
malignant tumors, including colon, gastric and sensitivity and specificity. Other cells stained
breast cancers, Lymphomas and others. In certain with this antibody are tissue macrophages
cancers, such as Peripheral Nerve Sheath Tumors, and osteoclasts, which also express abundant
high expression of this protein is also associated TRAcP activity.
with poor patient survival. Type II topoisomer-
ases are the targets for anticancer drugs, such
as topoisomerase II inhibitor therapies like the
anthracyclines (Doxorubicin and Epirubicin).
CLONE RBT-Topo 2a CLONE N/A CLONE 9C5
ISOTYPE IgG ISOTYPE N/A ISOTYPE IgG2b
CONTROL Cervical, Breast Cancer CONTROL Infected Tissue CONTROL Hairy Cell Leukemia
LOCALIZATION Nuclear LOCALIZATION Cell Wall LOCALIZATION Cytoplasmic

67
Tryptase TSH TTF-1
IHC of Tryptase on an IHC of TSH on an FFPE Pituitary Tissue IHC of TTF-1 on an FFPE Lung Tissue
FFPE H. pylori Infected Stomach Tissue
Tryptase is the most abundant secretory granule- Thyroid-stimulating hormone (TSH or thyrotropin) Thyroid transcription factor-1 (TTF-1) is a protein
derived serine proteinase contained in mast cells is a hormone synthesized and secreted by that regulates transcription of genes specific to the
and has recently been used as a marker for mast thyrotrope cells in the anterior pituitary gland thyroid, lung and diencephalon. It is also known
cell activation. It is involved in allergenic response which regulates the endocrine function of the as thyroid-specific enhancer binding protein
and is suspected to act as a mitogen for fibroblast thyroid gland. TSH stimulates the thyroid gland and NKX-2. It is used as a marker to determine if
lines. Elevated levels of serum tryptase occur in to secrete the hormones thyroxine (T4) and a tumor oringinates in the lung or thyroid. TTF-1
both anaphylactic and anaphylactoid reactions, triiodothyronine (T3). TSH production is controlled positive cells are found in Type II pneumocytes and
but a negative test does not exclude anaphy- by a Thyrotropin-Releasing Hormone (TRH), Clara cells in the lung. In the thyroid, follicular and
laxis. Mast cells contain a number of preformed which is manufactured in the hypothalamus and parafollicular cells are positive.
chemical mediators such as histamine, chymase, transported to the pituitary gland, where it
carboxypeptidase and proteolytic tryptase. increases TSH production and release. Somatostatin TTF-1 is useful in differentiating primary
is also produced by the hypothalamus and has Adenocarcinoma of the Lung from Metastatic
Human mast cell tryptase is considered to be an an opposite effect on the pituitary production of Carcinomas of the breast and Malignant Mesothe-
important marker of mast cell activation as well TSH, decreasing or inhibiting its release. lioma. It can also be used to differentiate Small-
as an important mediator of inflammation. Anti- Cell Lung Carcinoma from lymphoid infiltrates.
tryptase is a good marker for mast cells, basophils, TSH is a useful marker in classification of pituitary For lung cancers, Adenocarcinomas are usually
and their derivatives. tumors and the study of pituitary disease. TSH positive, while Squamous Cell Carcinomas and
antibody primarily reacts with TSH-producing cells. Large Cell Carcinomas are rarely positive. Small-
Cell Carcinomas (of any primary site) are usually
positive.
CLONE G3 CLONE N/A CLONE 8G7G3/1
ISOTYPE IgG1 ISOTYPE N/A ISOTYPE IgG1
CONTROL Mast Cell Containing Tissue CONTROL Normal Pituitary CONTROL Adenocarcinoma of Lung,
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic Normal Lung, Thyroid

Tyrosinase VEGF Villin
IHC of Tyrosinase on an IHC of VEGF on an FFPE Placenta Tissue IHC of Villin on an FFPE Colon Tissue
FFPE Malignant Melanoma Tissue
Tyrosinase is an enzyme that catalyzes the Vascular endothelial growth factor (VEGF) is an Villin is an actin-binding protein that contains
oxidation of phenols (such as tyrosine) and is important signaling protein involved in both gelsolin domains capped by a ”headpiece”
widespread in plants and animals. Tyrosinase is vasculogenesis (the de novo formation of the consisting of a fast and independently-
a copper-containing enzyme present in plant embryonic circulatory system) and angiogenesis folding three-helix bundle stabilized by
and animal tissues that catalyzes the production (the growth of blood vessels from pre-existing hydrophobic interactions. The headpiece domain
of melanin and other pigments from tyrosine by vasculature). As its name implies, VEGF activity is a commonly-studied protein in molecular
oxidation. The gene for Tyrosinase is regulated is restricted mainly to cells of the vascular dynamics due to its fast-folding kinetics and short
by the Microphthalmia-associated transcription endothelium, although it has an effect on a primary sequence. It is a regulator of the actin
factor. A mutation in the tyrosinase gene leads to limited number of other cell types (e.g., stimula- cytoskeleton and is expressed mainly in the brush
impaired tyrosinase production resulting in Type I tion monocyte/macrophage migration). border in animals.
Oculocutaneous Albinism, a hereditary disease
that affects 1 in 17,000 people in the U.S. VEGF has been implicated with poor prognosis in Anti-Villin labels the brush border area in the
breast cancer. The overexpression of VEGF may be gastrointestinal mucosal epithelium. This antibody
Anti-Tyrosinase has been found to be quite specific an early step in the process of metastasis, a step has been useful in differentiating Gastrointestinal
for melanotic lesions such as Malignant Melanoma involved in the “angiogenic” switch. Although Adenocarcinoma, Neuroendocrine Carcinomas
and Melanotic Neurofibroma. Essentially no VEGF has been correlated with poor survival, its and Ovarian Adenocarcinomas from Adenocar-
carcinomas express this marker. exact mechanism of action in the progression of cinomas of other organs. Also labeled by this
tumors remains unclear. VEGF is also released in antibody are Merkel cells of the skin.
rheumatoid arthritis in response to TNF-alpha,
increasing endothelial permeability and swelling
and also stimulating angiogenesis (formation of
capillaries). Once released, VEGF may elicit several
responses. It may cause a cell to survive, move, or
further differentiate. Hence, VEGF is a potential
target for the treatment of cancer. The first
anti-VEGF drug, a monoclonal antibody named
bevacizumab, was approved by the FDA in 2004.
CLONE Ty/G5 CLONE RBT-VEGF CLONE CWWB1
ISOTYPE IgG2a ISOTYPE IgG ISOTYPE IgG1
CONTROL Malignant Melanoma, Skin CONTROL Angiosarcoma, Angioma CONTROL Small Bowel Mucosa,
LOCALIZATION Cytoplasmic LOCALIZATION Cytoplasmic, Cell Surface Colonic Mucosa
LOCALIZATION Cytoplasmic, Membranous

69
Vimentin WT1 ZAP-70
IHC of Vimentin on an FFPE Kidney Tissue IHC of WT1 on an IHC of ZAP-70 on an FFPE Tonsil Tissue
FFPE Malignant Mesothelioma Tissue
Vimentin is a member of the intermediate filament Wilms’ Tumor Protein (WT1) is a suppressor gene ZAP-70 is an abbrevation for Zeta-chain-associated
family of proteins. Intermediate filaments are an located on Chromosome 11p13. Mutations of the protein kinase 70 (70 is the molecular weight in
important structural feature of eukary- WT1 gene on Chromosome 11 are observed in kDa). The protein is a member of the protein-
otic cells. Together with microtubules and actin approximately 20% of Wilms tumors. At least half tyrosine kinase family. ZAP-70 is normally
microfilaments, they make up the cytoskeleton. of the Wilms tumors with mutations in WT1 also expressed in T-cells and natural killer cells
carry mutations in CTNNB1, the gene encoding and has a critical role in the initiation of T-cell
Expression of vimentin, when used in conjunction the proto-oncogene beta-catenin. signaling.
with keratin, is helpful in distinguishing melanomas
from Undifferentiated Carcinomas and Large-Cell Wilms’ tumor is a neoplasm of the kidneys that ZAP-70 in B-cells is used as a prognostic marker
Lymphomas. All Melanomas and Schwannomas typically occurs in children. It is also known as in identifying different forms of Chronic Lympho-
react strongly with vimentin. This antibody a Nephroblastoma. WT1 has been identified cytic Leukemia (CLL). ZAP-70 protein is expressed
recognizes a 57 kDa intermediate filament. It in proliferative mesothelial cells, Malignant in leukemic cells in approximately 25% of Chronic
labels a variety of mesenchymal cells, including Mesothelioma, Ovarian Cystadenocarcinoma, Lymphocytic Leukemia (CLL) cases as well. ZAP-70
melanocytes, lymph cells, endothelial cells and Gonadoblastoma, Nephroblastoma and expression is an excellent surrogate marker for
fibroblasts. Non-reactivity of vimentin antibody Desmoplastic Small Round Cell Tumor. Lung the distinction between the Ig-mutated (ZAP-70
is often considered more useful than its presence, Adenocarcinomas rarely stain positive with this negative) and Ig-unmutated (ZAP-70 positive) CLL
since there are a few tumors that do not contain antibody. subtypes and can identify patient groups with
vimentin (e.g., Hepatoma and Seminoma). divergent clinical courses. The ZAP-70 positive
Ig-unmutated CLL cases have a poorer prognosis.
CLONE V9 CLONE 6F-H2 CLONE 2F3.2
ISOTYPE IgG1/K ISOTYPE IgG1/K ISOTYPE IgG2a
CONTROL Tonsil, Lymph Node CONTROL Malignant Mesothelioma, CONTROL Tonsil, Lymph Node, Chronic
LOCALIZATION Cytoplasmic Kidney, Testicle Lymphocytic Leukemia
LOCALIZATION Nuclear LOCALIZATION Cytoplasmic

Antibodies for Immunofluorescence
Wendy Bakeman –
Production
“Our commitment to our customers is to manufacture products for Molecular

Pathology that are safe, effective and in compliance with the highest
FDA standards.”
Immunofluorescence Antibodies
IF of IgA on a Frozen Kidney IF of Fibrinogen on a Frozen Kidney IF of IgG on a Frozen Kidney
• High Affinity Purified Antibodies Conjugated to FITC

• Highly Sensitive & Specific
• Low Background
• Validated for Transplantation & Autoimmunity Studies
• For in Vitro Diagnostic Use
CAT. # PRESENTATION VOL
BSB 3000 Albumin / FITC 1.0 ml

BSB 3001 C1q / FITC 1.0 ml
BSB 3002 C3c / FITC 1.0 ml
BSB 3003 C4c / FITC 1.0 ml
BSB 3004 Fibrinogen / FITC 1.0 ml
BSB 3005 IgA / FITC 1.0 ml
BSB 3006 IgD / FITC 1.0 ml
BSB 3011 IgE / FITC (concentrated) 1.0 ml
BSB 3007 IgG / FITC 1.0 ml
BSB 3008 IgM / FITC 1.0 ml
BSB 3009 Kappa / FITC 1.0 ml
BSB 3010 Lambda / FITC 1.0 ml
For in Vitro Diagnostic Use 10 tests per ml considering 100µl per tissue
Detection Systems for IHC
Emin Oroudjev –
Director of Laboratory Operations
“Our goal is to constantly expand our line of products for Molecular Pathology,
by integrating the latest advances in Technology and Science into a most
convenient, reliable and robust high quality product for our customers.”
ImmunoDetector HRP
For the Immunohistochemical detection of antigens in cells and formalin-fixed or frozen tissues
IHC of Cytokeratin 20 on an IHC of HPV on an IHC of Cytokeratin Pan-OSCAR on an

FFPE Colon Carcinoma FFPE LSIL of the Cervix FFPE Colon Carcinoma
• Biotin-Streptavidin, 3-Step Immunohistochemistry Detection Technology

• Ready-to-Use, High Sensitivity System especially designed for Immunohistochemistry
of formalin-fixed or frozen tissues
• Universal: Detects Mouse or Rabbit antibodies
• DAB or AEC Configurations
CAT. # PRESENTATION VOL CAT. # PRESENTATION VOL
ImmunoDetector HRP Detection Systems ImmunoDetector HRP Link & label
BSB 0001 Mouse/Rabbit ImmunoDetector HRP w/DAB 15.0 ml BSB 0001LH Mouse/Rabbit ImmunoDetector Biotin 15.0 ml
BSB 0002 Mouse/Rabbit ImmunoDetector HRP w/AEC 15.0 ml BSB 0003LH Mouse/Rabbit ImmunoDetector Biotin 50.0 ml
BSB 0004 Mouse/Rabbit ImmunoDetector HRP w/AEC 50.0 ml BSB 0007LH Mouse/Rabbit ImmunoDetector Biotin 200.0 ml
BSB 0006 Mouse/Rabbit ImmunoDetector HRP w/AEC 100.0 ml
BSB 0007 Mouse/Rabbit ImmunoDetector HRP w/DAB 200.0 ml BSB 0001L Mouse/Rabbit ImmunoDetector Biotin Link 15.0 ml
BSB 0008 Mouse/Rabbit ImmunoDetector HRP w/AEC 200.0 ml BSB 0003L Mouse/Rabbit ImmunoDetector Biotin Link 50.0 ml
BSB 0009 Mouse/Rabbit ImmunoDetector HRP w/DAB 1000.0 ml BSB 0005L Mouse/Rabbit ImmunoDetector Biotin Link 100.0 ml
BSB 0010 Mouse/Rabbit ImmunoDetector HRP w/AEC 1000.0 ml BSB 0007L Mouse/Rabbit ImmunoDetector Biotin Link 200.0 ml
BSB 0009L Mouse/Rabbit ImmunoDetector Biotin Link 1000.0 ml
BSB 0001H Mouse/Rabbit ImmunoDetector HRP Label 15.0 ml

75
ImmunoDetector AP
IHC of Progesterone Receptor on an IHC of Cytokeratin Pan Cocktail AE1 & AE3 on an IHC of Estrogen Receptor on an
FFPE of Breast Carcinoma FFPE Prostate Carcinoma FFPE Breast Carcinoma
• Biotin-Streptavidin, 3-Step Immunohistochemistry Detection Technology

• ALK Red, ALK Blue, ALK Magenta and ALK Brown Configurations
ImmunoDetector AP Detection Systems
BSB 0082 Mouse/Rabbit ImmunoDetector AP, w/ALK Magenta 15.0 ml

PolyDetector HRP
IHC of CD5 on an FFPE IHC of CD61 on an IHC of CD99 on an

Non-Hodgkin Lymphoma PolyDetector HRP/DAB FFPE Bone Marrow Tissue FFPE Thymus Tissue
• Non-Biotin, 2-Step Immunohistochemistry Detection Technology

• Developed with Proprietary Tandem Hyperlabeling Technology used to directly labeled
Immunoglobulins with enzymes
• DAB or AEC Configurations
PolyDetector HRP Detection Systems PolyDetector HRP Detection Systems (continued)
BSB 0201 Mouse/Rabbit PolyDetector HRP w/DAB 15.0 ml BSB 0217 Rabbit PolyDetector HRP w/DAB 15.0 ml
BSB 0202 Mouse/Rabbit PolyDetector HRP w/AEC 15.0 ml BSB 0218 Rabbit PolyDetector HRP w/AEC 15.0 ml
BSB 0207A Mouse/Rabbit PolyDetector HRP w/DAB 1000.0 ml BSB 0223A Rabbit PolyDetector HRP w/DAB 1000.0 ml
BSB 0208A Mouse/Rabbit PolyDetector HRP w/AEC 1000.0 ml BSB 0224A Rabbit PolyDetector HRP w/AEC 1000.0 ml
BSB 0209 Mouse PolyDetector HRP w/DAB 15.0 ml PolyDetector HRP LabelPrediluted
BSB 0210 Mouse PolyDetector HRP w/AEC 15.0 ml
BSB 0211 Mouse PolyDetector HRP w/DAB 50.0 ml BSB 0201H Mouse/Rabbit PolyDetector HRP Label 15.0 ml
BSB 0212 Mouse PolyDetector HRP w/AEC 50.0 ml BSB 0203H Mouse/Rabbit PolyDetector HRP Label 50.0 ml
BSB 0213 Mouse PolyDetector HRP w/DAB 100.0 ml BSB 0205H Mouse/Rabbit PolyDetector HRP Label 100.0 ml
BSB 0214 Mouse PolyDetector HRP w/AEC 100.0 ml BSB 0207H Mouse/Rabbit PolyDetector HRP Label 200.0 ml
BSB 0215 Mouse PolyDetector HRP w/DAB 200.0 ml BSB 0207AH Mouse/Rabbit PolyDetector HRP Label 1000.0 ml
BSB 0216 Mouse PolyDetector HRP w/AEC 200.0 ml
BSB 0215A Mouse PolyDetector HRP w/DAB 1000.0 ml PolyDetector HRP Label Concentrates
BSB 0216A Mouse PolyDetector HRP w/AEC 1000.0 ml
BSB 0225H Mouse PolyDetector HRP (concentrated) 1.0 ml
BSB 0226H Rabbit PolyDetector HRP (concentrated) 1.0 ml
77
HPV CytoDetector HRP/DAB

For the Detection of HPV in Cervical Cytological Specimens
LSIL, HPV ICC on a LSIL, HPV ICC on a LSIL, HPV ICC on a

CytoLayer Cervical Specimen CytoLayer Cervical Specimen CytoLayer Cervical Specimen
• Non-Biotin, 2-Step Immunocytochemistry Detection Technology

• Developed with Proprietary Tandem Hyperlabeling Technology used to directly labeled
Immunoglobulins with enzymes
• High Sensitivity specially designed for Immunocytochemistry of cervical cytology specimens
• Optimized for ThinPrep, SurePath and CytoLayer liquid-based cytologies
• Kit includes positive cell controls for maximum reliability
• For Research Use Only
CAT. # PRESENTATION QTY
Complete Detection Systems for ICC
BSB 0248 HPV CytoDetector HRP/DAB 70 tests

BSB 0248S HPV CytoDetector Control Slides 5 slides
For Research Use Only For research use only in the United States.
HER-2 neu PolyDetector HRP/DAB

For the Immunohistochemical detection of HER-2 neu in formalin-fixed paraffin-embedded tissues
IHC of HER-2neu 1+ IHC of HER-2 neu 2+ IHC of HER-2 neu 3+

Breast Carcinoma Breast Carcinoma Breast Carcinoma
• Semi-quantitative IHC test for the evaluation of HER2-neu overexpression in FFPE breast
cancer tissues
• Non-Biotin, 2-Step Immunohistochemistry Detection Technology developed with Proprietary
Tandem Hyperlabeling Technology used to directly labeled Immunoglobulins with enzymes
• Kits include all reagents, solutions, tissues and reagent controls
• For maximum reliability, all kits include Tissue Microarray control slides with tissues
that are negative, 1+, 2+ and 3+ signals
Complete Detection Systems for IHC
BSB 0245 HER-2 neu PolyDetector HRP/DAB 70 tests

79
ER/PR PolyDetector HRP/DAB

For the Immunohistochemical detection of Estrogen and Progesterone receptors in formalin-fixed paraffin-embedded tissues
IHC of ER IHC of ER IHC of PR

Ductal Breast Carcinoma Ductal Breast Carcinoma Ductal Breast Carcinoma
• Immunohistochemical test for the evaluation of ER and PR in FFPE tissues

that are negative and positive for ER and PR
BSB 0251 ER/PR PolyDetector HRP/DAB 70 tests

CD117 c-Kit PolyDetector HRP/DAB

For the Immunohistochemical detection of Estrogen and Progesterone receptors in formalin-fixed paraffin-embedded tissues
IHC oc CD117 on an IHC oc CD117 on an IHC oc CD117 on an

FFPE GIST Tissue FFPE Duodenum Tissue FFPE GIST Tissue
• Immunohistochemical test for the evaluation of CD117 c-Kit in FFPE tissues

that are negative and positive signals for CD117 c-Kit
BSB 0254 CD117 c-Kit PolyDetector HRP/DAB 60 tests

Substrate-Chromogen Systems
Maurie Patel –
Production
“At Bio SB, we strive to produce high tech immunochemicals for Cancer
Research and in Vitro Diagnostics, and provide our customers with the highest
quality products that enable us to live up to our mission of manufacturing the
best Bioscience products for the World.”
82
Substrate-Chromogen Systems for use with HRP Detection Systems
IHC of CD61 on an IHC of COX2 on an IHC of MLH1 on an

FFPE Bone Marrow Tissue with AEC FFPE Colon Cancer Tissue with DAB FFPE Colon Cancer Tissue with HRP Black
• High Sensitivity
• Low Background
• AEC supplied as Ready-to-Use Format
• DAB supplied as two components
• HRP Black supplied as three components
Substrate-Chromogen Systems for use with HRP Detection Systems Substrate-Chromogen Systems for use with HRP Detection Systems (continued)
BSB 0011 ImmunoDetector Liquid AEC Ready-To-Use 15.0 ml BSB 0087 PolyDetector HRP Black kit 15.0 ml
BSB 0014 ImmunoDetector Liquid AEC Ready-To-Use 200.0 ml BSB 0090A PolyDetector HRP Black kit 200.0 ml
BSB 0061A ImmunoDetector Liquid AEC Ready-To-use 500.0 ml BSB 0090B PolyDetector HRP Black kit 500.0 ml
BSB 0061 ImmunoDetector Liquid AEC Ready-To-use 1000.0 ml BSB 0090C PolyDetector HRP Black kit 1000.0 ml
BSB 0015 ImmunoDetector Liquid DAB kit 15.0 ml

BSB 0018A ImmunoDetector Liquid DAB kit 500.0 ml
BSB 0018B ImmunoDetector Liquid DAB kit 1000.0 ml
BSB 0019F ImmunoDetector DAB Buffer 100.0 ml

BSB 0019E ImmunoDetector DAB Buffer 200.0 ml
BSB 0019D ImmunoDetector DAB Buffer 500.0 ml
BSB 0019 ImmunoDetector DAB Buffer 1,000.0 ml
BSB 0019A ImmunoDetector DAB Chromogen 100.0 ml

BSB 0019B ImmunoDetector DAB Chromogen 50.0 ml
BSB 0019C ImmunoDetector DAB Chromogen 12.0 ml
BSB 0019G ImmunoDetector DAB Chromogen 6.0 ml
83
Substrate-Chromogen Systems for use with AP Detection Systems
IHC of ER on an IHC of Ki67 on an IHC of p63 on an

FFPE Breast Cancer Tissue with ALK Magenta FFPE Breast Cancer Tissue with ALK Blue FFPE Prostate Cancer Tissue with ALK Red
• High Sensitivity
• Low Background
• Alk Blue, Alk Red and Alk Brown supplied as Ready-to-Use Formats
• ALK Magenta supplied as two components
Substrate-Chromogen Systems for use with AP Detection Systems
BSB 0062 PolyDetector Alk Blue Ready-To-Use 15.0 ml

BSB 0067 PolyDetector Alk Red Ready-To-Use 15.0 ml

BSB 0072 PolyDetector Alk Brown Ready-To-Use 15.0 ml

BSB 0077 PolyDetector Alk Magenta 15.0 ml

Ancillaries for Immunohistochemistry
Matt Tracz –
Administration
“Bio SB is fully committed to develop and manufacture state of the art quality
IVD reagents while providing superior customer service.”
Ancillaries for Immunohistochemistry
Retrievers and Enzymes Primary Antibody Negative Controls

BSB 0023 ImmunoRetreiver 20X with Citrate 50.0 ml BSB 0040A Mouse Negative Control 3.0 ml
BSB 0020 ImmunoRetreiver 20X with Citrate 200.0 ml BSB 0040B Mouse Negative Control 6.0 ml
BSB 0021 ImmunoRetreiver 20X with Citrate 500.0 ml BSB 0040C Mouse Negative Control 15.0 ml
BSB 0022 ImmunoRetreiver 20X with Citrate 1000.0 ml BSB 0041A Rabbit Negative Control 3.0 ml
BSB 0041B Rabbit Negative Control 6.0 ml
BSB 0033 ImmunoRetreiver 20X with EDTA 50.0 ml BSB 0041C Rabbit Negative Control 15.0 ml
BSB 0030 ImmunoRetreiver 20X with EDTA 200.0 ml
BSB 0031 ImmunoRetreiver 20X with EDTA 500.0 ml Washers and Detergent
BSB 0032 ImmunoRetreiver 20X with EDTA 1000.0 ml
BSB 0029 Immuno/DNA Washe 10X 200.0 ml
BSB 0108 ImmunoDNA Digestor 15.0 ml BSB 0042 Immuno/DNA Washer 10X 1000.0 ml
BSB 0109 ImmunoDNA Digestor 50.0 ml
BSB 0110 ImmunoDNA Digestor 100.0 ml BSB 0060 HybriWash 20X 200.0 ml
BSB 0111 ImmunoDNA Digestor 200.0 ml BSB 0060A HybriWash 20X 50.0 ml
BSB 0112 ImmunoDNA Digestor 1000.0 ml
BSB 0045 Tween 20 100.0 ml
Dilutents and Blockers BSB 0046 Tween 20 500.0 ml
BSB 0113 ImmunoDetector Protein Block / Antibody Diluent 15.0 ml Stabilizing Buffers for Enzyme Conjugates
BSB 0040 ImmunoDetector Protein Block / Antibody Diluent 50.0 ml
BSB 0041 ImmunoDetector Protein Block / Antibody Diluent 100.0 ml BSB 0043 PolyDetector HRP Buffer 1000.0 ml
BSB 0114 ImmunoDetector Protein Block / Antibody Diluent 200.0 ml BSB 0044 PolyDetector AP Buffer 1000.0 ml
BSB 0115 ImmunoDetector Protein Block / Antibody Diluent 1000.0 ml
Mounting Media
BSB 0103 ImmunoDNA Background Blocker 15.0 ml BSB 0090 Aqua Mounter 15.0 ml
BSB 0107 ImmunoDNA Background Blocker 1000.0 ml
BSB 0094 Perma Mounter 15.0 ml
BSB 0050 PolyDetector Peroxidase Block 15.0 ml BSB 0095 Perma Mounter 50.0 ml
BSB 0053 PolyDetector Peroxidase Block 200.0 ml
BSB 0054 PolyDetector Peroxidase Block 1000.0 ml Counterstainers
BSB 0055 PolyDetector AP Block 15.0 ml BSB 0024 Hematoxylin Counterstainer 15..0 ml
BSB 0056 PolyDetector AP Block 50.0 ml BSB 0025 Hematoxylin Counterstainer 50.0 ml
BSB 0098 ImmunoDetector Biotin Blocker 15.0 ml BSB 0116 Nuclear Fast Red Counterstainer 15.0 ml
BSB 0121 Nuclear Fast Red Counterstainer 1000.0 ml
BSB 0122 Methyl Green Counterstainer 15.0 ml

BSB 0125 Methyl Green Counterstainer 200 .0ml
For in Vitro Diagnostic Use
FISH & CISH Products
Christopher Casalaspi –
Quality Control
“We at Bio SB excell to insure that all our products meet the highest quality
by performing rigorous quality control methodologies that meet the
FDA QSR/cGMP standards.”
ZytoLight® – Reliable multi-target detection using Fluorescence in situ Hybridization!
INTRODUCTION
ZytoLight® products are designed for the identification of genetic aberrations
e.g. translocations, deletions, amplifications, and chromosomal aneuploidies by
Fluorescence in situ Hybridization (FISH) in formalin-fixed, paraffin-embedded
tissue sections, cell samples, blood or bone marrow smears, and metaphase
chromosome spreads.
HIGH SENSITIVITY AND SPECIFICITY

ZytoLight® FISH probes are direct labeled using the unique ZytoLight® Direct
Label System II providing improved signal intensity. All ZytoLight® single copy
(SPECTM) probes are processed by the unique ZytoLight® Repeat Subtraction
Technique resulting in advanced specificity and less background. No further
blocking of repetitive sequences is needed!
ZYTOLIGHT® SPECTM AND CENTM PROBES

ZytoLight® SPEC TM probes hybridize to specific, single copy DNA sequences of
the human genome. ZytoLight® SPECTM probes are available for the detection
of a variety of chromosomal aberrations associated with tumors and genetic
diseases.
ZytoLight® CENTM probes hybridize to highly repetitive human satellite DNA

sequences located at the centromeric regions of chromosomes producing
sharp, bright signals specific for each individual chromosome.
ZYTOLIGHT® KITS – CONVENIENT SOLUTIONS

For making FISH analysis reliable and user-friendly, all ZytoLight® FISH probes
can be combined with the ZytoLight® FISH-Tissue Implementation Kit (Z-2028-
20). Also available now, specific for FISH analyses on cytology specimens,
the ZytoLight® FISH-Cytology Implementation Kit (Z-2099-20). Both
Implementation Kits include all necessary pretreatment solutions, wash buffers
and DAPI/Antifade solution and a detailed protocol to perform successful FISH
experiments. Additionally, for some major targets, complete kits including
probes and all necessary reagents are available.
The ZytoLight® system uses directly labeled FISH probes 1. Eliminating the
need to detect the probes with fluorophore-coupled antibodies. The probes
are detected by fluorescence microscopy using appropriate filter sets 2. Due
to an exciter filter 3. Full-spectrum light, emitted by the microscope lamp 4. Is
reduced to light of a defined wavelength that specifically excites the fluorophore
of the probe. This light is reflected onto the specimen by a dichroic mirror 5. The
fluorophore emits light of longer wavelengths that passes the mirror. Finally, a
barrier filter 6. reduces the emitted light to a defined wavelength that can be
detected.
89
ZytoLight® – Reliable multi-target detection using Fluorescence in situ Hybridization!
FISH of HER-2 neu on an FISH of EGFR on an FISH of MDM2 on an

FFPE Breast Carcinoma FFPE Colon Carcinoma FFPE Liposcarcinoma
• ZytoLight® products for Fluorescence in situ Hybridization (FISH) are designed for the identification of genetic aberrations e.g. translocations, deletions,
amplifications, and chromosomal aneuploidies associated with tumors and genetic diseases.
CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

ZytoLight Single Color Probes ZytoLight Dual Color Probes (continued)
Z-2001-200 ZytoLight CEN 3 Probe 200 µl Z-2084-200 ZytoLight SPEC VHL/CEN 3 Dual Color Probe 200 µl
Z-2002-200 ZytoLight CEN 6 Probe 200 µl Z-2087-200 ZytoLight SPEC MET/CEN 7 Dual Color Probe 200 µl
Z-2003-200 ZytoLight CEN 7 Probe 200 µl Z-2090-200 ZytoLight SPEC CMYC Dual Color Break Apart Probe 200 µl
Z-2004-200 ZytoLight CEN 8 Probe 200 µl Z-2091-200 ZytoLight SPEC TERT/5q31 Dual Color Probe 200 µl
Z-2005-200 ZytoLight CEN 11 Probe 200 µl Z-2092-200 ZytoLight SPEC CMYC/CEN 8 Dual Color Probe 200 µl
Z-2006-200 ZytoLight CEN 17 Probe 200 µl Z-2094-200 ZytoLight porcine X/Y Dual Color Probe 200 µl
Z-2007-200 ZytoLight CEN 18 Probe 200 µl Z-2096-50 ZytoLight SPEC EWSR1 Dual Color Break Apart Probe 50 µl
Z-2008-200 ZytoLight CEN X Probe 200 µl Z-2097-50 ZytoLight SPEC SYT Dual Color Break Apart Probe 50 µl
Z-2010-200 ZytoLight CEN Y Probe 200 µl Z-2098-200 ZytoLight SPEC TYMS/CEN 18 Dual Color Probe 200 µl
Z-2049-200 ZytoLight SPEC 2q11 Probe 200 µl Z-2100-50 ZytoLight SPEC CHOP Dual Color Break Apart Probe 50 µl
Z-2050-200 ZytoLight CEN 12 Probe 200 µl Z-2103-200 ZytoLight SPEC CDK4/CEN 12 Dual Color Probe 200 µl
Z-2067-200 ZytoLight CEN 9 Probe 200 µl Z-2104-10 ZytoLight Aneusomy Probe Set Dual Color Probe 2x50 µl
Z-2079-200 ZytoLight CEN 10 Probe 200 µl Z-2104-40 ZytoLight Aneusomy Probe Set Dual Color Probe 2x200 µl
Z-2083-200 ZytoLight CEN 4 Probe 200 µl Z-2105-200 ZytoLight SPEC CMYC/IGH Dual Color Dual Fusion Probe 200 µl
Z-2085-200 ZytoLight SPEC 13q12 Probe 200 µl Z-2107-200 ZytoLight SPEC EGR1/5p15 Dual Color Probe 200 µl
Z-2086-200 ZytoLight SPEC 21q22 Probe 200 µl Z-2108-200 ZytoLight SPEC CCND1 Dual Color Break Apart Probe 200 µl
Z-2101-200 ZytoLight SPEC 1p12 Probe 200 µl Z-2110-200 ZytoLight SPEC IGH Dual Color Break Apart Probe 200 µl
Z-2123-200 ZytoLight CEN Y (DYZ3) Probe 200 µ Z-2111-200 ZytoLight SPEC BCR/ABL Dual Color Dual Fusion Probe 200 µl
Z-2114-200 ZytoLight SPEC BCL2/IGH Dual Color Dual Fusion Probe 200 µl
ZytoLight Dual Color Probes Z-2119-200 ZytoLight SPEC PDGFB Dual Color Break Apart Probe 200 µl
Z-2013-200 ZytoLight SPEC MDM2/CEN 12 Dual Color Probe 200 µl Z-2120-200 ZytoLight CEN Y/X Dual Color Probe 200 µl
Z-2013-50 ZytoLight SPEC MDM2/CEN 12 Dual Color Probe 50 µl Z-2121-200 ZytoLight SPEC COL1A1 Dual Color Break Apart Probe 200 µl
Z-2014-200 ZytoLight SPEC MAML2 Dual Color Break Apart Probe 200 µl Z-2124-200 ZytoLight SPEC ALK Dual Color Break Apart Probe 200 µl
Z-2015-200 ZytoLight SPEC HER2/CEN 17 Dual Color Probe 200 µl Z-2124-50 ZytoLight SPEC ALK Dual Color Break Apart Probe 50 µl
Z-2015-50 ZytoLight SPEC HER2/CEN 17 Dual Color Probe 50 µl ZytoLight Triple Color Probes
Z-2016-200 ZytoLight CEN X/Y Dual Color Probe 200 µl
Z-2016-50 ZytoLight CEN X/Y Dual Color Probe 50 µl Z-2093-200 ZytoLight SPEC HER2/TOP2A/CEN 17 Triple Color Probe 200 µl
Z-2018-200 ZytoLight RMS I Probe Dual Color Probe 200 µl Z-2093-50 ZytoLight SPEC HER2/TOP2A/CEN 17 Triple Color Probe 50 µl
Z-2018-50 ZytoLight RMS I Probe Dual Color Probe 50 µl Z-2095-200 ZytoLight SPEC 13/CEN 18/SPEC 21 Triple Color Probe 200 µl
Z-2019-200 ZytoLight RMS II Probe Dual Color Probe 200 µl Z-2095-50 ZytoLight SPEC 13/CEN 18/SPEC 21 Triple Color Probe 50 µl
Z-2019-50 ZytoLight RMS II Probe Dual Color Probe 50 µl Z-2117-200 ZytoLight SPEC ALK/EML4 TriCheck Probe 200 µl
Z-2033-200 ZytoLight SPEC EGFR/CEN 7 Dual Color Probe 200 µl Z-2117-50 ZytoLight SPEC ALK/EML4 TriCheck Probe 50 µl
Z-2033-50 ZytoLight SPEC EGFR/CEN 7 Dual Color Probe 50 µl
Z-2056-200 ZytoLight SPEC HER3/CEN 12 Dual Color Probe 200 µl ZytoLight Quad Color Probes
Z-2057-200 ZytoLight SPEC HER4/2q11 Dual Color Probe 200 µl Z-2081-200 ZytoLight SPEC p16/CEN 3/7/17 Quadruple Color Probe 200 µl
Z-2062-200 ZytoLight SPEC FHIT/CEN 3 Dual Color Probe 200 µl Z-2081-50 ZytoLight SPEC p16/CEN 3/7/17 Quadruple Color Probe 50 µl
Z-2063-200 ZytoLight SPEC p16/CEN 9 Dual Color Probe 200 µl
Z-2069-200 ZytoLight SPEC ESR1/CEN 6 Dual Color Probe 200 µl ZytoLight FISH KITS
Z-2069-50 ZytoLight SPEC ESR1/CEN 6 Dual Color Probe 50 µl Z-2020-20 ZytoLight SPEC HER2/CEN 17 Dual Color Probe Kit 20
Z-2071-200 ZytoLight SPEC CCND1/CEN 11 Dual Color Probe 200 µl Z-2020-5 ZytoLight SPEC HER2/CEN 17 Dual Color Probe Kit 5
Z-2072-200 ZytoLight SPEC FGFR1/CEN 8 Dual Color Probe 200 µl Z-2025-20 ZytoLight SPEC MDM2/CEN 12 Dual Color Probe Kit 20
Z-2074-200 ZytoLight SPEC NMYC/2q11 Dual Color Probe 200 µl Z-2025-5 ZytoLight SPEC MDM2/CEN 12 Dual Color Probe Kit 5
Z-2075-200 ZytoLight SPEC 1p36/1q25 Dual Color Probe 200 µl Z-2028-20 ZytoLight FISH-Tissue Implementation Kit 20
Z-2075-50 ZytoLight SPEC 1p36/1q25 Dual Color Probe 50 µl Z-2028-5 ZytoLight FISH-Tissue Implementation Kit 5
Z-2076-200 ZytoLight SPEC 19q13/19p13 Dual Color Probe 200 µl Z-2070-20 ZytoLight SPEC ESR1/CEN 6 Dual Color Probe Kit 20
Z-2076-50 ZytoLight SPEC 19q13/19p13 Dual Color Probe 50 µl Z-2070-5 ZytoLight SPEC ESR1/CEN 6 Dual Color Probe Kit 5
Z-2078-200 ZytoLight SPEC PTEN/CEN 10 Dual Color Probe 200 µl
Z-2080-200 ZytoLight SPEC MDM4/1p12 Dual Color Probe 200 µl
Z-2082-200 ZytoLight SPEC FGFR3/CEN 4 Dual Color Probe 200 µl
For Research Use Only For research use only in the United States. 100 tests per ml considering 10µl per test
ZytoDot® – Reliable and simple detection of genomic alterations using light microscopy!
INTRODUCTION INTRODUCTION
The ZytoDot® products are designed for the detection of aneuploidies and gene The ZytoDot® 2CTM products are designed for the simultaneous detection of
amplifications by Chromogenic in situ Hybridization (CISH) in formalin-fixed, two different genomic targets by chromogenic in situ Hybridization (CISH) in
paraffin-embedded tissue sections, cell samples, blood or bone marrow smears, formalinfixed, paraffin-embedded tissue sections, cell samples, and blood
and metaphase chromosome spreads. or bone marrow smears. This two color system is especially useful for the
differentiation of aneuploidies from gene amplifications, and the detection of
CISH: A RELIABLE ALTERNATIVE TO FISH deletions and translocations.
High concordance between CISH and FISH ranging from 92-100% has been
shown by numerous international studies for HER2 amplification. ADVANTAGES OF ZYTODOT® 2C TM
• Simultaneous observation of tissue morphology and CISH signals at 40x
ADVANTAGES OF CISH OVER FISH using light microscopy
• Quick and easy interpretation of results comparable to IHC • Two targets detected simultaneously
• Simultaneous observation of tissue morphology and CISH signals • High contrasting distinct red and green signals
• Storage of slides at room temperature - CISH signals are permanent • Quick and easy interpretation of results comparable to IHC
• No costly fluorescent microscope needed • Standardized and complete kits
• No costly fluorescent microscope needed
HIGH SIGNAL-TO-NOISE RATIO
The ZytoDot® probes are processed by the unique ZytoVision® Repeat Subtraction ZYTODOT® 2C TM IMPROVEMENTS
Technique resulting in advanced specificity and less background. No further The well established ZytoDot® 2CTM system has been carefully revised to optimize
blocking of repetitive sequences is needed! its handling and performance. Handling steps were reduced by approx. 25%
due to an optimized protocol including less antibody & washing steps and
ZYTODOT® KITS – CONVENIENT SOLUTIONS 2-component chromogenic substrates. This means a reduction by approx. 20%
For making CISH analysis reliable and user-friendly, all ZytoDot® CISH probes on day 1 and by approx. 50% on day 2! Procedure time is reduced to approx. 1¾
can be combined with the ZytoDot® CISH Implementation Kit (C-3018-40) h per day due to shortened incubation times and less antibody & washing steps!
which includes all necessary pretreatment solutions, wash buffers, antibodies, Re-designed chromogenic substrates and improved antibody-cocktails lead to
chromogenic substrates, counterstaining solution, mounting solution and stronger signals while showing less background staining and occur even in sub-
a detailed protocol to perform successful CISH experiments. Additionally, for optimal pre-treated tissue sections.
some major targets, complete kits including probes and all necessary reagents
are available. ZYTODOT® KITS – STANDARDIZED SOLUTIONS
For making CISH analysis reliable and user-friendly, complete ZytoDot® 2C TM kits
The ZytoDot® system uses are available for some major targets. These kits include a ZytoDot® 2C TM probe,
Digoxigenin-labeled probes all necessary pretreatment solutions, wash buffers, antibodies, chromogenic
substrates, counterstaining and mounting solutions, and a detailed protocol.
1. Which are, after blocking
For other targets, any separately available ZytoDot® 2CTM probe can be
2. Detected using a Mouse-anti- combined with ZytoDot® 2CTM Implementation Kits resulting in target specific
Digoxigenin antibody kit solutions.
3. This antibody is detected by a
polymerized HRP-Goat-anti-Mouse The ZytoDot® 2CTM system uses DIG- and DNP-labeled probe cocktails targting
antibody different genomic sections (see diagram on page 91)
4. The enzymatic reaction of DAB 1. Which are detected using a Mouse-anti-DIG/Rabbitanti-DNP cocktail
5. Leads to the formation of strong 2. These antibodies are detected by a unique cocktail of polymerized HRP-
permanent brown signals that can Goat-anti-Mouse/AP-Goat-anti-Rabbit antibodies
be visualized by light microscopy
3. The enzymatic reaction of AP-Red
using a 40x objective.
4. and HRP-Green
5. leads to the formation of strong permanent red respectively green signals
that can be visualized by light microscopy using a 40x objective.
91
ZytoDot® – Reliable and simple detection of genomic alterations using light microscopy!
CISH of HER-2 neu on an CISH of FGR1 on an CISH of TOPO2A on an

FFPE Breast Carcinoma FFPE Prostate Carcinoma FFPE Breast Carcinoma
• ZytoDot® products for Chromogenic in situ Hybridization (CISH) are designed for the detection of aneuploidies and gene amplifications associated with tumors
and genetic diseases using an IHC-like procedure and light microscopy.
CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION QTY
ZytoDot Single Color Probes ZytoDot Dual Color Probes
C-3001-100 ZytoDot SPEC HER2 Probe 100 µl C-3032-100 ZytoDot 2C SPEC HER2/CEN 17 Probe 100 µl
C-3001-400 ZytoDot SPEC HER2 Probe 400 µl C-3032-400 ZytoDot 2C SPEC HER2/CEN 17 Probe 400 µl
C-3002-400 ZytoDot CEN 6 Probe 400 µl C-3033-100 ZytoDot 2C SPEC EGFR/CEN 7 Probe 100 µl
C-3006-400 ZytoDot CEN 17 Probe 400 µl C-3033-400 ZytoDot 2C SPEC EGFR/CEN 7 Probe 400 µl
C-3007-100 ZytoDot SPEC EGFR Probe 100 µl C-3040-400 ZytoDot 2C SPEC TOP2A/CEN 17 Probe 400 µl
C-3007-400 ZytoDot SPEC EGFR Probe 400 µl C-3043-100 ZytoDot 2C SPEC EWSR1 Break Apart Probe 100 µl
C-3008-400 ZytoDot CEN 7 Probe 400 µl C-3046-100 ZytoDot 2C SPEC SYT Break Apart Probe 100 µl
C-3012-400 ZytoDot SPEC MDM2 Probe 400 µl C-3048-400 ZytoDot 2C CEN X/Y Probe 400 µl
C-3013-400 ZytoDot SPEC CMYC Probe 400 µl C-3049-100 ZytoDot 2C SPEC MDM2/CEN12 Probe 100 µl
C-3014-400 ZytoDot CEN 12 Probe 400 µl C-3049-400 ZytoDot 2C SPEC MDM2/CEN12 Probe 400 µl
C-3016-400 ZytoDot CEN 8 Probe 400 µl C-3050-400 ZytoDot 2C SPEC FGFR1/CEN8 Probe 400 µl
C-3020-400 ZytoDot CEN Y Probe 400 µl C-3053-400 ZytoDot 2C SPEC PTEN/CEN10 Probe 400 µl
C-3021-400 ZytoDot SPEC TOP2A Probe 400 µl
C-3023-400 ZytoDot SPEC FGFR1 Probe 400 µl ZytoDot CISH KITS
C-3024-400 ZytoDot SPEC ESR1 Probe 400 µl
C-3025-400 ZytoDot CEN X Probe 400 µl C-3003-10 ZytoDot SPEC HER2 Probe Kit 10
C-3026-400 ZytoDot SPEC 21q22 Probe 400 µl C-3003-40 ZytoDot SPEC HER2 Probe Kit 40
C-3029-400 ZytoDot SPEC NMYC Probe 400 µl C-3004-40 ZytoDot Pretreatment Kit 40
C-3034-400 ZytoDot SPEC CCND1 Probe 400 µl C-3005-10 ZytoDot CISH Polymer Detection Kit 10
C-3045-400 ZytoDot CEN 3 Probe 400 µl C-3005-40 ZytoDot CISH Polymer Detection Kit 40
C-3051-400 ZytoDot SPEC 2q11 Probe 400 µl C-3018-10 ZytoDot CISH Implementation Kit 10
C-3052-400 ZytoDot SPEC 13q12 Probe 400µl C-3018-40 ZytoDot CISH Implementation Kit 40
C-3022-10 ZytoDot 2C SPEC HER2/CEN 17 Probe Kit 10
C-3022-40 ZytoDot 2C SPEC HER2/CEN 17 Probe Kit 40
C-3028-40 ZytoDot 2C CISH Polymer Detection Kit 40
C-3044-10 ZytoDot 2C CISH Implementation Kit 10
C-3044-40 ZytoDot 2C CISH Implementation Kit 40
ZytoFast® – Achieving Chromogenic in situ Hybridization results in just 4 hours!
INTRODUCTION
The ZytoFast® products are designed for outstandingly fast detection and
discrimination of human pathogen viruses, e.g. HPV, EBV, CMV, and the
determination of lymphocyte clonality by detecting Ig-k and Ig-l light chain
RNA by Chromogenic in situ Hybridization (CISH) in formalin-fixed, paraffin-
embedded tissue sections and cell samples.
ZYTOFAST®: OUTSTANDINGLY FAST CISH

Optimized protocols and faster tissue penetration due to short oligonucleotide
probes of the ZytoFast® system make the ZytoFast® CISH procedure
outstandingly fast.
Single color results can be achieved within just 4 hours, with hands-on time
being only about 2 hours!
HIGH SENSITIVITY AND SPECIFICITY

All ZytoFast® probes are tagged using the unique ZytoFast® HighTag System
providing improved signal intensity! High specificity without risk of cross-
hybridizations is obtained due to optimized oligonucleotide probes.
ADVANTAGES OF CISH
• Simultaneous observation of tissue morphology and CISH signals
• No risk of false positives due to mispriming or contamination as with PCR
• Easy method comparable to IHC
• No costly equipment needed The ZytoFast® system uses oligonucleotide probes tagged with Biotin or
• Ability to test archival specimens Digoxigenin 1. Which are detected using enzyme-conjugated antibodies
• High sensitivity and specificity or streptavidin targeting the tags 2. The enzymatic reaction of chromogenic
substrates 3. e.g. BCIP/NBT or AEC, leads to the formation of strong color
ZYTOFAST® KITS – USER FRIENDLY SOLUTIONS precipitates that can be visualized by light microscopy.
CISH analysis has been made reliable and user friendly because for many targets
complete kits are available, including all necessary pretreatment solutions,
wash buffers, antibodies, chromogenic substrates, positive and negative control
probes as well as a detailed protocol to perform successful CISH experiments.
Additionally, all ZytoFast® probes are available separately. Thus, if an increased
sensitivity is demanded, the Digoxigenin-labeled probes can be combined
easily with any ZytoFast® PLUS CISH Implementation Kit.
93
ZytoFast® – Achieving Chromogenic in situ Hybridization results in just 4 hours!
CISH of HPV on an CISH of EBV on an CISH of lg-Kappa/Lambda on an

FFPE Cervical Cancer FFPE Hodgkin’s Lymphoma FFPE Tonsil Tissue
• ZytoFast® products for Chromogenic in situ Hybridization (CISH) are designed for the detection and discrimination of human pathogen viruses e.g. HPV, EBV,
CMV and the determination of lymphocyte clonality by detecting Ig-κ and Ig-λ light chain RNA.
ZytoFast Complete Kits (Digoxigenin/Biotin labeled) ZytoFast CISH Detections Systems for the Detection of Biotin Probes
T-1005-10 ZytoFast human lg-kappa/lg-lambda CISH Kit 10 T-1006-40 ZytoFast AP-Streptavidin Detection Kit 40
T-1005-40 ZytoFast human lg-kappa/lg-lambda CISH Kit 40 T-1070-40 ZytoFast CISH Implementation Kit AP-NBT/BCIP 40
T-1071-40 ZytoFast CISH Implementation Kit HRP-AEC 40
ZytoFast Biotin & Digoxigenin Labeled Probes (Digoxigenin/Biotin labeled)
ZytoFast CISH Detections Systems for the Detection of Digoxigenin Probes
T-1017-400 ZytoFast human lg-kappa/lg-lambda Probe 400 µl
T-1061-10 ZytoFast PLUS CISH Implementation Kit AP-NBT/BCIP 10
ZytoFast Biotin Labeled Probes (Biotin labeled) T-1061-40 ZytoFast PLUS CISH Implementation Kit AP-NBT/BCIP 40
T-1062-10 ZytoFast PLUS CISH Implementation Kit HRP-AEC 10
T-1013-400 ZytoFast CMV Probe 400 µl T-1062-40 ZytoFast PLUS CISH Implementation Kit HRP-AEC 40
T-1014-400 ZytoFast EBV Probe 400 µl T-1063-10 ZytoFast PLUS CISH Implementation Kit HRP-DAB 10
T-1015-400 ZytoFast human lg-kappa Probe 400 µl T-1063-40 ZytoFast PLUS CISH Implementation Kit HRP-DAB 40
T-1016-400 ZytoFast human lg-lambda Probe 400 µl T-1065-40 ZytoFast PLUS Pretreatment Kit 40
T-1018-400 ZytoFast RNA (+) Control Probe 400 µl T-1066-10 ZytoFast PLUS CISH Polymer Detection Kit AP-NBT/BCIP 10
T-1019-400 ZytoFast RNA (-) Control Probe 400 µl T-1066-40 ZytoFast PLUS CISH Polymer Detection Kit AP-NBT/BCIP 40
T-1022-400 ZytoFast DNA (+) Control Probe 400 µl T-1067-10 ZytoFast PLUS CISH Polymer Detection Kit HRP-AEC 10
T-1023-400 ZytoFast DNA (-) Control Probe 400 µl T-1067-40 ZytoFast PLUS CISH Polymer Detection Kit HRP-AEC 40
T-1032-400 ZytoFast HPV type 6/11 Probe 400 µl T-1068-40 ZytoFast PLUS CISH Polymer Detection Kit HRP-DAB 40
T-1035-400 ZytoFast HPV type 16/18 Probe 400 µl T-1073-10 ZytoFast PLUS CISH Implementation Kit HRP-HRP-Green 10
T-1038-400 ZytoFast HPV type 31/33 Probe 400 µl T-1073-40 ZytoFast PLUS CISH Implementation Kit HRP-HRP-Green 40
T-1040-400 ZytoFast HPV type 16/18/31/33/35 High Risk Probe 400 µl
T-1044-400 ZytoFast HPV type 6/11/16/18/31/33/35 Screening Probe 400 µl
ZytoFast Digoxigenin Labeled Probes (Digoxigenin labeled)
T-1053-400 ZytoFast DNA (+) Control Probe 400 µl

T-1054-400 ZytoFast DNA (-) Control Probe 400 µl
T-1055-400 ZytoFast HPV type 6/11 Probe 400 µl
T-1113-400 ZytoFast CMV Probe 400 µl
T-1114-400 ZytoFast EBV Probe (Digoxigenin labeled) 400 µl
T-1115-400 ZytoFast human lg-kappa Probe 400 µl
T-1116-400 ZytoFast human lg-lambda Probe 400 µl
T-1118-400 ZytoFast RNA (+) Control Probe 400 µl
T-1119-400 ZytoFast RNA (-) Control Probe 400 µl
T-1140-400 ZytoFast HPV High-Risk (HR) Types Probe
16/18/31/33/35/39/45/51/52/56/58/59/66/68/82 400 µl
T-1144-400 ZytoFast HPV Screening Probe
6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/82 400 µl
Ancillaries and Equipment for FISH & CISH
Ancillaries for FISH & CISH Equipment
AB-0001-30 Mouse-anti-DIG 30 ml E-4003-1 DAPI Single Bandpass Filter Set 1

AB-0001-4 Mouse-anti-DIG 4 ml E-4010-1 DAPI/ZyGreen/ZyOrange Triple Bandpass Filter Set 1
AB-0002-4 Anti-Mouse-HRP-Polymer 4 ml E-4012-1 ZyGreen Single Bandpass Filter Set v2 1
AB-0009-4 AP-Streptavidin 4 ml E-4013-1 ZyOrange Single Bandpass Filter Set v2 1
AB-0014-4 Anti-DIG/DNP-Mix 4 ml E-4016-1 ZyGreen/ZyOrange Dual Bandpass Filter Set v2 1
BS-0001-4 Blocking Solution 4 ml E-4017-1 ZyRed Single Bandpass Filter Set v2 1
C-3011-40 ZytoDot Wash Buffer Set 40 E-4026-1 ZyBlue Single Bandpass Filter Set v2 1
C-3015-100 DAB Solution Set 100 E-4027-1 ZyGold Single Bandpass Filter Set v2 1
C-3038-100 ZytoDot AP-Red Solution Set 100 E-4028-1 ZyBlue/ZyGreen/ZyOrange Triple Bandpass Filter Set 1
C-3039-100 ZytoDot HRP-Green Solution Set 100
CS-0002-20 Nuclear Blue Solution 20 ml
E-4005-125 Fixogum Rubber Cement 125 g
E-4005-50 Fixogum Rubber Cement 50 g
E-4006-2 HPV Control Slide Set 1
E-4007-2 HER2 Control Slide Set 1
E-4009-2 EGFR Control Slide Set 1
E-4023-2 EBV, CMV, HSV, and SV40 Control Slide Set 1
ES-0001-1000 Pepsin Solution 1000 ml
ES-0001-8 Pepsin Solution Set 2 x 4 ml
ES-0002-4 Cytology Pepsin Solution 4 ml
MT-0001-0.8 DAPI/Antifade-Solution 0.8 ml
MT-0002-0.8 DAPI/Antifade-Solution (ultra) 0.8 ml
MT-0003-0.8 DAPI/Antifade-Solution (weak) 0.8 ml
PT-0001-1000 Heat Pretreatment Solution Citric 2 x 500 ml
PT-0002-500 Heat Pretreatment Solution EDTA 500 ml
PT-0006-100 Formaldehyde Dilution Buffer Set 2 x 50ml
SB-0004-4 NBT/BCIP 4 ml
SB-0005-4 AEC Solution 4 ml
WB-0001-500 Wash Buffer SSC 500 ml
WB-0002-50 25x Wash Buffer A 50 ml
WB-0003-50 20x SSC Solution 50 ml
WB-0004-1000 PBS/Tween 1 tabl.
WB-0005-50 20x Wash Buffer TBS 50 ml
WB-0006-0.5 2x Oligo Buffer 0.5 ml
Z-2099-20 ZytoLight FISH-Cytology Implementation Kit 20
95
Equipment & Slides
Joe Vargas –
Administration
“At Bio SB we are proud to market to the Molecular Pathology community,

innovative products and technology for the benefit of humanity.”
Wave RPD System – Totally Automated IHC in One Hour!
SYSTEM INFORMATION EASE OF USE

Using advanced proprietary technology, the revolutionary Celerus Wave® RPD With the Wave RPD System, it’s easy to achieve totally automated Rapid IHC®
System performs totally automated Rapid IHC® (deparaffinization through in any laboratory. Cartridge-based reagents and detection chemistries are
counterstain) on formalin-fixed, paraffin-embedded (FFPE) tissue specimens provided ready-to-use. There’s no mixing, no preparation and no guessing. With
in about one hour, and n frozen tissue samples in 15 minutes. Sophisticated intuitive Wave Manager software onboard, and a highly visible touch-screen,
instrument design, innovative system components and advanced software training requirements are minimized.
capabilities synergistically combine for unparalleled speed, standardized test
results, high-quality staining and ease-of-use. STANDARDIZED RESULTS
The Celerus Wave RPD System uses parallel processing to deliver the most
UNPARALLELED standardized results available. Parallel processing ensures that all slides are
H B 6 G I : G ! SPEED
; 6 H I : G ¸ G 6 E > 9 > = 8
The Celerus Wave® RPD System will become the laboratory workhorse – capable treated identically.
of producing more test results per shift that any other IHC staining system.
HIGH QUALITY STAINING
If Lean Processing is laboratory’s objective, the Wave RPD System improves Consistent, high-quality staining is always the result on the Wave RPD System
overall throughout by delivering smaller batches more often. and pathologists can feel confident in their diagnosis. Compared to other IHC
staining systems, the Wave RPD System delivers superior staining quality in a
fraction of the time.
I^bZidÄghiha^YZ/&]djg &'- LIMITLESS FLEXIBILITY

Ha^YZhhiV^cZYeZg-]djgh]^[i/&'- When additional capacity is required for large-volume laboratories, or for
&&' specific high-volume applications, additional Wave RPD systems can operate
as independent workstations or from a central unit. The outcome is limitless
capacity and flexibility while delivering results in record time.
.+
LEAN PROCESSES MAXIMIZED
With the Wave RPD System, cases move through the laboratory and to the
-% pathologist without delay. The Wave RPD System allows the option to batch
cases by patient, and send those slides to the next workstation after without
IDI6AH A> 9:H
+) requiring manual slide sorting before or after the Rapid IHC® run.
THE WAVE PRIMARY ANTIBODY CARTRIDGE

)- The Wave Primary Antibody Cartridge (PAC) is the
reservoir for Wave ready-to-use and user-fillable
(' primary antibodies. The PAC snaps into the linear
Reagent Magazine (LRM), completing the antibody
and detection chemistry combination necessary to
&+ perform totally automated, Rapid IHC® on the Wave
RPD System.
The PAC contains an embedded Smart Tag for automated reagent management
and quality assurance.
& ' ( ) * + , -
=DJGH
8ZaZgjhLVkZGE9Djieji
97
THE WAVE SLIDE RACK PLUG-N-PLAY REAGENTS®

The Wave Slide Rack used innovative technology Proprietary Wave RPD reagents are provided ready-to-use with no mixing or
to make Rapid IHC® a reality. The subtle, consistent preparation required. The distinct cartridge-based Linear Reagent Magazine
movement of the Wave Slide Rack increases (LRM) includes all pretreatment and detection reagents, hematoxylin and wash
saturation and binding rates, and reduces buffer. The Wave Primary Antibody Cartridge (PAC) is the reservoir for Wave ready-
biochemical reaction times. The Wave Slide Rack to-use and user-fillable primary antibodies. The LRM and PAC work together to
holds 16 slides and is designed to generate smaller perform totally automated, Rapid IHC® in one hour on the Wave RPD System.
batches of stained slides more frequently. This
supports Lean Processing, an objective of many ADVANCED WASTE MANAGEMENT
pathology laboratories for increased productivity. The innovative approach to waste management utilized by the Wave RPD System
completely eliminates the need to handle and dispose of liquid hazardous waste.
THE WAVE WICKING CASSETTE No more lifting heavy, bulk fluid waste containers. The Wave Wicking Cassette,
The Wave Wicking Cassette eliminates the need for captures minimal reagent waste and is disposed of as a solid waste according to
liquid hazardous waste disposal. Minimal reagent laboratory procedures.
waste is captured on an absorbent wicking material
which advances with each staining run. When full, LAN/LIS COMPATIBILITY
the entire casette is disposed of according to local Residing on the Wave RPD instrument, exclusive Wave Manager software can
solid waste management procedures. It’s simple, be accessed via the laboratory’s Local Area Network (LAN) from any computer
efficient and revolutionary. (locally or remotely), using any web browser. This conserves valuable laboratory
space and provides the ability to generate reports, review and manage cases,
Like all Wave System consumables, an embedded and adjust priorities without being at the instrument itself. The Wave RPD System
Smart Tag manages the life of the wave Wicking is compatible with many Laboratory Information Systems (LIS) to further
Cassette. improve laboratory workflow.
WAVE MANAGER SOFTWARE SMART TAGS

The Wave RPD System includes exclusive Wave A read/writable digital memory chip is embedded in every Wave RPD consumable
Manager software and a web server integrated product. Smart Tags track usage, lot numbers and expiration dates, and enable
in each unit. Remote access is possible from any consumable products to be used on any Wave RPD instrument, in any laboratory,
computer, and any web browser, for accessing cases at any time. There’s no longer a need to spend valuable time registering reagents.
or generating reports. With an onboard touch screen
to control the intuitive user interface, training on the SMART LOAD TOOL
Wave RPD is minimal and easy The Smart Load tool helps manage and prioritize slides based upon user-
defined parameters such as First In, First Out (FIFO), or by antibody, doctor or
THE WAVE LINEAR REAGENT MAGAZINE case. Whether slide requests are entered manually or via a laboratory Information
The Wave Linear Reagent Magazine (LRM) improves System (LIS), the Smart Load Tool helps the user organize slides accessioned into
immunohistochemistry (IHC) by standardizing the Wave Manager and provides the most efficient way to perform Rapid IHC® on
reagent chemistries into a complete and convenient the Wave RPD System.
package. The self-contained LRM includes all
pretreatment reagents, detection chemistries, QUALITY ASSURANCE
hematoxylin and wash buffer necessary to perform Reports for patient cases and consumables are generated with the Wave Manager
totally automated, Rapid IHC® on the Wave RPD software. The Run Reports and Slide reports functions are easily customized
System. with user-defined fields to provide traceability from consumable to patient to
pathologist. Reports are run locally or remotely using any web browser and
The LRM contains an embedded Smart Tag for seamlessly exported to Microsoft Excel® for further analysis, or provided as an
automated reagent management and quality Adobe® PDF file.
assurance.
limitle S S fl e x i b i l i t y
FFPE TISSUE F E AT U R E WAV E R P D SYS T E M

The Wave RPD System performs totally automated Rapid IHC® on formalin-
fixed, paraffin-embedded (FFPE) tissue in about one hour. Unique and efficient Total Automation (Dewax through Counterstain)
cartridge-based reagents (deparaffinization, antigen retrieval, antibody,
detection chemistry and counterstain) are delivered automatically and IHC, ICC, IF, ISH
consistently.
The Wave Manager software provides a variety of user-defined protocols for Time to First Slide / Frozen Section 15 Minutes
desired assay sensitivity.
Time to First Slide / FFPE (IHC) 75 Minutes
FROZEN TISSUE
Procedures such as Mohs micrographic surgery use IHC as an adjunctive test IHC Shift Throughput (8-Hour) 102 Slides
to aid in the assessment of surgical margins. However, traditional IHC methods
do not provide the time sensitive results desired for such procedures. With
Liquid Hazardous Waste None
the ability to deliver Rapid IHC® in 15 minutes on frozen tissue specimens,
Wave RPD technology provides adjunctive clinical information to derma to
pathologists and surgeons in minutes. Scalable Capacity
CYTOLOGY Bench Top

Immunocy to chemistry (ICC) can be performed on standard cytology
preparations, or on paraffin-embedded cell pellets, using various protocols on LIS / LIMS Compatibility
the Wave RPD System.
Weight 61 kg 135 lbs
Use Celerus Ready-to-use PACs, or another preferred antibody with the Celerus
User-Fillable PAC, to perform ICC on your slide-based cytology preparations.
Power Requirements 15A @ 100-240 VAC
IN SITU HYBRIDIZATION (RAPID ISHTM)
Rapid ISHTM occurs using the same technology that accelerates Rapid IHC®. Dimensions 110 x 60 x 70 cm
Two-color FISH (fluorescent) or CISH (chromogenic) on the Wave RPD System (W x H x D) 43 x 23.5 x 27.5 in
delivers high-quality molecular results in a fraction of the time compared to
other systems.
DIRECT IMMUNOFLUORESCENCE
With several protocols to choose from, the Wave RPD System performs direct
immunofluorescence (IF) procedures (on frozen tissue samples) using direct IF
Linear Reagent Magazine and fluorescent antibodies of your choice with the
User-Fillable PAC.
The Wave RPD System and its components are RoHS

compliment and meet standards to reduce the use of
hazardous materials in its design and manufacture.
99
Wave RPD Components and Accessories
Melan A on an
FFPE Melanoma Tissue
CAT. # PRODUCT DESCRIPTION QTY
INSTRUMENTATION
014-2601-110 Wave RPD System Kit (110V) - Includes items listed in Wave RPD System Kit Contents. 1
014-2601-220 Wave RPD System Kit (220V) - Includes items listed in Wave RPD System Kit Contents. 1
014-2600-110 Wave RPD Instrument (110V) 1
WAVE RPD SYSTEM KIT CONTENTS
007-0023-000 PAC Bin (12 PAC Capacity) 1

007-0024-000 LRM Bin (10 LRM Capacity) 1
014-2400-000 Uninterruptable Power Supply (110V) 1
014-2500-000 Wicking Cassette 1
014-2504-000 PAC Programmer 1
014-2606-000 Wave RPD Slide Rack (16-Slide Carrier) 2
014-2507-000 Slide Label Printer 1
014-2509-000 Wave Manager Laptop Computer 1
014-2510-000 Report Printer 1
014-2517-000 Slide Labels 500
014-2518-000 Slide Label Printer Ribbon 1
001-1200-000 Postively Charged Slides 144
------------------- Region Appropriate Power Cables 1
WAVE LINEAR REAGENT MAGAZINES (LRMs)
014-2001-080 Wave Mouse DAB – Anti-Mouse Polymer, HRP, DAB, Hematoxylin and Wash Buffer 80 tests
014-2002-080 Wave Rabbit DAB – Anti-Rabbit Polymer, HRP, DAB, Hematoxylin and Wash Buffer 80 tests
014-2003-080 Wave Universal DAB – Universal Polymer, HRP, DAB, Hematoxylin and Wash Buffer 80 tests
014-2010-080 Wave Mouse DAB Gold – Anti-Mouse Polymer, HRP, DAB, Hematoxylin and Wash Buffer, Peroxidase Block 80 tests
014-2011-080 Wave Rabbit DAB Gold – Anti-Rabbit Polymer, HRP, DAB, Hematoxylin and Wash Buffer, Peroxidase Block 80 tests
014-2009-080 Wave Universal Red – Universal Polymer, Alkaline Phosphatase, Hematoxylin and Wash Buffer 80 tests
014-2013-200 Wave Direct IF – Rapid Immunofluorescence Reagent 200 tests
014-2016-120 Wave RPD Tris Pretreatment – Deparaffinization and Antigen Retrieval 120 tests
014-2017-120 Wave RPD Citrate Pretreatment – Deparaffinization and Antigen Retrieval 120 tests
Wave RPD Components and Accessories
AE1/AE3 on an
FFPE Breast Carcinoma Tissue
CAT. # PRODUCT DESCRIPTION QTY
WAVE ACCESSORIES
007-0023-000 PAC Bin (12 PAC Capacity) 1

007-0024-000 LRM Bin (10 LRM Capacity) 1
014-2500-000 Wicking Cassette 1
014-2502-200 User Fillable Primary Antibody Cartridge (PAC), 200-Tests 1
014-2504-000 PAC Programmer 1
014-2506-000 Wave Slide Rack (16-Slide Carrier) 1
014-2507-000 Slide Label Printer 1
014-2509-000 Wave Manager Laptop Computer 1
014-2510-000 Report Printer 1
014-2512-000 PAC Rack (16 PAC Capacity) 1
014-2516-025 Riptide Steam Strips 25
014-2517-000 Slide Labels 500
014-2518-000 Slide Label Printer Ribbon 1
014-2519-000 Riptide Gasket 1
014-2520-000 Riptide Slide Holder (24 Slide Capacity) 1
014-2521-000 Riptide Staining Dish 1
014-2522-000 Riptide Staining Jar (5 Slide Capacity) 1
014-2523-000 Riptide Heat Shield 1
014-2606-000 Wave RPD Slide Rack (16-Slide Carrier) 1
014-3000-500 Target Retrieval Solution (Tris), 0.5 Liter, 20X 1
014-3001-500 Primary Antibody Diluent (500ml) 1
014-3002-500 Target Retrieval Solution (Citrate), 0.5 Liter, 10X 1
014-3003-001 Loading Buffer (Tris), 0.5 Liter, 1X 1
014-3003-010 Loading Buffer (Tris), 0.5 Liter, 10X 1
101
Wave RPD Antibodies
PSA on an
FFPE Prostate Tissue
CAT. # PRODUCT DESCRIPTION CLONE SPECIES
Antibodies - 50 TEST RTU (PAC)
014-1021-050 Actin, Muscle Specific HHF35 Mouse

014-1027-050 Actin, Smooth Muscle CGA7,B Mouse
014-1095-050 Androgen Receptor AR-D12 Mouse
014-1122-050 Bcl-2 BCL2/A4 Mouse
014-1063-050 Bcl-6 LN22 Mouse
014-1006-050 CA125 (Ovarian Cancer Antigen) Ov185:1 Mouse
014-1007-050 CA19-9 (Sialyl Lewisa) CA241:5:1:4 Mouse
014-1097-050 Caldesmon CALD-31 Mouse
014-1008-050 Calretinin Poly Rabbit
014-1009-050 Carcinoembryonic Antigen (CEA) 12-140-10 Mouse
014-1090-050 CD3 SP7 Rabbit
014-1064-050 CD4 1F6 Mouse
014-1091-050 CD5 SP19 Rabbit
014-1049-050 CD7 LP15 Mouse
014-1080-050 CD8 C8/144B Mouse
014-1051-050 CD10 56C6 Mouse
014-1069-050 CD15 BY87 Mouse
014-1000-050 CD20 L26 Mouse
014-1127-050 CD23 SP23 Rabbit
014-1052-050 CD30 1G12 Mouse
014-1098-050 CD31 1A10 Mouse
014-1053-050 CD34 QBEnd/10 Mouse
014-1011-050 CD43 DFT1 Mouse
014-1087-050 CD45 (Leukocyte Common Antigen) 2B11 & PD7/26 Mouse
014-1012-050 CD45RO UCHL1 Mouse
014-1017-050 CD56 1B6 Mouse
014-1099-050 CD57 NK1 Mouse
014-1100-050 CD68 CD68/G2 Mouse
014-1089-050 CD79a JCB117 Mouse
014-1057-050 CD117 T595 Mouse
014-1075-050 CDX2 CDX2-88 Mouse
014-1082-050 Chromogranin A LK2H10 Mouse
014-1123-050 COX-2 SP21 Rabbit
014-1102-050 Cytokeratin 5 SP27 Rabbit
014-1079-050 Cytokeratin 7 K72 Mouse
014-1088-050 Cytokeratin 8 35βH11 Mouse
014-1056-050 Cytokeratin 8/18 5D3 Mouse
Wave RPD Antibodies
CD1a on an
FFPE Thymus Tissue
CAT. # PRODUCT DESCRIPTION CLONE SPECIES
Antibodies - 50 TEST RTU (PAC) (continued)
014-1101-050 Cytokeratin 19 b170 Mouse

014-1034-050 Cytokeratin 20 Ks20.8 Mouse
014-1002-050 Cytokeratin AE1/AE3 AE1/AE3 Mouse
014-1060-050 Cytokeratin High Molecular Weight 34βE12 Mouse
014-1077-050 Cytomegalovirus (CMV) ** DDG9 & CCH2 Mouse
014-1016-050 Desmin DE-B-5 Mouse
014-1103-050 Dog-1 SP31 Rabbit
014-1058-050 E-Cadherin 36B5 Mouse
014-1104-050 Epithelial Cell Adhesion Molecule (Ep-CAM) BerEP4 Mouse
014-1073-050 Epithelial Membrane Antigen (EMA) GP1.4 Mouse
014-1019-050 Glial Fibrillary Acidic Protein (GFAP) GA5 Mouse
014-1105-050 Glypican-3 1G12 Mouse
014-1005-050 Helicobactor pylori 10B10.2 Mouse
014-1066-050 Hepatocyte Specific Antigen (HSA) OCH1E5 Mouse
014-1067-050 Kappa Poly Rabbit
014-1107-050 Ki67 SP6 Rabbit
014-1068-050 Lambda Light Chain Poly Rabbit
014-1124-050 Mammaglobin 304-1A5 Mouse
014-1083-050 Melan A M2-7C10 Mouse
014-1076-050 Melanoma Cocktail HMB45+M2-7C10+M2-9E3 Mouse
014-1030-050 Melanosome HMB45 Mouse
014-1109-050 MUC5AC CLH2 Mouse
014-1110-050 MUC6 CLH5 Mouse
014-1072-050 Myosin Heavy Chain SMMS-1 Mouse
014-1003-050 Negative Control (NC) - -
014-1022-050 Neuron Specific Enolase (NSE) BBS/NC/V1H14 Mouse
014-1023-050 P53 DO7 Mouse
014-1061-050 P63 7JUL Mouse
014-1078-050 Prostate Specific Acid Phosphatase (PSAP) PASE/4LJ Mouse
014-1025-050 Prostate Specific Antigen (PSA) ** 35H9 Mouse
014-1114-050 Renal Cell Carcinoma (RCC) PN-15 Mouse
014-1026-050 S100 Poly Rabbit
014-1115-050 TAG72 Tag72-22 Mouse
014-1116-050 Thyroid Transcription Factor-1 (TTF-1) 8G7G3/1 Mouse
014-1117-050 Tyrosinase Ty/G5 Mouse
014-1029-050 Vimentin V9 Mouse
014-1059-050 vonWillebrand Factor (vWF) 36B11 Mouse
014-1071-050 Wilms’ Tumor 1 (WT1) 6F-H2 Mouse
103
Electric Pressure Cooker and Slides
HEAT RETRIEVAL CAT. # DESCRIPTION QTY

Heat-induced epitope retrieval (HIER) is a pretreatment procedure used prior
to immunohistochemistry (IHC) or in situ hybridization (ISH) procedures Pressure Cooker and Staining Dishes
to improve staining by modifying the molecular conformation of ‘target’
proteins or nucleic acids through an exposure of slide-mounted specimen BSB 7008 Digital Pressure Cooker 1
material (sectioned tissue and other cellular preparations) to a heated buffer BSB 7009 Plastic Staining Dish 1
solution. This heat permeabilization is needed because additive fixation with BSB 7010 Slide Holder, 24 places 1
aldehyde-based fixatives causes protein and nucleic acid cross-linking,
resulting in changes in the conformation of some epitopes or nucleic acids Slides
that interfere with their ability to be recognized by complementary antibodies
or nucleic acid probes. BSB 7006 Probe On Plus Slides 72
BSB 7007 Probe On Slides 72
The Electric Pressure Cooker is a precision-controlled heating instrument that BSB 7011 Superfrost Plus Slides 72
is capable of maintaining constant and reliable temperatures while minimizing BSB 7012 Colorfrost Slides 72
the potential for evaporation of the Retriever solution. BSB 7013 Capillary-gap Slides 130um, Gold 72
BSB 7014 Cytology Microsope Slides 72
BSB 7028 Hydrophylic Plus Slides 100
Hydrophilic Plus Slides for Molecular Pathology
HYDROPHILIC PLUS SLIDES FOR MOLECULAR PATHOLOGY WATER TO SLIDE SURFACE CONTACT ANGLE
The Hydrophilic Plus Slides are novel positively charged hydrophilic slides
that prevent tissue detachment after thermal permeabilization and prior to IHC, Hydrophobic Surface Hydrophilic Surface
ICC, CISH or FISH protocols.
• The Hydrophilic Plus glass slides carry approximately three-times the

number of positive charges compared to the commercial positively-
charged slides
• The Hydrophilic Plus glass slides are strongly hydrophilic
• The Hydrophilic Plus glass slides display improved tissue-adhesion
characteristics compared to other commercially available slides
• All commercially available positively-charged microscope slides were Hydrophobicity and hydrophilidity were assessed by measuring the contact
found to be hydrophobic. angles of water drops on microscope slide surfaces; the smaller the contact
angle, the greater the hydrophilicity. Image analyses of contact angles produced
CHARACTERISTICS OF HYDROPHILIC SLIDES the following results:
Water Distribution and Surface Contact Angles for Untreated, Hydrophobic and
Hydrophilic Slides • Color Frost (untreated) contact angles: 24.90+/- 2.170
• Probe On Plus (positively charged) contact angles: 37.80 +/- 2.330.
• Hydrophilic Plus slides contact angles:15.80 +/- 0.70
Results showed that the Hydrophlic Plus slides had significantly smaller contact
angles.
DENSITY OF POSITIVE CHARGES AND INTENSITY OF AMINO GROUPS ON

NON-CHARGED, HYDROPHOBIC AND HYDROPHILIC SLIDES MEASURED BY
X-RAY PHOTOELECTRON SPECTROSCOPY
A 200ul drop of colored TBS was spread over the total working area of the
different microscope slides (estimated at 1100mm2). The TBS spread over 85%
of the working surface of untreated microscope slides and over 86.5% of the
Bio SB Hydrophilic Plus slides.In contrast, TBS was only able to cover 15% of
working surface of the Prob On Plus slides. These results demonstrated the
hydrophilic nature of the Hydrophilic Plus slide surface.
105
RELATIVE PERCENTAGE OF AMINO GROUPS ON UNTREATED, HYDROPHOBIC WATER AND AIR BUBBLES TRAPPING, TISSUE DAMAGE AND WRINKLING
AND HYDROPHILIC SLIDES MEASURED BY X-RAY PHOTOELECTRON AFTER MOUNTING TISSUES ON HYDROPHOBIC AND HYDROPHILIC SLIDES
SPECTROSCOPY
Reduced water to slide surface contact angles for hydrophilic slides (when
compared to a standard hydrophobic charged slides) allows water to form a single
thin continuous layer rather than a layer of water drops separated by air bubbles.
This prevents micro air bubbles from being captured under tissue sections and
in turn reduces the development of possible artifacts, such as bubbles or water
drops, which can interfere with tissue attachment to the slide. Generally, a
Hydrophilic Plus Slides are prepared by covalent coupling of positively charged more uniform and thinner layer of water under the cut tissue section results in
amino groups directly to the slide. The relative concentration of amino groups less trapping of bubbles and tissue wrinkling, and facilitates faster drying after
on various slides was measured by X-ray spectroscopy. Results showed that mounting on Hydrophilic Plus slides.
Hydrophilic Plus slides contained approximately 3-times the number of amino
groups compared to hydrophobic slides and greater than 30-times the number PERCENTAGE OF AVERAGE TISSUE RETENTION AND IHC SIGNAL WITH THE
of amino groups measured on untreated slides. The high density of amino DIFFERENT EXPERIMENTAL SLIDES
groups confers hydrophilic properties to the coated slides
Slide Name Brand Tissue Retention IHC Signal Background
The highest density of positive charges on the surface of hydrophilic slides
increases their wetting ability when compared to standard hydrophobic positively Hydrophilic Plus Bio SB, Inc 90 - 100% 3- 4 / +
charged slides. Increased hydrophilic interaction on the slide surface reduces Superfrost Plus Company A 10- 50% 3- 3+ / +
nonspecific adsorption of hydrophobic agents, and improves tissue adhesion to
Probe On Plus Company A 10- 50% 3- 3+ / +
the slides.
Color Mark Company B 5 - 40% 3- 3+ / +
Snow Coat X-tra Company C 5 - 30% 3- 3+ / +
Silanized In-House 5 - 40% 3- 3+ / +
Tissue adhesion after was measured on various types of microscope slides. The
results showed that Hydrophilic Plus slides had the highest percentage of tissue
retention (90-100%).
MACROSCOPIC COMPARISON OF TISSUE RETENTION AND IHC OF Ki67 AND MICROSCOPIC COMPARISON OF TISSUE RETENTION AND IHC OF Ki67 AND
CD31 USING COLORMARK AND HYDROPHILIC PLUS SLIDES CD31 USING PROBE ON PLUS AND HYDROPHILIC PLUS SLIDES
Ki67 CD31 IHC PROBE On PLUS HYDROPHILIC PLUS
Hydrophobic Hydrophilic Hydrophobic Hydrophilic
Ki67
Ki67
CD31
CD31
Stable and strong adhesion of biological samples to microscope slide surfaces is Our studies have shown that the Hydrophilic Plus Slides are suitable for
important in achieving successful sample preparation and staining. Untreated IHC, ICC, CISH and FISH and are superior in their capacity to retain tissues
glass surfaces or positively-charged modified surfaces of microscope slides that otherwise tend to detach from slides after thermal antigen retrieval
often do not provide strong enough retention for some biological samples. This procedures. In general, 90 to 100% of tissues that were damaged or detached
can lead to a full or partial sample loss or sample deformation. The Hydrophilic from traditional hydrophobic slides were fully retained by the hydrophilic slides
Plus Slides with highly positively charged hydrophilic surfaces, have shown without affecting tissue morphology and the quality of IHC signals.
to be superior to other slides with traditional hydrophobic positively charged
surfaces for tissue retention.
107
MICROSCOPIC COMPARISON OF IHC SIGNAL INTENSITY OF MELANOMA An interesting and unexpected observation surfaced during the course of our
HMB-45 ON SUPERFROST PLUS AND HYDROPHILIC PLUS SLIDES studies – IHC signals were more intense when using Hydrophilic Plus Slides.
Although the reasons for this finding are unknown, we are investigating the
possibility that hydrophilic surfaces improve efficiencies of immunological
SUPERFROST PLUS HYDROPHILIC PLUS reactions.
Hydrophilic Plus Slides are very effective tools in handling tissues that are
likely to sustain damage, loss, or detachment after thermal antigen retrieval
procedures.
Hydrophilic Plus Slides have shown to be reliable and superior alternatives to

other slides with traditional hydrophobic positively charged surfaces, and are
another effective tools when handling tissues that tend to get damaged, lost,
or detached after thermal antigen retrieval procedures prior to IHC, ICC, CISH
and FISH procedures.
109
Liquid-Based Cytology
Maria Sur –
Regulatory Affairs
“BIO SB develops, manufactures and markets products in accordance with

FDA QSR 21 CFR Part 820 cGMP. These guidelines enable us to produce an
IVD product that meets the highest in Vitro Diagnostic standards.”
CytoLayer of a normal Pap smear CytoLayer of HSIL Pap smear CytoLayer of HSIL Pap smear
• CytoLayer helps to reduce the number of false negatives and more readily detects high-degree lesions as
opposed to the traditional Pap smear
• Cellular samples are more uniform and are easier to read
• Elements that interfere with readings are reduced or eliminated
• Easy procedure with a minimum investment in equipment
• Remnant cells may be used for additional tests including HPV, Chlamydia, Gonorrhea, etc.
CytoLayer Protocol
Perform standard
staining protocol Take sample with Cervex brush
Transfer 750ml of cell suspension

to sedimentation chamber Vortex sample
and incubate 15 minutes
Dilute and vortex pellet Add 10ml of sample

for 30 seconds to centrifugation tube
Centrifuge samples and density

For in Vitro Diagnostic Use gradient for 10 minutes
111
CAT. # DESCRIPTION VOL/QTY CAT. # DESCRIPTION VOL/QTY
EQUIPMENT ACCESSORIES FOR LIQUID CYTOLOGY
BSB 4000-P CytoLayer Press 1 BSB 4016 Cervex Brush 100

BSB 4000-V CytoLayer Vortex Lx 1 BSB 4017 Cervex Brush 1000
BSB 4000-C CytoLayer CentrifugeModel Lx w ith Four-Place Swinging
Buckets and 40-15ml tube adapters 1 BSB 4018 CytoLayer Sedimentation Chambers 100
BSB 4019 CytoLayer Sedimentation Chambers 500
GYNECOLOGICAL LIQUID CYTOLOGY BSB 4034 CytoLayer Sedimentation Chambers 1000
(Fixative-Solution, Cervex Brush, Sedimentation Chambers, 15 ml Conical BSB 4020 15 ml Conical Centrifuge Tubes 50
Centrifuge Tubes, 1ml & 3 ml Transfer Pipettes, Microscope Slides, Density BSB 4021 15 ml Conical Centrifuge Tubes 500
Gradient & Slide Treatment Solution) BSB 4038 15 ml Conical Centrifuge Tubes 1000
BSB 4001 CytoLayer Gyn Liquid Cytology System 100 BSB 4022 1 ml Transfer Pipettes 100
BSB 4004 CytoLayer Gyn Liquid Cytology System 1000
BSB 4024 CytoLayer Microscope Slides 72
NON-GYNECOLOGICAL LIQUID CYTOLOGY BSB 4025 CytoLayer Microscope Slides 1440
(Fixative, Sedimentation Chambers, Tubes, Transfer Pipettes, Microscope BSB 4026 CytoLayer Slide Treatment Solution 100.0 ml
Slides, Density Gradient) BSB 4027 CytoLayer Slide Treatment Solution 500.0 ml
BSB 4032 CytoLayer Slide Treatment Solution 1000.0 ml
BSB 4006 CytoLayer Non-Gyn Liquid Cytology System 100
BSB 4007 CytoLayer Non-Gyn Liquid Cytology System 300 BSB 4028 CytoLayer Density Gradient 105.0 ml
ACCESSORIES FOR LIQUID CYTOLOGY BSB 4030 CytoLayer Lysis Solution 1000.0 ml
BSB 4031 CytoLayer Lysis Solution 3800.0 ml
BSB 4010 CytoLayer Fixative, 20 ml 100
BSB 4012 CytoLayer Gyn Accessories Cytology Kit 100

(Cervex Brush, Sedimentation Chambers, Tubes, Transfer Pipettes, Microscope

Slides, Slide Treatment Solution and Density Gradient)
BSB 4014 CytoLayer Non-Gyn Accessories Cytology Kit 100

(Sedimentation Chambers, Tubes, Transfer Pipettes, Microscope Slides, Slide

Treatment Solution and Density Gradient)
ANTIBODY TYPE ANTIBODY TYPE ANTIBODY TYPE

CLONE CLONE CLONE
ISOTYPE ISOTYPE ISOTYPE
CONTROL CONTROL CONTROL
LOCALIZATION LOCALIZATION LOCALIZATION
113
Single & Multiplex PCR
Andre Sanchez –
Research & Development
“Our goal at Bio SB is to constantly expand our line of products by bringing to

our customers the latest advances in Science and Technology.“
ANTIBODY TYPE ANTIBODY TYPE ANTIBODY TYPE

CLONE CLONE CLONE
ISOTYPE ISOTYPE ISOTYPE
CONTROL CONTROL CONTROL
LOCALIZATION LOCALIZATION LOCALIZATION
DNA/RNA Isolation Kits, RT PCR Kits and Ancillary Products
CAT. # DESCRIPTION VOL/QTY CAT. # DESCRIPTION VOL/QTY
DNA/RNA ISOLATION KITS BUFFERS AND ANCILLARY PRODUCTS (continued)
SA-40001 BDtract Genomic DNA Isolation Kit 100 BU-00031 50X Denhardt’s Reagent 50.0 ml
SA-40002 BDtract Genomic DNA Isolation Kit 50 BU-00032 Proteinase K, 20mg/mL 1.0 ml
SA-40003 RDtract RNA/DNA Isolation Kit 100 BU-00033 dNTPs, 2.5mM 1.0 ml
SA-40004 RDtract RNA/DNA Isolation Kit 50 BU-00034 M13K07 Helper Phage 1.0 ml
SA-40005 Gstract Total RNA Isolation Kit 100 BU-00035 E. coli, TG1 Cells 1
SA-40006 Gstract Total RNA Isolation Kit 50 BU-00036 E. coli, HB2151 Cells 1
BU-00037 pUC18, 1mg/ml 100.0 ul
RT KITS BU-00038 pUC19, 1mg/ml 100.0 ul
BU-00039 pUC119, 1mg/ml 100.0 ul
RT-40001 RTeasy Reverse Transcription Kit 10 BU-00040 pBR322, 1mg/ml 100.0 ul
RT-40002 RTeasy Reverse Transcription Kit 50 TAQ-00100 Native Taq Polymerase 100.0 U
RT-40003 Single-Step RT-PCR Kit 50 TAQ-00250 Native Taq Polymerase 250.0 U
TAQ-0500 Native Taq Polymerase 500.0 U
BUFFERS AND ANCILLARY PRODUCTS TAQ-00001 Native Taq Polymerase 1000.0 U
BU-00001 GC Normalizer 3.0 mL

BU-00002 DMSO 1.0 mL
BU-00003 10X MPCR Buffer 1 200
BU-00012 50X TAE Buffer, 1000.0 ml
BU-00013 10X TBE Buffer 1000.0 ml
BU-00014 6X Gel Loading Buffer 6x 1.5 ml
BU-00015 10X Gel Loading Solution I 6x 1.5 ml
BU-00016 EtBr, 10mg/mL 10.0 ml
BU-00017 10X MOPS Buffer 1000.0 ml
BU-00018 10X SDS Solution 500.0 ml
BU-00019 20X SSC Buffer 1000.0 ml
BU-00020 0.5M EDTA, pH8.0 500.0 ml
BU-00021 Double-Distilled H2O 1000.0 ml
BU-00022 DEPC Double-Distilled H2O 1000.0 ml
BU-00023 DNA M.W. Marker, 100bp Ladder 100x 0.5 ml
BU-00024 DNA M.W. Marker, 20bp Ladder 100x 0.5 ml
BU-00025 DNA M.W. Marker, 1kb Ladder 0.5 ml
BU-00026 DNA M.W. Marker, 5kb Ladder 0.5 ml
BU-00027 Agarose 100.0 g
BU-00028 Agarose 500.0 g
BU-00029 Ampicillin, 50mg/mL 1.0 ml
BU-00030 Kanamycin, 10mg/mL 1.0 ml
For Research Use Only
115
Single & Multiplex PCR
SINGLE & MULTIPLEX PCR Maxim’s RT-MPCR kits are ideal for use in the analysis and comparison of when,
Polymerase Chain Reaction (PCR) selectively amplifies discrete segments of where, and to what degree genes are expressed, also known as gene expression
DNA. One of the major applications of PCR is to detect and quantify mRNA profiling. Eventually, gene expression profiling will further our understanding
species through its highly sensitive and specific amplification. The growing of the control and mode of action of individual gene products. DNA chip
abundance of genomic sequence data invites increasingly large-scale genetic technology is currently the most common method for determining gene
analysis, which is gradually proving useful in clinical analysis. abundance in a total RNA or poly(A) RNA sample, but this method is limited
by low sensitivity and high cost. DNA chips may serve a better purpose as a
Maxim’s PCR single primer kits are designed to avoid formation of “primer- discovery tool to identify genes related to a specific biological process, followed
dimers” during amplification. The PCR primers can be used for regular PCR or by using MPCR. MCPR can be a tool to further analyze the performance of genes
Real-time PCR. Maxim’s positive control primer is sequence-confirmed and copy in genetic profiling and quantative assays.
number defined, so this can be used as a template for regular PCR or standard
curve for real-time PCR. Maxim’s single PCR kit is designed for its flexibility. It can ADVANTAGES:
be used with any other company’s SyBr Green kits in Real-time PCR. • Diversity: MPCR Kits cover diverse applications from basic pathway gene
expression profiling to diagnostic pathogen identification.
KIT COMPONENTS FOR SINGLE PCR KITS • Conserves genetic material: only a single reaction is necessary to amplify
multiple genes of interest
Kit Components 100 Reactions Storage • Efficiency: One reaction is sufficient to amplify multiple genes
simultaneously in a single reaction.
Pre-mixed Primers 1000 μl -20°C
KIT COMPONENTS FOR MULTIPLEX PCR KITS
Optimized PCR Buffer 750 μl x 4 tubes -20°C
(Chemicals, enhancer, stabilizer, dNTPs)
Kit Components 50 Reactions 100 Reactions Storage
Positive Control 100 μl -20°C
M.W. marker, 100 bp ladder 100 μl -20°C Optimized MPCR Buffer 1250 µL 1250 µL x 2 -20°C
ddH2O 1000 μl -20°C Positive Control 50 µL 50 µL x 2 -20°C
Primer mixture 250 µL 250 µL x 2 -20°C
DNA M.W. Marker (100 bp Ladder) 100 µL 100 µL x 2 -20°C
Maxim’s RT-MPCR provides an accurate method to detect multiple gene
expression by simultaneously amplifying all the genes under the same ddH2O (DNase free) 2.0 mL 2.0 µL x 2 -20°C
conditions. MPCR kits combine PCR amplification technology and multiple
target detection throughput in a single tube. Maxim has developed proprietary
technology that overcomes the non-specific amplification of PCR products
between primers. The PCR products, also known as amplicons, are amplified
efficiently to give relatively quantitative results from amplicon to amplicon, and
sample to sample.
MPCR’s capacity to simultaneously quantify multiple mRNA species from a

single sample of RNA allows comparative analysis of different mRNA species
within samples. Variations in RNA isolation, initial quantification errors or
tube-to-tube variations in RT and PCR can be compensated by including
a known housekeeping gene. MPCR can also be performed on total RNA
prepared by standard methods without further purification of poly (A) RNA.
PCR Flowchart
Multiple Diseases
Initial Screening with DNA Chip
DNA Chip
Disease-Associated Genes Disease-Associated Genes
Customer Service Routine Multiple

MPCR Screening Kit Genes Screening
Quantative with House-Keeping Control Quantative with Competition Quantative with FRET Probe
Dual-PCR QC-PCR Single PCR Real-Time PCR

DP-10xxx QP-10xxx SP-10xxx TP-10xxx/TM-60xxx
Amplicon
Cloning (PCR Product) Cloning
Protein Expression Vector Isotype Dual Promoter Vector

or
Non-Isotype
Antigen Protein Labeling In Vitro Transcripts
Animal Immunization DNA & cDNA Probe RNA Probe

IH-60xxx
Antibody
Southern Northern In Situ

Hybridzation Hybridzation Hybridzation
Histochemistry Western Blot
117
Human Gene Primer – Single PCR Kits
CAT. # GENE ACCESSION DESCRIPTION bp
No.
SP-10002 18S rRNA X03205 18S rRNA Gene, Primer Set Plus Positive Control 554 bp
SP-10005 18S rRNA X03205 18S rRNA Gene, Primer Set Plus Positive Control 489 bp
SP-10008 28S rRNA M11167 28S rRNA Gene, Primer Set Plus Positive Control 494 bp
SP-10009 Actin, alpha J05192 Alpha-Actin, Primer Set Plus Positive Control 598 bp
SP-10031 Actin, beta X00351 Beta-Actin, Primer Set Plus Positive Control 303 bp
SP-10033 Actin, beta X00351 Beta-Actin, Primer Set Plus Positive Control 474 bp
SP-10013 ADM NM_001124 Adrenomedullin, Primer Set Plus Positive Control 212 bp
SP-10014 ADM Receptor NM_007264 Adrenomedullin Receptor, Primer Set Plus Positive Control 244 bp
SP-10015 AFP J00077 Alpha-Fetoprotein, Primer Set Plus Positive Control 224 bp
SP-10596 Androgen Receptor M27423 Androgen Receptor, Primer Set Plus Positive Control 282 bp
SP-10684 Angiogenin M11567 Angiogenin, Primer Set Plus Positive Control 259 bp
SP-10693 Angiopoietin-1 NM_001146 Angiopoietin-1, Primer Set Plus Positive Control 174 bp
SP-10016 Angiopoietin-1 NM_001146 Angiopoietin-1, Primer Set Plus Positive Control 472 bp
SP-10017 Angiopoietin-2 NM_001147 Angiopoietin-2, Primer Set Plus Positive Control, 200 bp
SP-10020 APAF1 AF013263 Apaf-1(Caspase activator), Primer Set Plus Positive Control 498 bp
SP-10063 B7RP-1 AF216749 B7-Related Protein-1, Primer Set Plus Positive Control 351 bp
SP-10037 Bad AF021792 BAD, Primer Set Plus Positive Control 192 bp
SP-10038 Bax L22473 BAX-alpha, Primer Set Plus Positive Control 140 bp
SP-10039 Bax L22473 BAX-alpha, Primer Set Plus Positive Control 272 bp
SP-10727 Beta-Actin NM_001101 Beta-Actin, Primer Set Plus Positive Control 540 bp
SP-10696 Beta-Actin NM_001101 Beta-Actin (Exon1-3) Primer, Positive Set 642 bp
SP-10043 Bcl-2 M14745 BCL-2, Primer Set Plus Positive Control 235 bp
SP-10698 Bcl-xL L20121 Bcl-xL, Primer Set Plus Positive Control 291 bp
SP-10044 Bcl-xL; Bcl-xS Z23115 Bcl-xL & Bcl-xS, Primer Set Plus Positive Control xL:371 bp/xS:183 bp
SP-10053 bcr-ABL X02596 bcr Primer Set (Internal Control), Plus Positive Control 281 bp
SP-10051 bcr-ABL, Acute AF113911 bcr-ABL (All), Primer Set Plus Positive Control 307 bp
SP-10054 bcr-ABL M14752 ABL Primer Set (Internal Control), Plus Positive Control 137 bp
SP-10049 bcr-ABL, Chronic AJ131466 bcr-ABL (CML), Primer Set Plus Positive Control 232/157 bp
SP-10050 bcr-ABL, Chronic AJ131467 bcr-ABL (CML), Primer Set Plus Positive Control 193/118 bp
SP-10058 BRCA1 Exon 2 L78833 BRCA1 Exon 2, Primer Set Plus Positive Control 258 bp
B (continued)
SP-10059 BRCA1 Exon 11 U14680 BRCA1 Exon 11, Primer Set Plus Positive Control 1100 bp
SP-10062 BRCA1 Exon Zinc Finger U14680 BRCA1 Zinc, Primer Set Plus Positive Control 270 bp
SP-10071 C5A Receptor X58674 C5A Receptor for Chemoattractants, Primer Set Plus Positive Control 676 bp
SP-10142 Calcitonin Receptor L76380 Calcitonin Receptor-like, Primer Set Plus Positive Control 259 bp
SP-10344 Caspase-1 (ICE) M87507 ICE (Caspase-1), Primer Set Plus Positive Control 289 bp
SP-10358 Caspase-2 (ICH1L&S) U13021 & U13022 ICH1, Primer Set Plus Positive Control 187 bp
SP-10139 Caspase-3 (CPP-32) U13737 CPP-32 (LICE, Caspase-3), Primer Set Plus Positive Control 320 bp
SP-10359 Caspase-4 (ICH2) U25804 ICH2 (Caspase-4), Primer Set Plus Positive Control 360 bp
SP-10352 Caspase-5 (ICHre3) U28015 Caspase-5, Primer Set Plus Positive Control 256 bp
SP-10492 Caspase-6 (MCH2) U20536 Caspase-6, Primer Set Plus Positive Control 419 bp
SP-10345 Caspase-8 (FLICE) U58143 Caspase-8 (Flice), Primer Set Plus Positive Control 405 bp
SP-10077 CCR-1 L09230 CCR1, Primer Set Plus Positive Control 363 bp
SP-10078 CCR-2a D29984 CCR2a, Primer Set Plus Positive Control 163 bp
SP-10079 CCR-3 U28694 CCR3, Primer Set Plus Positive Control 318 bp
SP-10080 CCR-4 X85740 CCR4, Primer Set Plus Positive Control 287 bp
SP-10093 CCR-7 L08176 CCR7, Primer Set Plus Positive Control 214 bp
SP-10082 CCR-11 NM_016557 CCR11, Primer Set Plus Positive Control 299 bp
SP-10098 CD14 M86511.1 CD14 Molecule, Primer Set Plus Positive Control 207 bp
SP-10099 CD152 XM_028176 CD152 Molecule, Primer Set Plus Positive Control 254 bp
SP-10100 CD19 M21097.1 CD19 Molecule, Primer Set Plus Positive Control 174 bp
SP-10101 CD28 NM_006139 CD28 Molecule, Primer Set Plus Positive Control 452 bp
SP-10102 CD3 NM_000732.1 CD3 Molecule, Primer Set Plus Positive Control 330 bp
SP-10105 CD4 M12807 CD4 Molecule, Primer Set Plus Positive Control 438 bp
SP-10103 CD40 AJ300189.1 CD40 Molecule, Primer Set Plus Positive Control 233 bp
SP-10104 CD40 Ligand L07414 CD40 Ligand Molecule, Primer Set Plus Positive Control 255 bp
SP-10108 CD45 Y00062.1 CD45 Molecule, Primer Set Plus Positive Control 388 bp
SP-10111 CD8, alpha M26313 CD8 Molecule, Primer Set Plus Positive Control 335 bp
SP-10112 CD8, alpha M26313 CD8 Molecule, Primer Set Plus Positive Control 246 bp
119
C (continued)
SP-10110 CD80 BC042665 CD80 Molecule, Primer Set Plus Positive Control 189 bp
SP-10113 CD86 NM_006889 CD86 Molecule, Primer Set Plus Positive Control 154 bp
SP-10706 CDC2 NM_033379.2/NM_001786 CDC2, Primer Set Plus Positive Control I: 895 bp; II: 724 bp
SP-10115 CEA M29540.1 CEA Gene, Primer Set Plus Positive Control 358 bp
SP-10477 c-jun M29039 c-jun Gene, Primer Set Plus Positive Control 246 bp
SP-10129 CK19 Y00503.1 CK-19, Primer Set Plus Positive Control 293 bp
SP-10499 cMET J02958 cMET Oncogene, Primer Set Plus Positive Control 392 bp
SP-10529 c-myc V00568 c-myc, Primer Set Plus Positive Control 371 bp
SP-10712 COX1 NM_000962 COX1, Primer Set Plus Positive Control 218 bp
SP-10705 COX2 BC013734 COX2, Primer Set Plus Positive Control 279 bp
SP-10127 CTGF M92934 CTGF, Primer Set Plus Positive Control 402 bp
SP-10151 CXCR-1 & 2 M68932 CXCR-1 & 2 Gene, Primer Set Plus Positive Control 191 bp
SP-10152 CXCR-3 BC034403 CXCR3 Gene, Primer Set Plus Positive Control 303 bp
SP-10153 CXCR-4 BC020968 CXCR4 Gene, Primer Set Plus Positive Control 249 bp
SP-10703 DAF NM_000574 DAF, Primer Set Plus Positive Control 195 bp
SP-10163 Dystrophine, Exon 8 U60822.1 Dystrophine, Exon 8, Primer Set Plus Positive Control 360 bp
SP-10164 Dystrophine, Exon 17 X13045 Dystrophine, Exon 17, Primer Set Plus Positive Control 415 bp
SP-10166 Dystrophine, Exon 19 M36673.1 Dystrophine, Exon 19, Primer Set Plus Positive Control 459 bp
SP-10167 Dystrophine, Exon 44 X13046 Dystrophine, Exon 44/Exon X, Primer Set Plus Positive Control 267 bp
SP-10169 Dystrophine, Exon 45 X13048 Dystrophine, Exon 45/Exon Z, Primer Set Plus Positive Control 547 bp
SP-10170 Dystrophine, Exon 48 X13047 Dystrophine, Exon 48/Exon Y, Primer Set Plus Positive Control 506 bp
SP-10171 Dystrophine, Exon 12 AF213412 Dystrophine, Exon 12, Primer Set Plus Positive Control 332 bp
SP-10172 Dystrophine, Exon 51 X51934 Dystrophine, Exon 51, Primer Set Plus Positive Control 388 bp
SP-10174 Dystrophine, Promoter AF276053.1 Dystrophine, Muscle-Specific Promoter, Primer Set Plus Positive Control 535 bp
SP-10177 Dystrophine, Exon 13 AF213413 Dystrophine, Exon 13/Chrom. X, Primer Set Plus Positive Control 238 bp
SP-10178 Dystrophine, Exon 43 L41634 Dystrophine, Exon 43, Primer Set Plus Positive Control 357 bp
SP-10180 Dystrophine, Exon 50 AJ271220 Dystrophine, Exon 50, Primer Set Plus Positive Control 271 bp
SP-10182 Dystrophine, Exon 60 NM_004023 Dystrophine, Exon 60, Primer Set Plus Positive Control 139 bp
SP-10183 Dystrophine, Exon 49 AJ271220 Dystrophine, Exon 49, Primer Set Plus Positive Control 439 bp
SP-10208 EGF X04571 Epidermal Growth Factor (EGF), Primer Set Plus Positive Control 393 bp
SP-10209 EGFR X00588 Epidermal Growth Factor Receptor, Primer Set Plus Positive Control 351 bp
SP-10210 ENA-78 X78686 ENA-78, Primer Set Plus Positive Control 296 bp
SP-10724 EPO NM_000799 Erythropoietin (EPO), Primer Set Plus Positive Control 179 bp
SP-10725 EPOR NM_000121 Erythropoietin Receptor (EPOR), Primer Set Plus Positive Control 149 bp
SP-10022 Factor V M16967 Coagulation Factor V Gene, Primer Set Plus Positive Control 288 bp
SP-10213 FADD U24231 FADD Gene, Primer Set Plus Positive Control 205 bp
SP-10214 FAK L13616 Focal Adhesion Kinase (FAK), Primer Set Plus Positive Control 247 bp
SP-10216 FAS M67454 FAS Gene, Primer Set Plus Positive Control 427 bp
SP-10215 Fas Ligand U08137 Fas Ligand, Primer Set Plus Positive Control 251 bp
SP-10220 FGF2 NM_002006 FGF2, Primer Set Plus Positive Control 254 bp
SP-10690 FGFR3 NM_022965 Fibroblast Growth Factor Receptor 3, Primer Set Plus Positive Control 198 bp
SP-10661 FLK1 AF035121 VEGF receptor (FLK1), Primer Set Plus Positive Control 408 bp
SP-10660 FLT1 AF063657 VEGF receptor (FLT1), Primer Set Plus Positive Control 554 bp
SP-10225 FLT4 X68203.1 FLT4 Ligand, Primer Set Plus Positive Control 250 bp
SP-10230 FPR M76673 Formyl-peptide Receptor, Primer Set Plus Positive Control 718 bp
SP-10229 FOS V01512 c-FOS Oncogene, Primer Set Plus Positive Control 241 bp
SP-10219 FRDA U43748 Frataxin (FRDA) Gene, Primer Set Plus Positive Control 341 bp
SP-10231 GAPDH M33197 GAPDH, Primer Set Plus Positive Control 226 bp
SP-10145 G-CSF M27087 G-CSF, Primer Set Plus Positive Control 192 bp
SP-10586 Globin, beta J00179 Sickle Cell Anemia-Hemoglobin C, Primer Set Plus Positive Control 249 bp
SP-10064 Globin, Beta J00179 b-Thalassemia, Chinese, Primer Set Plus Positive Control 825 bp
SP-10065 Globin, Beta J00179 b-Thalassemia, Chinese, Primer Set Plus Positive Control 664 bp
SP-10066 Globin, Beta J00179 b-Thalassemia, Mediterranean, Primer Set Plus Positive Control 825 bp
SP-10067 Globin, Beta J00179 b-Thalassemia, Mediterranean, Primer Set Plus Positive Control 664 bp
121
G (continued)
SP-10070 Globin, Beta U01317 b-Thalassemia, None Chinese or Mediterranean, Primer Set Plus Positive Control 825 bp
SP-10252 GM-CSF Receptor M73832 GM-Colony Stimulating Factor Receptor, Primer Set Plus Positive Control 609 bp
SP-10251 GM-CSF NM_000758 GM-Colony Stimulating Factor, Primer Set Plus Positive Control 423 bp
SP-10655 G-prot. V28 U20350 G protein-coupled receptor V28, Primer Set Plus Positive Control 349 bp
SP-10257 GRP M73481 GRP Receptor, Primer Set Plus Positive Control 108 bp
SP-10699 HER2 Receptor M11730 HER2 Receptor, Primer Set Plus Positive Control 356 bp
SP-10271 hCG, beta J00117 HCG-Beta, Primer Set Plus Positive Control 500 bp
SP-10281 HGF M73239 Hepatocyte Growth Factor, Primer Set Plus Positive Control 681 bp
SP-10285 his tRNA X05345 his tRNA, Primer Set Plus Positive Control 110 bp
SP-10295 HMOX1 BC001491 heme-oxygenase 1, Primer Set Plus Positive Control 871 bp
SP-10321 HOXB13 U57052 HOXB13 Gene, Primer Set Plus Positive Control 259 bp
SP-10594 HPRT M26434 STR, HPRT, AGAT, 7-16 Repeat, Primer Set Plus Positive Control 283 bp
SP-10730 HPRT1 NM_000194 HPRT1, Primer Set Plus Positive Control 171 bp
SP-10580 H-ras 1 V00574 H-ras 1 gene, Primer Set Plus Positive Control 542 bp
SP-10259 H-ras, EXON1 V00574 H-Ras Exon 1, Primer Set Plus Positive Control 109 bp
SP-10260 H-ras EXON2 V00574 H-Ras Exon 2, Primer Set Plus Positive Control 194 bp
SP-10313 HSP-70 M11717 Heat-Shock Protein-70, Primer Set Plus Positive Control 250 bp
SP-10360 ICAM-1 J03132 ICAM-1, Primer Set Plus Positive Control 232 bp
SP-10363 ICOS NM_012092 Inducible T-cell Co-Stimulator, Primer Set Plus Positive Control 256 bp
SP-10375 IFIT1 NM_001548 Interferon Inducer Protein IFIT1, Primer Set Plus Positive Control 404 bp
SP-10472 IRF3 NM_001571 Interferon Regulatory Factor 3, Primer Set Plus Positive Control 254 bp
SP-10364 IFN-Alpha V00544 Interferon-alpha, Primer Set Plus Positive Control 229 bp
SP-10365 IFN-Alpha V00544 Interferon-alpha, Primer Set Plus Positive Control 567 bp
SP-10366 IFN-Beta M25460 Interferon-beta, Primer Set Plus Positive Control 347 bp
SP-10367 IFNA2 NM_000605 Interferon-alpha 2, Primer Set Plus Positive Control 192 bp
SP-10373 IFN-gamma M29383 Interferon-gamma, Primer Set Plus Positive Control 293 bp
SP-10374 IFNGR1 NM_000416 Interferon-gamma Receptor 1, Primer Set Plus Positive Control 185 bp
SP-10382 IGF-1 NM_000618 Insulin-Like Growth Factor I, Primer Set Plus Positive Control 184 bp
SP-10379 IGF-2 X00910 Insulin-Like Growth Factor II, Primer Set Plus Positive Control 472 bp
SP-10385 IGF-2 NM_000612 Insulin-Like Growth Factor II, Primer Set Plus Positive Control 231 bp
SP-10323 IGFBP1 NM_000596 Insulin-like Growth Factor Binding protein-1, Primer Set Plus Positive Control 201 bp
I (continued)
SP-10331 IGFBP6 BC011708 Insulin-like Growth Factor Binding protein-6, Primer Set Plus Positive Control 409 bp
SP-10386 IkBL factor X77909 IkBL Factor, Primer Set Plus Positive Control 158 bp
SP-10451 IL-1 alpha M15329 IL1-alpha, Primer Set Plus Positive Control 816 bp
SP-10459 IL-1 beta M15330 IL1-beta, Primer Set Plus Positive Control 556 bp
SP-10674 IL-2 V00564 IL2, Primer Set Plus Positive Control 300 bp
SP-10465 IL-2 receptor X01057 Interleukin 2 Receptor, Primer Set Plus Positive Control 398 bp
SP-10429 IL-3 M14743 IL3, Primer Set Plus Positive Control 633 bp
SP-10430 IL-4 NM_000589 IL4, Primer Set Plus Positive Control 270 bp
SP-10435 IL-4 Receptor X52425 IL4 Receptor, Primer Set Plus Positive Control 279 bp
SP-10442 IL-5 receptor M75914 IL5 Receptor, Primer Set Plus Positive Control 303 bp
SP-10466 IL-6 receptor X12830 Interleukin 6 Receptor, Primer Set Plus Positive Control 251 bp
SP-10467 IL-6r gp130 M57230 Interleukin 6 Receptor gp130, Primer Set Plus Positive Control 814 bp
SP-10256 IL-6r, gp80 X58298 Interleukin 6 Receptor gp80, Primer Set Plus Positive Control 247 bp
SP-10448 IL-8 XM_003501 IL8, Primer Set Plus Positive Control 173 bp
SP-10449 IL-8 receptor, High M73969 IL8 receptor, High, Primer Set Plus Positive Control 680 bp
SP-10447 IL-8 receptor, Low X65858 IL8 receptor, Low, Primer Set Plus Positive Control 679 bp
SP-10399 IL-10 Receptor NM_001558 IL10 Receptor, Primer Set Plus Positive Control 273 bp
SP-10463 IL-12, p35 subunit M38443 IL12, p35, Primer Set Plus Positive Control 323 bp
SP-10404 IL-12, p40 subunit NM_002187 IL12, p40, Primer Set Plus Positive Control 336 bp
SP-10412 IL-13 X69079 IL13, Primer Set Plus Positive Control 299 bp
SP-10413 IL-13 X69079 IL13, Primer Set Plus Positive Control 178 bp
SP-10418 IL-14 AF516206 IL14, Primer Set Plus Positive Control 245 bp
SP-10420 IL-18 E17135 IL18, Primer Set Plus Positive Control 265 bp
SP-10473 Insulin BC005255 Insulin, Primer Set Plus Positive Control 216 bp
SP-10470 IP-10 NM_001565 Small Inducible Cytokine B10 Precursor, Primer Set Plus Positive Control 199 bp
123
SP-10480 KGF S81661 Keratinocyte Growth Factor, Primer Set Plus Positive Control 246 bp
SP-10581 K-ras, Asp 12 mutant M34904 K-ras Proto-oncogene, Primer Set Plus Positive Control 128 bp
SP-10478 K-ras, EXON1 L00045 K-ras Exon 1, Primer Set Plus Positive Control 162 bp
SP-10479 K-ras, EXON2 L00046 K-ras Exon 2, Primer Set Plus Positive Control 133 bp
SP-10481 L32 X03342 L32, Primer Set Plus Positive Control 242 bp
SP-10482 L32 X03342 L32, Primer Set Plus Positive Control 143 bp
SP-10485 LIF X13967 Leukemia Inhibitory Factor, Primer Set Plus Positive Control 375 bp
SP-10685 LRP1 NM_002332 Lipoprotein Receptor Protein, Primer Set Plus Positive Control 156 bp
SP-10708 Lymphotoxin-Alpha NM_000595 Lymphotoxin-Alpha, Primer Set Plus Positive Control 214 bp
SP-10709 Lymphotoxin-Beta NM_002341 Lymphotoxin-Beta, Primer Set Plus Positive Control 201 bp (I)/154 (II)
SP-10520 MAP Kinase AF031135 Mitogen-Activated Protein Kinase 11, Primer Set Plus Positive Control 316 bp
SP-10495 MCP-1 S71513 Small Inducible Cytokine A2, Primer Set Plus Positive Control 277 bp
SP-10496 MCP-2 NM_005623 Small Inducible Cytokine A8, Primer Set Plus Positive Control 326 bp
SP-10742 MD2 NM_015364 Lymphocyte Antigen 96 (LY96), Primer Set Plus Positive Control 114 bp
SP-10528 Metallothionein V00594 Metallothionein, Primer Set Plus Positive Control 203 bp
SP-10733 MIG NM_002416.1 MIG, Primer Set Plus Positive Control 359 bp
SP-10731 MIP-1a NM_002983 MIP-1(CCL3), Primer Set Plus Positive Control 212 bp
SP-10504 MIP-1b NM_002984 Small Inducible Cytokine A4, Primer Set Plus Positive Control 187 bp
SP-10509 MMP-1 NM_002421 MMP-1 Gene, Primer Set Plus Positive Control 229 bp
SP-10516 MMP-3 J03209 MMP-3 Gene, Primer Set Plus Positive Control 351 bp
SP-10517 MMP-7 Z11887 MMP-7 Gene, Primer Set Plus Positive Control 281 bp
SP-10512 MMP-13 X75308 MMP-13 Gene, Primer Set Plus Positive Control 416 bp
SP-10508 MMP-14 NM_004995 MT-MMP-1(MMP-14) Gene, Primer Set Plus Positive Control 223 bp
SP-10720 Myosin NM_002471 Myosin, heavy polypeptide 6 & 7, Primer Set Plus Positive Control 246 bp
SP-10539 NFkB M62399 NF kapper-b Factor, P65, Primer Set Plus Positive Control 409 bp
SP-10538 NF-AT U85428 NF-AT Factor, Primer Set Plus Positive Control 321 bp
N (continued)
SP-10542 NF-ATc U08015 NF ATc Factor, Primer Set Plus Positive Control 271 bp
SP-10714 NIS NM_000453 NIS, Primer Set Plus Positive Control 348 bp
SP-10702 NOD2 NM_022162 NOD2, Primer Set Plus Positive Control 255 bp
SP-10545 nNOS D16408 Neuronal Nitric Oxide Synthase, Primer Set Plus Positive Control 341 bp
SP-10543 eNOS M93718 Endothelia Nitric Oxide Synthase, Primer Set Plus Positive Control 430 bp
SP-10544 iNOS U05810 Inducible Nitric Oxide Synthase, Primer Set Plus Positive Control 231 bp
SP-10536 N-ras, Exon1 M57430 N-Ras Exon 1, Primer Set Plus Positive Control 118 bp
SP-10537 N-ras, Exon2 L00041 N-Ras Exon 2, Primer Set Plus Positive Control 103 bp
SP-10553 OCT-2 X53468 OCT-2 Factor, Primer Set Plus Positive Control 211 bp
SP-10554 P16 U12818 P16 Oncogene MTS1 Exon 1, Primer Set Plus Positive Control 340 bp
SP-10556 P16 S69805 P16 Oncogene MTS2 Exon 2, Primer Set Plus Positive Control 417 bp
SP-10559 P16 S69805 P16 Oncogene MTS2 Exon 2, Primer Set Plus Positive Control 260 bp
SP-10728 P21 NM_000389 P21, Primer Set Plus Positive Control 340 bp
SP-10564 P53 K03199 P53 Oncogene, Primer Set Plus Positive Control 205 bp
SP-10563 P53, Exon 10-11 U94788 P53 Exon 10-11, Primer Set Plus Positive Control 1143 bp (DNA)/223 bp (cDNA)
SP-10560 P53, Exon 2-4 U94788 P53 Oncogene Exon 2-4, Primer Set Plus Positive Control 535 bp
SP-10552 P69 2-5A synthetase M87284 2’-5’-oligoadenylate synthetase 2 (OAS), Primer Set Plus Positive Control 330 bp
SP-10567 Paired box gene 8 BC001060 Paired Box Gene 8, Primer Set Plus Positive Control 403 bp
SP-10715 PCNA BC042439 Proliferating Cell Nuclear Antigen (PCNA), Primer Set Plus Positive Control 142 bp
SP-10689 PEDF U29953 Pigment Epithelium-Derived Factor (PEDF), Primer Set Plus Positive Control 188 bp
SP-10487 Phospholipase A2 M86400 Phospholipase A2, Primer Set Plus Positive Control 365 bp
SP-10488 Phospholipase A2 M86400 Phospholipase A2, Primer Set Plus Positive Control 483 bp
SP-10572 PML-rar fusion protein M73779 PML-rar fusion protein Primer, Positive Set 253 bp
SP-10576 PSA M26663 Prostate Specific Antigen Primer, Positive Set 286 bp
SP-10571 PLAP NM_001632 Placental Alkaline Phosphatase Primer, Positive Set 302 bp
SP-10574 Proteolipid (PLP) M15027 Myelin Proteolipid (PLP) gene Primer, Positive Set 195 bp
SP-10575 PRX-2 U81600 PRX-2, Primer Set Plus Positive Control 206 bp
SP-10573 PSMA AY101595 Prostate Specific Membrane Antigen, Primer Set Plus Positive Control 289 bp
125
SP-10577 RAB38 NM_022337 RAB38, Primer Set Plus Positive Control 350 bp
SP-10578 Rantes NM_002985 Small Inducible Cytokine A5 (RANTES), Primer Set Plus Positive Control 291 bp
SP-10582 Relaxin V00578 Relaxin H1 Gene, Primer Set Plus Positive Control 419 bp
SP-10587 SDF-1a L36034 SDF-1a, Primer Set Plus Positive Control 400 bp
SP-10589 SGP-2 D14077 Sulfated Glycoprotein (SGP-2), Primer Set Plus Positive Control 474 bp
SP-10591 SRY L08063 SRY Gene, Primer Set Plus Positive Control 600 bp
SP-10592 SRY L08063 SRY Gene, Primer Set Plus Positive Control 398 bp
SP-10593 SSI-1 AJ322759 Sequence Surrounding NotI Site, Primer Set Plus Positive Control 195 bp
SP-10734 TCRA U51444 Sequence Surrounding NotI Site, Primer Set Plus Positive Control 283 bp
SP-10644 Telomerase Protein-1 U86136.1 Telomerase-associated protein 1, Primer Set Plus Positive Control 292 bp
SP-10320 Telomerase RNA AF221907 Telomerase RNA Gene, Primer Set Plus Positive Control 159 bp
SP-10649 Telomerase RT NM_003219.1 Telomerase reverse transcriptase (TERT), Primer Set Plus Positive Control 255 bp
SP-10598 TFR M11507 Transferrin Receptor (TFR), Primer Set Plus Positive Control 612 bp
SP-10599 TFR M11507 Transferrin Receptor (TFR), Primer Set Plus Positive Control 484 bp
SP-10716 TGFA M31172 Transforming Growth Factor-alpha (TGFA), Primer Set Plus Positive Control 282 bp
SP-10602 TGF-alpha M31172 Transforming Growth Factor-alpha (TGFA), Primer Set Plus Positive Control 139 bp
SP-10603 TGF-beta X02812 Transforming Growth Factor-beta, Primer Set Plus Positive Control 161 bp
SP-10604 TGF-beta J03241 Transforming Growth Factor-b3, Primer Set Plus Positive Control 222 bp
SP-10605 TGF-beta 1 X02812 Transforming Growth Factor-b1, Primer Set Plus Positive Control 328 bp
SP-10606 TGF-beta 1 X02812 Transforming Growth Factor-b1, Primer Set Plus Positive Control 163 bp
SP-10609 TGF-beta 2 M19154 Transforming Growth Factor b2, Primer Set Plus Positive Control 497 bp
SP-10611 TGF-beta Receptor L07594 Transforming Growth Factor-b Receptor, Primer Set Plus Positive Control 259 bp
SP-10612 Thrombin Receptor M62424 Thrombin Receptor, Primer Set Plus Positive Control 367 bp
SP-10613 TIE-1 NM_005424.1 Tyrosine Kinase Receptor (TIE) -1, Primer Set Plus Positive Control 212 bp
SP-10614 TIE-2 L06139.1 Tyrosine Kinase Receptor (TIE) -2, Primer Set Plus Positive Control 350 bp
SP-10617 TIMP-2 XM_012690 TIMP-2, Primer Set Plus Positive Control 110 bp
SP-10630 Thymidylate Synthase X02308 Thymidylate Synthase, Primer Set Plus Positive Control 171 bp
SP-10631 TNF-a M13049 Tumor Necrosis Factor (TNF)-alpha, Primer Set Plus Positive Control 311 bp
SP-10641 TNF-a receptor M75861 TNF Receptor-I, Primer Set Plus Positive Control 490 bp
SP-10642 TNF-a receptor M38549 TNF Receptor-II, Primer Set Plus Positive Control 225 bp
T (continued)
SP-10639 TNF- b X01393 Tumor Necrosis Factor (TNF)-beta, Primer Set Plus Positive Control 618 bp
SP-10618 Toll-Like Receptor 1 U88540 Toll-Like Receptor 1, Primer Set Plus Positive Control 519 bp
SP-10692 Toll-Like Receptor 6 NM_006068 Toll-Like Receptor 6, Primer Set Plus Positive Control 153 bp
SP-10749 Toll-Like Receptor 9 NM_017442 Toll-Like Receptor 9, Primer Set Plus Positive Control 260 bp
SP-10646 Tradd L41690 TRADD, Primer Set Plus Positive Control 152 bp
SP-10647 Trail U37518 Trail, Primer Set Plus Positive Control 167 bp
SP-10648 Tryptase M33494 Tryptase, Primer Set Plus Positive Control 184 bp
SP-10717 TSHR NM_000369 TSHR, Primer Set Plus Positive Control 200 bp
SP-10650 TTF-1 NM_003317 Thyroid Transcription Factor 1, Primer Set Plus Positive Control 301 bp
SP-10651 TTF-2 Y13386.1 Thyroid Transcription Factor 2, Primer Set Plus Positive Control 259 bp
SP-10597 Tubulinc alpha K00558 Alpha-Tubulin Gene, Primer Set Plus Positive Control 869 bp
SP-10595 Tyrosine-hydroxylase M23597 Tyrosine Hydroxylase, promoter region, Primer Set Plus Positive Control 195 bp
SP-10652 Ubiquitin NM_021009 Ubiquitin C, Primer Set Plus Positive Control 254 bp
SP-10657 VEGF AF214570 VEGF Isoform 121/165/189, Primer Set Plus Positive Control 104/234/306 bp
SP-10659 VEGF AF214570 VEGF (All), Primer Set Plus Positive Control 294 bp
SP-10658 VEGF-C NM_005429.1 VEGF-C, Primer Set Plus Positive Control 351 bp
SP-10663 Vimentin X56134 Vimentin, Primer Set Plus Positive Control 361 bp
SP-10704 X & Y chromosomal X14439 Human X & Y chromosome homologous region, Primer Set Plus Positive Control Y:977/X:788 bp
SP-10322 Y chromosomal X06325 Human testis-expressed protein gene, Primer Set Plus Positive Control 799 bp
127
Infectious Pathogen Gene Primer – Single PCR Kits
ADENOVRIUS
SP-10011 Major Coat Protein AF043303 Major Coat Protein, Primer Set Plus Positive Control 484 bp
SP-10012 Hexon AJ272604 Hexon, Primer Set Plus Positive Control 463 bp
CORONAVIRUS
SP-10144 M-Protein X15498 M-Protein, Primer Set Plus Positive Control 315 bp
CYTOMEGALOVIRUS (CMV)
SP-10135 Glycoprotein B X04606 Glycoprotein B, Primer Set Plus Positive Control 222 bp
SP-10133 MIEG M21295 Major Immediately Early Gene, Primer Set Plus Positive Control 435 bp
SP-10697 MIEG M21295 Major Immediately Early Gene, Primer Set Plus Positive Control 146 bp
SP-10134 Matrix Protein pp65 M15120 Matrix Protein (pp65), Primer Set Plus Positive Control 400 bp
SP-10136 Pol M14708 Pol, Primer Set Plus Positive Control 215 bp
ENTEROVIRUS
SP-10212 VP2-VP4 NC_001656 Non-coding Region, Primer Set Plus Positive Control 654 bp
EPSTEIN-BARR VIRUS (EBV)
SP-10199 BamC X67777.1 Bam C, Primer Set Plus Positive Control 121 bp
SP-10198 BamW X53316 Bam W, Primer Set Plus Positive Control 122 bp
SP-10200 BMLF1 M80517 BMLF1, Primer Set Plus Positive Control 265 bp
SP-10196 BNRF1 X67777 BNRF1, Primer Set Plus Positive Control 225 bp
SP-10202 EBNA-2A Bam hY K03332.1 EBNA-2A Bam hY, Primer Set Plus Positive Control 89 bp
SP-10203 EBNA-2B Bam hY K03332 EBNA-2B Bam hY, Primer Set Plus Positive Control 89 bp
SP-10201 EMLF1 M80517 EMLF1, Primer Set Plus Positive Control 288 bp
SP-10197 IR3 J02079 Simple Repeat Sequences (IR3), Primer Set Plus Positive Control 240 bp
HEPATITIS A VIRUS (HAV)
SP-10261 VP3-VP1 M14707 VP3-VP1 Gene, Primer Set Plus Positive Control 247 bp
HEPATITIS B VIRUS (HBV)
SP-10732 Core Region V00867 Core Antigen, Primer Set Plus Positive Control 122 bp
HEPATITIS B VIRUS (HBV) (continued)
SP-10264 Pre-Core/Core V00867 Pre-Core/Core Antigen, Primer Set Plus Positive Control 632 bp
SP-10267 Pre-S V00867 Pre-S, Primer Set Plus Positive Control 587 bp
SP-10268 Pre-S2 V00867 Pre-S2 Antigen, Primer Set Plus Positive Control 119 bp
SP-10269 Pre-S2-S V00867 Pre-S2-S, Primer Set Plus Positive Control 477 bp
SP-10270 Surface Antigen V00867 Surface Antigen, Primer Set Plus Positive Control 257 bp
HEPATITIS C VIRUS (HCV)
SP-10272 5UTR’ L40552 5’UTR Unknown Region, Primer Set Plus Positive Control 193 bp
SP-10273 5UTR’ L40552 5’UTR Unknown Region, Primer Set Plus Positive Control 159bp
HEPATITIS D VIRUS (HDV)
SP-10279 ORF5 X04451 ORF5, Primer Set Plus Positive Control 714 bp
SP-10277 ORF9 X04451 ORF9, Primer Set Plus Positive Control 168 bp
SP-10278 Unknown Coding Region M21021 Unknown Coding Region, Primer Set Plus Positive Control 477 bp
HEPATITIS D VIRUS (HEV)
SP-10280 RNA Dep. RNA Pol NC_001434 RNA Dependent RNA Polymerase, Primer Set Plus Positive Control 116 bp
HERPES SIMPLEX VIRUS (HSV)
SP-10319 DNA polymerase X04771 Type I and II, DNA Polymerase, Primer Set Plus Positive Control 92 bp
SP-10314 DNA polymerase X04771 Type I, DNA Polymerase, Primer Set Plus Positive Control 105 bp
SP-10315 ICPO M74421 Type I, ICPO, Primer Set Plus Positive Control 230 bp
SP-10316 IE110 X04614 Type I, TK/LAT, Primer Set Plus Positive Control 195 bp
SP-10317 DNA polymerase M16321 Type II, DNA Polymerase, Primer Set Plus Positive Control 106 bp
HERPESVIRUS TYPE 6 (HHV6)
SP-10283 ORF-4L M68963 Major Capsid Protein (ORF-4L), Primer Set Plus Positive Control 480 bp
SP-10282 ORF-13R M68963 ORF-13R, Primer Set Plus Positive Control 223 bp
129
HERPESVIRUS TYPE 6 (HHV6) (continued)
SP-10284 ORF-16 M68963 Alkaline Exonclease (ORF-16), Primer Set Plus Positive Control 523 bp
IMMUNODEFICIENCY VIRUS (HIV)
SP-10288 gag K02007 HIV-I, gag, Primer Set Plus Positive Control 215 bp
SP-10290 DNA polymerase K02007 HIV-I, Pol, Primer Set Plus Positive Control 105 bp
SP-10287 Envelope K02007 HIV-I, Env, Primer Set Plus Positive Control 142 bp
SP-10286 Envelope K02007 HIV-I, Env, Primer Set Plus Positive Control 310 bp
SP-10289 nef K02007 HIV-I, nef, Primer Set Plus Positive Control 151 bp
SP-10291 Vif K02007 HIV-I, Vif, Primer Set Plus Positive Control 322 bp
SP-10293 gag K02007 HIV-I/II, gag, Primer Set Plus Positive Control 291 bp
HUMAN PAPILLOMAVIRUS (HPV)
SP-10297 E6 V01116 HPV-i, E6 Gene, Primer Set Plus Positive Control 300 bp
SP-10298 E6 X63594 HPV-6, E6 Gene, Primer Set Plus Positive Control 263 bp
SP-10299 E6 M14199 HPV-11, E6 Gene, Primer Set Plus Positive Control 144 bp
SP-10300 E6 K02718 HPV-16, E6 Gene, Primer Set Plus Positive Control 601 bp
SP-10301 E6 X04773 HPV-18, E6 Gene, Primer Set Plus Positive Control 360 bp
SP-10302 E6 J04353 HPV-31, E6 Gene, Primer Set Plus Positive Control 350 bp
SP-10303 E6 M12732 HPV-33, E6 Gene, Primer Set Plus Positive Control 413 bp
SP-10750 E6 NC_001952 HPV-52, E6 Gene, Primer Set Plus Positive Control 155 bp
SP-10751 E6 NC_001443 HPV-58, E6 Gene, Primer Set Plus Positive Control 295 bp
SP-10296 Generic type L1 all of above Mixed Type, L1 Gene, Primer Set Plus Positive Control 449-452 bp
INFLUENZA VIRUS
SP-10376 Hemaglutinin M58657 Type A, Hemaglutinin, Primer Set Plus Positive Control 390 bp
SP-10377 MMP M1 & M2 AF255370 Type A, Hemaglutinin, Primer Set Plus Positive Control 191 bp
SP-10378 HA Gene NC_002204 Type B, HA, Primer Set Plus Positive Control 318 bp
PARA-INFLUENZA VIRUS
SP-10686 Hemaglutinin X57213 Para-Influenza 1 Virus, Primer Set Plus Positive Control 530 bp
SP-10687 Hemaglutinin X57559 Para-Influenza 2 Virus, Primer Set Plus Positive Control 368 bp
SP-10688 Hemaglutinin NC_001796 Para-Influenza 3 Virus, Primer Set Plus Positive Control 285 bp
RESPIRATORY SYNCYTIAL VIRUS (RSV)
SP-10583 Gene 1C M11486 Gene 1C, Primer Set Plus Positive Control 246 bp
SP-10584 Gene 1C/1B M11486 Gene 1C/1B, Primer Set Plus Positive Control 246 bp
RHINO VIRUS
SP-10312 VP3-VP1 X02316 VP3-VP1, Primer Set Plus Positive Control 547 bp
T-CELL LEUKEMIA VIRUS (HTLV)
SP-10629 DNA polymerase AF326584 Type I and II, Pol, Primer Set Plus Positive Control 186 bp
SP-10626 Tax D00294 Type I and II, Tax, Primer Set Plus Positive Control 159 bp
SP-10623 DNA polymerase D00294 Type I, Pol, Primer Set Plus Positive Control 237 bp
SP-10628 Envelope M10060 Type II, Env, Primer Set Plus Positive Control 203 bp
SP-10627 DNA polymerase M10060 Type II, Pol, Primer Set Plus Positive Control 103 bp
VARICELLA-ZOSTER VIRUS (VZV)
SP-10665 44 Kd Protein Gene X04370 44 Kd Protein, Primer Set Plus Positive Control 224 bp
SP-10752 ORF61 AF314219 ORF61, Primer Set Plus Positive Control 262 bp
SP-10753 ORF62 AY253719 ORF62 , Primer Set Plus Positive Control 307 bp
SP-10754 ORF63 A Y548171 ORF63 A, Primer Set Plus Positive Control 198 bp
BORRELIA
SP-10042 Lyme Disease M58433 B. burgdon (Lyme Disease), Primer Set Plus Positive Control 371 bp
CHLAMYDIA
SP-10551 16S rRNA Z49873 C. pneumoniae, 16S rRNA Gene, Primer Set Plus Positive Control 871 bp
SP-10147 Major Outer Membrane M14738 C. trachomatis, Major Outer Membrane, Primer Set Plus Positive Control 182 bp
SP-10148 Major Outer Membrane M14738 C. trachomatis, Major Outer Membrane, Primer Set Plus Positive Control 129 bp
SP-10149 Cryptic Plasmid X06707 C. trachomatis, Cryptic Plasmid, Primer Set Plus Positive Control 364 bp
ESCHERICHIA COLI
SP-10207 Cryptic Plasmid X06707 E. coli, Heat Labile Enterotoxin, Primer Set Plus Positive Control 301 bp
131
HELICOBACTER
SP-10304 Cag A L11714 Cag A, Primer Set Plus Positive Control 349 bp
SP-10305 Mr-26K Protein M55507 Species-Specific Antigen, Primer Set Plus Positive Control 303 bp
SP-10306 16S rRNA U00679 16S rRNA, Primer Set Plus Positive Control 110 bp
SP-10307 1.9 Kb Cloned DNA X60746 1.9 Kb Cloned Fragment, Primer Set Plus Positive Control 203 bp
SP-10308 FlaA Gene for flagellin X60746 Flagellin Gene, Primer Set Plus Positive Control 152 bp
SP-10309 UREA C Gene M60398 UREA C Gene, Primer Set Plus Positive Control 315 bp
SP-10311 UREA A Gene M60398 UREA A Gene, Primer Set Plus Positive Control 264 bp
LEGIONELLA
SP-10486 MIP AF095228 Unknown Coding Region, Primer Set Plus Positive Control 232 bp
MYCOBACTERIUM AVIUM
SP-10491 16S ribosomal rRNA M61672 Specific 16S rRNA Gene, Primer Set Plus Positive Control 134 bp
MYCOBACTERIUM TUBERCULOSIS
SP-10525 65K antigen M15467 65K Antigen, Primer Set Plus Positive Control 164 bp
SP-10526 65K antigen M15467 65K Antigen, Primer Set Plus Positive Control 116 bp
SP-10527 IS6110 Insertion M29899 IS6110 Insertion, Primer Set Plus Positive Control 412 bp
MYCOPLASMA
SP-10521 16S rRNA M24289 16S rRNA, Primer Set Plus Positive Control 500 bp
SP-10522 16S rRNA M24289 16S rRNA, Primer Set Plus Positive Control 320 bp
SP-10501 16S rRNA rrnB operon AJ002269 M. hominis, 16S rRNA, rrnB operon, Primer Set Plus Positive Control 311 bp
SP-10523 Attachment Protein P1 M18639 M. pneumoniae, Attachment Protein P1, Primer Set Plus Positive Control 375 bp
NEISSERIA
SP-10255 cppB M10316 cppB, Primer Set Plus Positive Control 298 bp
STREPTOCOCCUS AGALACTIAE
SP-10755 cAMP X72754 cAMP, Primer Set Plus Positive Control 257 bp
TREPONEMA
SP-10645 TmpA M10931 TmpA, Primer Set Plus Positive Control 225 bp
UREAPLASMA
SP-10654 Ure B M36190 Ure B, Primer Set Plus Positive Control 219 bp
YEAST
SP-10114 CDC37 X04288 CDC37, Primer Set Plus Positive Control 441 bp
SP-10130 CKA1 M22473 Casein kinase-II alpha, Primer Set Plus Positive Control 240 bp
SP-10131 CKA2 M33759 Casein kinase-II alpha, Primer Set Plus Positive Control 276 bp
SP-10132 CKB1 U21283 Casein kinase-II beta, Primer Set Plus Positive Control 191 bp
SP-10666 ZDS1 U63849 Zds1p, Primer Set Plus Positive Control 364 bp
SP-10667 ZDS2 U32938 Zds2p, Primer Set Plus Positive Control 374 bp
133
Gene Primer – Multiplex PCR Kits
CAT. # PRODUCT DESCRIPTION INTERNAL CONTROL RXNS
ANGIOGENESIS PATHWAYS
MP-70172 MPCR Kit for Human VEGF and Its Receptors Set-1 GAPDH 50
APOPTOSIS PATHWAYS
MP-70013 MPCR Kit for Human Apoptic Genes Set-1 GAPDH 50

MP-70020 MPCR Kit for Human Apoptic Genes Set-7 H18S 50
MP-70012 MPCR Kit for Human Apoptic Genes Set-7 H18S 100
CD MOLECULES
MP-70194 MPCR Kit for Human CD Molecules Set 1 GAPDH 50

MP-70196 MPCR Kit for Human CD Molecules Set 1 H18S 50
MP-70197 MPCR Kit for Human CD Molecules Set 1 H18S 100
MP-70200 MPCR Kit for Mouse CD Molecules Set 1 GAPDH 50
MP-70201 MPCR Kit for Mouse CD Molecules Set 1 GAPDH 100
CHEMOKINES AND RECEPTORS
MP-70039 MPCR Kit for Human Chemokine Receptor CCR Set-1 GAPDH 50
MP-70046 MPCR Kit for Human Chemokine Receptor CXCR Set-1 GAPDH 50
MP-70045 MPCR Kit for Human Chemokine Receptor CXCR Set-1 GAPDH 100
MP-70066 MPCR Kit for Human Chemokine Genes Set-1 GAPDH 50
CYTOKINES AND RECEPTORS
MP-70050 MPCR Kit for Human Cytokines Set-1 GAPDH 50

MP-70049 MPCR Kit for Human Cytokines Set-1 GAPDH 100
INFLAMMATION PATHWAYS
MP-70098 MPCR Kit for Human Inflammatory Cytokines Set-1 GAPDH 50

SEPSIS PATHWAYS
MP-70129 MPCR Kit for Human Sepsis Cytokines Set-1 GAPDH 50

TH1/ TH2 GENE EXPRESSION PROFILING
MP-70145 MPCR Kit for Human TH1/TH2 Cytokines Set-1 GAPDH 50

135
TH1/ TH2 GENE EXPRESSION PROFILING (continued)
INSULIN-LIKE GROWTH FACTORS AND THEIR BINDING PROTEINS
MP-70083 MPCR Kit for Human Insulin Binding Proteins GAPDH 50

MP-70082 MPCR Kit for Human Insulin Binding Proteins GAPDH 100
MP-70085 MPCR Kit for Human Insulin Binding Proteins H18S 50
MP-70084 MPCR Kit for Human Insulin Binding Proteins H18S 100
CELL CYCLING
MP-70226 MPCR Kits for Human Cell Cycling Genes GAPDH 50

MP-70225 MPCR Kits for Human Cell Cycling Genes GAPDH 100
DRUG RESISTANCE
MP-70228 MPCR Kits for Human Drug Resistance Genes GAPDH 50

MP-70227 MPCR Kits for Human Drug Resistance Genes GAPDH 100
GENETIC DISEASE-DMD/BMD
MP-70053 MPCR Kit for Human DMD/BMD Set I – 50

MP-70052 MPCR Kit for Human DMD/BMD Set I – 100
MP-70055 MPCR Kit for Human DMD/BMD Set II – 50
MP-70054 MPCR Kit for Human DMD/BMD Set II – 100
MP-70057 MPCR Kit for Human DMD/BMD Set I+II – 50
MP-70056 MPCR Kit for Human DMD/BMD Set I+II – 100
MP-70059 MPCR Kit for Human DMD/BMD New Set I+II – 50
MP-70058 MPCR Kit for Human DMD/BMD New Set I+II – 100
ONCOGENES
MP-70122 MPCR Kit for Human Oncogenes – 50

MP-70121 MPCR Kit for Human Oncogenes – 100
P53 ONCOGENES
MP-70124 MPCR Kit for Human P53 – 50

MP-70123 MPCR Kit for Human P53 – 100
RAS ONCOGENES
MP-70126 MPCR Kit for Human K- ras – 50

MP-70125 MPCR Kit for Human K- ras – 100
TELOMERASE ASSOCIATED –
MP-70140 MPCR Kit for Human Telomerase Genes H18S 50

MP-70139 MPCR Kit for Human Telomerase Genes H18S 100
THROMBOSIS ASSOCIATED
MP-70180 MPCR Kit for Human Thrombosis Point Mutations Detection – 50

MP-70179 MPCR Kit for Human Thrombosis Point Mutations Detection – 100
HOUSE-KEEPING GENES
MP-70076 Human House-Keeping Genes MPCR, Set 1 – 50

HELICOBACTER PYLORI
MP-70081 MPCR Kit for H. pylori Detection – 50

MP-70080 MPCR Kit for H. pylori Detection – 100
HIV
MP-70073 MPCR Kit for HIV Type I/II – 50

MP-70072 MPCR Kit for HIV Type I/II – 100
HUMAN PAPILLOMAVIRUS
MP-70079 MPCR Kit for Human Papillomavirus – 50

MP-70078 MPCR Kit for Human Papillomavirus – 100
137
HUMAN PAPILLOMAVIRUS (continued)
MP-70216 MPCR Kit for Human Papillomavirus Set 2 – 50

MP-70215 MPCR Kit for Human Papillomavirus Set 2 – 100
ATYPICAL PNEUMONIAS DISEASE
MP-70214 MPCR Kit for Atypical Pneumonias Diseases, PCP/MPN/LPN/ NUM – 50

MP-70213 MPCR Kit for Atypical Pneumonias Diseases, PCP/MPN/LPN/ NUM – 100
SEXUAL TRANSMITTED DISEASE
MP-70120 MPCR Kit for Sexual Transmitted Diseases, CTR/UU/NG – 50

MP-70119 MPCR Kit for Sexual Transmitted Diseases, CTR/UU/NG – 100
RESPIRATORY INFECTION ASSOCIATED
MP-70178 MPCR Kit for Respiratory Infection Associated Virus Set 2 – 50

MATRIX METALLOPROTEINASE ASSOCIATED PATHWAYS
MP-70109 MPCR Kit for Human Matrix, MMP Genes GAPDH 50

MP-70106 MPCR Kit for Human Matrix, MMP Genes GAPDH 100
MP-70110 MPCR Kit for Human Matrix, MMP Genes H18S 50
MP-70107 MPCR Kit for Human Matrix, MMP Genes H18S 100
MP-70111 MPCR Kit for Human MMP Genes Set-2 GAPDH 50
MP-70186 MPCR Kit for Human MMP Genes Set-2 18S 50
MP-70185 MPCR Kit for Human MMP Genes Set-2 18S 100
NITRIC OXIDE (NO) METABOLISM
MP-70116 MPCR Kit for Human NO Metabolism Genes GAPDH 50

MP-70115 MPCR Kit for Human NO Metabolism Genes GAPDH 100
HUMAN SEX DETERMINATION
MP-70136 MPCR Kit for Human Sex Determination – 50

MP-70135 MPCR Kit for Human Sex Determination – 100
SIGNAL TRANSDUCTION
MP-70142 MPCR Kit for Human TGF-b Superfamily Genes GAPDH 50

MP-70141 MPCR Kit for Human TGF-b Superfamily Genes GAPDH 100
MP-70224 MPCR Kit for Human TGF-b Superfamily Genes Set 2 GAPDH 50
MP-70223 MPCR Kit for Human TGF-b Superfamily Genes Set 2 GAPDH 100
SIGNALING RECEPTORS (TOLL-LIKE RECEPTORS)
MP-70138 MPCR Kit for Human Signaling Receptor TLRs GAPDH 50

MP-70137 MPCR Kit for Human Signaling Receptor TLRs GAPDH 100
MP-70189 MPCR Kit for Human Signaling Receptor Set 2 GAPDH 50
MP-70190 MPCR Kit for Human Signaling Receptor Set 2 GAPDH 100
MP-70060 MPCR Kit for Human Signaling Receptor Set 3 8S 50
MP-70061 MPCR Kit for Human Signaling Receptor Set 3 18S 100
TNF SIGNALING PATHWAYS
MP-70160 MPCR kit for Human TNF Signaling Genes GAPDH 50

MP-70159 MPCR kit for Human TNF Signaling Genes GAPDH 100
MP-70188 MPCR Kit for Human TNF Signaling Genes Set-2 GAPDH 50
MP-70187 MPCR Kit for Human TNF Signaling Genes Set-2 GAPDH 100
TRANSCRIPTIONAL FACTORS
MP-70168 MPCR Kit for Human Transcriptional Factors GAPDH 50

MP-70167 MPCR Kit for Human Transcriptional Factors GAPDH 100
Real Time PCR
Jairo Aguilar –
Administration
“Our goal is to provide our customers with superb customer service, while
supplying high technology products for Cancer Research and Diagnostics.”
Real Time PCR
APPLICATIONS OF REAL TIME PCR The subtype and target gene of the kit has covered the most common subtype
Real Time PCR can be used to help professionals determine viral load, monitor and target gene in the world. The Kit is updated every 6 months according to the
disease progression and response to therapy. GeneBank.
MAJOR AREAS OF APPLICATION ARE: Group/Subtypes n RealTime Detected

• Bacterial/Viral Load Quantification
• Pathogen Detection & Identification M/Subtype A 20 20
• Differential gene Expression M/Subtype B 20 20
• Therapeutic Drug Monitoring M/Subtype C 20 20
• SNP Genotyping M/Subtype D 20 20
• Validation of RNAi M/Subtype AE 20 20
• Genetic Disease Analysis M/Subtype F 20 20
• Food & Environmental Pathogen Detection
M/Subtype AG 20 20
• Forensic Studies
M/Subtype G 20 20
CHARACTERISTICS OF REAL TIME PCR KITS Group O 20 20
The following Real Time PCR Instruments can be used with the Shanghai ZJ Real Time PCR Kits:
I: LightCycler 1.0 (Internal Control is not included for this system) CONTENT OF KITS
II: LightCycler 2.0 Real Time PCR DNA Detection
III: PE5700, MJ-Opticon etc. single color systems
IV: ABI7000, ABI7300, ABI7500, ABI7900, ABI StepOne, StepOne plus, • Extraction Buffer (Nacl, etc.)
MJ-Opticon2, MJ-chromo4, MX3000P, MX3005P, SmartCycler II, Rotor-
• Reaction Mix (Primer, Probe, Tris-HCL, EDTA)
Gene6000, LightCycler® 480, iCycler iQ4, iCycler iQ5, etc., multi-color systems
• PCR Enzyme Mix (TAQ Enzymy, Glycerine)
HIGH SENSITIVITY, SPECIFICITY & REPRODUCIBILITY • Molecular Grade Water
In order to determine the sensitivity of the Shanghai ZJ’s HIV-1 Real time PCR Kit, a • Internal Control (Plasmid)
dilution series from 106 down to 100 IU/µl of HIV-1 RNA was set up and analyzed. The • Positive Control (1x107 Copies/ml) (Plasmid)
assays were carried out on three different days in the form of 8-fold determinations.
The results were determined by a probit analysis. The detection limit as determined Real Time PCR RNA Detection
for Shanghai ZJ’s HIV-1 Real Time PCR Kit was consistently 100 IU/ml. This means
that there was a 95% probability that 100 IU/ml will be detected. • Super Mix (Primer, Probe, Tris-HCL, EDTA)
• RT-PCR Enzyme Mix (TAQ Enzymy, glycerine)
SPECIFICITY
In order to check the specificity of the Shanghai ZJ’s HIV-1 Real Time PCK Kit, different • Molecular Grade Water
RNA & DNA listed here were analyzed. None of these led to a positive signal. Gene • Internal Control (Plasmid)
sequence analysis of the amplified region of HIV-1 showed a pronounced homology • Positive Control (1x107 Copies/ml) (Plasmid)
among the various HIV-1 subtypes, and no homology with other RNA. Utmost care
has been taken in the selection of the primers and probes used in all our Kits.
Vercella Zoster Virus Hepatitis B Virus N. Meningitis

Human Herpes Virus 1 & 2 Hepatitis C Virus S. Pneumonia
Epstein Barr Virus Hepatitis E Virus JEV
Cytomegalovirus TTV Mycobacterium Tuberculosis
Chlamydia pneumoniae HIV 2 Hepatitis A Virus
Parvovirus B19 West Nile Virus Staphylococcus Aureus
Dengue Virus I-IV H. Influenza Chickungunya Virus
Leprosy Malaria Scrub Typhus
B. pseudomallie Filaria Leptospira Interrogans
Treponema Pallidum BK Virus EBV/HAV
For research use only in the United States.
141
Real Time PCR
I: LIGHTCYCLER 1.0 (INTERNAL CONTROL IS NOT INCLUDED FOR THIS SYSTEM)

II: LIGHTCYCLER 2.0
III: PE5700, MJ-OPTICON ETC. SINGLE COLOR SYSTEMS
IV: ABI7000, ABI7300, ABI7500, ABI7900, ABI StepOne, ABI StepOne Plus, MJ-OPTICON2, MJ-CHROMO4, MX3000P, MX3005P, SMART CYCLER II,
ROTOR-GENE 6000, LIGHTCYCLER® 480; iCycler iQ4, iCycler iQ5, CFX96, ETC., MULTI-COLOR SYSTEMS
CAT. # INSTRUMENT PRODUCT DESCRIPTION NUCLEIC ACID RXNS

I II III IV
KIT SERIES OF HEPATITIS VIRUS
HR-0001-01 • • HAV Real Time RT-PCR Kit RNA 25

HR-0001-02 • • HAV Real Time RT-PCR Kit RNA 25
HD-0002-01 • • HBV Quantitative Real Time PCR Kit DNA 25
HD-0002-02 • • HBV Quantitative Real Time PCR Kit DNA 25
HD-0002-01-A • • HBV Quantitative Real Time PCR Kit (Packing with 4 diluted positive control) DNA 25
HD-0002-02-A • • HBV Quantitative Real Time PCR Kit (Packing with 4 diluted positive control) DNA 25
HD-0003-01 • HBV Quantitative & YMDD Mutation Real Time PCR Kit DNA 25
HD-0004-01 • • HBV Adefovir-Resistant Mutants Real Time PCR Kit DNA 25
HD-0004-03 • • HBV Adefovir-Resistant Mutants Real Time PCR Kit DNA 25
HD-0005-01 • • HBV Precore Site 1896 Mutation Real Time PCR Kit DNA 25
HD-0005-03 • • HBV Precore Site 1896 Mutation Real Time PCR Kit DNA 25
HD-0006-02 • HBV Genotype B & C Real Time PCR Kit DNA 25
HD-0006-01 • HBV Genotype B, C & D Real Time PCR Kit DNA 25
HD-0007-01 • • HBV cccDNA Real Time PCR Kit DNA 25
HD-0007-02 • • HBV cccDNA Real Time PCR Kit DNA 25
HR-0008-01 • • HCV Real Time RT-PCR Kit RNA 25
HR-0008-02 • • HCV Real Time RT-PCR Kit RNA 25
HR-0008-01-A • • HCV Real Time RT-PCR Kit (Packing with 4 diluted positive control) RNA 25
HR-0008-02-A • • HCV Real Time RT-PCR Kit (Packing with 4 diluted positive control) RNA 25
HR-0009-01 • • HCV Genotype Real Time RT-PCR Kit RNA 25
HR-0009-02 • • HCV Genotype Real Time RT-PCR Kit RNA 25
HR-0010-01 • • HDV Real Time RT-PCR Kit RNA 25
HR-0010-02 • • HDV Real Time RT-PCR Kit RNA 25
HR-0011-01 • • HEV Real Time RT-PCR Kit RNA 25
HR-0011-02 • • HEV Real Time RT-PCR Kit RNA 25
HR-0012-01 • • HGV Real Time RT-PCR Kit RNA 25
HR-0012-02 • • HGV Real Time RT-PCR Kit RNA 25
Real Time PCR

I II III IV
KIT SERIES OF HEPATITIS VIRUS (continued)
HD-0013-01 • • Transfusion-transmitted Virus (TTV) Real Time PCR Kit DNA 25

HD-0013-02 • • Transfusion-transmitted Virus (TTV) Real Time PCR Kit DNA 25
HD-0147-01 • • Low-concentration Hepatitis B Virus Real Time PCR Kit DNA 25
HD-0147-02 • • Low-concentration Hepatitis B Virus Real Time PCR Kit DNA 25
KIT SERIES OF SEXUALLY TRANSMITTED DISEASES
SD-0014-01 • • Neisseria Gonorrhoeae (NG) Real Time PCR Kit DNA 25

SD-0014-02 • • Neisseria Gonorrhoeae (NG) Real Time PCR Kit DNA 25
SD-0015-01 • • Ureaplasma Urealyticum (UU) Real Time PCR Kit DNA 25
SD-0015-02 • • Ureaplasma Urealyticum (UU) Real Time PCR Kit DNA 25
SD-0016-01 • • Chlamydia Trachomatis (CT) Real Time PCR Kit DNA 25
SD-0016-02 • • Chlamydia Trachomatis (CT) Real Time PCR Kit DNA 25
SD-0016-01-A • • Chlamydia Trachomatis (CT) Real Time PCR Kit (Packing with 4 diluted positive control) DNA 25
SD-0016-02-A • • Chlamydia Trachomatis (CT) Real Time PCR Kit (Packing with 4 diluted positive control) DNA 25
SD-0025-01 • CT & NG RealTime PCR Kit DNA 25
SD-0025-02 • CT & NG RealTime PCR Kit DNA 25
SD-0136-01 • • HSV I & II typing RealTime PCR Kit DNA 25
SD-0136-02 • • HSV I & II typing RealTime PCR Kit DNA 25
SD-0017-01 • • HSV I & II Real Time PCR Kit DNA 25
SD-0018-01 • • HPV 6 & 11 Real Time PCR Kit DNA 25
SD-0018-02 • • HPV 6 & 11 Real Time PCR Kit DNA 25
SD-0019-01 • • Treponema Pallidum (TP) Real Time PCR Kit DNA 25
SD-0019-02 • • Treponema Pallidum (TP) Real Time PCR Kit DNA 25
SR-0020-01 • • HIV-1 Real Time RT-PCR Kit RNA 25
SR-0020-01-A • • HIV-1 Real Time RT-PCR Kit (Packing with 4 diluted positive control) RNA 25
SR-0020-02-A • • HIV-1 Real Time RT-PCR Kit (Packing with 4 diluted positive control) RNA 25
OD-0022-01 • • HCMV Real Time PCR Kit DNA 25
OD-0022-02 • • HCMV Real Time PCR Kit DNA 25
OD-0022-01-A • • HCMV Real Time PCR Kit (Packing with 4 diluted positive control) DNA 25
OD-0022-02-A • • HCMV Real Time PCR Kit (Packing with 4 diluted positive control) DNA 25
OD-0023-01 • • EBV Real Time PCR Kit DNA 25
OD-0024-01 • • Varicella Zoster Virus (VZV) Real Time PCR Kit DNA 25
143
Real Time PCR

I II III IV
KIT SERIES OF PATHOGEN INFECTION IN ORGAN TRANSPLANTATION
OD-0026-01 • • Human Parvovirus (B19) Real Time PCR Kit DNA 25
OD-0026-02 • • Human Parvovirus (B19) Real Time PCR Kit DNA 25
OD-0102-01 • • Polyomavirus BK (PBK) Real Time PCR Kit DNA 25
OD-0102-02 • • Polyomavirus BK (PBK) Real Time PCR Kit DNA 25
OD-0169-01 • • Human Herpes Virus (HHV-6) Real Time PCR Kit DNA 25
KIT SERIES OF GENETIC DISEASES
GD-0027-01 • • Mitochondrion DNA site 11778 Mutation Real Time PCR Kit DNA 25
GD-0027-02 • • Mitochondrion DNA site 11778 Mutation Real Time PCR Kit DNA 25
GD-0028-01 • Gene 825T of Obesity Predisposed Real Time PCR Kit DNA 25
GD-0135-01 • • MTHFR C677T Mutation Real Time PCR Kit DNA 25
GD-0135-02 • • MTHFR C677T Mutation Real Time PCR Kit DNA 25
KIT SERIES OF TUMOR MALIGNANCIES
TR-0029-01 • • AFP mRNA Expression in Peripheral Blood Real Time RT-PCR Kit RNA 25
TR-0029-02 • • AFP mRNA Expression in Peripheral Blood Real Time RT-PCR Kit RNA 25
TD-0030-01 • • HPV 16 & 18 Real Time PCR Kit DNA 25
TD-0030-02 • • HPV 16 & 18 Real Time PCR Kit DNA 25
TD-0031-01 • • Uterine Cervix Cancer of High-risk HPV Genotype Related Real Time PCR Kit DNA 25
TD-0031-02 • • Uterine Cervix Cancer of High-risk HPV Genotype Related Real Time PCR Kit DNA 25
TR-0126-01 • • Leukemia BCR-ABL Fusion Gene Real Time PCR Kit RNA 25
TR-0126-02 • • Leukemia BCR-ABL Fusion Gene Real Time PCR Kit RNA 25
TR-0126-03 • • Leukemia BCR-ABL Fusion Gene (m-BCR) Real Time RT-PCR Kit RNA 25
TR-0126-04 • • Leukemia BCR-ABL Fusion Gene (m-BCR) Real Time RT-PCR Kit RNA 25
TR-0126-05 • • Leukemia BCR-ABL Fusion Gene (μ-BCR) Real Time RT-PCR Kit RNA 25
Real Time PCR

I II III IV
KIT SERIES OF TUMOR MALIGNANCIES (continued)
TR-0126-06 • • Leukemia BCR-ABL Fusion Gene (μ-BCR) Real Time RT-PCR Kit RNA 25
TR-0126-07 • • Leukemia BCR-ABL Fusion Gene (M-BCR) Real Time RT-PCR Kit RNA 25
TR-0126-08 • • Leukemia BCR-ABL Fusion Gene (M-BCR) Real Time RT-PCR Kit RNA 25
KIT SERIES OF INFECTIOUS DIARRHEA PATHOGENS
DD-0032-01 • • Vibrio Cholera Real Time PCR Kit DNA 25

DD-0032-02 • • Vibrio Cholera Real Time PCR Kit DNA 25
DD-0122-01 • • Vibrio Cholera (Gene CTX) Real Time PCR Kit DNA 25
DD-0122-02 • • Vibrio Cholera (Gene CTX) Real Time PCR Kit DNA 25
DD-0123-01 • • Vibrio Cholera 01 Real Time PCR Kit DNA 25
DD-0033-01 • • Shigella Real Time PCR Kit DNA 25
DD-0033-02 • • Shigella Real Time PCR Kit DNA 25
DD-0034-01 • • Salmonella Real Time PCR Kit DNA 25
DD-0035-01 • Salmonella & Shigella Real Time PCR Kit DNA 25
DD-0035-02 • Salmonella & Shigella Real Time PCR Kit DNA 25
DD-0036-01 • • Salmonella Typhi Real Time PCR Kit DNA 25
DD-0036-02 • • Salmonella Typhi Real Time PCR Kit DNA 25
DD-0037-01 • • Salmonella paratyphi Real Time PCR Kit DNA 25
DD-0037-02 • • Salmonella paratyphi Real Time PCR Kit DNA 25
DD-0038-01 • • Vibrio Parahaemolyticus Real Time PCR Kit DNA 25
DD-0091-01 • • Enteropathogenic E. Coli (EPEC) Real Time PCR Kit DNA 25
DD-0091-02 • • Enteropathogenic E. Coli (EPEC) Real Time PCR Kit DNA 25
DD-0092-01 • • Enterotoxigenic E. Coli (ETEC) Real Time PCR Kit DNA 25
DD-0092-02 • • Enterotoxigenic E. Coli (ETEC) Real Time PCR Kit DNA 25
DD-0093-01 • • Enteroinvasive E. Coli (EIEC) Real Time PCR Kit DNA 25
DD-0093-02 • • Enteroinvasive E. Coli (EIEC) Real Time PCR Kit DNA 25
DD-0094-01 • • Enteroadhesive E. Coli (EAEC) Real Time PCR Kit DNA 25
DD-0094-02 • • Enteroadhesive E. Coli (EAEC) Real Time PCR Kit DNA 25
DD-0095-01 • • Enterohemorrhagic E. Coli (EHEC) Real Time PCR Kit DNA 25
DD-0095-02 • • Enterohemorrhagic E. Coli (EHEC) Real Time PCR Kit DNA 25
DD-0134-01 • • Enterobacter sakazaii Real Time PCR Kit DNA 25
DD-0134-02 • • Enterobacter sakazaii Real Time PCR Kit DNA 25
145
Real Time PCR

I II III IV
KIT SERIES OF INFECTIOUS DIARRHEA PATHOGENS (continued)
DD-0039-01 • • E. Coli O157: H7 Real Time PCR Kit DNA 25

DD-0040-01 • • Campylobacter Jejuni Real Time PCR Kit DNA 25
DD-0041-01 • • Staphylococcus Aureus Real Time PCR Kit DNA 25
DD-0096-01 • • Methicillin-resistant Staphylococcus Aureus (MRSA) Real Time PCR Kit DNA 25
DD-0096-02 • • Methicillin-resistant Staphylococcus Aureus (MRSA) Real Time PCR Kit DNA 25
DD-0125-01 • • Vancomycin-resistant Staphylococcus Aureus (VRSA) Real Time PCR Kit DNA 25
DD-0125-02 • • Vancomycin-resistant Staphylococcus Aureus (VRSA) Real Time PCR Kit DNA 25
DD-0042-01 • • Bacillus Cereus Real Time PCR Kit DNA 25
DD-0042-02 • • Bacillus Cereus Real Time PCR Kit DNA 25
DD-0043-01 • • Enteric Adenovirus Real Time PCR Kit DNA 25
DD-0043-02 • • Enteric Adenovirus Real Time PCR Kit DNA 25
DD-0166-01 • • Clostridium Difficile Real Time PCR Kit DNA 25
DD-0166-02 • • Clostridium Difficile Real Time PCR Kit DNA 25
DD-0167-01 • • Clostridium Perfringens Real Time PCR Kit DNA 25
DD-0167-02 • • Clostridium Perfringens Real Time PCR Kit DNA 25
DD-0168-01 • • Cryptosporidium Tyzzer Real Time PCR Kit DNA 25
DD-0168-02 • • Cryptosporidium Tyzzer Real Time PCR Kit DNA 25
DR-0044-01 • • Rotavirus (Group A) Real Time RT-PCR Kit RNA 25
DR-0044-02 • • Rotavirus (Group A) Real Time RT-PCR Kit RNA 25
DR-0045-01 • • Norovirus Real Time RT-PCR Kit RNA 25
DR-0045-02 • • Norovirus Real Time RT-PCR Kit RNA 25
DR-0150-01 • • Human Astrovirus (HAstV) Real Time RT-PCR Kit RNA 25
DR-0150-02 • • Human Astrovirus (HAstV) Real Time RT-PCR Kit RNA 25
DR-0164-01 • • Sapovirus (SV) Real Time RT-PCR Kit RNA 25
DR-0164-02 • • Sapovirus (SV) Real Time RT-PCR Kit RNA 25
DR-0165-01 • • Picobirnavirus (PBV) Real Time RT-PCR Kit RNA 25
DR-0165-02 • • Picobirnavirus (PBV) Real Time RT-PCR Kit RNA 25
Real Time PCR

I II III IV
KIT SERIES OF FOODSTUFF PATHOGENS

DD-0127-01 • • Yersinia Enterocolitica Real Time PCR Kit DNA 25
DD-0127-02 • • Yersinia Enterocolitica Real Time PCR Kit DNA 25
DD-0128-01 • • Listeria Monocytogenes Real Time PCR Kit DNA 25
DD-0128-02 • • Listeria Monocytogenes Real Time PCR Kit DNA 25
DD-0129-01 • • Vibrio Vulnificus Real Time PCR Kit DNA 25
DD-0129-02 • • Vibrio Vulnificus Real Time PCR Kit DNA 25
DD-0130-01 • • Vibrio Alginolyticus Real Time PCR Kit DNA 25
DD-0130-02 • • Vibrio Alginolyticus Real Time PCR Kit DNA 25
DD-0151-01 • • Botulinus (Types A/B/E/F) Real Time PCR Kit DNA 25
DD-0151-02 • • Botulinus (Types A/B/E/F) Real Time PCR Kit DNA 25
DD-0155-01 • • Toxic Gene of Vibrio Parahaemolyticus Real Time PCR Kit DNA 25
DD-0155-02 • • Toxic Gene of Vibrio Parahaemolyticus Real Time PCR Kit DNA 25
KIT SERIES OF RESPIRATORY DISEASE PATHOGENS
RR-0046-01 • • SARS Coronavirus (SARS-CoV) Real Time RT-PCR Kit RNA 25

RR-0046-02 • • SARS Coronavirus (SARS-CoV) Real Time RT-PCR Kit RNA 25
YF-RR-0138-02 • New Influenza A Virus Real Time RT-PCR Panel RNA 25
YF-RR-0139-01 • • New Influenza A Virus (H1N1) Real Time RT-PCR Kit RNA 25
YF-RR-0139-02 • • New Influenza A Virus (H1N1) Real Time RT-PCR Kit RNA 25
RR-0145-01 • • Oseltamivir Resistant H274Y Influenza A Virus Real Time RT-PCR Kit RNA 25
RR-0145-02 • • Oseltamivir Resistant H274Y Influenza A Virus Real Time RT-PCR Kit RNA 25
RR-0149-01 • • Influenza Virus C Real Time RT-PCR Kit RNA 25
RR-0149-02 • • Influenza Virus C Real Time RT-PCR Kit RNA 25
RR-0047-01 • • Avian Influenza Virus Real Time RT-PCR Kit RNA 25
RR-0204-01 • • Avian Influenza Virus H5 Real Time RT-PCR Kit RNA 25
RR-0048-01 • • Avian Influenza Virus H5N1 Real Time RT-PCR Kit RNA 25
RR-0049-01 • • Avian Influenza Vvirus H7 Real Time RT-PCR Kit RNA 25
147
Real Time PCR

I II III IV
KIT SERIES OF RESPIRATORY DISEASE PATHOGENS (continued)

RR-0051-01 • • Influenza Virus A Real Time RT-PCR Kit RNA 25
RR-0051-02 • • Influenza Virus A Real Time RT-PCR Kit RNA 25
RR-0052-01 • • Subtype H1 of Influenza Virus A Real Time RT-PCR Kit RNA 25
RR-0053-01 • • Influenza Virus B Real Time RT-PCR Kit RNA 25
RR-0053-02 • • Influenza Virus B Real Time RT-PCR Kit RNA 25
RR-0097-01 • Influenza Virus A&B Real Time RT-PCR Kit RNA 25
RR-0097-02 • Influenza Virus A&B Real Time RT-PCR Kit RNA 25
RR-0156-01 • • Human Parainfluenza Virus Type 1 Real Time RT-PCR Kit RNA 25
RR-0160-01 • • Respiratory Syncytial Virus (RSV) Typing A&B Real Time RT-PCR Kit RNA 25
RR-0160-02 • • Respiratory Syncytial Virus (RSV) Typing A&B Real Time RT-PCR Kit RNA 25
RR-0162-01 • • Human Metapneumovirus (hMPV) Real Time RT-PCR Kit RNA 25
RR-0162-02 • • Human Metapneumovirus (hMPV) Real Time RT-PCR Kit RNA 25
RR-0054-01 • • Measles Virus Real Time RT-PCR Kit RNA 25
RR-0054-02 • • Measles Virus Real Time RT-PCR Kit RNA 25
RR-0055-01 • • Rubella Virus Real Time RT-PCR Kit RNA 25
RR-0055-02 • • Rubella Virus Real Time RT-PCR Kit RNA 25
RR-0056-01 • • Mumps Virus Real Time RT-PCR Kit RNA 25
RR-0056-02 • • Mumps Virus Real Time RT-PCR Kit RNA 25
Real Time PCR

I II III IV
KIT SERIES OF RESPIRATORY DISEASE PATHOGENS (continued)
RR-0098-01 • • Respiratory Syncytial Virus (RSV) Real Time RT-PCR Kit RNA 25
RR-0098-02 • • Respiratory Syncytial Virus (RSV) Real Time RT-PCR Kit RNA 25
RD-0195-01 • • Respiratory Adenovirus Real Time PCR Kit DNA 25
RD-0195-02 • • Respiratory Adenovirus Real Time PCR Kit DNA 25
RD-0057-01 • • Legionella Pneumophila Real Time PCR Kit DNA 25
RD-0057-02 • • Legionella Pneumophila Real Time PCR Kit DNA 25
RD-0121-01 • • Hemophilus Influenza B Real Time PCR Kit DNA 25
RD-0121-02 • • Hemophilus Influenza B Real Time PCR Kit DNA 25
RD-0058-01 • • Meningococcus Real Time PCR Kit DNA 25
RD-0058-02 • • Meningococcus Real Time PCR Kit DNA 25
RD-0059-01 • • Streptococcus Pyogenes Real Time PCR Kit DNA 25
RD-0059-02 • • Streptococcus Pyogenes Real Time PCR Kit DNA 25
RD-0060-01 • • Mycobacterium Tuberculosis (TB) Real Time PCR Kit DNA 25
RD-0060-02 • • Mycobacterium Tuberculosis (TB) Real Time PCR Kit DNA 25
RD-0060-01-A • • Mycobacterium Tuberculosis (TB) Real Time PCR Kit (Packing with 4 diluted positive control) DNA 25
RD-0060-02-A • • Mycobacterium Tuberculosis (TB) Real Time PCR Kit (Packing with 4 diluted positive control) DNA 25
RD-0061-01 • • Bordetella Pertussis Real Time PCR Kit DNA 25
RD-0061-02 • • Bordetella Pertussis Real Time PCR Kit DNA 25
RD-0062-01 • • Bacillus Diphtheriae Real Time PCR Kit DNA 25
RD-0062-02 • • Bacillus Diphtheriae Real Time PCR Kit DNA 25
RD-0131-01 • • Human Bocavirus (HBoV) Real Time PCR Kit DNA 25
RD-0131-02 • • Human Bocavirus (HBoV) Real Time PCR Kit DNA 25
RD-0099-01 • • Clamydia Pneumoniae (CP) Real Time PCR Kit DNA 25
RD-0099-02 • • Clamydia Pneumoniae (CP) Real Time PCR Kit DNA 25
RD-0100-01 • • Mycoplasma Pneumoniae (MP) Real Time PCR Kit DNA 25
RD-0100-02 • • Mycoplasma Pneumoniae (MP) Real Time PCR Kit DNA 25
RD-0146-01 • • Streptococcus Pneumoniae Real Time PCR Kit DNA 25
RD-0146-02 • • Streptococcus Pneumoniae Real Time PCR Kit DNA 25
ER-0101-01 • • Dengue Virus General-type Real Time RT-PCR Kit RNA 25
ER-0101-02 • • Dengue Virus General-type Real Time RT-PCR Kit RNA 25
RR-0197-01 • • Human Coronavirus(HCoV-229E) Real Time RT-PCR Kit RNA 25
RR-0197-02 • • Human Coronavirus(HCoV-229E) Real Time RT-PCR Kit RNA 25
RR-0198-01 • • Human Coronavirus(HCoV-HKU1) Real Time RT-PCR Kit RNA 25
RR-0198-02 • • Human Coronavirus(HCoV-HKU1) Real Time RT-PCR Kit RNA 25
RR-0199-01 • • Human Coronavirus(HCoV-NL63) Real Time RT-PCR Kit RNA 25
RR-0199-02 • • Human Coronavirus(HCoV-NL63) Real Time RT-PCR Kit RNA 25
RR-0211-01 • • Human Coronavirus(HCoV-OC43) Real Time RT-PCR Kit RNA 25
RR-0211-02 • • Human Coronavirus(HCoV-OC43) Real Time RT-PCR Kit RNA 25
149
Real Time PCR

I II III IV
KIT SERIES OF INSECT VECTOR
ER-0133-01 • • Crimean-Congo Hemorrhagic Fever Virus (CCHFV) Real Time RT-PCR Kit RNA 25
ER-0133-02 • • Crimean-Congo Hemorrhagic Fever Virus (CCHFV) Real Time RT-PCR Kit RNA 25
ER-0063-01 • • Dengue Virus I Real Time RT-PCR Kit RNA 25
ER-0063-02 • • Dengue Virus I Real Time RT-PCR Kit RNA 25
ER-0063-03 • • Dengue Virus II Real Time RT-PCR Kit RNA 25
ER-0063-04 • • Dengue Virus II Real Time RT-PCR Kit RNA 25
ER-0064-01 • • Dengue Virus III Real Time RT-PCR Kit RNA 25
ER-0064-02 • • Dengue Virus III Real Time RT-PCR Kit RNA 25
ER-0064-03 • • Dengue Virus IV Real Time RT-PCR Kit RNA 25
ER-0064-04 • • Dengue Virus IV Real Time RT-PCR Kit RNA 25
ER-0065-01 • • Japanese Encephalitis Virus (JEV) Real Time RT-PCR Kit RNA 25
ED-0066-01 • • Malaria Parasite Real Time PCR Kit DNA 25
ED-0066-02 • • Malaria Parasite Real Time PCR Kit DNA 25
ED-0163-01 • • Borrelia burgdrferi (Bb) Real Time PCR Kit DNA 25
ED-0163-02 • • Borrelia burgdrferi (Bb) Real Time PCR Kit DNA 25
ER-0067-01 • • Chikungunya Virus Real Time RT-PCR Kit RNA 25
ER-0067-02 • • Chikungunya Virus Real Time RT-PCR Kit RNA 25
ER-0068-01 • • West Nile Virus Real Time RT-PCR Kit RNA 25
ER-0068-02 • • West Nile Virus Real Time RT-PCR Kit RNA 25
ER-0170-01 • • Nipah Virus (NiV) Real Time RT-PCR Kit RNA 25
ER-0170-02 • • Nipah Virus (NiV) Real Time RT-PCR Kit RNA 25
ER-0172-01 • • Tick-borne Encephalitis Virus (TBEV) Real Time RT-PCR Kit RNA 25
ER-0172-02 • • Tick-borne Encephalitis Virus (TBEV) Real Time RT-PCR Kit RNA 25
ER-0173-01 • • Toscana Virus (TOSV) Real Time RT-PCR Kit RNA 25
ER-0173-02 • • Toscana Virus (TOSV) Real Time RT-PCR Kit RNA 25
ED-0213-01 • • Coxiella burnetti Real Time RT-PCR Kit RNA 25
ED-0213-02 • • Coxiella burnetti Real Time RT-PCR Kit RNA 25
Real Time PCR

I II III IV
KIT SERIES OF ZOONOSIS

ZD-0069-01 • • Streptococcus Suis Real Time PCR Kit DNA 25
ZR-0070-01 • • Rabies Virus Real Time RT-PCR Kit RNA 25
ZD-0071-01 • • Brucella Real Time PCR Kit DNA 25
ZR-0072-01 • • Foot-and-Mouth Disease Virus (FMDV) Real Time RT-PCR Kit RNA 25
ZD-0073-01 • • Bacillus Anthrax Real Time PCR Kit DNA 25
ZD-0074-01 • • Leptospira Real Time PCR Kit DNA 25
ZD-0075-01 • • Toxoplasma Gondii Real Time PCR Kit DNA 25
ZD-0075-02 • • Toxoplasma Gondii Real Time PCR Kit DNA 25
ZD-0076-01 • • Monkeypox Virus Real Time PCR Kit DNA 25
ZD-0076-02 • • Monkeypox Virus Real Time PCR Kit DNA 25
KIT SERIES OF ANIMAL RELATED DISEASES
AR-0103-01 • • Porcine Reproductive and Respiratory Syndrome (PRRSV) Real Time RT-PCR Kit RNA 25
AR-0103-02 • • Porcine Reproductive and Respiratory Syndrome (PRRSV) Real Time RT-PCR Kit RNA 25
AR-0104-01 • • Classical Swine Fever Virus(CSFV) Real Time RT-PCR Kit RNA 25
AR-0104-02 • • Classical Swine Fever Virus(CSFV) Real Time RT-PCR Kit RNA 25
AD-0105-01 • • Pseudorabies virus Real Time PCR Kit DNA 25
AD-0105-02 • • Pseudorabies virus Real Time PCR Kit DNA 25
151
Real Time PCR

I II III IV
KIT SERIES OF ANIMAL RELATED DISEASES (continued)
AR-0106-01 • • Newcastle Disease Virus (NDV) Real Time RT-PCR Kit RNA 25
AR-0106-02 • • Newcastle Disease Virus (NDV) Real Time RT-PCR Kit RNA 25
AD-0120-01 • • Infectious Hypodermal and Hematopoietic Necrosis Virus Real Time PCR Kit DNA 25
AD-0120-02 • • Infectious Hypodermal and Hematopoietic Necrosis Virus Real Time PCR Kit DNA 25
AR-0200-01 • • Taura Syndrome Virus (TSV) Real Time RT-PCR Kit RNA 25
AR-0200-02 • • Taura Syndrome Virus (TSV) Real Time RT-PCR Kit RNA 25
AR-0201-01 • • Yellow Head Virus (YHV) Real Time RT-PCR Kit RNA 25
AR-0201-02 • • Yellow Head Virus (YHV) Real Time RT-PCR Kit RNA 25
AD-0088-01 • • White Spot Syndrome Virus (WSSV) Real Time PCR Kit DNA 25
AD-0088-02 • • White Spot Syndrome Virus (WSSV) Real Time PCR Kit DNA 25
AR-0209-01 • • Infectious Myonecrosis Virus (IMNV) Real Time RT-PCR Kit RNA 25
AR-0209-02 • • Infectious Myonecrosis Virus (IMNV) Real Time RT-PCR Kit RNA 25
QD-0086-01 • • Yersinia pestis Real Time PCR Kit DNA 25
QD-0086-02 • • Yersinia pestis Real Time PCR Kit DNA 25
OTHERS
AD-0148-01 • • Swine DNA Real Time PCR Kit DNA 25

AD-0148-02 • • Swine DNA Real Time PCR Kit DNA 25
QR-0078-01 • • Poliovirus 1 Real Time RT-PCR Kit RNA 25
Real Time PCR

I II III IV
OTHERS (continued)
QR-0202-01 • • Coxsackie Virus Real Time RT-PCR Kit RNA 25

QR-0202-02 • • Coxsackie Virus Real Time RT-PCR Kit RNA 25
QR-0081-01 • • Coxsackie Virus A24 Real Time RT-PCR Kit RNA 25
QR-0081-02 • • Coxsackie Virus A24 Real Time RT-PCR Kit RNA 25
QD-0082-01 • • Pneumocystis Carinii Real Time PCR Kit DNA 25
QD-0082-02 • • Pneumocystis Carinii Real Time PCR Kit DNA 25
QD-0085-01 • • Schistosomiasis Real Time PCR Kit DNA 25
QD-0085-02 • • Schistosomiasis Real Time PCR Kit DNA 25
QR-0205-01 • • Enterovirus 71(EV71) Real Time RT-PCR RNA 25
QR-0205-02 • • Enterovirus 71(EV71) Real Time RT-PCR RNA 25
QR-0206-01 • • Enterovirus Real Time RT-PCR Kit RNA 25
QR-0206-02 • • Enterovirus Real Time RT-PCR Kit RNA 25
QR-0207-01 • • Coxsackie virus A16 Real Time RT-PCR Kit RNA 25
QR-0207-02 • • Coxsackie virus A16 Real Time RT-PCR Kit RNA 25
QR-0208-01 • • Enterovirus 70 (EV70) Real Time RT-PCR Kit RNA 25
QR-0208-02 • • Enterovirus 70 (EV70) Real Time RT-PCR Kit RNA 25
QR-0154-01 • • Enterovirus 71 & Coxsackie Virus A16 Real Time RT-PCR Kit RNA 25
QR-0154-02 • • Enterovirus 71 & Coxsackie Virus A16 Real Time RT-PCR Kit RNA 25
QR-0171-01 • • Parechovirus Real Time RT-PCR Kit RNA 25
QR-0171-02 • • Parechovirus Real Time RT-PCR Kit RNA 25
QR-0087-01 • • Hantavirus Renal Syndrome General-type I&II Real Time RT-PCR Kit RNA 25
QR-0087-02 • • Hantavirus Renal Syndrome General-type I&II Real Time RT-PCR Kit RNA 25
QR-0089-01 • • Hantavirus Renal Syndrome Typing I & II Real Time RT-PCR Kit RNA 25
QR-0089-03 • • Hantavirus Renal Syndrome Typing I & II Real Time RT-PCR Kit RNA 25
QR-0090-01 • • Hantavirus Pulmonary Syndrome Real Time RT-PCR Kit RNA 25
QR-0090-02 • • Hantavirus Pulmonary Syndrome Real Time RT-PCR Kit RNA 25
QD-0203-01 • • Pseudomonas Aeruginosa Real Time PCR Kit DNA 25
QD-0203-02 • • Pseudomonas Aeruginosa Real Time PCR Kit DNA 25
QR-0132-01 • • GAPDH (Human) Real Time RT-PCR Kit RNA 25
QR-0132-02 • • GAPDH (Human) Real Time RT-PCR Kit RNA 25
QD-0186-01 • • Aeromonas Hydrophila Real Time PCR Kit DNA 25
QD-0186-02 • • Aeromonas Hydrophila Real Time PCR Kit DNA 25
QR-0220-01 • • Ebola Virus (EBOV) Real Time RT-PCR Kit RNA 25
QR-0220-02 • • Ebola Virus (EBOV) Real Time RT-PCR Kit RNA 25
QR-0221-01 • • Marburg Virus (MBV) Real Time RT-PCR Kit RNA 25
QR-0221-02 • • Marburg Virus (MBV) Real Time RT-PCR Kit RNA 25
153
Real Time PCR

I II III IV
CONVENTIONAL PCR KITS
AR-0103-03 – – – – Porcine Reproductive and Respiratory Syndrome (PRRSV) RT-PCR Kit RNA 25
ZD-0069-03 – – – – Streptococcus Suis PCR Kit DNA 25
AR-0104-03 – – – – Classical Swine Fever Virus (CSFV) RT-PCR Kit RNA 25
ZR-0070-03 – – – – Rabies Virus RT-PCR Kit RNA 25
AD-0105-03 – – – – Pseudorabies virus PCR Kit DNA 25
ZR-0072-03 – – – – Foot-and-Mouth Disease Virus (FMDV) RT-PCR Kit RNA 25
ZD-0071-03 – – – – Brucella PCR Kit DNA 25
ER-0065-03 – – – – Japanese Encephalitis Virus (JEV) RT-PCR Kit RNA 25
RR-0047-03 – – – – Avian Influenza Virus RT-PCR Kit RNA 25
AR-0106-03 – – – – Newcastle Disease Virus (NDV) RT-PCR Kit RNA 25
DD-0034-03 – – – – Salmonella PCR Kit DNA 25
ZD-0073-03 – – – – Bacillus Anthrax PCR Kit DNA 25
ZD-0074-03 – – – – Leptospira PCR Kit DNA 25
ZD-0174-03 – – – – Brucella Abortus PCR kit DNA 25
ZD-0175-03 – – – – Brucella Melitensis PCR kit DNA 25
ZD-0176-03 – – – – Brucella Ovis PCR kit DNA 25
ZD-0177-03 – – – – Foot-and-Mouth Disease Virus (FMDV) A Strain RT-PCR Kit DNA 25
ZD-0178-03 – – – – Foot-and-Mouth Disease Virus (FMDV) O Strain RT-PCR Kit DNA 25
ZD-0179-03 – – – – Foot-and-Mouth Disease Virus (FMDV) Asia 1 Strain RT-PCR Kit DNA 25
AR-0107-03 – – – – Vesicular Stomatitis Virus (VSV) RT-PCR Kit RNA 25
AD-0108-03 – – – – Contagious Bovine Pleuropneumonia PCR Kit DNA 25
AR-0109-03 – – – – Rinderpest Virus (RPV) RT-PCR Kit RNA 25
AR-0110-03 – – – – Peste Des Petits Ruminants Virus (PPRV) RT-PCR Kit RNA 25
AD-0111-03 – – – – Sheep and Goat Pox PCR Kit DNA 25
AR-0112-03 – – – – Africa Horse Sickness Virus RT-PCR Kit RNA 25
AR-0113-03 – – – – Swine Vesicular Disease Virus (SVDV) RT-PCR Kit RNA 25
AR-0114-03 – – – – African Swine Fever Virus (ASFV) RT-PCR Kit RNA 25
AD-0115-03 – – – – Neethling Virus PCR Kit DNA 25
AR-0116-03 – – – – Rift Valley Fever Virus (RVFV) RT-PCR Kit RNA 25
AR-0117-03 – – – – Bluetongue Virus (BTV) RT-PCR Kit RNA 25
AD-0118-03 – – – – Pasteurella Multocida PCR Kit DNA 25
AR-0119-03 – – – – Infectious Bursal Disease Virus (IBDV) RT-PCR Kit RNA 25
AR-0200-03 – – – – Taura Syndrome Virus (TSV) RT-PCR Kit RNA 25
AR-0201-03 – – – – Yellow Head Virus (YHV) RT-PCR Kit RNA 25
AD-0088-03 – – – – White Spot Syndrome Virus PCR Kit DNA 25
QR-0210-03 – – – – EV-U, EV71 & CA16 PCR Kit RNA 25
DNA/RNA Isolation Kits and Automated Nucleic Acid Extraction System
PRODUCT INTRODUCTION CAT. # DESCRIPTION QTY

The Liferiver™ EX2400/EX4800 Automated Nucleic Acid Extraction System
uses an advanced magnetic bead isolation technology to purify high quality ME-0001 RNA Isolation Kit 50
DNA and RNA to be used for PCR Applications. The corresponding RNA/DNA ME-0010 RNA Isolation Kit (Paramagnetic Beads Column Method) 50
Isolation Kit can extract high-purity nucleic acids from various samples such
ME-0013 Whole Blood Genomic DNA Isolation Kit 50
as whole blood, serum, plasma, feces, milk and cells. The instrument is well-
designed and easy to operate. It is time-saving, less labor-intensive, and always IE-0001 EX-2400 Automated Nucleic Extraction System 24
provides consistent and efficient results. The EX2400/EX4800 is particularly IE-0002 EX-4800 Automated Nucleic Extraction System 48
suited for nucleic acid extractions used in genome research, molecular biology
research and clinical genetic testing.
OPERATING PRINCIPLE
Using the magnetic bead isolation technology, the instrument can extract the
whole nucleic acid from the sample by the collection, release and diversion of
the magnetic bead based on the movement between the magnetic bar and
magnetic cap.
See the main steps in the process of nucleic acid extraction:
1. Adsorption: Add the magnetic bead into the sample binging solution,
vibrate and blend adequately. The released nucleic acid will be adsorbed on
the surface of the magnetic bead.
2. Washing: Collect and transfer the magnetic bead in the first procedure
into the washing buffer and wash repeatedly to eliminate the impurity.
3. Elution: Transfer the magnetic bead into the elution buffer after vibrating
and blending adequately. The target nucleic acid will drop from the surface
of the magnetic bead and dissolve into the elution buffer.
155
DNA/RNA Isolation Kits and Automated Nucleic Acid Extraction System
CHARACTERISTIC PARAMETER AND SPECIFICATIONS

Automation & High Throughput Product Name EX2400 Automated EX4800 Automated
Automated nucleic acid purification, without tedious repeated centrifugation, Cat. # IE-0001 IE-0002
can process 24/48 samples one time.
Sample Volume 20-200μl 20-200μl
One Button Operation Sample Quantity 24 units/time 48 units/time
Built-in standard procedures, one-button operation. The EX4800 is specifically CMOD 1 2
designed with dual modules that can operate independently to greatly improve
Sample Handling Time 20-40 min 20-40 min
work efficiency.
Magnetic Bead ≥99% ≥99%
Safe and Reliable Collection Efficiency
Enclosed extraction and disposable supplies can reduce the risk of harm to the 96 Well Plate 2 4
operator caused by chemicals and pathogenic microorganisms.
Magnetic Bar 24 48
Stable Result Magnetic Cap (disposable) 2 strips (12 well/strip) 4 strips (12 well/strip)
Automation can avoid errors caused by manual operation, so the results will be Keypad Start/Stop/Direction Start/Stop/Direction
more stable.
Monitor LCD (text display) LCD (text display)
Fast Extraction UV lamp available available
Extract 1-48 samlpes at once in only 30 minutes time. Boundary Dimension 45 x 38 x 43cm 95 x 38 x 40cm
Pollution Control Net Weight 20kg 44kg
The built-in UV lamp makes it easy to clear the nucleic acid that may exist in the Operation Condition Room temperature Room temperature
extraction enviroment.
Molecular Pathology Technical Index
Dr. Alfonso Heras –

President & CEO
“This Molecular Pathology Technical Section is a compilation of current

published information about the use of our products and technologies.
We hope this section will be a useful quick technical reference to better
identify and use our antibodies, probes or PCR products. We try to provide
the most up-to-date information; however, we encourage our customers
to independently validate the applications and proper use of any of our
products and protocols.”
Antibodies for IHC Categorical Reference

Carcinoma Markers Hematopoietic Markers CD45RO . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Pituitary Markers
CD56 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
AMACRacemase/P504S . . . . . . . . . . . . 10 CD31 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 ACTH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
CD57 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
BCA-225 . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 CD34 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 FSH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
CD74 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
CA-125 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 CD61 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 GH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
CD79a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
CA15-3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 CD138 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 LH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Cyclin D1 . . . . . . . . . . . . . . . . . . . . . . . . . . 30
CA19-9 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Glycophorin A . . . . . . . . . . . . . . . . . . . . . 42 Prolactin . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Follicular Dendritic Cell . . . . . . . . . . . . . 39
Caldesmon . . . . . . . . . . . . . . . . . . . . . . . . 14 Spectrin . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 TSH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Calponin. . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Tryptase . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
IgD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
CD44 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Prostate Markers
IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
CDX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 Hodgkin’s Group
IgM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 Cytokeratin HMW/34betaE12 . . . . . . . 33
CEA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
CD15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Kappa Light Chains . . . . . . . . . . . . . . . . 48 Cytokeratin 5 & 6 . . . . . . . . . . . . . . . . . . . 30
Collagen Type IV . . . . . . . . . . . . . . . . . . . 29
CD30 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Lambda . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 p63 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Cytokeratin HMW/34betaE12 . . . . . . . 33
Fascin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 PAX-5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 Alpha-Methylacyl-CoA
Cytokeratin 8/35Beta11 . . . . . . . . . . . . 31
PD-1/CD279 . . . . . . . . . . . . . . . . . . . . . . . 59 Racemase/P504S. . . . . . . . . . . . . . . . . . . 10
Cytokeratin/Pan-OSCAR . . . . . . . . . . . . 34
Infectious Agents PSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Cytokeratin 5 & 6 . . . . . . . . . . . . . . . . . . . 30
Melanoma Markers PSAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Cytokeratin 7 . . . . . . . . . . . . . . . . . . . . . . 31 Cytomegalovirus . . . . . . . . . . . . . . . . . . . 35
Cytokeratin 8 & 18 . . . . . . . . . . . . . . . . . 31 Epstein Barr Virus . . . . . . . . . . . . . . . . . . 37 CD63 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Sarcoma Markers
Cytokeratin 14 . . . . . . . . . . . . . . . . . . . . . 32 Helicobacter Pylori . . . . . . . . . . . . . . . . . 43 MART-1/Melan-A . . . . . . . . . . . . . . . . . . . 51
Cytokeratin 17 . . . . . . . . . . . . . . . . . . . . . 32 Hepatitis B Virus Core Antigen . . . . . . 43 Melanoma/HMB-45 . . . . . . . . . . . . . . . . 51 Actin, Muscle Specific . . . . . . . . . . . . . . . .9
Cytokeratin 19 . . . . . . . . . . . . . . . . . . . . . 32 Hepatitis B Virus Surface Antigen . . . 44 MiTF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 Actin, Smooth Muscle . . . . . . . . . . . . . . . .9
Cytokeratin 20 . . . . . . . . . . . . . . . . . . . . . 33 Herpes Simplex Virus I & II . . . . . . . . . . 45 S-100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 Caldesmon . . . . . . . . . . . . . . . . . . . . . . . . 14
Cytokeratin/Pan-Cocktail AE1 & AE3 34 Parvovirus B19 . . . . . . . . . . . . . . . . . . . . . 59 Tyrosinase . . . . . . . . . . . . . . . . . . . . . . . . . 68 Calponin. . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Cytokeratin HMW/AE3 . . . . . . . . . . . . . 33 Pneumocystis carinii . . . . . . . . . . . . . . . 60 CD34 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Cytokeratin LMW/AE1 . . . . . . . . . . . . . . 34 Toxoplasma gondii . . . . . . . . . . . . . . . . . 66 Mesothelioma Markers CD99 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
E-Cadherin. . . . . . . . . . . . . . . . . . . . . . . . . 36 CD117 c-Kit PolyDetector HRP/DAB . 80
Calretinin . . . . . . . . . . . . . . . . . . . . . . . . . . 15
EMA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Leukemia/Histiocytic Markers Desmin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Cytokeratin 5 & 6 . . . . . . . . . . . . . . . . . . . 30
EpCAM/Epithelial Specific Antigen. . 37 DOG1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Alpha-1-Antichymotrypsin . . . . . . . . . . .8 WT1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
GCDFP-15 . . . . . . . . . . . . . . . . . . . . . . . . . 40 Factor VIII-Related Antigen . . . . . . . . . 38
Alpha-1-Antitrypsin . . . . . . . . . . . . . . . . . .8
Glypican-3 . . . . . . . . . . . . . . . . . . . . . . . . . 42 Fli-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
CD61 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Neural & Neuroendocrine
Inhibin Alpha . . . . . . . . . . . . . . . . . . . . . . 47 HHV-8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
CD68 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Ksp-Cadherin . . . . . . . . . . . . . . . . . . . . . . 49 Calcitonin. . . . . . . . . . . . . . . . . . . . . . . . . . 14 Myogenin . . . . . . . . . . . . . . . . . . . . . . . . . 55
CD163 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Mammaglobin . . . . . . . . . . . . . . . . . . . . 50 Chromogranin A . . . . . . . . . . . . . . . . . . . 29 Myoglobin . . . . . . . . . . . . . . . . . . . . . . . . . 55
Factor XIIIa . . . . . . . . . . . . . . . . . . . . . . . . . 38
MUC1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 Gastrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Vimentin. . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Glycophorin A . . . . . . . . . . . . . . . . . . . . . 42
MUC2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 GFAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Granzyme B. . . . . . . . . . . . . . . . . . . . . . . . 42
MUC5AC . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 Glucagon . . . . . . . . . . . . . . . . . . . . . . . . . . 41 Undifferentiated Tumor Markers
Lysozyme . . . . . . . . . . . . . . . . . . . . . . . . . . 50
MUC6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 Insulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 Actin, Muscle Specific . . . . . . . . . . . . . . . .9
Macrophage/HAM-56 . . . . . . . . . . . . . . 50
NGFR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 Myelin Basic Protein . . . . . . . . . . . . . . . . 54 CD45 (LCA) . . . . . . . . . . . . . . . . . . . . . . . . 22
Myeloperoxidase. . . . . . . . . . . . . . . . . . . 55
p63 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58 Neurofilament . . . . . . . . . . . . . . . . . . . . . 56 CD99 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Spectrin . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Renal Cell Carcinoma . . . . . . . . . . . . . . . 62 NSE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 Cytokeratin/Pan-Cocktail AE1 & AE3 34
TdT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
TAG-72 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 Somatostatin . . . . . . . . . . . . . . . . . . . . . . 63 Galectin-3 . . . . . . . . . . . . . . . . . . . . . . . . . 40
TRAcP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Thyroglobulin. . . . . . . . . . . . . . . . . . . . . . 65 Synaptophysin . . . . . . . . . . . . . . . . . . . . . 64 Myogenin . . . . . . . . . . . . . . . . . . . . . . . . . 55
TTF-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 S-100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Lymphoma Markers
Villin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68 Other Vimentin. . . . . . . . . . . . . . . . . . . . . . . . . . . 69
WT1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 ALK-1/CD246 . . . . . . . . . . . . . . . . . . . . . . 10
Androgen Receptor . . . . . . . . . . . . . . . . 11
bcl-2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Beta-Catenin . . . . . . . . . . . . . . . . . . . . . . . 13
Endothelial Markers bcl-6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
CD34 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
CD1a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
CD31 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Collagen Type IV . . . . . . . . . . . . . . . . . . . 29
CD2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
CD34 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 COX-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
CD3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
CD105/Endoglin . . . . . . . . . . . . . . . . . . . 26 Estrogen Receptor . . . . . . . . . . . . . . . . . 37
CD4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Factor VIII-Related Antigen . . . . . . . . . 38 Hepatocyte Specific Antigen
CD5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Fli-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 /Hep Par 1 . . . . . . . . . . . . . . . . . . . . . . . . . 44
CD7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Podoplanin/D2-40 . . . . . . . . . . . . . . . . . 60 HER-2/Neu (c-erbB-2) . . . . . . . . . . . 44, 45
CD8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Ki-67 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
CD10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Germ Cell Tumor MLH1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
CD19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
MSH2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Alpha-Fetoprotein . . . . . . . . . . . . . . . . . 10 CD20 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
MSH6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
hCG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43 CD21 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Myosin, Smooth Muscle . . . . . . . . . . . . 56
p57 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58 CD23 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
p27 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
PLAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 CD25 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
p53 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
CD35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Progesterone Receptor . . . . . . . . . . . . 61
CD43 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Zap-70 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
CD45R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Antibody Type, Clone, Isotype, Control, Localization, Dilution Range
Antibody Name Antibody Type Clone Isotype Tissue Control Localization Ab Dilution Range Page
A-1-Antichymotrypsin rabbit polyclonal IgG Tonsil, Lymph Node Cytoplasmic 1000-5000 8
A-1-Antitrypsin rabbit polyclonal IgG Tonsil, Lymph Node Cytoplasmic 100-500 8
ACTH rabbit polyclonal IgG Normal Pituitary Cytoplasmic 100-500 8
Actin, Muscle Specific mouse HHF35 IgG1/K Skeletal Muscle Cytoplasmic 50-200 9
Actin, Smooth Muscle mouse ASM/H12 IgG2a/K Appendix, Uterus Cytoplasmic 500-2000 9
Adenovirus mouse 20/11 and 2/6 IgG1 Infected Tissue Cytoplasmic, Nuclear 25-100 9
ALK-1/CD246 RMab RBT-ALK1 IgG Anaplastic Large Cell Lymphoma Cytoplasmic, Nuclear 250-1000 10
Alpha-Fetoprotein rabbit polyclonal IgG Fetal Liver Cytoplasmic 100-500 10
AMACRacemase/ P504S RMab RBT-AMACR IgG Prostatic Adenocarcinoma Cytoplasmic 50-200 10
Androgen Receptor mouse AR-D12 IgG1 Prostatic Adenocarcinoma Nuclear 250-1000 11
Bax mouse SPM336 IgG1/K Normal Breast, Tonsil Cytoplasmic & Cell Membrane 50-200 11
BCA-225 mouse Cu-18 IgG1/K Breast Carcinoma Cytoplasmic 25-100 11
bcl-2 mouse BCL2/A4 IgG1/K Tonsil, Lymph Node Cytoplasmic 50-200 12
bcl-6 mouse BCL6/12 IgG2b Tonsil, Lymph Node Nuclear 50-200 12
bcl-X rabbit polyclonal IgG Hodgkin’s Lymphoma Cytoplasmic and Nuclear Membrane 250-100 12
Beta-Catenin mouse 14 IgG1 Breast, Abdomen Nuclear 50-200 13
CA-125 mouse OC125 IgG1/K Ovarian Carcinoma, Epithelioid Mesothelioma Cytoplasmic and Membranous 250-1000 13
CA15-3 mouse DF3 IgG1/K Breast, Pancreas, Salivary Gland Cytoplasmic 50-300 13
CA19-9 mouse 121SLE IgM Colon, Salivary Gland Cytoplasmic 25-100 14
Calcitonin rabbit polyclonal IgG Thyroid, Medullary Carcinoma of Thyroid Cytoplasmic 250-100 14
Caldesmon mouse CALD-31 IgG1/K Appendix, Uterus, Leiomyoma Cytoplasmic 100-400 14
Calponin mouse CALP-A6 IgG1/K Appendix, Uterus, Leiomyoma Cytoplasmic 50-200 15
Calretinin RMab EP1798 IgG Malignant Mesothelioma, Benign Mesotheilial Cells Cytoplasmic, Nuclear 50-250 15
CD1a RMab EP80 IgG Skin, Thymus Cytoplasmic, Membranous 25-100 15
CD2 mouse AB75 IgG1/K Tonsil Membranous 25-100 16
CD3 RMab RBT-CD3 IgG Tonsil, Lymph Node Membranous 100-500 16
CD7 mouse LP15 IgG2b Tonsil, Lymph Node Membranous 10-50 17
CD8 mouse C8/144B IgG/K Tonsil, Lymph Node Membranous 250-1000 17
CD10 mouse 56C6 IgG1 Kidney, Tonsil, Lymph Node Cytoplasmic, Membranous 10-40 18
CD15 mouse SPM119 IgM/K Hodgkin’s Lymphoma Cytoplasmic, Membranous 50-200 18
CD19 mouse MRQ-36 IgG1/K Tonsil, Lymph Node Membranous 25-100 18
CD20 mouse L26 IgG2a/K Tonsil, Lymph Node Membranous 50-250 19
CD21 RMab EP64 IgG Tonsil, Lymph Node Membranous 50-250 19
CD23 mouse 1B12 IgG Tonsil, Lymph Node Membranous 25-100 19
CD25 mouse 4C9 IgG2b Mastocytosis, Tonsil, Small Bowel Cytoplasmic, Membranous 25-100 20
CD30 mouse Ber-H2 IgG1/K Hodgkin’s Lymphoma Membranous 100-500 20
CD31 mouse 1A10 IgG1/K Tonsil, Placenta, Appendix Membranous 50-200 20
CD34 mouse QBEnd/10 IgG1 Tonsil, Placenta, Appendix Membranous 100-500 21
CD35 mouse RLB25 IgG2b Tonsil, Lymph Node Membranous 25-100 21
CD38 mouse SPC32 IgG1 Tonsil, Lymph Node Membranous 25-100 21
CD43 mouse MT1 IgG1 Tonsil, Lymph Node Membranous 100-500 22
CD44 mouse MRQ-13 IgG2a Tonsil, Kidney, Esophageal CA Membranous 250-1000 22
CD45 mouse 2B11 & PD7/26 IgG1/K Tonsil, Lymph Node Membranous 250-1000 22
CD45R mouse MB1 IgG1 Tonsil, Lymph Node Membranous 25-100 23
CD45RA mouse 111-1C5 IgG1/K Tonsil, Lymph Node Membranous 25-100 23
CD45RO mouse UCHL-1 IgG2a/K Tonsil, Lymph Node Membranous 250-1000 23
CD56 mouse 123C3.D5 IgG1/K Neuroblastoma Membranous 200-800 24
CD57 mouse CD57/B8 IgM/K Tonsil, Lymph Node Membranous 100-500 24
CD61 mouse 2f2 IgG1/K Bone Marrow Cytoplasmic 50-200 24
CD63 mouse NKI/C3 IgG1/K Malignant Melanoma Cytoplasmic, Membranous 1000-4000 25
CD68 mouse CD68/G2 IgG1 Tonsil, Lymph Node Cytoplasmic, Membranous 25-100 25
CD74 mouse LN2 IgG1 Tonsil, Lymph Node Cytoplasmic, Membranous 25-100 25
CD79a mouse JCB117 IgG1/K Tonsil, Lymph Node Membranous 250-1000 26
CD99 mouse CD99/B5 IgG1/K Ependyma, Pancreas, Ewing’s Carcoma, Thymus Cytoplasmic, Membranous 25-100 26
CD105/Endoglin mouse MRQ-14 IgG1/K Tonsil, Renal Cell Carcinoma Cytoplasmic 25-100 26
CD117 b RMab YR145 IgG GIST, Skin, Testes, Breast Cytoplasmic, Membranous 250-1000 27
CD123, IL-3Ra mouse CD123-D3 IgG1/K Tonsil, Lymph Node, Kikuchi-Fujimoto Disease Membranous 25-100 27
CD138 mouse B-A38 IgG1 Tonsil, Plasmacytoma Membranous 50-200 27
CD163 mouse MRQ-26 IgG1 Placenta, Tonsil, Lymph Node Cytoplasmic, Membranous 25-100 28
CDX2 RMab EP25 IgG Adenocarcinoma of Colon, Normal Colon Nuclear 250-1000 28
CEA mouse CEA31 IgG1/K Colon Cytoplasmic 500-2000 28
Chromogranin A mouse LK2H10 IgG1/K Pancreas Cytoplasmic 250-1000 29
Collagen Type IV mouse CIV22 IgG1/K Muscle, Lung Cytoplasmic 100-500 29
COX-2 RMab RBT-COX2 IgG Adenocarcinoma of Colon Cytoplasmic 50-200 29
Cyclin D1 RMab RBT14 IgG Breast Carcinoma, Mantle Cell Lymphoma Nuclear 50-200 30
Cyclin D3 mouse SPM241 IgG1/K Tonsil, Breast Carcinoma Nuclear 50-200 30
Cytokeratin 5 & 6 mouse D5/16B4 IgG1 Mesothelioma, Prostate Cytoplasmic 25-100 30
Cytokeratin 7 mouse K72 IgG1/K Salivary Gland, Lung Adenocarcinoma Cytoplasmic 50-300 31
Cytokeratin 8/35BH11 mouse 35betaH11 IgM Prostate, Colon Cytoplasmic 50-200 31
Cytokeratin 8 &18 mouse B22.1&B23.1 IgG1 Prostate, Pancreas, Salivary Gland Cytoplasmic 200-800 31
Cytokeratin 14 mouse LL002 IgG3 Squamous Mucosa, Squamous Carcinoma Cytoplasmic 100-400 32
Cytokeratin 17 mouse EP98 IgG Small Intestine, Colon Mucosa, Bladder, Thyroid Ca Cytoplasmic 25-100 32
Cytokeratin 19 RMab EP72 IgG Colon Carcinoma, Colon Mucosa, Bladder, Thyroid Ca Cytoplasmic 50-200 32
Cytokeratin 20 mouse Ks20.8 IgG2a/K Colon Carcinoma, Colon Mucosa, Bladder Cytoplasmic 250-1000 33
Cytokeratin HMW/34BE12 mouse 34betaE12 IgG1/K Prostate Cytoplasmic 50-200 33
Cytokeratin HMW/AE3 mouse AE3 IgG1 Prostate, Bladder, Salivary Gland Cytoplasmic 50-200 33
Cytokeratin LMW/AE1 mouse AE1 IgG1 Prostate, Salivary Gland Cytoplasmic 100-500 34
Cytokeratin Pan Cocktail, AE1&AE3 mouse AE1/AE3 IgG1 Prostate, Skin, Colon, Stomach, Salivary Gland Cytoplasmic 250-1000 34
Cytokeratin Pan-OSCAR mouse OSCAR IgG2a Prostate, Skin, Colon, Stomach Cytoplasmic 25-100 34
Cytomegalovirus mouse DDG9/CCH2 IgG2/K, IgG1/K Infected Tissue Nuclear 10-50 35
Desmin mouse D33 IgG1/K Skeletal Muscle Cytoplasmic 25-100 35
DOG1 RMab RBT-DOG1 IgG GIST Cytoplasmic, Membranous 250-1000 35
E-Cadherin RMab EP700Y IgG Pancreas, Lung Carcinoma Membranous 100-500 36
EGFR mouse 31G7 IgG1 Skin, Placenta, Squamous Cell Carcinoma Cell Membrane 50-200 36
EMA mouse E29 IgG2a/K Breast, Skin Membranous 500-2000 36
EpCAM/Epithelial Specific Antigen mouse Ber-EP4 IgG1/K Adenocarcinoma Cytoplasmic 25-100 37
Epstein Barr Virus, LMP mouse CS1-4 IgG1 Infected Tissue, Hodgkin’s Lymphoma Cytoplasmic 25-100 37
Estrogen Receptor RMab RBT11 IgG Breast Carcinoma Nuclear 50-250 37
Factor VIII-Related Antigen rabbit polyclonal IgG Skin, Placenta Cytoplasmic 50-250 38
Factor XIIIa mouse AC-1A1 IgG1 Dermatofibroma, Placenta Cytoplasmic 50-250 38
Fascin mouse 55-k2 IgG1 Hodgkin’s Lymphoma, Lymph Node, Tonsil Cytoplasmic 50-200 38
Fli-1 mouse MRQ-1 IgG2b Angiosarcoma, hemanogiomas Nuclear 25-100 39
Follicular Dendritic Cell mouse CNA.42 IgM/K Tonsil, Lymph Node Cytoplasmic 25-100 39
FSH rabbit polyclonal IgG Normal Pituitary Cytoplasmic 50-200 39
Galectin-3 mouse 9C4 IgG1 Papillary, Follicular Carcinoma of Thyroid Cytoplasmic 25-100 40
Gastrin rabbit polyclonal IgG Stomach Cytoplasmic 500-2000 40
GCDFP-15 mouse 23A3 IgG2a Breast, Breast Carcinoma, Sweat Glands in Skin Cytoplasmic 100-500 40
GFAP mouse G-A-5 IgG1 Brain Cytoplasmic 50-200 41
GH rabbit polyclonal IgG Normal Pituitary Cytoplasmic 250-1000 41
Glucagon rabbit polyclonal IgG Pancreas Cytoplasmic 25-100 41
Glycophorin A mouse GA-R2 (HIR2) IgG2b/K Bone Marrow Membranous 100-500 42
Glypican-3 mouse 1G12 IgG1 Hepatocellular Carcinoma Cytoplasmic 500-2000 42
Granzyme B rabbit polyclonal IgG Tonsil, Lymph Node Cytoplasmic (Granular) 25-100 42
hCG rabbit polyclonal IgG Placenta Cytoplasmic 100-500 43
Helicobacter pylori rabbit polyclonal IgG Infected Stomach Mucosa Cell Wall 250-1000 43
Hepatitus B Virus Core Antigen rabbit polyclonal IgG Infected Liver Nuclear 25-100 43
Hepatitus B Virus Surface Antigen mouse T9 IgG1 Infected Liver Cytoplasmic 25-100 44
Hepatocyte Specific Antigen/HepPar1 mouse OCH1E5 IgG1/K Liver Cytoplasmic 10-50 44
HER-2 neu mouse HER-24 IgG1 Breast Carcinoma Membranous 100-500 44
HER-2 neu RMab RMab RBT-HER2 IgG Breast Carcinoma Membranous 250-750 45
Herpes Simplex Virus I & II rabbit polyclonal IgG Infected Tissue Nuclear, Cytoplasmic 25-100 45
HHV-8 mouse 13B10 IgG1 Kaposi’s Sarcoma Nuclear 25-100 45
HPV mouse SB 24 IgG1/K Infected Tissue Nuclear 25-100 46
IgA rabbit polyclonal IgG Tonsil, Lymph Node Cytoplasmic 2500-10000 46
IgD rabbit polyclonal IgG Tonsil, Lymph Node Cytoplasmic 500-2000 46
IgG rabbit polyclonal IgG Tonsil, Lymph Node Cytoplasmic 2500-10000 47
IgM rabbit polyclonal IgG Tonsil, Lymph Node Cytoplasmic 100-500 47
Inhibin Alpha mouse R1 IgG2a Adrenal Cortex, Placenta, Testis, Corpus Luteum Cytoplasmic 10-50 47
Insulin rabbit polyclonal IgG Pancreas Cytoplasmic 50-200 48
Kappa Light Chains mouse Kap-56 IgG1/K Tonsil, Lymph Node Cytoplasmic 500-2000 48
Ki-67 RMab EP5 IgG Breast Carcinoma, Astrocytoma, Colon Carcinoma Nuclear 25-100 48
Ksp-Cadherin mouse MRQ-33 IgG1 Kidney, Chromophobe Renal Cell Carcinoma Membranous, Cytoplasmic 25-100 49
Lambda mouse Lamb14 IgG2a Tonsil, Lymph Node Cytoplasmic 500-2000 49
LH rabbit polyclonal IgG Normal Pituitary Cytoplasmic 1000-5000 49
Lysozyme rabbit polyclonal IgG Tonsil, Lymph Node Cytoplasmic 100-400 50
Macrophage/ HAM-56 mouse HAM-56 IgM/K Tonsil, Lymph Node Cytoplasmic 250-1000 50
Mammaglobin RMab RMab 31A5 IgG Breast Carcinoma Cytoplasmic 10-50 50
Mart-1/Melan-A mouse M2-7C10 IgG2b/K Normal Skin, Melanoma Cytoplasmic 500-2000 51
MCM2 RMab RBT-MCM2 IgG HSIL, Cervical, Breast Cancer Nuclear 100-500 51
Melanoma/HMB-45 mouse HMB-45 IgG1/K Melanoma Cytoplasmic 250-1000 51
MiTF mouse C5/D5 IgG1/K Melanoma Nuclear 50-200 52
MLH1 mouse G168-728 IgG2a Colon Mucosa, Colon Carcinoma Nuclear 25-100 52
MSH2 mouse G219-1129 IgG1 Colon Mucosa, Colon Carcinoma Nuclear 50-200 52
MSH6 mouse 44 IgG1 Colon Mucosa, Colon Carcinoma Nuclear 50-200 53
MUC1 mouse MRQ-17 IgG1 Breast, Colon Adenocarcinoma Cytoplasmic, Cell Surface 50-200 53
MUC2 mouse MRQ-18 IgG1/K Small Intestine, Colon, Colon Adenocarcinoma Cytoplasmic, Cell Surface 50-200 53
MUC5AC mouse CLH2 IgG1 Stomach Cytoplasmic 50-100 54
MUC6 mouse CLH5 IgG1 Stomach Cytoplasmic 100-500 54
Myelin Basic Protein rabbit polyclonal IgG Brain Cytoplasmic 250-1000 54
Myeloperoxidase rabbit polyclonal IgG Bone Marrow Cytoplasmic 250-1000 55
Myogenin mouse F5D IgG1/K Rhabdomyosarcoma Nuclear 10-50 55
Myoglobin rabbit polyclonal IgG Skeletal Muscle Cytoplasmic 100-500 55
Myosin, Smooth Muscle Heavy Chain mouse SMM-H24 IgG1/K Intestine, Breast Cytoplasmic 100-500 56
Neuroblastoma mouse NB84a IgG1 Neuroblastoma Cytoplasmic 25-100 56
Neurofilament mouse 2F11 IgG1/K Brain Cytoplasmic 250-1000 56
NGFR mouse NGFR/c10 IgG1 Breast, CNS Tumor Cytoplasmic 500-2000 57
NSE mouse SPM347 IgG1 Pancreas Cytoplasmic 50-200 57
p27 mouse SX53G8 IgG1/K Colon AdenoCa, Non-Small Cell Lung Ca, Prostate Nuclear 10-50 57
p53 mouse DO7 IgG2b/K Colon, Breast Carcinoma Nuclear 500-1500 58
p57 mouse Kp10 IgG2b/K Placenta, Colon Carcinoma Nuclear 1000-5000 58
p63 mouse 4A4 IgG2a/K Normal Prostate, Breast Nuclear 100-500 58
Parvovirus B19 mouse R92F6 IgG1 Infected Tissue Nuclear, Cytoplasmic 100-500 59
PAX-5 RMab RBT-PAX5 IgG Tonsil, Lymph Node Nuclear 50-200 59
PD-1/CD279 mouse MRQ-22 IgG1 Tonsil, Lymph Node Cytoplasmic 100-500 59
PLAP RMab EPR6141 IgG Placenta Cytoplasmic 100-500 60
Pneumocystis Carinii mouse 3F6 IgM/K Infected Tissue Membranous 25-100 60
Podoplanin/D2-40 mouse D2-40 IgG1 Tonsil, Lymph Node, Lymphangioma Cytoplasmic 25-100 60
Progesterone Receptor RMab RBT22 IgG Breast Carcinoma Nuclear 50-250 61
Prolactin rabbit polyclonal IgG Normal Pituitary Cytoplasmic 250-1000 61
PSA mouse A6-B/E3 IgG1/K Prostate Cytoplasmic 250-1000 61
PSAP mouse PASE/4LJ IgG1 Prostate Cytoplasmic 50-200 62
PSMA RMab EPR6253 IgG Prostate Cytoplasmic 100-500 62
Renal Cell Carcinoma mouse PN-15 IgG1/K Kidney, Renal Cell Carcinoma Cytoplasmic, Membranous 25-100 62
Retinoblastoma/Rb mouse SPM353 IgG1/K Colon, Breast Carcinoma Nuclear 25-100 63
S-100 l mouse 4C4.9 IgG2a Melanoma Cytoplasmic 100-500 63
Somatostatin rabbit polyclonal IgG Pancreas Cytoplasmic 250-1000 63
Spectrin mouse RBC2/3D5 IgG2b/K Bone Marrow Membranous 25-100 64
Synaptophysin rabbit polyclonal IgG Pancreas Synaptophysin 250-1000 64
TAG-72 mouse Tag72-22 IgG1/K Breast Carcinoma Cytoplasmic 250-1000 64
TdT rabbit polyclonal IgG TdT Positive Lymphoma, Thymus Nuclear 250-1000 65
Thyroglobulin mouse 2H11+6E1 IgG1 Thyroid Cytoplasmic 100-500 65
TIA-1 mouse TIA-1 IgG1 Tonsil, Spleen, Anaplastic Large Cell Lymphoma Cytoplasmic (Granular) 25-100 65
Topoisomerase II alpha RMab RBT-Topo2a IgG Cervical, Breast Cancer Nuclear 50-200 66
Toxoplasma gondii rabbit polyclonal IgG Infected Tissue Cell Wall 25-100 66
TRAcP mouse 9C5 IgG2b Hairy Cell Leukemia Cytoplasmic 25-100 66
Tryptase mouse G3 IgG1 Mast Cell Containing Tissue Cytoplasmic 250-1000 67
TSH rabbit polyclonal IgG Normal Pituitary Cytoplasmic 500-2000 67
TTF-1 mouse 8G7G3/1 IgG1 Adenocarcinoma of Lung, Normal Lung, Thyroid Nuclear 200-800 67
Tyrosinase mouse Ty/G5 IgG2a Malignant Melanoma, Skin Cytoplasmic 50-200 68
VEGF RMab RBT-VEGF IgG Angiosarcoma, Angioma Cytoplasmic, Cell Surface 25-50 68
Villin mouse CWWB1 IgG1 Small Bowel Mucosa, Colonic Mucosa Cytoplasmic, Membranous 10-50 68
Vimentin mouse V9 IgG1/K Tonsil, Lymph Node Cytoplasmic 25-100 69
WT1 mouse 6F-H2 IgG1/K Malignant Mesothelioma, Kidney, Testicle Nuclear 25-100 69
Zap-70 mouse 2F3.2 IgG2a Tonsil, Lymph Node, Chronic Lymphocytic Leukemia Cytoplasmic 1000-4000 69
Carcimonas
CARCINOMAS 1 CK Cocktail CK 7 CK 20 CK, LMW CK, HMW CK 5 p63 Vimentin
Hepatocellular Carcinoma - - - - - - - -
Renal Cell Carcinoma + - - + - - - +
Bladder Adenocarcinoma + + +/- + + - - -
Salivary Gland Carcinoma + + - + + + + -
Thyroid Carcinoma + + - + - - +
Breast Carcinoma + + - + + - - -
Lung Adenocarcinoma + + - + + - - -
Colorectal Adenocarcinoma + - + + - - - -
Prostatic Adenocarcinoma + - - + - - - -
Transitional Cell Carcinoma + + + + + + + -
Ovarian Carcinoma, Non Mucinous + + - + + + - -
Cervical Carcinoma + + - - - - -
Sweat Gland Carcinoma + + - + + -
Pancreatic Carcinoma + + - + +/- - - -
Gastric Carcinoma + + - - - -
Squamous Cell Carcinoma + - - + + + + -
Endometrial Adenocarcinoma + + - + +
CARCINOMAS 1 TTF-1 Thyroglobulin GCDFP-15 ER/PR CEA (polyclonal) CDX-2 Villin Hep-Par1
Hepatocellular Carcinoma + - - - + - - +
Renal Cell Carcinoma - - - - - - - -
Bladder Adenocarcinoma - - - - + + -
Salivary Gland Carcinoma - - - + - - -
Thyroid Carcinoma + + - - - - - -
Breast Carcinoma - - + +/- - - - -
Lung Adenocarcinoma + - - - + - - -
Colorectal Adenocarcinoma - - - - + + + -
Prostatic Adenocarcinoma - - - - - - - -
Transitional Cell Carcinoma - - - - - - - -
Ovarian Carcinoma, Non Mucinous - - - + - - - -
Cervical Carcinoma - - - - + - - -
Sweat Gland Carcinoma - - - + - - -
Pancreatic Carcinoma - - - - + - - -
Gastric Carcinoma - - - - + + + -
Squamous Cell Carcinoma - - - - - - - -
Endometrial Adenocarcinoma - - - + - - - -
CARCINOMAS 1 RCC CD10 Beta-Catenin A-1-Antitrypsin
Hepatocellular Carcinoma - + - +/-

Renal Cell Carcinoma + + - +
Bladder Adenocarcinoma - + -
Salivary Gland Carcinoma - - -
Thyroid Carcinoma - - -
Breast Carcinoma - - - -
Lung Adenocarcinoma - - -
Colorectal Adenocarcinoma - + + -
Prostatic Adenocarcinoma - + - -
Transitional Cell Carcinoma - + - -
Ovarian Carcinoma, Non Mucinous - - - -
Cervical Carcinoma - - -
Sweat Gland Carcinoma - - -
Pancreatic Carcinoma - +/- - -
Gastric Carcinoma - - -
Squamous Cell Carcinoma - - - -
Endometrial Adenocarcinoma - + -
163
Carcimonas
CARCINOMAS 2 CK 7 CK 20 CDX-2 Villin TTF-1 Napsin A PSA/PSAP Caveolin-1

Caveolin-1
Breast Carcinoma + - - - - - - ++
Lung Adenocarcinoma + - - - + + - - -
Transitional Cell (Bladder) Carcinoma + + - - - - - - -
Colorectal Adenocarcinoma - + + + - - - ++
Prostatic Adenocarcinoma - - - - - - + +/-+/-
CARCINOMAS 2 Mammaglobin GCDFP-15
Breast Carcinoma + +
Lung Adenocarcinoma - -
Transitional Cell (Bladder) Carcinoma - -
Colorectal Adenocarcinoma - -
Prostatic Adenocarcinoma - -
SQUAMOUS VS.
TRANSITIONAL CARCINOMA CK, 34bE12 p63 CK 5 Thrombomodulin CK 7 CK 20 Uroplakin III COX-2
Squamous Carcinoma + + + + - - - -
Transitional Cell Carcinoma + + -/+ + + + + +
SMALL CELL CARCINOMA VS.

MERKEL CELL CARCINOMA TTF-1 CEA CK 20 Chromogranin A E-Cadherin Neurofilament CD117 Synaptophysin
Merkel Cell Carcinoma - + + + + + + +

Small Cell Carcinoma + - - - - - +/- +
CUTANEOUS NEOPLASM CD10 Androgen Receptor CK 20 CD34 Ber-EP4 bcl-2 C19
Basal Cell Carcinoma + + - - + + +

Trichoepithelioma - - + + + + +
Merkel Cell Carcinoma - - + - + + +
Microcystic Adnexal Carcinoma +/- - - - -/+ +
Sebaceous Carcinoma +/- + - - + +/- -
Sebaceous Adenoma - + - - + + -
CARCINOMAS:
DIFFERENTIAL DIAGNOSIS Androgen Receptor BCA-225 GCDFP-15 ER/PR Mammaglobin Ny-BR-1 PSA/PSAP CD44
Salivary Duct Carcinoma + + + - - - - -

Breast Carcinoma + (apocrine) + + +/- + + - +
Prostate Carcinoma + - - - - - + +
(nuclear)
CARCINOMAS:
PROSTATE LESIONS PSA/PSAP P504s CK, 34bE12 p63 CK 7 Thrombomodulin Uroplakin III PAX-2
Prostate Carcinoma + + - - - - - -
Urothelial Carcinoma - - + + + + + -
Nephrogenic Adenoma - + +/- - + - - +
CARCINOMAS:
LUNG CARCINOMAS CD56 Chromogranin A Synaptophysin CK 7 Napsin A p63 TTF-1 BG8
Small Cell Carcinoma + -/+ +/- - - - + +

Adenocarcinoma - - - + + - + +
Squamous Cell Carcinoma - - - - - + - +
Large Cell Neuroendocrine Carcinoma + + + +/- - - +/-
Carcimonas
CARCINOMAS: COLON VS.

OVARIAN CARCINOMA CK 7 CK 20 CEA CDX-2 Villin CA19-9 Ep-CAM WT1
Ovarian Carcinoma, Serous + - + - + + + +

Ovarian Carcinoma, Mucinous +/- +/- - + + + + -
Ovarian Endometrioid Carcinoma + - - - +/- + -/+
Colon Carcinoma - + + + + + + -

OVARIAN CARCINOMA CA-125 CK 5/6 PAX-8
Ovarian Carcinoma, Serous + - +

Ovarian Carcinoma, Mucinous - -
Ovarian Endometrioid Carcinoma + - +
Colon Carcinoma - - -
CARCINOMAS: MUCIN
EXPRESSION IN NEOPLASMS MUC1 MUC2 MUC5AC MUC6
Pancreatic Adenocarcinoma + - + -
Lung Carcinoma, Signet Ring + - +
Ovarian Adenocarcinoma + - +
Gastric Carcinoma - -/+ + -/+
Cervical Adenocarcinoma + - + -
Esophageal Carcinoma + - +
Paget’s Extramammary + -/+ + -
Cholangiocarcinoma + - +/- -
Salivary Duct Adenocarcinoma - + - +
Colon Carcinoma, Signet Ring - + - -
Prostate Carcinoma - +/- - -
Pancreatic Intraductal Papillary Carcinoma - + + +
HCC - - - -
Adrenocortical Carcinoma - - - -
Breast Carcinoma + - - -
Lung Carcinoma + - -
Kidney Carcinoma + - -
Bladder Carcinoma + - -
Endometrial Carcinoma + - - -
Ovarian Carcinoma, Mucinous + - +
Renal Cell Carcinoma + - -
Urothelial Carcinoma + - -
Appendiceal Adenocarcinoma - + + -
Barrett’s Esophagus + + + -
Pancreatic Mucinous Cystic - - + -
Breast Colloid Carcinoma + + - +
CARCINOMAS: MUCINS
EXPRESSION IN ORGANS MUC1 MUC2 MUC4 MUC5AC MUC6
Stomach + - + + +
Small Intestine - + - - +
Colon - + - -
Pancreas + - - - +
CARCINOMAS: AMPULLARY
CARCINOMA (ENTERIC VS. DUCTAL) CK17 Hep-Par1 CDX-2
Enteric - + -
Ductal + - -/+
165
Carcimonas

PROSTATE ADENOCARCINOMA CDX-2 CK 20 CEA CA19-9 PSA P504s
Colon Adenocarcinoma + + + + - -
Prostate Adenocarcinoma - - - - + +
Organ Specific
ORGAN SPECIFIC:
PANCREATIC TUMORS Synaptophysin Chromogranin A Insulin Glucagon Gastrin Somatostatin MUC4 CD56
Pancreatic Adenocarcinoma - - - - - - + -
Neuroendocrine Tumor + + +/- +/- +/- +/- - +
Solid Pseudopapillary + - - - - +
Pancreatic Ductal Carcinoma - - - - - -
Acinic Cell Carcinoma - - - - - -
Pancreatoblastoma - + - - - - - +
Benign Pancreas + + + + - + - -
ORGAN SPECIFIC:
PANCREATIC TUMORS B-Catenin PGP 9.5 CK 19 CA19-9 bcl-10 E-Cadherin CD10 Maspin
Pancreatic Adenocarcinoma - - + + - +/- +

Neuroendocrine Tumor + + +/- +/- - - - -
Solid Pseudopapillary + - - - - - + -
Pancreatic Ductal Carcinoma +/- - + - +/- +/- +
Acinic Cell Carcinoma + - + -/+ + + +/- -
Pancreatoblastoma + - - - + - - +
Benign Pancreas + - - - - - -
ORGAN SPECIFIC:
BRAIN CNS TUMORS GFAP Neurofilament Synaptophysin S-100 CK Cocktail PR EMA Vimentin
Astrocytoma + /- - - + - - - +
Glioblastoma + - - + - - - +
Oligodendriglioma - - - + - - - +
Ependymoma +/- - - + - - - -/+
Choroid Plexus Carcinoma -/+ - + + + - -
Central Neurocytoma -/+ - +/- - - - - -
Neuroblastoma +/- + +/- +/- - - - -
Pineocytoma -/+ - + + - - -
Meningioma - - - - - + + +
Schwannoma + - - + -/+ - - +
Rhabdoid Tumors - +/- +/- + + +
Metastatic Carcinoma - - - - + -/+ + -/+
ORGAN SPECIFIC:
BRAIN CNS TUMORS NGFR INI-1 SOX2
Astrocytoma + + +
Glioblastoma - + +
Oligodendriglioma - + +
Ependymoma + + +
Choroid Plexus Carcinoma - +
Central Neurocytoma + + +
Neuroblastoma + + -
Pineocytoma - + -
Meningioma - + -
Schwannoma + -
Rhabdoid Tumors -
Metastatic Carcinoma - -
167
Organ Specific
ORGAN SPECIFIC: KIDNEY

RENAL EPITHELIAL TUMORS RCC CD10 PAX-2 Vimentin Ksp-Cadherin Parvalbumin CD117 Ep-CAM
Clear Cell Renal Cell Carcinoma + + + + - - - -

Chromophobe RCC - - - - + + + +
Oncocytoma - - - - + + + -
ORGAN SPECIFIC: KIDNEY

RENAL EPITHELIAL TUMORS Caveolin-1 PAX-8 pVHL
Clear Cell Renal Cell Carcinoma + + +

Chromophobe RCC + + +
Oncocytoma +/- + +
ORGAN SPECIFIC:
BREAST CARCINOMA CK 7 CK 20 ER/PR CD44 CA15-3 CA19-9 p63 CK5
Infiltrating Ductal Carcinoma + - + + + - - -

Adenoid Cystic Carcinoma + - - - + + + +
ORGAN SPECIFIC:
BREAST CARCINOMA CD117
Infiltrating Ductal Carcinoma -

Adenoid Cystic Carcinoma +
ORGAN SPECIFIC: BREAST VS.

LUNG VS. PROSTATE CARCINOMA GCDFP-15 Mammaglobin CA15-3 Caveolin-1 PSA TTF-1 Napsin A
Breast Carcinoma + + + + - - -
Lung Carcinoma - - - - - + +
Prostate Carcinoma - - - +/- + - -
ORGAN SPECIFIC:
DIFFERENTIAL DIAGNOSIS
OF PARATHYROID TUMORS Chromogranin A Synaptophysin PTH S-100 TTF-1 Calcitonin PAX-8
Parathyroid Tumors + + + - - - -
Follicular Cell Tumors - - - +/- + - +
Medullary Thyroid Carcinoma + + - - + + +
ORGAN SPECIFIC:
SEX CORD STROMAL TUMORS Calretinin Inhibin CD99 CK 7 EMA Vimentin MART-1M
Granulosa Cell Tumors + + + - - + +

Sertoli-Leydig Cell Tumors + + -/+ + - + +
Gynandroblastoma + +
Gonadoblastomas + + + - - + -
Organ Specific
ORGAN SPECIFIC: UTERUS: 1st Trimester 2nd Trimester 3rd Trimester

TROPHOBLASTIC CELLS hCG hPL hCG hPL hCG hPL
Cytotrophoblast - - - - - -
Intermediate Trophoblast 1-24% 25-49% -/+ 50-74% 1-24% 1-49%
Syncytiotrophoblast >75% 1-24% 25-49% 50-74% 1-24% >75%
ORGAN SPECIFIC: UTERUS:

TROPHOBLASTIC PROLIFERATIONS p57 hCG PLAP hPL CK Cocktail Vimentin
Partial Mole + Weak, diffuse + Weak, diffuse Strong, diffuse -

Complete Mole - Strong, diffuse Weak, focal Weak, focal Strong, diffuse -
Choriocarcinoma - Strong, diffuse Weak, focal Weak, focal Strong, diffuse -
Placental Site Tumor Strong, focal Srong, diffuse Strong, diffuse Strong, diffuse Strong, diffuse
ORGAN SPECIFIC:
SKIN: ADNEXAL TUMORS CK 7 CK 20 S-100 EMA GCDFP-15 CD15
Merkel Cell Carcinoma - + - + - -

Sebaceous Tumor + - - - - +
Apocrine Tumor - - +/- + +/-
Eccrine Tumor - + + - -
ORGAN SPECIFIC: BREAST LESION GCDFP-15 Mammaglobin B-Catenin E-Cadherin CK, 34bE12 p120
Lobular + + - - + + (cytoplasmic)
Ductal + + + (membranous) + - + (membranous)
ORGAN SPECIFIC: MENINGIOMAS

FROM HISTOLOGIC MIMICS Claudin 1 EMA S-100 P CD34 GFAP
Meningothelial Meningioma + + - - -
Atypical Meningioma + + - + -
Fibrous Meningioma - + + - -
Solitary Fibrous Tumor - - - + -
Meningeal Hemangiopericytoma - - - + -
Schwannoma +/- - + - +
ORGAN SPECIFIC: RENAL CELL

CARCINOMA VS.
HEMANGIOBLASTOMA D2-40 FLI-1 CD31 CK Cocktail CD10
Metastatic Renal Cell Carcinoma - - - + +

Hemangioblastoma + + + - -
ORGAN SPECIFIC:
OVARIAN CARCINOMAS PAX-8 WT1 CA-125 CEA pVHL
Ovarian Carcinoma, Serous + + + + -

Ovarian Carcinoma, Mucinous - - - - -
Ovarian Endometrioid Carcinoma + - + - -
Ovarian Clear Cell Carcinoma + - + - +
ORGAN SPECIFIC: SKIN:

PAGETOID TUMORS CK, LMW CK, HMW S-100 CEA Vimentin
Melanoma - - + - +
Paget’s Disease + - -/+ + -
Bowen’s Disease + + - - -
169
Organ Specific
ORGAN SPECIFIC: SKIN: BASAL VS.

SQUAMOUS CELL CARCINOMA CK Cocktail Ep-CAM EMA bcl-2
Basal Cell Carcinoma + + - +

Squamous Cell Carcinoma + - + -
ORGAN SPECIFIC: PERINEURIOMA

VS. NEUROFIBROMA Claudin 1 EMA S-100 GLUT1
Perineurioma + + - +
Neurofibroma + + - -
ORGAN SPECIFIC: BREAST

CARCINOMA IN-SITU VS.
INFILTRATING BREAST CARCINOMA Calponin SM Myosin p63
Breast Carcinoma in-situ + + +

Infiltrating Breast Carcinoma - - -
ORGAN SPECIFIC: PANCREAS VS.

PANCREATIC ADENOCARCINOMA pVHL S-100 P Maspin
Pancreas + - -
Pancreatic Intraepithelial Neoplasia - + +
Pancreatic Adenocarcinoma - + +
Lymphomas
LYMPHOMAS: B-CELL LYMPHOMAS CD45 CD20 CD79a bcl-2 bcl-6 CD10 CD23 Cyclin D1
Follicular + + + + + + - -
CLL/SLL + + + + - - + -
Mantle Cell + + + + - - - +
Marginal Zone BCL + + + + - - - -
Lymphoplasmacytic + + + + - - - -
Diffuse Large Cell Lymphoma + + + + + - - -
Burkitt Lymphoma + + + - + + - -
Hairy Cell Leukemia + + + + - - - -
LYMPHOMAS: B-CELL LYMPHOMAS PAX-5 BOB.1 Oct-2 PU.1 p27Kip1 IgD MUM1 T-beta
Follicular + + + + + + - -
CLL/SLL + + + + + + + +
Mantle Cell + + + + + + - -
Marginal Zone BCL + + + + + -/+ + +
Lymphoplasmacytic + + + - + +
Diffuse Large Cell Lymphoma + + + + - - + -
Burkitt Lymphoma + - - - -
Hairy Cell Leukemia + - - +
LYMPHOMAS: B-CELL LYMPHOMAS TRAcP Annexin A1 CD5 CD43 CD3 ZAP-70 CD25 FOXP1
Follicular - - - - - - -
CLL/SLL - - + + - +/-
Mantle Cell - - + + - - - -/+
Marginal Zone BCL +/- - - - - -
Lymphoplasmacytic - - - - - - -
Diffuse Large Cell Lymphoma - - - - - +
Burkitt Lymphoma - - + - -
Hairy Cell Leukemia + + - - - +
LYMPHOMAS: B-CELL LYMPHOMAS TCL1
Follicular +
CLL/SLL +
Mantle Cell +
Marginal Zone BCL -
Lymphoplasmacytic +
Diffuse Large Cell Lymphoma -/+
Burkitt Lymphoma +
Hairy Cell Leukemia
LYMPHOMAS: T-CELL LYMPHOMAS CD45 CD2 CD3 CD4 CD5 CD7 CD8 CD25
Angioblastic + + + + + + +/- +
Lymphoblastic + +/- + +/- + + +/- +
Subcutaneous Panniculitic + + + - + + +/- -
Lennert’s + + + - + - +
NK-Type + + + - - + - +
Cutaneous + + + + - + - -
Peripheral + + + + + - - +
Mycosis Fungoides + + + + + - - +
171
Lymphomas
LYMPHOMAS:
ACUTE MYELOID LEUKEMIA MPO CD68 Factor VIII CD61 Hemoglobin A BOB.1 Oct-2 Glycophorin A
Acute Myeloid, M0 - - - - - - - -
Myeloblast, M1&2 + + - - - -
Promyelocytic, M3 + + - - - + +
Myelomonocytic, M4 + + - - - - + -
Monoblastic, M5 + + - - - - + -
Acute Myeloid, M6 + - - - - - +
Megakaryocytic, M7 - - + + - +/- -
Megakaryoblast + + + +
LYMPHOMAS:
ACUTE MYELOID LEUKEMIA Spectrin CD34 CD43 CD74 CD45 Lysozyme CD138
Acute Myeloid, M0 - + + + + + +
Myeloblast, M1&2 - - + + + + +
Promyelocytic, M3 - + -
Myelomonocytic, M4 - + + + + +
Monoblastic, M5 - - + + + +
Acute Myeloid, M6 + - - +
Megakaryocytic, M7 - -
Megakaryoblast -
LYMPHOMAS: LYMPHOBLASTIC
LYMPHOMAS, BCL VS. TCL TDT CD10 PAX-5 CD20 CD19 CD3 CD5 CD7
Lymphoblastic BCL + +/- + +/- + - - -

Lymphoblastic TCL + + - - - + +/- +
LYMPHOMAS: LYMPHOBLASTIC
LYMPHOMAS, BCL VS. TCL CD117 CD74
Lymphoblastic BCL - +
Lymphoblastic TCL - -
LYMPHOMAS: PLASMA CELLS CD138 CD79a EMA MUM1 CD56 Cyclin D1 CD43 CD20
Plasma Cell Tumor + + + + + - - -
LYMPHOMAS: PLASMA CELLS CD19
Plasma Cell Tumor -
LYMPHOMAS:
LYMPH NODE HISTIOCYTOSIS CD68 S-100 CD1a Lysozyme CD21/CD35 FDC PD-1
Reactive + - - + - - -
Langerhans + + + + - - -
Sinus Histiocytosis with
Massive Lymphadenopathy + + - + - - -
Follicular Dendritic Cell Tumor - - - - + + +
Dermatopathic Lymphadenitis - + + + - - -
LYMPHOMAS: HISTIOCYTIC LESIONS CD45 CD4 CD68 Lysozyme CD163 Factor XIIIa CD20 CD3
Histiocytic Lesions + + + + + + - -
Lymphomas
LYMPHOMAS:
HISTIOCYTIC PROLIFERATION S-100 CD68 Vimentin Lysozyme CD1a Factor XIIIa HAM56
Juvenile Xanthogranuloma - + + + - + +
Langerhans Cell Histiocytosis + + + + + - +
Dermatofibroma - + + - - + +
LYMPHOMAS: IMMUNOGLOBULIN,
HEAVY AND LIGHT CHAIN IgA IgG IgD IgM Kappa Lambda
Secretory Meningioma + - - +
Microvillous Lymphoma - - - +
Cutaneous Lymphoma - - - -
Myeloma + + +/- - + +
Diffuse LBCL - + - + + +
Marginal Zone Lymphoma - - -/+ + + +
SLL/CLL - - + + + +
LYMPHOMAS: B-CELL, MATURATION CD20 CD79a CD19
Pro-B - + +
Pre-B - + +
Late Pre-B + + +
Mantle B-cells + + +
Centroblastic + + +
Centrocytic + + +
Plasmablasts - + -
Plasma cells - + -
LYMPHOMAS: HIGH GRADE

LYMPHOMA, BCL VS. TCL CD20 CD45R CD43 CD45RO CD3
Low Grade BCL + + - - -

High Grade BCL + + - - -
Low Grade TCL - - + + +
High Grade TCL - - + + +/-
LYMPHOMAS: FOLLICULAR
LYMPHOMA VS. REACTIVE FOLLICLES bcl-2 bcl-6 CD10 Ki-67
Follicular Lymphoma + + + -
Reactive Follicles - + + +
LYMPHOMAS: MASTOCYTOSIS Tryptase CD117 CD25 CD163 CD2
Mastocytosis + + + - +
Reactive Mast Cells + + - + -
Myelomastocytic Leukemia + + - -
173
Lymphomas
LYMPHOMAS: SPLENIC HEMATOPOIETIC

PROLIFERATIONS IN NEOPLASTIC
AND BENIGN DISORDERS MPO CD34 CD117 CD68 Hemoglobin A
Chronic Myelogenous Leukemia + -/+ +/- + -

Chronic Idiopathic Myelofibrosis + +/- -/+ -
Myelodysplastic Syndrome + -/+ -
Myelodysplastic / Myeloproliferative Disorders + - - + -
Mastocytosis + - + -
Erythroid Disorders +/- - - -/+ +
Splenic Lymphoma -/+ - - -
Acute Myeloid Leukemia + + + + -
Polycythemia Vera + + +
Product Index
A-1-Antichymotrypsin. . . . . . . . . . . . . . . .8 CD117 c-Kit PolyDetector HRP/DAB . 80 Hepatocyte Specific Antigen Pneumocystis carinii . . . . . . . . . . . . . . . 60
A-1-Antitrypsin . . . . . . . . . . . . . . . . . . . . . .8 CD123 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 /Hep Par 1 . . . . . . . . . . . . . . . . . . . . . . . . . 44 Podoplanin/D2-40 . . . . . . . . . . . . . . . . . 60
ACTH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8 CD138 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 HER-2 neu, MMab . . . . . . . . . . . . . . . . . . 44 PolyDetector HRP . . . . . . . . . . . . . . . . . . 76
Actin, Muscle Specific . . . . . . . . . . . . . . . .9 CD163 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 HER-2 neu, PolyDetector HRP/DAB. . 78 Progesterone Receptor . . . . . . . . . . . . 61
Actin, Smooth Muscle . . . . . . . . . . . . . . . .9 CD246 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 HER-2 neu, RMab. . . . . . . . . . . . . . . . . . . 45 Prolactin . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Adenovirus . . . . . . . . . . . . . . . . . . . . . . . . . .9 CD279 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 Herpes Simplex Virus I & II . . . . . . . . . . 45 PSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
ALK-1/CD246 . . . . . . . . . . . . . . . . . . . . . . 10 CDX2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 HHV-8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 PSAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Alpha-Fetoprotein . . . . . . . . . . . . . . . . . 10 CEA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 HMB-45. . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 PSMA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
AMACRacemase/P504S . . . . . . . . . . . . 10 Chromogranin A . . . . . . . . . . . . . . . . . . . 29 HPV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Real Time PCR. . . . . . . . . . . . . . . . . . . . . 138
Ancillaries and Equipment Collagen Type IV . . . . . . . . . . . . . . . . . . . 29 HPV CytoDetector HRP/DAB . . . . . . . . 77 Renal Cell Carcinoma . . . . . . . . . . . . . . . 62
for FISH & CISH . . . . . . . . . . . . . . . . . . . . . 94 COX-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 Human Gene Primer – Single PCR Kits115 Retinoblastoma/Rb . . . . . . . . . . . . . . . . 63
Ancillaries for Immunohistochemistry .86 Cyclin D1 . . . . . . . . . . . . . . . . . . . . . . . . . . 30 Hydrophilic Plus Slides S-100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Androgen Receptor . . . . . . . . . . . . . . . . 11 Cyclin D3 . . . . . . . . . . . . . . . . . . . . . . . . . . 30 for Molecular Pathology . . . . . . . . . . . . 103 Single & Multiplex PCR . . . . . . . . . . . . 113
Automated Nucleic Acid Cytokeratin 5&6 . . . . . . . . . . . . . . . . . . . . 30 IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Somatostatin . . . . . . . . . . . . . . . . . . . . . . 63
Extraction System . . . . . . . . . . . . . . . . . 153 Cytokeratin 7 . . . . . . . . . . . . . . . . . . . . . . 31 IgD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Spectrin . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Bax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Cytokeratin 8/35Beta11 . . . . . . . . . . . . 31 IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 Substrate-Chromogen Systems for
BCA-225 . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Cytokeratin 8&18 . . . . . . . . . . . . . . . . . . 31 IgM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 use with HRP Detection Systems. . . . 82
bcl-2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Cytokeratin 14 . . . . . . . . . . . . . . . . . . . . . 32 Immunofluorescence Antibodies . . . 72 Substrate-Chromogen Systems for
bcl-6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Cytokeratin 17 . . . . . . . . . . . . . . . . . . . . . 32 ImmunoDetector HRP . . . . . . . . . . . . . . 74 use with AP Detection Systems . . . . . 83
bcl-X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Cytokeratin 19 . . . . . . . . . . . . . . . . . . . . . 32 ImmunoDetector AP . . . . . . . . . . . . . . . 75 Synaptophysin . . . . . . . . . . . . . . . . . . . . . 64
Beta-Catenin . . . . . . . . . . . . . . . . . . . . . . . 13 Cytokeratin 20 . . . . . . . . . . . . . . . . . . . . . 33 Infectious Pathogen Gene Primer – TAG-72 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
CA-125 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Cytokeratin HMW/34betaE12 . . . . . . . 33 Single PCR Kits . . . . . . . . . . . . . . . . . . . . 125 TdT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
CA15-3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Cytokeratin HMW/AE3 . . . . . . . . . . . . . 33 Inhibin Alpha . . . . . . . . . . . . . . . . . . . . . . 47 Thyroglobulin. . . . . . . . . . . . . . . . . . . . . . 65
CA19-9 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Cytokeratin LMW/AE1 . . . . . . . . . . . . . . 34 Insulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 TIA-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Calcitonin. . . . . . . . . . . . . . . . . . . . . . . . . . 14 Cytokeratin/Pan-Cocktail AE1&AE3 . 34 Kappa Light Chains . . . . . . . . . . . . . . . . 48 Topoisomerase II alpha . . . . . . . . . . . . . 66
Caldesmon . . . . . . . . . . . . . . . . . . . . . . . . 14 Cytokeratin/Pan- OSCAR . . . . . . . . . . . 34 Ki-67 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 Toxoplasma gondii . . . . . . . . . . . . . . . . . 66
Calponin. . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Cytomegalovirus . . . . . . . . . . . . . . . . . . . 35 Ksp-Cadherin . . . . . . . . . . . . . . . . . . . . . . 49 TRAcP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Calretinin . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Desmin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Lambda . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 Tryptase . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
CD1a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 DOG1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 LH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 TSH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
CD2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 DNA/RNA Isolation Kits, Liquid-Based Cytology . . . . . . . . . . . . 108 TTF-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
CD3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 RT PCR Kits and Ancillary Products . 112 Lysozyme . . . . . . . . . . . . . . . . . . . . . . . . . . 50 Tyrosinase . . . . . . . . . . . . . . . . . . . . . . . . . 68
CD4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 E-Cadherin. . . . . . . . . . . . . . . . . . . . . . . . . 36 Macrophage/HAM-56 . . . . . . . . . . . . . . 50 VEGF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
CD5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 EGFR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Mammaglobin . . . . . . . . . . . . . . . . . . . . 50 Villin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
CD7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Electric Pressure Cooker and Slides .102 MART-1/Melan-A . . . . . . . . . . . . . . . . . . . 51 Vimentin. . . . . . . . . . . . . . . . . . . . . . . . . . . 69
CD8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Endoglin. . . . . . . . . . . . . . . . . . . . . . . . . . . 26 MCM-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 Wave RPD Antibodies . . . . . . . . . . . . . 100
CD10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 EMA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Melan-A . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 Wave RPD Components
CD15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 EpCAM/Epithelial Specific Antigen. . 37 Melanoma/HMB-45 . . . . . . . . . . . . . . . . 51 and Accessories . . . . . . . . . . . . . . . . . . . . 98
CD19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Epithelial Specific Antigen . . . . . . . . . . 37 MiTF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 Wave RPD System . . . . . . . . . . . . . . . . . . 96
CD20 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Epstein Barr Virus . . . . . . . . . . . . . . . . . . 37 MLH1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 WT1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
CD21 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 ER/PR PolyDetector HRP/DAB. . . . . . . 79 MSH2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 Zap-70 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
CD23 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Estrogen Receptor . . . . . . . . . . . . . . . . . 37 MSH6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 ZytoLight® . . . . . . . . . . . . . . . . . . . . . . . . . 88
CD25 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Factor VIII-Related Antigen . . . . . . . . . 38 MUC1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 ZytoDot® . . . . . . . . . . . . . . . . . . . . . . . . . . 90
CD30 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Factor XIIIa . . . . . . . . . . . . . . . . . . . . . . . . . 38 MUC2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 ZytoFast® . . . . . . . . . . . . . . . . . . . . . . . . . . 92
CD31 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Fascin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 MUC5AC . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
CD34 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Fli-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 MUC6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
CD35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Follicular Dendritic Cell . . . . . . . . . . . . . 39 Myelin Basic Protein . . . . . . . . . . . . . . . . 54
CD38 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 FSH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 Myeloperoxidase. . . . . . . . . . . . . . . . . . . 55
CD43 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Galectin-3 . . . . . . . . . . . . . . . . . . . . . . . . . 40 Myogenin . . . . . . . . . . . . . . . . . . . . . . . . . 55
CD44 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Gastrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Myoglobin . . . . . . . . . . . . . . . . . . . . . . . . . 55
CD45 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 GCDFP-15 . . . . . . . . . . . . . . . . . . . . . . . . . 40 Myosin, Smooth Muscle . . . . . . . . . . . . 56
CD45R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Gene Primer – Multiplex PCR Kits . . 131 Neuroblastoma . . . . . . . . . . . . . . . . . . . . 56
CD45RA . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 GFAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 Neurofilament . . . . . . . . . . . . . . . . . . . . . 56
CD45RO . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 GH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 NGFR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
CD56 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Glucagon . . . . . . . . . . . . . . . . . . . . . . . . . . 41 NSE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
CD57 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Glycophorin A . . . . . . . . . . . . . . . . . . . . . 42 p27 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
CD61 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Glypican-3 . . . . . . . . . . . . . . . . . . . . . . . . . 42 p53 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
CD63 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Granzyme B. . . . . . . . . . . . . . . . . . . . . . . . 42 p57 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
CD68 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 HAM-56 . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 p63 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
CD74 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 hCG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43 Parvovirus B19 . . . . . . . . . . . . . . . . . . . . . 59
CD79a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Helicobacter Pylori . . . . . . . . . . . . . . . . . 43 PAX-5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
CD99 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Hep Par 1 . . . . . . . . . . . . . . . . . . . . . . . . . . 44 PCR Flowchart . . . . . . . . . . . . . . . . . . . . 114
CD105/Endoglin . . . . . . . . . . . . . . . . . . . 26 Hepatitis B Virus Core Antigen . . . . . . 43 PD-1/CD279 . . . . . . . . . . . . . . . . . . . . . . . 59
CD117 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Hepatitis B Virus Surface Antigen . . . 44 PLAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
175
Ordering Information
BIO SB, INC.
Please call our Customer Service department from 9:00 A.M. to 5:00 P.M. (PST), Monday through Friday, to place an order or to enquire about an existing order.
Telephone: +1-805-692-2768
Fax: +1-805-692-2769
E-mail: info@biosb.com
Mail Orders: Bio SB, Inc.
Attention to: Customer Service
69 Santa Felicia Dr.
Santa Barbara, CA 93117
To expedite the order process, please include the following information on your purchase order or correspondence:
• Purchase Order Number

• Customer Number
• Name, phone and fax number of person ordering
• Shipping address (please do not use P.O. Box number)
• Billing address (if different from above)
• Name of product, catalog number, quantity and price
• Special shipping instructions
• Credit card number and expiration date (for credit card payments)
INTERNATIONAL ORDERS
Please visit http://www.biosb.com/disributors.html or E-mail us at info@biosb.com
OPENING A NEW BIO SB ACCOUNT

First time orders paid by credit card (see under Payment) will be processed and shipped immediately. For other payment methods please accept a delivery time of
up to five business days for credit verification purposes.
CREDIT TERMS
Net 30 days in U.S. Dollars, upon approval. Overdue accounts are subject to a finance charge of 1.5% per month (18% per annum).
CONFIRMING ORDERS
To avoid duplication of your shipment, please mark boldly “confirming order - please do not ship” on your order.
PRICING
All prices are quoted in U.S. dollars, exclusive of state and county sales tax, where applicable. Prices are valid only for shipments within U.S. and are subject to change
without notice. Please inquire about our standing order and quantity discount policies.
SHIPPING
Shipping and handling charges are prepaid and added to the invoice. They vary with the destination, weight and content, and are available upon request at order
entry and are indicated on the invoice. Reagent orders received by 2:00 P.M. (PST), Monday through Thursday, will generally be Expedited Shipping for Next Day
Delivery. Early A.M. and Saturday delivery are available upon request.
PAYMENT
All payments must be made in U.S. dollars. We accept MasterCard, VISA, American Express, Diners and Discovery.
RETURN POLICY
Reagents are covered by the following Total Quality Assurance policy which states:
If you are not completely satisfied with the quality of our reagents, you may return them to us for a refund or replacement, at our option. Bio SB’s liability is limited
to a refund or replacement, at our option. Please obtain a Return Material Authorization (RMA) number from Customer Service prior to the return of a product.
Returns, which are not caused by unsatisfactory product performance, must be made within 30 days of delivery and will be subject to a 30% processing fee. Returns
or replacements cannot be accommodated for expired products. All products sent without an RMA number will be returned to sender.
Bio SB, Inc. Distributors

AUSTRALIA COLOMBIA FRANCE, TUNISIA & ALGERIA
Diagnostic Technology Pty Ltd. Interglobal Commerce Association, Inc. Diagomics
Suite 45, 7 Narabang Way 13360 Southwest 91 Terrace, Unit F 7, Place de Bologne #106
Belrose NSW 2085 Miami, FL 33186 - USA 31000 Toulouse - France
Australia Tel/Fax: +1-305-382 0643 Tel: +33-6-8313-4101
Tel: +61-2-9986-2011 Contact: Juan Carlos Cuello Contact: Gwenola Tanneau
Fax: +61-2-9986-2022 E-mail: icas@bellsouth.net E-mail: info@diagomics.com
Contact: Mark Van Asten Website: www.diagomics.com
E-mail: info@diagnostictechnology.com.au
Website: www.diagnostictechnology.com.au COSTA RICA
GERMANY
Laboratorios Zeledón, S.A.
500 m Norte y 75 m Oeste de la Estación de Hölzel Diagnostika Handels GmbH
BRAZIL Hansaring 10
Bomberos
Lupe Industria Tecnologica de De Santo Domingo de Heredia D-50670 Köln
Equipamentos p/Laboratorio Ltda San José, Costa Rica 1042-1100 Germany
Rua Robertson 517 Centro América Tel: +49-221-126-0266
Cambuci - Cep: 01543-010 Tel: +506 2244-1853 & +505 2244-0400 Fax: +49-221-126-0267
Sao Paulo - SP - Brasil Fax: +506 2244-1905 Contact: Mrs. Yvonne Nienhaus
Tel: +55-11-2738-2447 & 2738-2445 Contact: Javier Zeledón E-mail: info@hoelzel.de
Fax: +55-11-2738-2446 E-mail: jzeledon@labzel.com Website: www.hoelzel-biotech.com
Contact: Martin Francisco Martins Website: www.labzel.com
E-mail: martin@lupetec.ind.com.br GREECE
Websites: www.lupe.com.br & www.lupetec.ind.br
ECUADOR M. Kallifronas Company
Acces-Lab 4, Euripidou Street 69
BULGARIA Athens, 105 59 - Greece
Mariano Jimbo N40-90 y Gaspar de Villaroel
BioSystems Ltd. Quito - Ecuador Tel: +30-210-321-8871
2, 6th September Str. Tel: +593-245-6500, 243-7131 & 243-7139 Contact: Michael A. Callifronas
1000 Sofia Contact: Sandra Benalcazar E-mail: a.kallifronas@gmail.com
Bulgaria E-mail: info@acceslab.com.ec Website: www.kallifronas.com
Tel: +359-2-9860807 & sandra.benalcazar@acceslab.com.ec
Fax: +359-2-9860807 Website: www.acceslab.com.ec GUATEMALA
Contact: Dr. Pavel Rashev
E-mail: office_bio@mbox.contact.bg Corporación Patologica Contemporánea
Website: : www.biosystems.bg EGYPT 3ra Calle 9-78, Zona 1
Porto Med Cd. de Guatemala - Guatemala, C.A.
1 El Safa Street, Infront of Wadi El Nile Hospital Tel: +502-2238-0436
CHILE Contact: Fernando Molina Lee
El Kobba EL Gedeedah
Polycompany International Ltda. Cairo, Egypt E-mail: info@copac.com.gt
Poeta Vicente Huidobro #4041 Tel: +20-2-2451-5185 Website: www.copac.com.gt
Macul - Santiago - Chile Fax: +20-2-2451-5185
Tel: +56-2-221-7760 Contact: Dr. Abd El Aziz Beltagy HONDURAS
Fax: +56-2-221-8255 & Mr. Mohammed Osman
Contact: Alejandro Mucientes E-mail: info@porto-med.com RC Lab S. de R.L.
E-mail: polycompany@gmail.com Website: www.porto-med.com Col. Alameda #712
& manager@polycompany.tie.cl Tegucigalpa - Honduras
Tel: +504-232-6398
Imerlab Importaciones EL SALVADOR Contact: Liza Caceres
Segunda Transversal #6164 Rowalt Pharmaceutical S.A. de C.V. E-mail: caceres@amnettgu.com
San Miguel - Santiago - Chile Avenida Libertad No. 419
Tel: +56-2-359-0043, 312-3855 & 9-231-1714 Colonia Libertad INDIA
Fax: +56-2-359-0043 San Salvador - El Salvador, C.A.
Contact: Juan Carlos González Tel: +503-225-8974 M.J. Diagnostics
E-mail: imer@vtr.net Contact: Walter Ernesto Rodríguez Rivas E-153
Website: www.imerlab.cl E-mail: rowalt@navegante.com.sv West Patel Nagar
New Delhi - 110 008 - India
Tel: +91-98-18212433 & +91-11-25884379
CHINA FINLAND Fax: +91-11-25885464
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Nuppulinnan Laboratoriopalvelu Oy Contact: Rajesh Bajaj
No.31 Kexueyuan Road, Changping District Jokelantie 346, Halli D E-mail: mjdiagnostics3012@hotmail.com
Beijing 102206 05430 Nuppulinna - Finland
China Tel: +358-20-792-0350
Contact: Mr. Yu Tao Contact: Harri Kamarainen
Tel: +86-10-595-288-88 E-mail: nuppulinna@dlc.fi
Fax: +86-10-897-058-49 Website: www.dlc.fi
E-mail: wantaibp@mx.cei.gov.cn & wtexport@ystwt.com
& market@ystwt.com
Website: www.ystwt.com
JAPAN PAKISTAN Hong Jing Co., Ltd.
5F, No. 174, SEC 1
BIOSJ DNA Scientific Systems Chung-Shan Rd., Young-Ho City
138 Enmado-cho Office # 03, ST # 03, G.T. Road Taipei, Taiwan, R.O.C.
Moriyama City P.O. Mughalpura, Lahore Tel: +886 2 3233-8585 # 213
Shiga, 524-0042 - Japan Pakistan Fax: +886 2 3233-8686
Tel: +81-77-582-4463 Tel: +92-42-3681-4201 Skype: hongjing6668
Fax: +81-77-582-4463 Contact: Fayyaz Ahmad Facebook: http://ppt.cc/AtAa
Contact: Yoichi Tani E-mail: dnafitc@hotmail.com Contact: Lisa Tsai
E-mail: support@biosj.com E-mail: lisa@hongjing.com.tw
Website: www.biosj.co& viano84@yahoo.com Website: www.hongjing.com.tw
Contact: Martin Barilani
PERU
E-mail: martin.barilani@visurltda.com BioMaxim, S.R.L.
Website: www.visurltda.com Av. Arequipa 2450, Of. 1109 THAILAND
Lima 14 - Peru Biomed Diagnostics Co., Ltd.
Tel: +511-221-0672 96/38 Moo 6 Bangkraui-Sainoi Rd.
JORDAN Fax: +511-221-3493 Bangkraui, Nontaburi, 11130
Planet Biotechnologies L.L.C. Contact: Dr. Alberto Rafaelli V. & Lic. Renato Rafaelli Thailand
122 Wasfi Al Tal Street, Suite #103 E-mail: biomaxim@hotmail.com Tel: +66-2-879-6026
P.O. Box 928051 Fax: +66-2-879-6065
Amman 11190 - Jordan Contact: Nantawadee Akrawichien
Tel: +962-6-565-9045
SAUDI ARABIA
E-mail: nan@biomedthai.com
Fax: +962-6-565-9046 Al-Saman Medical Website: www.biomedthai.com
Contact: Mr. Sultan Rahbani P.O. Box: 12248
E-mail: info@planet-biotechnologies.com Jeddah 21473 - Saudi Arabia
& sultan_rahbani@planet-biotechnologies.com Tel: +966-2-263-0440 TURKEY
Website: www.planet-biotechnologies.com Fax: +966-2-2630653 BioGen Medical Instruments Trading Co. Ltd.
Contact: Younis Mostafa Tekstilkent Koza Plaza, A Blok Kat 18 No: 67
E-mail: Med@alsamman.com.sa 34235 Esenler, Istanbul - Turkey
MALAYSIA & viano84@yahoo.com Tel: +90-212-438-6590
Biomarketing Services (M) SDN BHD FCT: +90-533-471-7148
21, Jalan 4/62A, Bandar Menjalara, Kepong Fax: +90-212-438-6594
52200 Kuala Lumpur
SINGAPORE
Skype: biogenmedikal
Malaysia Biomed Diagnostics Pte., Ltd. Contact: Havva Erkan and Ismail Erkan
Tel: +603-6273-3068 18, Boon Lay Way, #05-105/108 E-mail: biogen@biogen.com.tr
Fax: +603-6272-0093 Tradehub 21 Website: www.boiogen.com.tr
Contact: Mr. Liew HC, Sales Singapore 609966
Ms. Wendy Chong, Ordering & Shipping Contact: Shawn Lim & Irene Kum
E-mail: liew@biomarketing.com.my Tel: +65-6298-4347 URUGUAY
& wendy@biomarketing.com.my Fax: +65-6298-4723 Visur Productos Diagnósticos Limitada
Website: www.biomarketing.com.my E-mail: sales@biomed.com.sg 26 de Marzo 1208, Ap # 501
Website: www.biomed.com.sg Montevideo, C.P. 11300, Uruguay
MEXICO Tel: +598 2708-6099
SOUTH KOREA Fax: +598 2708-4739
Diagnocell Laboratorios, S. A. de C.V. Contact: Martin Barilani
José María Rico No. 212 Int. 306 J.One LifeScience (J1LS) E-mail: martin.barilani@visurltda.com
Colonia del Valle - 03100 México, D. F. A-1917 Twin Tower B/D 275-3 Website: www.visurltda.com
Tel: +52-55-5536-8708, 5536-8659 & 1107-8833 Yangjae-dong, Seocho-gu
Fax: +52-55-5536-8761 Seoul, Korea
Contact: Patricia Reyes Tel: +82-2-577-8943 VENEZUELA
E-mail: diagnocelllabs@yahoo.com.mx Fax: +82-2-577-8946 Loginca
Contacts: Sung Ho, Jung & Hye Min, Kim Avenida Principal Colinas de Bello Monte
E-mail: hosiwoobo@gmail.com & hyemin1228@gmail.com Torre Financiera, Piso 15-C
MOROCCO
Caracas 1050, Venezuela
Progen Sarl Tel: +58-212-751-5732
Rue Ibnou Katir, Redidence Al Mawlid
TAIWAN
& 7519189 & 751937
Imm C, #11, 20380 Li-Tzung Biotechnology, Inc. Contact: Pascual Lambiase
Casablanca - Morocco 3F.-1, No. 211, Hebei 2nd Rd. E-mail: loginca@cantv.net & loginca@gmail.com
Tel: + 212-522-98-5005 Sanmin District Website: www.loginca.com
Fax: + 212-522-98-5006 Kaohsiung City 807 - Taiwan (ROC)
Contact: Hassan Baziz Tel: +886-7-241-1512
E-mail: hassan.baziz@vital.ma Fax: +886-7-241-1643 UNITED STATES OF AMERICA
Contact: Andrew Lin Bio SB, Inc.
E-mail: leica.andrew@gmail.com & li.tzung@msa.hinet.net 69 Santa Felicia Dr.
Santa Barbara, CA 93117 - U.S.A.
Tel: +1-805-692-2768
Contact: Mateusz Tracz & Joe Vargas
E-mail: info@biosb.com
info@biosb.com
info@biosb.com• •www.biosb.com
www.biosb.com
JORDAN SAUDI ARABIA URUGUAY
Planet Biotechnologies L.L.C. Al-Saman Medical Visur Productos Diagnósticos Limitada
122 Wasfi Al Tal Street, Suite #103 P.O. Box: 12248 26 de Marzo 1208, Ap # 501
P.O. Box 928051 Jeddah 21473 - Saudi Arabia Montevideo, C.P. 11300, Uruguay
Amman 11190 - Jordan Tel: +966-2-263-0440 Tel: +598 2708-6099
Tel: +962-6-565-9045 Fax: +966-2-2630653 Fax: +598 2708-4739
Fax: +962-6-565-9046 Contact: Younis Mostafa Contact: Martin Barilani
Contact: Mr. Sultan Rahbani E-mail: Med@alsamman.com.sa E-mail: martin.barilani@visurltda.com
E-mail: info@planet-biotechnologies.com & viano84@yahoo.com Website: www.visurltda.com
& sultan_rahbani@planet-biotechnologies.com
Website: www.planet-biotechnologies.com VENEZUELA
SOUTH KOREA
J.One LifeScience (J1LS) Loginca
MALAYSIA A-1917 Twin Tower B/D 275-3 Avenida Principal Colinas de Bello Monte
Biomarketing Services (M) SDN BHD Yangjae-dong, Seocho-gu Torre Financiera, Piso 15-C
21, Jalan 4/62A, Bandar Menjalara, Kepong Seoul, Korea Caracas 1050, Venezuela
52200 Kuala Lumpur Tel: +82-2-577-8943 Tel: +58-212-751-5732
Malaysia Fax: +82-2-577-8946 & 7519189 & 751937
Tel: +603-6273-3068 Contacts: Sung Ho, Jung & Hye Min, Kim Contact: Pascual Lambiase
Fax: +603-6272-0093 E-mail: hosiwoobo@gmail.com & hyemin1228@gmail.com E-mail: loginca@cantv.net & loginca@gmail.com
Contact: Mr. Liew HC, Sales Website: www.loginca.com
Ms. Wendy Chong, Ordering & Shipping
E-mail: liew@biomarketing.com.my
TAIWAN
UNITED STATES OF AMERICA
& wendy@biomarketing.com.my Li-Tzung Biotechnology, Inc.
Website: www.biomarketing.com.my 3F.-1, No. 211, Hebei 2nd Rd. Bio SB, Inc.
Sanmin District 69 Santa Felicia Dr.
Kaohsiung City 807 - Taiwan (ROC) Santa Barbara, CA 93117 - U.S.A.
MEXICO Tel: +886-7-241-1512 Tel: +1-805-692-2768
Diagnocell Laboratorios, S. A. de C.V. Fax: +886-7-241-1643 Contact: Mateusz Tracz & Joe Vargas
José María Rico No. 212 Int. 306 Contact: Andrew Lin E-mail: info@biosb.com
Colonia del Valle - 03100 México, D. F. E-mail: leica.andrew@gmail.com & li.tzung@msa.hinet.net
Tel: +52-55-5536-8708, 5536-8659 & 1107-8833
Hong Jing Co., Ltd.
Fax: +52-55-5536-8761
5F, No. 174, SEC 1
Contact: Patricia Reyes
Chung-Shan Rd., Young-Ho City
E-mail: diagnocelllabs@yahoo.com.mx
Taipei, Taiwan, R.O.C.
Tel: +886 2 3233-8585 # 213
MOROCCO Fax: +886 2 3233-8686
Skype: hongjing6668
Progen Sarl
Facebook: http://ppt.cc/AtAa
Rue Ibnou Katir, Redidence Al Mawlid
Contact: Lisa Tsai
Imm C, #11, 20380
E-mail: lisa@hongjing.com.tw
Casablanca - Morocco
Website: www.hongjing.com.tw
Tel: + 212-522-98-5005
Fax: + 212-522-98-5006
Contact: Hassan Baziz THAILAND
E-mail: hassan.baziz@vital.ma
Biomed Diagnostics Co., Ltd.
96/38 Moo 6 Bangkraui-Sainoi Rd.
PAKISTAN Bangkraui, Nontaburi, 11130
Thailand
DNA Scientific Systems
Tel: +66-2-879-6026
Office # 03, ST # 03, G.T. Road
Fax: +66-2-879-6065
P.O. Mughalpura, Lahore
Contact: Nantawadee Akrawichien
Pakistan
E-mail: nan@biomedthai.com
Tel: +92-42-3681-4201
Website: www.biomedthai.com
Contact: Fayyaz Ahmad
E-mail: dnafitc@hotmail.com
TURKEY
PERU BioGen Medical Instruments Trading Co. Ltd.
Tekstilkent Koza Plaza, A Blok Kat 18 No: 67
BioMaxim, S.R.L.
34235 Esenler, Istanbul - Turkey
Av. Arequipa 2450, Of. 1109
Tel: +90-212-438-6590
Lima 14 - Peru
FCT: +90-533-471-7148
Tel: +511-221-0672
Fax: +90-212-438-6594
Fax: +511-221-3493
Skype: biogenmedikal
Contact: Dr. Alberto Rafaelli V. & Lic. Renato Rafaelli
Contact: Havva Erkan and Ismail Erkan
E-mail: biomaxim@hotmail.com
E-mail: biogen@biogen.com.tr
Website: www.boiogen.com.tr
info@biosb.com
info@biosb.com• •www.biosb.com
www.biosb.com
2011 v2

Bio SB Antibodies Reagents 2014 Femg

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Bio SB Antibodies Reagents 2014 Femg

Uploaded by

Copyright:

Available Formats

Bio SB, Inc.

Our mission is to develop high-quality immunochemicals while providing outstanding technical

Dr. Alfonso Heras

ZytoFast – Products for CISH HPV | EBV | CMV | Ig-Kappa | Ig-Lambda

Ancillaries for FISH & CISH

New Rabbit Monoclonal Antibodies

Antibodies for Immunofluorescence. . . . . . . . . . . . . . . . . . . . 71

Detection Systems for IHC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .73

Analyte Specific Reagent

FISH & CISH Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

Equipment and Slides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95

Liquid-Based Cytology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109

Molecular Pathology Technical Index . . . . . . . . . . . . . . . . . . 157 113

Analyte Specific Reagent

“Our Objective is to develop, manufacture and market easy-to-use, safe,

Alpha-1-Antichymotrypsin A-1-Antitrypsin ACTH

Alpha-1-Antichymotrypsin is a glycoprotein found Alpha-1-Antitrypsin (A1AT) is a glycoprotein Adrenocorticotropic Hormone (ACTH or

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

Actin, Muscle-Specific Actin, Smooth-Muscle Adenovirus

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

ALK-1/CD246 Alpha-Fetoprotein Alpha-Methylacyl-CoA

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

Androgen Receptor Bax BCA-225

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

bcl-2 bcl-6 bcl-X

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

Beta-Catenin CA-125 CA15-3

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CA19-9 Calcitonin Caldesmon

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

Calponin Calretinin CD1a

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD2 CD3 CD4

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD5 CD7 CD8

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD10 CD15 CD19

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD20 CD21 CD23

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD25 CD30 CD31

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD34 CD35 CD38

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD43 CD44 CD45

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD45R CD45RA CD45RO

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD56 CD57 CD61

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD63 CD68 CD74

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD79a CD99 CD105/Endoglin

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD117 CD123 CD138

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

CD163 CDX2 CEA

IHC of CD163 on an FFPE Tonsil Tissue IHC of CDX2 on an IHC of CEA on an

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

Chromogranin A Collagen Type IV COX-2

CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY CAT. # PRESENTATION VOL/QTY

Cyclin D1 Cyclin D3 Cytokeratin 5 & 6

IHC of Cyclin D1 on an IHC of Cyclin D3 on an IHC of CK 5 and 6 on an FFPE Prostate Tissue